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RESUMO  
 
O padrão de consumo da 3,4-metilenodioximetanfetamina (MDMA, ecstasy) está 
intimamente associado à administração concomitante de uma panóplia de outras substâncias. 
Além de várias drogas que são intencionalmente ingeridas com o intuito de alcançar efeitos 
específicos, outras substâncias são por vezes administradas como parte de esquemas 
terapêuticos, ou inadvertidamente consumidas como contaminantes das pastilhas de ecstasy. 
Não obstante o facto da presença simultânea destas substâncias ter um potencial efeito 
negativo na toxicidade da MDMA, o efeito pernicioso da administração de misturas tem 
recebido relativamente pouca atenção por parte da comunidade científica, já que a maioria dos 
estudos disponíveis está confinada à análise toxicológica das substâncias individualmente. 
Deste modo, o nosso grupo propôs-se averiguar se a combinação de substâncias 
anfetamínicas seria capaz de produzir efeitos tóxicos significativos, distintos daqueles 
observados para as substâncias individualmente. Uma vez que estas substâncias apresentam 
mecanismos farmacológicos e metabólicos sobreponíveis, existe um claro potencial para a 
ocorrência de interações. 
Os perfis de citotoxicidade da MDMA e de três outras anfetaminas, a metanfetamina 
(METH), a 4-metiltioanfetamina (4-MTA), e a d-anfetamina (d-AMP), frequentemente 
presentes nas pastilhas de ecstasy, como contaminantes, ou em substituição da MDMA, ou 
ainda intencionalmente ingeridas para aumentar os efeitos desejados desta droga, foram 
analisados utilizando o ensaio de redução do brometo de 3-(4,5-dimetil-tiazol-2-il)-2,5-
difeniltetrazólio (MTT) numa linha celular de hepatocarcinoma humano (as células HepG2). 
Em seguida, os efeitos de três combinações diferentes foram previstos a partir dos perfis 
citotóxicos individuais de todos os componentes da mistura, aplicando dois conceitos 
matemáticos amplamente utilizados em farmacologia, o modelo de adição de concentração 
(CA) e o de ação independente (IA). A verificação experimental da toxicidade originada pela 
mistura confirmou as expectativas da CA, revelando um evidente efeito aditivo. De particular 
interesse, foi a demonstração de efeitos de mistura relevantes mesmo quando cada anfetamina 
estava presente em níveis que eram individualmente inócuos, enfatizando os riscos associados 
ao abuso de múltiplas drogas. 
Outros fatores inerentes ao consumo da MDMA, nomeadamente a hipertermia 
induzida pela droga, a bioativação metabólica produzindo espécies reactivas, a alteração na 
liberação de catecolaminas e respectivo metabolismo, o comprometimento da função 
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mitocondrial, a apoptose, e as respostas imunes, parecem estar implicados na 
hepatotoxicidade induzida por esta substância. Por conseguinte, a nossa investigação 
pretendeu confirmar a aplicabilidade da CA em cenários experimentais mais realistas que 
procuram mimetizar o fígado in vivo de forma mais fidedigna. Especificamente, nós 
pretendemos (i) avaliar os efeitos de mistura em hepatócitos primários, (ii) perceber a 
influência da hipertermia nesta avaliação, e (iii) investigar o impacto do efeito de mistura da 
MDMA com os seus três principais metabolitos humanos. 
Quando a influência do aumento da temperatura na aplicabilidade dos dois modelos de 
previsão foi investigada, confirmou- se que a CA é o modelo mais adequado para prever os 
efeitos da mistura de anfetaminas também em condições de hipertermia (40,5 ºC), em células 
HepG2. Surpreendentemente, os nossos resultados demonstraram que, para esta temperatura, 
incrementos muito pequenos nas concentrações de cada substância ou da mistura promoviam 
aumentos muito acentuados na resposta citotóxica, oscilando rapidamente entre efeitos quase 
indetectáveis a efeitos altamente deletérios. Estas observações reforçam a hipótese de uma 
provável redução da ‘janela de segurança’ destas drogas, quando combinadas, in vivo e, 
consequentemente, de um aumento dos riscos a que os consumidores de ecstasy estão 
expostos nos cenários de consumo. Os mecanismos subjacentes à toxicidade exigem uma 
investigação mais aprofundada, no entanto, os nossos dados indicam que a perturbação da 
homeostase antioxidante (através do aumento da produção de espécies reactivas de oxigénio e 
de azoto e depleção de glutationa) com insuficiência mitocondrial e consequente perturbação 
do estado energético celular parecem desempenhar um papel crítico na citotoxicidade 
observada.  
Os efeitos de mistura de anfetaminas também foram analisados em hepatócitos 
primários de rato, um modelo que é metabolicamente mais representativo dos hepatócitos in 
vivo. A uma temperatura de incubação fisiológica (37 °C), os resultados obtidos em 
hepatócitos primários e células HepG2 foram muito semelhantes. No entanto, a uma 
temperatura de incubação superior (40,5 °C), a toxicidade dos composto individualmente e da 
mistura aumentam significativamente nas células primárias. A aceleração da taxa metabólica 
esperada a temperaturas de incubação mais elevadas pode explicar, pelo menos parcialmente, 
o aumento da susceptibilidade dos hepatócitos primários à citotoxicidade das drogas e da sua 
mistura. A previsão dos efeitos citotóxicos pela CA mostrou-se novamente precisa em células 
primárias para ambas as temperaturas de incubação. 
Estudos suplementares foram realizados aplicando o mesmo modelo experimental 
para avaliar os efeitos de uma mistura equipotente (uma mistura em que cada um dos seus 
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componentes está presente numa concentração que induz um efeito citotóxico semelhante) de 
MDMA e dos seus três principais metabolitos humanos, a 3,4-metilenodioxianfetamina 
(MDA), a N-metil-α-metildopamina (N-Me-α-MeDA ) e a α-metildopamina (α-Meda), com o 
objetivo de simular a mistura produzida in vivo após bioactivação metabólica da MDMA. 
Também neste caso, foram observados efeitos aditivos significativos, em conformidade com 
as previsões pela CA, mesmo quando as substâncias estavam presentes em concentrações 
baixas, não citotóxicas, salientando a contribuição do metabolismo da MDMA para 
citotoxicidade nas células hepáticas. 
Finalmente, investigámos os mecanismos subjacentes à morte celular induzida pelas 
anfetaminas testadas. Após 24 h de exposição às quatro anfetaminas, individualmente ou em 
mistura, a concentrações equieffectivas (i.e. concentrações que induziram 25% de morte 
celular, conforme avaliado pelo ensaio de redução do MTT), a mortalidade das HepG2 
ocorreu preferencialmente por apoptose, quando testada a uma temperatura de incubação 
fisiológica (37 °C). Esta letalidade foi exacerbada com o aumento do período de incubação 
para 48 h. Quando a temperatura de incubação foi aumentada para 40,5 °C, a necrose tornou-
se o tipo de morte celular privilegiado, para ambos os períodos de incubação (24 h e 48 h). 
Em consonância com estes resultados, os níveis de ATP intracelular sofreram uma redução 
acentuada quando as células foram incubadas com as substâncias individuais e em mistura a 
40,5 °C, efeito esse que não foi observado a 37 °C. Uma investigação mais profunda dos 
mecanismos apoptóticos intervenientes mostraram um declínio nos níveis de mRNA dos 
genes BCL-2 e BCL-XL, com um simultâneo aumento de BAX, BIM, BAD (apenas para 
MDMA), PUMA e BID. A elevação dos níveis proteicos de Bax, Bim (fracções EL, S e L), 
Bid clivado, Puma e Bak foram, posteriormente, confirmados. De acordo com a informação 
presentemente disponível na literatura, os marcadores Puma, Bim e Bak nunca antes tinham 
sido associados com a toxicidade induzida por anfetaminas. Resultados adicionais mostraram 
o envolvimento da ativação da caspase-3/-7, mas não de alterações no potencial de membrana 
mitocondrial (∆ψm), na apoptose induzida por estas anfetaminas, isoladamente e em mistura, 
nas condições experimentais testadas. A proteólise da poli (ADP-ribose) polimerase (PARP), 
após 24 h de exposição aos compostos referidos, confirmou a lesão celular. De um modo 
geral, para todos os parâmetros avaliados, não foram observadas diferenças significativas 
entre as anfetaminas individualmente e a sua mistura, suportando a hipótese de que os efeitos 
da combinação de anfetaminas são aditivos e que os seus componentes agem de uma forma 
semelhante para promover a morte da célula hepática. 
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Concluindo, os resultados apresentados na presente dissertação permitiram-nos 
concluir que os derivados anfetamínicos atuam aditivamente para produzir efeitos de mistura 
expressivos, mesmo quando as substâncias estão presentes em quantidades que, 
individualmente, não apresentam efeito citotóxico relevante. Esta citotoxicidade foi 
particularmente significativa em hipertermia. Os nossos resultados evidenciaram ainda que os 
efeitos de misturas de anfetaminas podem ser previstos pelo modelo da CA. O modelo de IA, 
por sua vez, mostrou-se ineficaz na antecipação da resposta deste tipo de combinações, 
subestimando a toxicidade inerente à administração concomitante de derivados anfetamínicos. 
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ABSTRACT 
 
3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) is often consumed in a polydrug 
abuse pattern, where the co-occurrence of other substances is common. In addition to several 
drugs that are intentionally taken to achieve certain effects, other substances are ingested as 
part of therapeutic schemes, or inadvertently consumed as contaminants in ecstasy tablets. 
Notwithstanding the great potential of this polydrug abuse to negatively impact on MDMA-
elicited toxicity, joint detrimental effects have received rather little attention from the 
scientific community with most available investigations heavily relying on single-drug 
studies. 
We became very interested in evaluating whether amphetamines in combination were 
able to yield significant effects, distinct from those observed for the individual drugs. We had 
anticipated that potential interactions between amphetamines could occur, since these drugs 
have overlapping mechanistic, metabolic and detoxifying pathways. 
The cytotoxic profiles of MDMA and three other amphetamines, methamphetamine 
(METH), 4-methyltioamphetamine (4-MTA), and d-amphetamine (d-AMP), widely found in 
ecstasy pills in addition to, or instead of MDMA, or intentionally co-ingested to enhance the 
desired MDMA effects, were recorded using the 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) viability assay in a human liver carcinoma cell line 
(HepG2 cells). Then, the combination effects of three different mixtures were predicted on the 
basis of the individual concentration-response curves of all the components, by using two 
mathematical concepts broadly employed in pharmacology, the concentration addition (CA) 
and the independent action (IA) models. Experimental mixture testing confirmed CA 
expectations, revealing a clear additive effect. Of particular interest, we demonstrated that 
there were substantial mixture effects even when each amphetamine was present at levels that 
were individually ineffective, thus emphasizing the risks linked to polydrug abuse. 
Other detrimental factors, such as hyperthermia, bioactivation into reactive species, 
the altered release and metabolism of neurotransmitters, impairment of mitochondrial 
function, apoptosis, and immune responses are thought to play a decisive role in 
amphetamine-induced hepatotoxicity. Accordingly, our research further aimed at confirming 
the applicability of CA in experimental scenarios that more closely mimic the liver in vivo. 
Specifically, we sought (i) to evaluate mixture effects in primary hepatocytes, (ii) to assess the 
Abstract 
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influence of increased temperature on these evaluations and (iii) to investigate the 
significance of the three major human MDMA metabolites in the mixture-related toxicity. 
When the influence of temperature on the applicability of the two predictive models 
was investigated, CA was confirmed to be the most appropriate model in predicting 
amphetamine mixture effects also in hyperthermic conditions (40.5 ºC), in HepG2 cells. 
Remarkably, our data evidenced that, at this temperature, very small variations in the 
concentrations of each drug or the mixture prompted sharp increases in cytotoxic responses, 
which quickly shifted from roughly undetectable to highly detrimental effects. These 
observations emphasize the potential reduction in the ‘safety window’ of these drugs in vivo 
and the consequent increased risks that ecstasy abusers are exposed to. The mechanisms 
underlying the observed toxicity require exhaustive clarification, but our data indicate that 
antioxidative homeostasis disruption (increased production of reactive species and glutathione 
depletion) with consequent mitochondrial impairment and disturbance of the energetic 
cellular status seems to play a critical role in the observed cytotoxic effects. 
Amphetamine mixtures were also analysed in primary rat hepatocytes, a model that is 
metabolically more representative of the hepatocytes in vivo. At a physiological incubation 
temperature (37 °C), the results obtained in primary hepatocytes and HepG2 cells were very 
consistent. Nevertheless, at a higher incubation temperature (40.5 °C), individual and mixture 
toxicities were significantly higher in primary cells. We hypothesized that the expected 
acceleration of the metabolic rate at higher incubation temperatures could explain the 
increased susceptibility of the primary hepatocytes. Additionally, the accuracy of the CA 
prediction was also demonstrated in primary cells at both incubation temperature settings. 
Further studies were undertaken by applying the same experimental design to assess 
the effects of an equipotent mixture (a mixture containing the individual drugs at 
concentrations eliciting similar cytotoxic effects) of MDMA and its three main human 
metabolites 3,4-methylenedioxyamphetamine (MDA), N-methyl-α-methyldopamine (N-Me-
α-MeDA) and α-methyldopamine (α-MeDA), aiming to simulate the mixture produced in vivo 
after MDMA administration. Also in this case, significant additive effects conforming to CA 
predictions were observed, even when the substances were present at low, non-cytotoxic 
concentrations, emphasizing hazard implications of MDMA metabolism to liver cells. 
Ultimately, we searched for the mechanisms underlying the observed amphetamine-
induced cell death. For that purpose, the substances were tested at equieffective 
concentrations (i.e. at concentrations producing 25% of cell death, as measured by the MTT 
assay). After 24 h of exposure to the individual and combined amphetamines at a 
Abstract 
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physiological incubation temperature (37 oC), HepG2 mortality occurred preferentially by 
apoptosis. Lethality was exacerbated with the increase of the incubation period to 48 h. When 
the incubation temperature was raised to 40.5 oC, necrosis became the privileged type of cell 
death, for both incubation times (24 h and 48 h). Consistent with these findings, ATP 
intracellular levels suffered a marked depletion at 40.5 oC, an effect which was not observed 
at 37 oC. Thorough investigations of the triggered apoptotic mechanisms showed a decline in 
BCL-2 and BCL-XL mRNA levels, with concurrent upregulation of BAX, BIM, BAD (only for 
MDMA), PUMA and BID genes. Elevation of Bax, cleaved Bid, Puma, Bak and Bim (EL, S 
and L isoforms) proteins were further confirmed. To the best of our knowledge, Puma, Bim 
and Bak had never been linked with the toxicity induced by amphetamines. Additional results 
showed that time-dependent caspase-3/-7 activation, but not mitochondrial membrane 
potential (∆ψm) disruption, may also mediate amphetamine-induced apoptosis, at least under 
our experimental conditions. The cell dismantling was confirmed by poly (ADP-ribose) 
polymerase (PARP) proteolysis, after 24 h exposures. Overall, for all the parameters 
evaluated, no relevant differences were detected between individual amphetamines and the 
mixture (all tested at equipotent concentrations), strengthening the hypothesis that 
amphetamine combination effects are additive and the entire mixture components act in a 
similar way to promote hepatic cell death. 
In conclusion, the results presented in this thesis demonstrated for the first time that 
the amphetamine derivatives act additively to produce substantial mixture effects, even when 
the substances are present in amounts that individually do not elicit detrimental responses. 
This cytotoxicity was particularly significant in hyperthermia. Additionally, our results 
showed that the effects of mixtures of amphetamines can be predicted with accuracy by the 
CA model. The model of IA, in turn, was ineffective in anticipating mixture effects of such 
combinations, vastly underestimating the inherent toxicity of concomitant administration 
amphetamine derivatives.  
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PART I – GENERAL INTRODUCTION 
 
The current dissertation is divided into three parts. The first part is an introduction in which 
the information available in the scientific literature will be presented. This section will focus 
on the toxicocokinetics, toxicodynamics and toxicological properties of MDMA, as well as on 
the influence of various aspects on the occurrence of adverse reactions to this drug, with 
emphasis on the potential for interactions with other substances, particularly with other 
amphetamines, including methamphetamine (METH), d-amphetamine (d-Amp) and 4-
methylthioamphetamine (4-MTA). Then, a brief description of the methodology currently 
employed for the evaluation of mixture effects will be presented. In the second part, the 
experimental work is presented in the form of the five publications that were originated. 
These include the specific aims of each study, the detailed description of the experimental 
protocols, the attained results, the statistical analysis of the data, and the discussion for each 
study. The third part consists of the general and integrated discussion of the results obtained 
in the five different studies. The final conclusions of this dissertation and the references 
consulted are also presented in the fourth and fifth sections, respectively. 
 
 
1. 3,4-Methylenedioxymethamphetamine (MDMA) 
 
In the late 1980s, the recreational use of synthetic drugs like amphetamines became quite 
popular, attracting the attention of the scientific community, the media, and the society in 
general, and in particular of the young individuals that are the ‘victims’ of this phenomenon. 
Among this type of drugs, also known as designer drugs, one of the most notorious is 3,4-
methylenedioxymethamphetamine (MDMA), commonly known as ecstasy. MDMA abuse is 
associated with all-night dance sessions occurring during the weekend, specifically in the 
techno music scenes designated as raves. The popularity of the drug can be explained by the 
range of effects that its users experience after consumption, which include euphoria, increased 
energy, increased sexual desire, and facilitation of social interaction (Baylen and Rosenberg 
2006). 
Because the number of severe and/or fatal acute intoxications is relatively low when 
the vast number of consumers is considered, one of the most worrisome particularities 
associated with the consumption of this drug is the widespread misconception that it 
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represents little danger for the user. However, designer drugs comprise genuine hazards and 
severe and even fatal adverse reactions can arise as a direct consequence of the drug’s action, 
or associated with the adoption of other risk behaviours, such as driving under the influence 
of stupefacients, promiscuous and unprotected sexual intercourse (linked with sexually-
transmitted diseases), among others (Becona Iglesias et al. 2011; Dunn et al. 2010; Hittner 
and Schachne 2012). These concerns are further reinforced by the ease with which 
recreational drugs, in particular amphetamines, are acquired and even synthesized (Carmo 
2007). 
One additional critical problem associated with ecstasy intake is the enormous 
unpredictability and variability of the possible detrimental effects of this drug, often 
independent of the amount of drug ingested or the circumstances in which it is taken 
(Carvalho et al. 2010). This suggests a strong variation among individual responses to the 
drug and the existence of predisposing factors for the expression of ecstasy toxicity. Also, 
among the plethora of factors that may impact the toxic effects elicited by ecstasy misuse is 
the simultaneous intake of other substances (Carvalho et al. 2012). 
The exposure of ecstasy abusers to other substances relates not only to the intentional 
licit and/or illicit polydrug abuse patterns (aiming at modulating the effects of MDMA), 
which are conventionally associated with this drug, but also to the intake of pharmaceuticals 
during treatment regimens and to the presence of several other substances (stimulants or not) 
that appear as contaminants in ecstasy tablets (Carvalho et al. 2012; Mohamed et al. 2011). 
Contrasting with pharmaceuticals that are comprehensively studied in clinical trials, 
particularly in what concerns the characterization of their pharmacokinetics, amphetamine 
derivatives appearing on the illicit drug market are consumed without any sort of risk 
assessment. In fact, depending on the illegal source of these so-called 'party drugs' the content 
and purity can vary enormously. The analysis of seized tablets disclosed a large disparity in 
the amount of active substance per tablet and also revealed a large number of other substances 
present along with MDMA in ecstasy pills, including excipients (sodium bicarbonate, talc, 
sugars), and other drugs (stimulant or not), such as caffeine, lysergic acid diethylamide 
(LSD), paracetamol and other amphetamines (Carmo 2007; Carvalho et al. 2012; Mohamed et 
al. 2011). The awareness of the influence of these factors on the toxicity of MDMA is crucial 
for the establishment of measures to prevent risk and to undertake appropriate therapeutic 
strategies for the treatment of intoxications. 
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1.1. Historical perspective: from the clinic to the dance scene 
 
MDMA was originally synthesized by Merck in 1912, and later patented in Germany in 1914. 
The objective of its synthesis was the development of an anorectic drug for use as an appetite 
suppressant (Hegadoren et al. 1999a), or as a precursor agent for new therapeutically active 
compounds (Green et al. 2003). MDMA was never used with such purposes but the 
psychiatric community advocated its use as a therapeutic adjunct to enhance the ability of 
introspection and induce feelings of trust and empathy between patients and psychotherapists 
(Green et al. 2003). This property has led to the classification of MDMA as belonging to a 
new pharmacological class, the entactogens (from the Greek contact with the intimate) 
(Nichols et al. 1986). The first report of MDMA psychostimulant activity belongs to 
Alexander Shulgin, who was, consequently, considered the ‘father’ of the drug (Shulgin and 
Nichols 1978).  
MDMA emerged as a drug of abuse in the late 1970s. Despite the controversy 
surrounding the therapeutic potential of MDMA, its use was prohibited due to its widespread 
use and high potential for abuse (Shulgin 1986). Albeit the restrictions on its usage and 
marketing, since the mid 1980s MDMA achieved impressive popularity as a drug of abuse 
worldwide, particularly among the youth. Its stimulant effects, associated with increased 
alertness, induced sense of well-being, feelings of trust and empathy, decreased inhibitions 
and moderate hallucinogenic effects, together with a false perception of safety, are 
responsible for its popularity (Green et al. 2003). 
 
 
1.2. MDMA misuse 
1.2.1. Epidemiology, consumption venues and patterns 
 
Several studies on the consumption patterns of ecstasy have been carried out. The 2011 
Annual Report on the State of Drugs Problem in Europe, reported that amphetamines, 
including ecstasy, are among the most commonly used illicit drugs in Europe, being the 
second most abused illicit substance (after cannabis), in many countries (EMCDDA 2011). 
About 11 million Europeans have tried ecstasy and about 2.5 million have used the drug 
during 2010 (EMCDDA 2011). MDMA abuse is more frequent among young adults, with 
males reporting levels of use much higher than females. Lifetime prevalence of MDMA use 
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among the 15–34 age group ranges from 0.6 % to 12.7 %, with most countries recording 
estimations between 2.1 % and 5.8 % (EMCDDA 2011). The epidemiology and pattern of 
ecstasy abuse have been the object of a number of reviews (Baghianimoghadam et al. 2009; 
Becona Iglesias et al. 2011; Breen et al. 2006; Chen et al. 2011; Degenhardt et al. 2009; 
EMCDDA 2011; Kinner et al. 2012; Krul et al. 2012; Licht et al. 2012; Mendes and Lomba 
2008; Ramtekkar et al. 2011; Scholey et al. 2004; Shamshiri Milani et al. 2011; Soar et al. 
2006; van Ours 2005; Wilkins et al. 2011). A detailed and updated analysis of these data on 
MDMA consumption patterns is presented in Table 1. 
MDMA is usually consumed at rave events or at parties and techno clubs that 
typically take place in overcrowded spaces with high ambient temperatures, loud repetitive 
electronic music and light shows (Klein and Kramer 2004). At these venues, MDMA 
consumers take the drug along with other psychoactive substances in a polydrug abuse pattern 
(Breen et al. 2006; Bruggisser et al. 2010; Chu et al. 2012; Falcon et al. 2010; Kinner et al. 
2012). Among the substances most often co-consumed with MDMA are tobacco, cannabis 
and ethanol (EtOH) (Lora-Tamayo et al. 2004; Scholey et al. 2004). Another common 
consumption pattern involves the use of anxiolytics and sedatives (benzodiazepines and 
opiates) together with stimulants, such as cocaine and, in many cases other amphetamines 
(Williamson et al. 1997; Wu et al. 2009).  
It is believed that many of these factors might impact the toxicity of MDMA, as in 
fact, most fatal intoxications reported in the literature are associated with MDMA abuse in 
these settings (CDC 2010; Cole and Sumnall 2003; Vanden Eede et al. 2012). 
 
 
1.2.2. Ecstasy trading: presentation forms and routes of 
administration 
 
Commonly, MDMA is marketed for oral use as tablets of diverse colours, shapes and sizes, 
decorated with a wide assortment of logos (Green et al. 2003). 
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Table 1. Patterns of recreational consumption of MDMA. 
 
Year Location Population n Age (years) Individuals consuming MDMA Number of pills Reference 
2011 On a cruise ship on 
the Baltic Sea 
Swedish clubbers 
attending a 40h 
electronic music dance 
event  
401 
(when boarding the 
ship, all passengers 
were required to pass 
by police officers and 
drug detecting dogs) 
18-45 16.2 % have tried 
0.3% uses a couple of times/month 
0.5% in the last 48h 
1.8 % when clubbing  
20.0% were polydrug users: the most commonly used drugs 
were amphetamines, followed by ecstasy/MDMA, cannabis, 
and cocaine 
 (Kinner et al. 2012) 
2006-2011 Victoria, Australia Drivers tested for 
presence of drugs 
853  17% used MDMA alone and 3.9% combined with METH 
and ∆(9)-tetrahydrocannabinol (that were the most common 
drugs with 77% and 42% prevalence, respectively) 
 (Chu et al. 2012) 
2010 Los Angeles 
County, USA 
Emergency department 
(ED) visits, all linked to 
a New Year's Eve event 
attended by 
approximately 45,000 
persons 
30 16-34 18 patients visited EDs for MDMA-related illness within 12 
h of the rave. 9 were female. In addition to using MDMA, 
13 also had used alcohol or other drugs, including marijuana 
and prescription medications. For the 6 patients (3 of whom 
were aged <21 years) with available serum alcohol levels, 
the mean blood alcohol concentration was 0.31 g/dL (range: 
0.19 g/dL-0.33 g/dL) 
1-6 tablets 
(MDMA and 
caffeine in nearly 
equal proportions, 
and a minor 
amount of N-
methylphthalimide) 
(CDC 2010) 
2010 Galicia (Santiago de 
Compostela, Lugo, 
A Coruña, Ferrol, 
Pontevedra, Ourense 
and Vigo) 
Young people 
(49.7% males) 
1214 15-25 33.4% have tried MDMA 
22.3% in the last year 
 (Becona Iglesias et al. 
2011) 
2010 Tehran (Iran) Iranian high school 
female students 
2350  2.3%  
(polydrug use linked with ecstasy misuse p< 0.001) 
 (Shamshiri Milani et 
al. 2011) 
2010 Ibiza (Spain) Mothers after giving 
birth  (a 3-cm-long 
proximal segment of 
maternal hair 
corresponding to the last 
trimester of pregnancy 
was analyzed) 
107  0.9 %   (Friguls et al. 2012) 
2010 Web-based survey 
(country of 
residence: 84% UK, 
4% Ireland, 8% 
Other in Europe, 5% 
North America, 2% 
Australia) 
Mephedrone users 
(individuals had taken 
mephedrone on at least 
one occasion in the past) 
1506 10-73 87% have tried 
11% typically taken with mephedrone 
 (Carhart-Harris et al. 
2011) 
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Table 1. Continued. 
 
Year Location Population n Age  (years) Individuals consuming MDMA 
Number 
of pills Reference 
2009 France Student population seen 
during the visit at the 
University medical 
facility 
808 20 (mean 
age) 
4% (at least once)  (Morvan et al. 2009) 
2007-2009 Murcia, Spain Pregnant women at 12th 
week gestation who 
decided voluntarily to 
interrupt their pregnancy 
142  1.4% were positive for MDMA 
5.6% cases of polydrug abuse 
 (Falcon et al. 2010) 
1997-2009 Swiss Exposure/abuse cases 
with psychostimulants 
reported to the Swiss 
Toxicological 
Information Centre 
433 11-62 Approximately 56.7% of MDMA exposures with a 
known medical outcome exhibited a polydrug abuse 
pattern. 
 (Bruggisser et al. 2010) 
2008 Europe Night club attenders 1341 16-35 28.7% (at least once in a lifetime)  (Bellis et al. 2008) 
2008 UK Drug abusers 80 20-22 86.3% (at least once in a lifetime) 1-6 (Cole et al. 2008) 
2008 Portugal MDMA abusers 223 13-23 53.8% occasional consumption (0-1times/month); 
6.7% polydrug abuse. 
34.5% regular consumption (> than once a month); 
35% polydrug abuse. 
11.7% excessive consumption (> than once a week); 
58.3% polydrug abuse. 
 (Mendes and Lomba 2008) 
2008 USA High school students  
(9th–12th grade) 
13917  4.9-7.4% (in the preceding month of the study).  (Pisetsky et al. 2008) 
2008 New Zealand General population 1902 (year 2006) 
5475 (year 1998) 
15-45 1.5% in 1998 
3.9% in 2006 
 (Wilkins and Sweetsur 
2008) 
2007 Switzerland Rave party attenders 302 16-46 40.4% (at least once in a lifetime) 
14.7% (1 to 3 times on the previous month of the 
study) 
 (Chinet et al. 2007) 
2007 Germany Disqualified drivers 247 18-29 14.6% had only consumed MDMA 
27% polydrug ingestion of designer drugs 
 (Dresen et al. 2007) 
2007 UK 
 
Drug users 40 18-45 85% at least once in a lifetime 1-4 (Goudie et al. 2007) 
2007 New York (USA) Gay and bisexual men 450 18-67 74.7%  (Halkitis et al. 2007) 
2007 USA MDMA users 48 18-35 97.9% (in the previous year of the study)  (Medina and Shear 2007) 
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Table 1. Continued. 
 
Year Location Population n Age  (years) Individuals consuming MDMA 
Number of 
pills Reference 
2007 Taiwan MDMA users 200 14-19 62.5% used 20 times 
29.5% polyconsumers 
 (Yen et al. 2007) 
2006 Taipei (Taiwan) Teenagers 2126 12-18 2-14.5%(at least once in a lifetime)  (Chou et al. 2006) 
2006 Australia MDMA users 216 19-39 28.2% combine MDMA with pharmaceuticals 2 (Copeland et al. 2006) 
2006 China Drug users   5.37%  (Fang et al. 2006) 
2006 New York (USA) Gay and bisexual man  
(GHB consumers) 
131 18-40+ 56.5%  (Halkitis et al. 2007) 
2006 Colorado (USA) Young people in polydrug 
abuse treatment 
782 10-32 34% (at least once in a lifetime)  (Hopfer et al. 2006) 
2006 New York (USA) Women attending night clubs 1104 18-49 44% (at least once in a lifetime)  (Parsons et al. 2006) 
2006 Italy Rave party attenders 2015 20-40 17-27.1% (at least once in a lifetime) 
9.5-16.2% (in the last year) 
4.4%-10% (in the last month) 
 (Pavarin 2006) 
2006 USA University students 1206  9% (at least once in a lifetime)  (Wish et al. 2006) 
2006 Texas (USA) Low income users 696 18-31 15.2% at least once in a lifetime; of these, 53% in 
the last year; 20% in the last 20 days) 
0,5-4 (Wu et al. 2006b) 
2006 New York (USA) Women attending to night 
clubs 
1104 18-49 44% (at least once in a lifetime)  (Parsons et al. 2006) 
2006 USA Designer drug users 19084 16-23 13% (at least once in a lifetime) 
6% (in the last year) 
 (Wu et al. 2006a) 
2005 Montreal 
(Canada) 
Rave party attenders 186 17-47 50% (at least once in a lifetime; 92.3% of these 
uses MDMA in combination with other drugs) 
1 (Barrett et al. 2005) 
2005 New York (USA) Gay and bisexual young man 569 17-28 47.9% (at least once in a lifetime) 
24.3% (chronic use; of these. 82.8% used at least 
once and 13.3% used more than 5 times in the last 
month) 
 (Clatts et al. 2005) 
2005 USA Gay and bisexual hispanic man 172  14% (in the last 6 months)  (Fernandez et al. 2005) 
2005 New York (USA) 6th, 7th and 8th grade students 23780  2.3% (at least once in a lifetime)  (Goldsamt et al. 2005) 
2005 New York (USA) Drug users 715 17-64 23.4% (at least once in a lifetime)  
11.9% (in the last 6 months) 
 (Ompad et al. 2005) 
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Table 1. Continued. 
 
Year Location Population n Age (years) Individuals consuming MDMA Number of pills Reference 
2004 USA Gay and bisexual men 150 31-50 14% (in the last 3 months)  (Crosby and Diclemente 
2004) 
2004 Ibiza (Spain) People arrested for 
drug possession 
70  77% (had only MDMA in urine) 
20% (MDMA + another designer 
drug) 
 (Lora-Tamayo et al. 2004) 
2004  Internet users 763 21-35 37% (at least once in a lifetime) 
39% beginners (1-9 times) 
48% moderate use (10-99 times) 
13% heavy use (more than 100 times) 
Beginners: 1-2 pills 
3% moderate users: > 4 pills 
14% heavy users: >4 pills 
(Scholey et al. 2004) 
2004 Denver, Colorado 
(USA) 
Homeless 186 16-25 25% (in the last 9 months)  (Van Leeuwen et al. 2004) 
2003 Australia Women 9512 22-27 15% (at least once in a lifetime)  (Turner et al. 2003) 
2003 Chicago (USA) Adult population 627 18-40 49% (at least once in a lifetime)  (Fendrich et al. 2003) 
2002 Montreal (Canada) Rave party attenders 210 16-32 65.2% (at least once in a lifetime)  (Gross et al. 2002) 
2001/2002 USA Asian American 
adolescents and young 
adults 
996 
adolescents 
1108 adults 
12-25 3.7 % (Ages 12–17) 
12.8% (Ages 18–25) 
 (Wu et al. 2011) 
2001/2002 USA Adult participants in 
the National 
Epidemiologic Survey 
on Alcohol and Related 
Conditions (NESARC) 
43093  1.6% reported lifetime ecstasy use 
(37% ecstasy-polydrug users; 29% 
ecstasy-marijuana-cocaine-moderate 
amphetamines users; 34% ecstasy-
marijuana-low prescription-type drugs 
users) 
 (Wu et al. 2009) 
2001 UK and Italy Young people 768 14-28 15% (less than 20 times) 
15.5% (more than 20 times) 
 (Parrott et al. 2001) 
2001 Edinburgh Drug users 122 16-47 80% ecstasy or amphetamine (of these 
35% take MDMA on a weekly basis) 
 (Riley et al. 2001) 
2001 UK Drug users 1151 18-29 96% (at least once in a lifetime) 
In the last year, 12% has used 2-3 
times/week; and 22% has used once a 
week 
55% consumed 2 or less  
25% consumed 4 or more 
(Winstock et al. 2001a) 
1999 South England Drug and alcohol users 100 16-21 22% (in the last 90 days) 
38% (at least once in a lifetime) 
 (Boys et al. 1999) 
1999 Australia MDMA users 329 15-46 89% (at least once a month) 1 (Topp et al. 1999) 
1997/1999 USA University students 14000 21-24 2.8% in 1997 and 4.7% in 1999  (Strote et al. 2002) 
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Table 1. Continued. 
 
Year Location Population n Age (years) Individuals consuming MDMA Number of pills Reference 
1998 Italy MDMA users 150 19-28 50% polydrug abusers 1 or less (Schifano et al. 1998) 
1997 West Australia Rave attenders 83 13-48 76% (at least once in a lifetime)  
41% (polydrug abuse) 
31.3% (on the last rave party) 
 (Lenton et al. 1997) 
(Boys et al. 1997) 
1997 UK Drug users 158 14-59 52% used during last year 
70% (on last month) 
2 (Williamson et al. 1997) 
1996 UK High School students 7722 15-16 7.3% of girls (at least once in a lifetime) 
9.2% of boys (at least once in a lifetime) 
 (Miller and Plant 1996) 
1996 UK University students 
(second year) 
3075 18-65 13% (at least once in a lifetime) 
5.2% (more than once or twice) 
2.7% (at least once a week) 
 (Webb et al. 1996) 
1995 Glasgow (UK) Rave party attenders 135 14-44 95% (at least once in raves)  (Forsyth 1995) 
1992 Sydney 
(Australia) 
MDMA users 100 16-48 68% (> 3 times) 
33% use drugs once a month or per trimester) 
18% use in special occasions 
9% less than 1 
71% used 1 
13% used 2 
7% used more than 2 
(Solowij et al. 1992) 
1986/1990 USA University students 742 (in 1986) 
1264 (in 1990) 
 15.5% (at least one time in 1986) 
24.3% (at least one time in 1990) 
 (Cuomo et al. 1994) 
1987 USA University students 369  39% at least once last year  (Peroutka 1987) 
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The most common names by which it is recognized in the market of illicit drugs are: 
Ecstasy, XTC, E, X, Adam, Lover's Speed and love drug. Ecstasy is now considerably cheaper 
than it was in the 1990s, when it originally became widely available. While there are some 
reports of tablets being sold for as little as EUR 1, most countries report mean retail prices in 
the range of EUR 4 to EUR 9 per tablet (http:// www.emcdda.europa.eu/publications/annual-
report/2011). 
Different administration routes are experienced to modulate the attained effects 
(Mechan et al. 2006; Pontes 2009; Solowij et al. 1992). Although MDMA oral administration 
is the most common (as pills, capsules or powder dissolved in water), nasal (snorting by 
inhalation of powder obtained by crushing tablets) (Gahlinger 2004), rectal (suppositories, 
known as shafting or shelving) and intravenous administrations (unusual) have also been 
described (Ramsey et al. 2001; Solowij et al. 1992). 
 
 
1.2.3. Ecstasy tablets – purity concerns 
 
Since MDMA is a drug clandestinely synthesized, dose and purity of the pills vary 
considerably, as can be seen in Table 2. Generally, the tablets contain between 80 mg and 150 
mg of MDMA, but higher dosages have also been found (up to 250 mg per tablet) (Green et 
al. 2003; Holden and Jackson 1996). The average MDMA content of ecstasy tablets tested in 
Europe in 2009 was between 3 and 108 mg, but the availability of high-dose ecstasy tablets 
containing higher amounts of MDMA was reported by several countries in 2011 on the 
Annual Report on the State of Drugs Problem (http:// 
www.emcdda.europa.eu/publications/annual-report/2011). Since ecstasy is a term often used 
to describe other chemically and pharmacologically related compounds, MDMA consumers 
may, inadvertently or not, ingest substances other than MDMA, which are marketed under the 
same designation. Additionally, other substances may be present in the tablets, including 
psychoactive analogues of amphetamines (present in a high percentage of ecstasy tablets), 
caffeine, ephedrine/pseudoephedrine, dextromethorphan (DXM), ketamine, acetaminophen, 
and atropine salicylates (Baggott et al. 2000; Carvalho et al. 2012; Mohamed et al. 2011; 
Parrott 2004a). These drugs are included in ecstasy tablets with the aim of alleviating the 
unpleasant ‘come-down’ effects of MDMA, such as anhedonia, dysphoria, and depression or 
to extend the duration of the ‘high’ (Mohamed et al. 2011).  
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Table 2. Impurity profile and MDMA content of pills sold as ecstasy. 
 
Study Year Local n Origin MDMA dose (mg/tablet) With MDMA Without MDMA 
Other substances in ecstasy tablets with 
MDMA 
(Morefield et al. 
2011) 
2011 Adelaide, 
Australia. 
28 
different 
batches 
Participants donated 
ecstasy pills for chemical 
analysis 
0-124 46.4% MDMA only 
17.9% MDMA + MDEA 
14.3% MDMA + METH 
 MDEA, ketamine, caffeine, 
MDA, pseudoephedrine 
(Macias and 
Furton 2011) 
2011 Florida, 
USA 
3 
different 
batches 
(#1, #2 
and #3) 
Three batches of seized 
ecstasy were provided by 
the Florida Highway Patrol 
Contraband Interdiction 
Program Division 
 25%, 17% and 8% MDMA 
for batch #1, #2 and #3, 
respectively 
 Batch #1 also presented piperonal, MDP-2-
POH, and MDP-2-P; Batch #2 also presented 
isosafrole, piperonal, and MDP-2-POH; Batch 
#3 presented 10% caffeine and also METH, 
isosafrole, MDP-2-POH, MDP-2-P, MDEA 
(Wood et al. 
2011) 
2011 London, 
UK 
101 Ecstasy tablets seized from 
individuals attending 
nightclubs 
58.7±22.9, with 
a range of 20-
131 mg per 
tablet. 
The majority (96.0%) of 
tablets contained less than 
100 mg MDMA per tablet. 
There appeared to be a 
bimodal distribution of 
MDMA content at 
approximately 20-40 mg per 
tablet and 60-80 mg per 
tablet. 
  
(Brunt et al. 
2012) 
2000-2010 Netherlands 5,786 Drug users that utilized 
voluntarily and 
anonymously the drug 
testing facilities of DIMS 
2.0–218.0 69.9% MDMA only 
2.5% MDMA+MDEA 
2% MDMA+mCPP 
1.2% MDMA+PMMA 
1.1% MDMA+AMP 
0.7% MDMA+MDA 
<0.1% MDMA+2-CB 
12.2% mCPP 
1.8% MDA 
1.6% BZP 
1.5% AMP 
1.5% mephedrone 
1.3% 2 C-B 
0.6% MDEA 
Metoclopramide, BZP, mephedrone, caffeine, 
p-fluoroamphetamine 
(Shetab 
Boushehri et al. 
2009) 
2009 Tehran, 
Iran 
13 The most abundant ecstasy 
type pills 
23.9-124.5mg     
(Mitrevski et al. 
2011) 
2006-2009 Macedonia 
and 
Australia 
24 Nine tablets were seized in 
Macedonia (2006–2007) 
and provided by 
Macedonian Police, and 15 
tablets were seized in 
Australia (2009) and 
provided by Australian 
Federal Police 
   Macedonian samples were rich in N-formyl-
MDMA and N-acetyl-MDMA and poor in 
3,4-MD-propane and 3,4-MDAcPh as 
compared to Australian samples. 2-
(Dimethylamino)-2-methyl-3-(3,4-
methylenedioxyphenyl)-propanenitrile has 
been detected only in samples from 
Macedonia. Presence of 3,4-
methylenedioxyphenyl derivative and 
apiperonyl methyl ether have been detected 
only in samples from Australia. 
AMP, amphetamine. BZP, benzylpiperazine. 2-CB, 4-bromo-2,5-dimethoxyphenethylamine. mCPP, meta-chlorophenylpiperazine. DIMS, Drug Information and Monitoring System. DOB, 2,5,-dimethoxy-4-bromoamphetamine. DXM, dextromethorphan. N-formyl-MDMA, 
N-formyl-3,4-methylenedioxymethamphetamine. LSD, lysergic acid diethylamide. MBDB, N-methyl-1,3-benzodioxolylbutanamine. MDA, 3,4-methylenedioxyamphetamine. 3,4-MDAcPh, 3,4-methylenedioxyacetophenone. MDB, 3,4-methylenedioxy-N-methylbenzylamine. 
MDEA, 3,4-methylenedioxy-N-ethylamphetamine. 3,4-MD propane, 3,4-methylenedioxyphenylpropane. MDP, 3,4-methylenedioxyphenyl-2-propanol. MDP-2-P, 3,4-methylenedioxyphenyl-2-propanone. MDP-2-POH, 1-(3,4-methylenedioxyphenyl)-2-propanol. METH, 
methamphetamine. MTA, 4-methylthioamphetamine. PCP, phencyclidine. PMA, para-methoxyamphetamine. PMMA, p-methoxymethamphetamine. 
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Table 2. Continued. 
Study Year Local n Origin MDMA dose, 
mg/tablet With MDMA Without MDMA 
Other substances in ecstasy tablets with 
MDMA 
(Vogels et al. 
2009) 
1993-2008 Netherlands 33,006 Ecstasy tablets that were 
handed in by numerous 
individual (potential) 
substance users 
 The number of tablets 
containing only MDMA was 
lowest around 1997, reaching 
the highest levels in 2000 and 
2004. From 1998 to 2008, the 
number of high-dose tablets 
(> or = 106 mg MDMA) 
gradually increased. 
Many tablets 
contained other 
substances in 
addition to or 
instead of MDMA 
(e.g. MDA, MDEA, 
MBDB, AMP and 
caffeine). 
After 2004, the purity of ecstasy tablets 
decreased again, caused mainly by a growing 
proportion of tablets containing meta-
chlorophenylpiperazine (mCPP). 
(Cheng et al. 
2006) 
2006 Hong Kong 89 Seizure 43 (average)   Ketamine, caffeine, salicylates, 
acetaminophen, chlorpheniramine, 
metronidazole, by-products of synthesis. 
(Tanner-Smith 
2006) 
2006 USA 1214 Submitted anonymously  39% only MDMA 46% MDA, DXM, caffeine, pseudoephedrine, 4-
MTA, low concentrations of ketamine, DOB, 
heroin, PCP, PMA. 
(Teng et al. 
2006) 
2002-2005 Taiwan 181 Seizure 16-193 66-71% only MDMA (the 
content of MDMA in 
MDMA only tablets varied 
from 89 to 133 mg/tablet) 
 There was a decreasing trend in MDMA 
content in these tablets over time. Other 
components commonly found besides MDMA 
included caffeine (18%), METH (7%), 
MDEA (7%) and AMP (4%). MDA, 
ketamine, ephedrine, diazepam, 
chlorzoxazone and nicotinamide were also 
detected. During the study period, the number 
of other drugs found as well as the 
combinations of different drugs detected in 
these tablets increased. 
(Mitrevski and 
Zdravkovski 
2005) 
2000-2004 Skopje, 
Macedonia 
24,229 Seized by Macedonian 
police 
 4880 tablets or 20% tablets 
contained MDMA as active 
ingredient 
19,287 tablets or 
79% contained d-
AMP as active 
ingredient 
METH, MDEA, MDA and MBDB 
(Drugs 2004) 2004 New 
Zealand 
8604 Seizure 30.2-172.4 Most of it  Ketamine, cocaine 
 
 
AMP, amphetamine. BZP, benzylpiperazine. 2-CB, 4-bromo-2,5-dimethoxyphenethylamine. mCPP, meta-chlorophenylpiperazine. DIMS, Drug Information and Monitoring System. DOB, 2,5,-dimethoxy-4-bromoamphetamine. DXM, dextromethorphan. N-formyl-MDMA, 
N-formyl-3,4-methylenedioxymethamphetamine. LSD, lysergic acid diethylamide. MBDB, N-methyl-1,3-benzodioxolylbutanamine. MDA, 3,4-methylenedioxyamphetamine. 3,4-MDAcPh, 3,4-methylenedioxyacetophenone. MDB, 3,4-methylenedioxy-N-methylbenzylamine. 
MDEA, 3,4-methylenedioxy-N-ethylamphetamine. 3,4-MD propane, 3,4-methylenedioxyphenylpropane. MDP, 3,4-methylenedioxyphenyl-2-propanol. MDP-2-P, 3,4-methylenedioxyphenyl-2-propanone. MDP-2-POH, 1-(3,4-methylenedioxyphenyl)-2-propanol. METH, 
methamphetamine. MTA, 4-methylthioamphetamine. PCP, phencyclidine. PMA, para-methoxyamphetamine. PMMA, p-methoxymethamphetamine. 
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Table 2. Continued. 
Study Year Local n Origin MDMA dose, 
mg/tablet With MDMA Without MDMA 
Other substances in ecstasy tablets with 
MDMA 
(Cheng et al. 
2003) 
2000-2001 Hong Kong 212 Seizure  MDMA tablets have made up 
98 and 71% of the total 
ecstasy tablets 
4-MTA, MDA and 
AMP 
Ketamine (present in 12% of tablets in 2000 
and 42% in 2001). MDP-2-P, MDP, MDB, 
piperonal and N-formyl-MDMA were the 
most common impurities detected in MDMA 
tablets seized 
(Cole et al. 
2002) 
2002 UK 80 Seizure Ranged from 20 
to 109 mg and 
the mean was in 
the 60-69 mg 
range 
100%  MDEA 
(Gimeno et al. 
2002) 
2002 France 10 Seizure  33.7±3.1%  Benzaldehyde, 1,3-benzodioxole, 3,4-
methylenedioxytoluene, AMP, METH, 1,2-
dimethyl-3-phenyl-aziridine, safrole, 3,4-
(Methylenedioxy)-phenylpropane, piperonal, 
p-Methoxymethamphetamine, MDA, N-
Methyl-1-[1,2-dimethoxy-4-(2-
aminopropyl)]benzene, among others 
(Spruit 2001) 2001 Netherlands 10,000 Seizure  48-60% only MDMA 
7-13% MDMA+X 
2-7% MDA ou 
MDEA 
MDA, MDEA, AMP 
(Baggott et al. 
2000) 
2000 USA 107 Submitted for analysis of 
tablets 
 63% MDMA, MDA or 
MDEA 
29% 21% contain DXM; Caffeine, ephedrine, 
pseudoephedrine, salicylates 
(Sherlock et al. 
1999) 
1999 UK 25 Amnesty  19-140 64% MDEA or MDMA 24% Ketamine, caffeine, 4-MTA, AMP 
paracetamol 
(Schifano et al. 
1998) 
1998 Italy 20,000 Seizure 100-150 85-90% MDA, MDEA, 
MBDB 
 
(Giroud et al. 
1997) 
1997 Switzerland      MDA, MDEA, MBDB, 2-CB, caffeine, 
ephedrine, polyols, LSD, testosterone, 
chloroquine, vasodilators 
(Milroy et al. 
1996) 
1996 UK 13  0,21-12 77% MDEA, MDMA, MDA, 
or mixtures 
  
(Renfroe 1986) 1986 USA 101   58 % only MDMA 
26% MDMA+X 
16% MDA 
 
AMP, amphetamine. BZP, benzylpiperazine. 2-CB, 4-bromo-2,5-dimethoxyphenethylamine. mCPP, meta-chlorophenylpiperazine. DIMS, Drug Information and Monitoring System. DOB, 2,5,-dimethoxy-4-bromoamphetamine. DXM, dextromethorphan. N-formyl-MDMA, 
N-formyl-3,4-methylenedioxymethamphetamine. LSD, lysergic acid diethylamide. MBDB, N-methyl-1,3-benzodioxolylbutanamine. MDA, 3,4-methylenedioxyamphetamine. 3,4-MDAcPh, 3,4-methylenedioxyacetophenone. MDB, 3,4-methylenedioxy-N-methylbenzylamine. 
MDEA, 3,4-methylenedioxy-N-ethylamphetamine. 3,4-MD propane, 3,4-methylenedioxyphenylpropane. MDP, 3,4-methylenedioxyphenyl-2-propanol. MDP-2-P, 3,4-methylenedioxyphenyl-2-propanone. MDP-2-POH, 1-(3,4-methylenedioxyphenyl)-2-propanol. METH, 
methamphetamine. MTA, 4-methylthioamphetamine. PCP, phencyclidine. PMA, para-methoxyamphetamine. PMMA, p-methoxymethamphetamine.  
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1.3. Pharmacokinetics 
1.3.1. Absorption, distribution and excretion 
 
The half-life of MDMA varies between 6 and 12 h and excretion is mainly hepatic and renal 
in the first 24 h after intake (delaTorre et al. 2004a; delaTorre et al. 2004b; Fallon et al. 1999; 
Hegadoren et al. 1999; Mas et al. 1999; Ramcharan et al. 1998). Despite being extensively 
metabolised by the liver, a significant fraction of the drug is generally excreted without 
biotransformation (delaTorre et al. 2004a). Since amphetamine derivatives are compounds 
with alkaline characteristics (pKa~ 9.9), and with relatively low molecular weight, these 
drugs readily cross cell membranes and lipidic layers, reaching the tissues and biological 
fluids with pH more acidic than blood, including saliva and sweat (delaTorre et al. 2004a). 
MDMA may be additionally detected in vitreous humor, hair and nails (delaTorre et al. 
2004a; Samyn et al. 2002). Due to its inherent properties (e.g. significant volume of 
distribution), MDMA is liable to post-mortem redistribution (De Letter et al. 2010). Post-
mortem studies revealed that MDMA accumulates in many tissues and organs where it 
reaches concentrations much higher than in the plasma: for example, it may be up to 18 times 
higher in the liver (De Letter et al. 2006; deLetter et al. 2004) and 30 times higher in the brain 
(Garcia-Repetto et al. 2003). Furthermore, literature suggests that the dose of MDMA 
ingested and the plasma concentrations achieved in fatal poisoning are not necessarily 
superior to those found in survival cases (Milroy 2011). 
MDMA pharmacokinetics also appear to be stereoselective (Fallon et al. 1999; 
Fitzgerald et al. 1990; Lanz et al. 1997; Lin et al. 1997; Meyer et al. 2002a; Moore et al. 1996; 
Pizarro et al. 2002; Pizarro et al. 2004; Ramcharan et al. 1998) 
 
 
1.3.2. Metabolism 
 
The metabolism of MDMA in humans is well documented (Carvalho et al. 2012; delaTorre et 
al. 2004a; delaTorre et al. 2004b; Kraemer and Maurer 2002). Due to the presence of the 
methylenedioxy ring, MDMA undergoes extensive metabolism, greater than other 
amphetamine-type compounds (delaTorre et al. 2004a). About 80% of MDMA is metabolized 
in the liver (delaTorre et al. 2004a). Foltz and Lim (1988; 1989) characterized the metabolism 
of MDMA and identified the four major metabolic pathways for MDMA in humans and rats, 
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namely, (i) N-demethylation, (ii) O-dealkylation (demethylenation) (iii) deamination and (iv) 
conjugation by methylation, glucuronidation or sulfonation. Figure 1 is a schematic 
representation of the metabolic pathways of MDMA.  
The metabolism of MDMA occurs via two main pathways: (i) methylenedioxy ring 
opening (the major metabolic pathway), followed by methylation of the resulting hydroxyl 
groups and/or conjugation with glucuronic acid or with the sulfonate anion (delaTorre et al. 
2004a; delaTorre et al. 2000a; Lim and Foltz 1989; Maurer et al. 2000) and (ii) the 
dealkylation of the amine group with formation of 3,4-methylenedioxyamphetamine (MDA) 
that retains biological activity (Johnson et al. 1988). The subsequent oxidation and 
deamination of the side chain leads to the formation of phenylketones that are oxidized to 
benzoic acid derivatives (Maurer 1996), which are then conjugated with glycine and excreted 
as hippuric acid derivatives (hippurates) (delaTorre et al. 2004b). 
The opening of the methylenedioxy ring of MDMA and MDA originates two catechol 
metabolites, N-methyl-α-methyldopamine (N-Me-α-MeDA) and α-methyldopamine (α-
MeDA), respectively. Both are subsequently methylated by the enzyme catechol-o-
methyltransferase (COMT). These metabolites are mostly present in plasma and urine as 
conjugates with glucuronide or with sulfonate anions (delaTorre et al. 2000a; delaTorre et al. 
2000b; Kraemer and Maurer 2002; Maurer 1996). The presence of the catechol group confers 
high reactivity to these metabolites, which easily oxidize, giving the corresponding o-quinone 
(Cho et al. 1999). The oxidation of quinones may also cause the formation of aminochromes 
(Bindoli et al. 1992), whose subsequent oxidation leads to the production of polymers of 
melanin type (Zhang and Dryhurst 1994). The cycles of reduction-oxidation (redox) 
associated with this metabolic conversion result in the formation of reactive oxygen (ROS) 
and nitrogen (RNS) species, which similarly to what occurs with quinones, might attack 
relevant intracellular nucleophilic groups, such as cysteine, reduced glutathione (GSH) and 
protein sulfhydryl groups, resulting in significant modification of macromolecules, including 
proteins, lipids and deoxyribonucleic acid (DNA) (Bindoli et al. 1992; Bolton et al. 2000). 
These quinones combine with one molecule of GSH to form adducts, which can 
further combine with a new molecule of GSH in a process that is also accompanied by the 
formation of ROS and RNS (Hiramatsu et al. 1990; Monks et al. 2004). The conjugation of 
catechols with glutathione has also been demonstrated, with consequent formation of toxic 
adducts (e.g. 5-(glutathion-S-yl)-α-MeDA) (Bai et al. 1999; Easton et al. 2003; Jones et al. 
2005; Miller et al. 1997).  
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Figure 1. MDMA metabolic pathways. I, N-demethylation; II, demethylenation; III, oxidative 
deamination; IV, o-methylation; MDMA, 3,4-methylenedioxymethamphetamine; MDA, 3,4-
methylenedioxyamphetamine; N-Me-α-MeDA or HHMA, N-methyl-α-methyldopamine or 3,4-
dihydroxymethamphetamine; α-MeDA, α-methyldopamine; HMMA, 4-hydroxy-3-
methoxymethamphetamine; HMA, 4-hydroxy-3-methoxyamphetamine. Adapted from Carvalho (2012). 
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The demethylenation of MDMA displays a two-step Michaelis-Menten kinetics, 
which comprises a high affinity component and another one of low affinity (Kreth et al. 
2000). The isoform 2D6 of cytochrome P450 (CYP450) catalyzes the low affinity component, 
while the high affinity component is mostly catalyzed by CYP1A2 and to a lesser extent by 
CYP2B6 and CYP3A4 (Kreth et al. 2000; Maurer et al. 2000; Tucker et al. 1994). The 
contribution of CYP2D6 to MDMA demethylenation was assessed in vitro and corresponds to 
approximately 50% in human liver and in microsomes expressing CYP2D6 (Ramamoorthy et 
al. 2002; Tucker et al. 1994), and to approximately 30% when assessed in vivo in humans 
(Segura et al. 2005). 
The velocity of the N-demethylation is approximately one order of magnitude lower 
than the demethylenation and is characterized by monophasic kinetics. In humans, it is 
catalyzed by the enzyme CYP2B6 with contribution of CYP2D6, CYP1A2 and CYP3A4,and 
in the rat by CYP2D1 and CYP1A2 (Kreth et al. 2000; Maurer et al. 2000). 
Since MDMA is predominantly metabolized by the CYP2D6 isoform of the CYP450 
enzyme complex (Ingelman-Sundberg et al. 1999), it is vulnerable to 
pharmacokinetic/toxicokinetic interactions with other substances (pharmaceuticals, drugs of 
abuse, food, etc.) that share or interfere with this metabolic pathway (Oesterheld et al. 2004). 
MDMA presents linear kinetics at low doses (delaTorre et al. 2004a; Mas et al. 1999) 
but non-linear pharmacokinetics at higher doses (similar to those commonly used for 
recreation) (delaTorre et al. 2004a; delaTorre et al. 2004b). This might be explained by the 
potential saturation of the metabolic pathways and by the interaction of some metabolites with 
the metabolic enzymes (delaTorre et al. 2004a). At higher concentrations, MDMA itself has 
been shown to be a CYP2D6 inhibitor through mechanisms that include a competitive 
interaction and/or the formation of a complex between the enzyme and the metabolites 
(Delaforge et al. 1999; delaTorre et al. 2000a; Heydari et al. 2004; Wu et al. 1997). This 
inhibition may occur within one hour after ingestion of MDMA, and the basal enzyme 
activity may only be restored after a period of at least 10 days (Yang et al. 2006). For this 
reason, repeated MDMA administration has the ability to transform the metabolizing 
phenotype of its users from an extensive metabolizer (expressing a fully functional enzyme) 
phenotype into a poor metabolizer (expressing non-functional or low levels of the enzymes) 
phenotype, regardless of the genotype of the individual. 
 
 
General introduction 
18 
 
1.4. Pharmacology 
 
As mentioned previously, MDMA causes an euphoric state, including an increased sense of 
energy, emotional openness, increased capacity for introspection, empathy, intense perception 
of sounds and colours, reduced negative thoughts and reduced inhibitions (Davison and 
Parrott 1997; delaTorre et al. 2004a; Hegadoren et al. 1999; Liechti and Vollenweider 2000a; 
Morgan 2000; Parrott and Stuart 1997). In addition to the desired effects, MDMA prompts 
acute sympathomimetic reactions, e.g., increased heart rate and blood pressure, and transient 
anxiety (Greer and Strassman 1985; Grinspoon and Bakalar 1986). The mechanisms involved 
in the onset of these effects will be briefly discussed. 
 
 
1.4.1. Effects on release, transport and neurotransmitter receptors of 
monoamines 
 
MDMA induces the release of sympathetic neurotransmitters from the vesicles in nerve 
terminals and in the adrenal medulla, specifically serotonin (5-HT) and the catecholamines 
noradrenaline (NA), adrenaline, and dopamine (DA). These neurotransmitters activate their 
respective receptors, resulting in the exacerbation of sympathetic stimulation (Carvalho et al. 
2012). 
The ability of MDMA to induce 5-HT release is greater than that recorded for the 
release of DA and NA in cells expressing the respective transporters (Verrico et al. 2005). 
MDMA selectivity for affecting 5-HT release was demonstrated both in vivo (Mechan et al. 
2002; Sabol and Seiden 1998; Yamamoto et al. 1995) and in vitro (Berger et al. 1992; Crespi 
et al. 1997; Nichols et al. 1982). The putative mechanisms for MDMA action at the 
serotonergic neuronal terminal are displayed in Figure 2. The increased release of 5-HT 
activates pre- and post-synaptic receptors, and triggers a sequence of intracellular pathways 
(e.g., via adenylate cyclase), resulting in the subsequent molecular and neurochemical effects 
(Callaway et al. 1990; Green et al. 2003; Morley et al. 2005; Simantov 2004).  
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Figure 2. Pharmacological mechanisms of action of MDMA at the synapse of the serotonergic neuronal 
terminal. MDMA binding to the presynaptic serotonin transporter (SERT) inhibits neuronal reuptake of 
serotonin (5-HT) (4) and increases 5-HT release by exchange with MDMA (1), in a process designated by 
diffusion-exchange (Rudnick and Wall 1992; Simantov 2004). As a consequence of MDMA transport into the 
neuron, the carrier is available on the internal surface of the membrane to bind to 5-HT and transport it into the 
synaptic cleft (Rudnick and Wall 1992). Along with the effect at the neuronal reuptake level, MDMA also exerts 
its action on vesicular uptake of 5-HT. At low concentrations, MDMA inhibits vesicular uptake of 5-HT 
(Gudelsky and Nash 1996; Nichols et al. 1982). At higher concentrations, MDMA penetrates into the synaptic 
vesicles by a passive diffusion process (Green et al. 2003). Once inside these vesicles, and since MDMA 
chemically behaves as a weak base, pH increases promoting the efflux of 5-HT contained therein (2), as 5-HT is 
maintained inside the vesicles through a proton gradient that is regulated by an ATP-dependent proton pump 
(Rudnick and Wall 1992). The increase of 5-HT levels is also due to the inhibition of the metabolic degradation 
of this neurotransmitter by mitochondrial monoamine oxidase (MAO) (3), and to the stimulation of 5-HT release 
into the synaptic cleft (5). The released 5-HT accumulates in the synaptic cleft where it stimulates 5-HT 
postsynaptic receptors (Simantov 2004) (6). Nevertheless, mechanisms that prevent disproportionate increase of 
5-HT levels in the synaptic cleft operate by self-regulating the release of 5-HT by presynaptic receptors (7), and 
by increasing formation of 5-HT metabolites and products of autoxidation in the synaptic cleft (8). MDMA also 
promotes the depletion of 5-HT reserves by causing inhibition of the biosynthesis of 5-HT by tryptophan 
hydroxylase (TH) (9). In addition to the indirect action of MDMA in stimulating the release of 5-HT, MDMA 
itself has affinity for 5-HT receptors and may activate them directly. Discontinuous arrows indicate inhibition 
and larger arrows indicate induction. Adapted from Carmo (2007). 
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The increase in DA release prompted by MDMA can result from: (i) the reversion of 
the transporter (Crespi et al. 1997) and/or (ii) the stimulation of DA synthesis by MDMA 
agonism of the 5-HT receptors (Bankson and Yamamoto 2004; Nash et al. 1990; Sprague et 
al. 1998; Yamamoto et al. 1995). Bruxism, tremors, hyperlocomotion, clonus and other long-
term neurotoxic outcomes are among the dopaminergic effects elicited by MDMA (Ball et al. 
2003; Bubar et al. 2004; Easton et al. 2003; O'Shea et al. 2001; Risbrough et al. 2006; Saadat 
et al. 2006). 
MDMA also acts on central and peripheral adrenergic system, triggering effects such 
as an increase in systolic and diastolic blood pressure (Green et al. 2003), peripheral 
vasoconstriction, pupil dilation, decreased salivation, decreased secretion of pancreatic 
enzymes and insulin, urinary retention, decreased gastric motility, piloerection (Vander et al. 
2001), and hyperactivity (Bexis and Docherty 2006; Selken and Nichols 2007).  
Due to the MDMA stimulating action on the release of 5-HT, repeated exposure to the 
drug depletes the reserves of these neurotransmitters, provoking depression in MDMA 
abusers a few days after consumption (mainly due to the MDMA action on the 5-HT system) 
(Gahlinger 2004). Repeated administration also diminishes the biological effects (acute 
tolerance by MDMA action on NA/adrenaline and DA systems) (delaTorre et al. 2004a). 
Since MDMA exerts serotonergic, dopaminergic and adrenergic actions it has the 
potential to undergo toxicodynamic interactions with compounds having the same or 
antagonistic mechanisms of action (Oesterheld et al. 2004). This potential interaction is 
discussed with further detail in section 2 of the introduction. 
 
 
1.4.2. Tryptophan hydroxylase (TH) and monoamine oxidase (MAO) 
inhibition 
 
The effects of MDMA on the neurotransmitter monoamines are also a consequence of the 
drug inhibitory effect on two important enzymes, tryptophan hydroxylase (TH) and 
monoamine oxidase (MAO). 
MDMA, at high doses, prevents the metabolic inactivation of the catecholamines by 
competitively inhibiting MAO (preferentially MAO-A, which has higher affinity for 5-HT) 
(Fig. 2). At low MDMA doses (below inhibitory effects), MAO is still involved in the 
metabolism of DA and 5-HT, leading to the formation of DA reactive metabolites and 
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hydrogen peroxide (H2O2) (Alves et al. 2007; Bolton et al. 2000; Carmo 2007; Carvalho et al. 
2012). 
MDMA and/or its metabolites also inhibit the enzyme TH (Fig. 2), which is the rate-
limiting enzyme in 5-HT synthesis (Green et al. 2003). 
 
 
1.4.3. Neuroendocrine effect 
 
The administration of MDMA leads to increased serum levels of corticosterone, prolactin, 
renin, aldosterone, thyroxine (T4) (Green et al. 2003; Sprague et al. 2003), cortisol, prolactin 
(Grob et al. 1996; Harris et al. 2002; Mas et al. 1999) adrenocorticotrophic hormone (ACTH 
or corticotrophin), antidiuretic hormone (or vasopressin) (delaTorre et al. 2004b; Grob et al. 
1996; Henry et al. 1998), gonadotropins follicle-stimulant hormone (FSH), luteinizing 
hormone (LH), testosterone (Dickerson et al. 2008), and oxytocin (Forsling et al. 2002; Wolff 
et al. 2006). The effect of MDMA on the release of oxytocin may play a critical role in 
MDMA pro-social effects and form the basis of reinforcement properties of this drug 
(Thompson et al. 2007). Some of the detrimental actions of the drug can be attributed to this 
neuroendocrine disturbance, as is the case of the potentially lethal hyponatremic effect of the 
drug associated with the increases in vasopressin (Green et al. 2003). 
 
 
1.4.4. Thermoregulation disturbance 
 
In humans, the hyperthermic effect of MDMA is well documented and increased body 
temperature is considered to be a potentially lethal consequence of MDMA intoxications 
(Henry et al. 1992), often associated with other complications elicited by the drug, such as 
rhabdomyolysis, acute renal failure, disseminated intravascular coagulation (DIC), multiple 
organ failure, and acidosis (Henry et al. 1992; Kalant 2001; Kendrick et al. 1977). Body 
temperatures greater than 41.7 ºC (Chadwick et al. 1991; Coore 1996; Hall and Henry 2006; 
Henry et al. 1992; Milroy et al. 1996; Screaton et al. 1992; Vanden Eede et al. 2012) and as 
high as 43.9 ºC (Milroy et al. 1996) have been reported in human MDMA intoxications. A 
rise in body temperature above 42 ° C is considered lethal although survival cases have been 
recorded (Logan et al. 1993). To aggravate this scenario, it is unlikely that a single 
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pharmaceutical will be entirely successful in reversing the hyperthermic effect (dantrolene has 
some efficiency), so careful body cooling using cold baths or ice packs remain the main 
clinical approach (Carvalho et al. 2012). 
The induction of hyperthermia is highly variable because it is dependent on 
environmental settings (such as ambient temperature) (Broening et al. 1995; Carvalho et al. 
2002a; Malberg and Seiden 1998), administered dose, and individual characteristics. The 
increased muscle activity associated with intense dancing, dehydration and high temperature 
of the venues that are often crowded aggravate the body temperature rise prompted by 
MDMA (delaTorre et al. 2004b). Supporting the importance of environmental factors is the 
fact that, when MDMA was administered in controlled clinical trials, the sharp increase in 
body temperature was not observed (temperature increments did not exceed 0.5 °C) 
(delaTorre et al. 2000b; Grob et al. 1996; Mas et al. 1999; Vollenweider et al. 1998). There 
are cases in which (i) MDMA-elicited hyperthermia is not observed, (ii) only one tablet 
triggered a fatal hyperthermic response (Gahlinger 2004) or (iii) the individual survived after 
checking in the emergency department with a body temperature of 42.9 º C after ingestion of 
three tablets of MDMA (Mallick and Bodenham 1997; Pontes 2009). 
There is considerable evidence suggesting that 5-HT does not play a direct role in the 
acute hyperthermic response of MDMA (Beveridge et al. 2004; Carvalho et al. 2012; Colado 
et al. 2004; Docherty and Green 2010; Green et al. 2004; Mechan et al. 2002; Saadat et al. 
2005) and the effect appears more related to the increased release of DA (Mechan et al. 2002). 
Nevertheless, 5-HT appears to modulate DA release (Alex and Pehek 2007) and also seems to 
influence the hyperthermic response, due to its effect on heat dissipation mechanisms (Saadat 
et al. 2005).  
Additionally, the hyperthermia resulting from the consumption of MDMA may be due 
to its action on both the central thermoregulatory centre, and on peripheral changes in blood 
flow and brown fat thermogenesis (Carvalho et al. 2012; Docherty and Green 2010; Pedersen 
and Blessing 2001; Pontes 2009). Several studies revealed a complex interaction between the 
hypothalamic–pituitary–thyroid (HPT) axis, the sympathetic nervous system, and the activity 
of uncoupling proteins (UCP) (Carvalho et al. 2012; Sprague et al. 2003). By activating 
anterior hypothalamus neurons, MDMA induces NA release and slightly increases T4 serum 
levels (Pontes 2009). NA, in turn, promotes vasoconstriction through the activation of 
vascular α1-adrenoreceptors, impairing heat dissipation, and together with thyroid hormones 
modulates thermogenesis by regulating the expression of UCP and/or synthesis of adrenergic 
receptors (Carvalho et al. 2012; Mills et al. 2004; Rusyniak and Sprague 2005). Through 
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activation of α1- and β3-adrenergic receptors, UCPs incorporate in mitochondria, dissociating 
the mitochondrial proton gradient from adenosine 5’-triphosphate (ATP) synthesis 
(mitochondrial uncoupling) and releasing the free energy as heat, in skeletal muscle and 
brown fat (Carvalho et al. 2012; Mills et al. 2004; Rusyniak and Sprague 2005; Sprague et al. 
2007). 
 
 
1.4.5. MDMA addiction, tolerance and withdrawal 
 
The addictive character of MDMA is presently a controversial matter, with a few studies 
providing evidence of MDMA abuse and dependence potential (Cottler et al. 2001; Schuster 
et al. 1998; Topp et al. 1999; Yen et al. 2007). In debate is the fact that criteria for abuse and 
dependence in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition 
(DSM-IV) are the same for all substances, with no regards to the pharmacology of the drug, 
which ultimately impacts its use pattern (Cottler et al. 2001). 
Symptoms of tolerance have been frequently reported, as the increasing frequency of 
MDMA use leads to a decrease of the emphatogenic effects desired by the abusers, which 
normally causes a gradual disinterest in the drug. However, in several cases, some of these 
individuals may increase the intake to overcome the tolerance effects and develop dependency 
(Jansen 1999). 
There are reports of individuals presenting withdrawal symptoms, including fatigue, 
loss of appetite, mood swings, anxiety, sleep disturbances, feelings of depression, and trouble 
concentrating (Cottler et al. 2001; Jansen 1999). The National Institute on Drug Abuse 
(NIDA) reported that withdrawal symptoms affect almost 60% of MDMA users 
(http://www.drugabuse.gov/pdf/rrmdma.pdf). 
 
 
1.5. Toxicity of MDMA 
 
MDMA became a popular drug of abuse due to its intense stimulating effects and because it 
was believed that toxic effects would be negligible (Pontes 2009). However, as its popularity 
increased, so did the number of fatalities and severe adverse events related to its use 
(Carvalho et al. 2012; De Letter et al. 2006; Pontes 2009). Some aspects of the pathogenesis 
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associated with MDMA-elicited toxicity remain unclear, such as the variability in the delay 
between drug exposure and the onset of the injury. Also, MDMA-induced toxicity is not 
always related to the dose intake and/or plasma concentrations (Milroy 2011), indicating the 
existence of alternative mechanisms for the occurrence of toxic effects (Carvalho et al. 2012; 
Pontes 2009). For example, there is one report of a fatal intoxication occurring with the 
ingestion of a single tablet (MDMA plasma concentration detected was 0.424 mg/L) 
(Chadwick et al. 1991), while in two other serious poisonings the individual survived after 
ingesting 30 pills (Shannon 2000), or 18 pills (plasma concentration detected was 4.05 mg/L) 
(Roberts and Wright 1993). Also, a virtually asymptomatic case was recorded after the 
ingestion of 42 tablets (resulting in a plasma concentration of 7.72 mg/L) (Henry et al. 1992). 
As presented in Table 3 and Table 4, the variability in plasma concentrations found in fatal 
and non-fatal poisonings is overwhelming. 
 
 
1.5.1. Lethal intoxications 
 
Deaths in which ecstasy is considered the causal agent are not very frequent, when compared 
with the high frequency of use (Carvalho et al. 2012; Pontes 2009). As an example, in the 
UK, in 1996, the mortality rate of people aged between 15 and 24 years old showed an index 
of 2-53 deaths per 100,000 ecstasy users (Greene et al. 2003). Recent data from the 2011 
European report suggest that deaths related to ecstasy are rare in most countries of the 
European Union (EU), particularly if ecstasy is the only drug involved (EMCDDA 2011). 
However, these deaths raise great concern, as they mostly occur sudden and unexpectedly in 
socially integrated young people (Carvalho et al. 2012; Pilgrim et al. 2009).  
Of concern are not only the directly-induced lethal intoxications, but also some deaths 
that are indirectly associated with MDMA consumption (e.g. depression that arises from 
consumption of MDMA leading to suicide, accidents due to risky behaviours while under the 
influence of ecstasy, among others) (Brookhuis et al. 2004; Kalant 2001; Lora-Tamayo et al. 
1997; Morland 2000; Verschraagen et al. 2007). Extensive reviews of ecstasy-related deaths 
are available in the literature (Carvalho et al. 2012; De Letter et al. 2006; Milroy 2011; Patel 
et al. 2004; Pontes 2009; Schifano 2004; Schifano et al. 2010; Schifano et al. 2003). Table 5 
summarizes some of these reported data. 
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Table 3. Blood and tissue concentrations of MDMA determined at autopsy after fatal intoxication. Adapted from Carvalho (2012). 
 
Blood Liverb Kidneyb Brainb Bileb Lungb Heartb Stomach  
mg/L 
(µM) 
µg/g µg/g µg/g mg/L µg/g µg/g µg/g Reference 
3.9 (20.2) 34       (Fernando et al. 2012) 
 22.26 801.14     835.97 (Dordevic and Tomasevic 2007) 
2.8a (14.5) 20.2  13.7     (Rohrig and Prouty 1992) 
0.58a 
(2.99) 
1.8        
0.18 (0.96) 13.23 9.82 12.79 27.34 10.7   (Fineschi and Masti 1996a) 
2.9 (14.9) 6.4   73    (Moore et al. 1996) 
3.10 (16.0) 26.20 13.0 15.6 14.2 13.0 14.0  (deLetter et al. 2002) 
3.18 (16.5) 4.86   1.41    (Garcia-Repetto et al. 2003) 
0.28 (1.45) 5.13  8.42 1.23 2.64    
0.17§ 
(0.88) 
0.18 0.05 0.14  1.46    
1.13 (5.8) 6.66 4.06 2.25 25.42 10.9 1.73  (Dams et al. 2003) 
7.2* (37.3) 29.7  29.1  36.6   (Sticht et al. 2003) 
0.271 (1.4) 4.87 1.44 0.69 22.07 3.62 0.38  (deLetter et al. 2004) 
13.51 (70) 103.5 111.9  86.95 101.2 140.1   
 
* mg/kg 
§ Determined before death 
a
 Peripheral blood levels (femoral) 
b
 Mean concentration values if different tissue portions were analyzed 
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Table 4. Blood concentrations of MDMA found at non-fatal and fatal intoxications. Adapted from Carvalho 
(2012). 
 
  MDMA blood concentration (µg/L) Study Reference 
Dose Number of pills  post-mortem   
   87 Fatal intoxication (Diffley et al. 2012) 
   9300 Fatal intoxication (Fernando et al. 2012) 
 3  1500 Fatal intoxication (Vanden Eede et al. 2012) 
  1200  Fatal intoxication (Sano et al. 2009) 
 1.5 <500  Fatal intoxication (Sauvageau 2008) 
   2900 Fatal intoxication (Moore et al. 1996) 
   3100a Fatal intoxication (deLetter et al. 2002) 
  1090 3180 Fatal intoxication (Garcia-Repetto et al. 2003) 
  40 280 Fatal intoxication  
  170  Fatal intoxication  
   1130a Fatal intoxication (Dams et al. 2003) 
   7200a ** Fatal intoxication (Sticht et al. 2003) 
   271b Fatal intoxication (deLetter et al. 2004) 
   13510a Fatal intoxication  
 4 230  Non-fatal intoxication (Greene et al. 2003) 
 5 350  Non-fatal intoxication  
 2 250  Non-fatal intoxication  
 2 130  Non-fatal intoxication  
 1 < 100  Non-fatal intoxication  
100-150  §7000  Non-fatal intoxication (Brown and Osterloh 1987) 
 50 
§R (-) 44000 
S-(+) 42000  Non-fatal intoxication (Ramcharan et al. 1998) 
 42 7720  Non-fatal intoxication (Randall 1992) 
 18 4050  Non-fatal intoxication (Roberts and Wright 1993) 
   1100 Fatal intoxication (Dowling et al. 1987) 
150 1,5  1000 Fatal intoxication  
 1  424 Fatal intoxication (Chadwick et al. 1991) 
   2000 Fatal intoxication (Suarez and Riemersma 1988) 
  2400  Fatal intoxication (Greene et al. 2003) 
  930  Fatal intoxication  
   2800a Fatal intoxication (Rohrig and Prouty 1992) 
   580a Fatal intoxication  
   180 Fatal intoxication (Fineschi and Masti 1996a) 
 
Cmax 
§
 Approximately 4 h after ingestion 
†
 n = 2 (individual values) 
‡
 n = 2 (mean ± SD) 
** mg/kg 
a
 Peripheral blood levels (femoral) 
b
 Subclavian blood values 
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As can be depicted in Table 5, Milroy (2011) reviewed seventy-seven deaths where 
MDMA was detected in body fluids/organs. In 13 of these cases, death was due to the toxic 
effects of MDMA alone, in 22 cases due to polydrug use, and in 24 cases death was attributed 
to trauma. The main outcome of his study was that no specific concentration can be 
considered lethal, as fatal MDMA concentrations overlap with non-fatal concentrations 
(Milroy 2011). As noted before, it can be clearly concluded from the data presented in Table 5 
that, in most cases of severe intoxication or death, MDMA is consumed in combination with 
alcohol and/or other drugs, such as cocaine, cannabinoids and other amphetamines (Morland 
2000; Verschraagen et al. 2007), which may also aggravate behavioural changes, increasing 
the risk of accident and also increasing the direct toxicity exerted by each drug. 
 
 
1.5.2. MDMA acute and long-term toxicity 
 
The acute adverse effects that occur after ingestion of MDMA in humans include increased 
blood pressure, increased heart rate, palpitations (delaTorre et al. 2000b; Downing 1986; 
Grob et al. 1996; Harris et al. 2002; Lester et al. 2000; Liechti et al. 2001; Liechti and 
Vollenweider 2000a; Liechti and Vollenweider 2000b; Mas et al. 1999; Vollenweider et al. 
1998), nausea, vomiting, hyponatremia (delaTorre et al. 2004b; Henry et al. 1998; Holden and 
Jackson 1996; Holmes et al. 1999; Kessel 1994; Matthai et al. 1996; Maxwell et al. 1993; 
Milroy et al. 1996; Satchell and Connaughton 1994), mydriasis, chills, sweating, tremor, 
trismus (jaw clenching), bruxism (teeth grinding) (Redfearn et al. 1998), sudden sensation of 
cold or heat, nystagmus, restlessness, irritability, and insomnia (Cole and Sumnall 2003; 
Green et al. 2003; Peroutka et al. 1988). It can also induce panic attacks, delirium and brief 
psychotic episodes that disappear quickly when the MDMA action ends (delaTorre et al. 
2004b). In addition to these immediate toxic effects, acute administration of MDMA can also 
lead to toxic effects of long duration that might persist for up to seven days after drug 
ingestion. These include fatigue, irritability, anxiety, depressed mood, insomnia, dizziness, 
and muscle tension (Cole and Sumnall 2003; delaTorre et al. 2004b).   
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Table 5. Deaths related to ecstasy. 
 
Reference Year Local Cases Sex/age (years)  
Cause of death/autopsy 
findings Postmortem toxicological analysis  
(Diffley et al. 
2012) 
2012 Oakland, 
USA. 
n=1 M/15 Catecholaminergic 
polymorphic ventricular 
tachycardia 
87 ng/mL MDMA in blood, 
approximately 12 hrs after 
ingestion; Marijuana 
(Fernando et al. 
2012) 
2012 Adelaide, 
Australia 
n=1 F/15 MDMA toxicity (edema, 
lungs congestion, neuronal 
hypoxic-ischemic changes 
in hippocampus), the 
manner suicide  
Blood (mg/L): 9.3 MDMA, 0.28 
MDA and 25 caffeine; Liver 
(mg/kg): 34 MDMA, 0.9 MDA 
and 25 caffeine; Stomach (mg/kg): 
530 MDMA and 550 caffeine; 
Urine (mg/L): 2.4 MDMA, 0.2 
MDA and 8.4 caffeine. 
(Vanden Eede 
et al. 2012) 
2012 Hague, 
Netherlands 
n=1 M/19 Massive rhabdomyolysis 
(hyperkalemia 
unresponsive to treatment) 
T=39.5°C at the moment of death; 
massive rhabdomyolysis and 
evidence of myocardial damage 
Serum potassium = 9.4 mmol/L. 
MDMA = 1.5 mg/L. No other 
amphetamines or other drugs were 
found. 
(Sano et al. 
2009) 
2009 Maebashi, 
Japan 
n=1 F/39 Multi-organ failure 
involving the brain, heart, 
lung, kidney, and liver 
Small foci of myocyte necrosis 
with a surrounding macrophage 
inflammatory response, foci of 
fibrosis, and calcification 
accompanied by myocyte necrosis.  
Centrilobular and mid-zonal 
hepatic necrosis with fatty 
degeneration and inflammation. 
Myoglobinuria. Degeneration of 
neurons throughout the whole 
brain and haemorrhagic foci in the 
pons and medulla. Serious 
bronchopneumonia. 
(Sauvageau 
2008) 
2008 Montreal, 
Canada 
n=1 F/13 Anaphylactic reaction to 
ecstasy 
Massive brain edema with 
anoxic/ischemic encephalopathy; 
lings congested;  Laryngeal 
edema;  increased neutrophils 
(16.2 x 109/L [reference range 1.4 
to 6.5 x 109/L]) 
(Pilgrim et al. 
2012) 
2002-2008 Victoria, 
Australia 
n=4 M/31 Mixed drug toxicity 
Serotonin toxicity 
Hepatitis C 
Pulmonary edema 
Contraction band necrosis 
left ventricular 
myocardium 
Cavity blood: MDMA 1.7 mg/L; 
MDA 0.1 mg/L; Amphetamine 
0.06  mg/L; Moclobemide 0.3  
mg/L; THC 6  ng/mL 
    M/24 Amphetamine toxicity 
Serotonin toxicity 
Pulmonary edema 
Cerebral edema 
Femoral blood:  MDMA 2.6 
mg/L; MDA 0.1 mg/L; 
Methamphetamine 0.1 mg/L; 
Moclobemide 0.7 mg/L 
    M/24 Mixed drug toxicity and 
coronary artery disease 
Serotonin toxicity 
Coronary artery 
atherosclerosis 
Pulmonary edema 
Femoral blood:  MDMA 1 mg/L; 
MDA 0.04 mg/L; 
Methamphetamine 0.2 mg/L; 
Amphetamine 0.02 mg/L; 
Moclobemide 15 mg/L 
    M/45 Mixed drug toxicity 
Serotonin toxicity 
Coronary artery 
atherosclerosis 
Pulmonary edema 
Femoral blood:  MDMA 2.0 
mg/L; MDA 0.07 mg/L; 
Methamphetamine 0.12 mg/L; 
Amphetamine 0.4 mg/L; 
Moclobemide 8.7  mg/L 
(Lin et al. 
2009) 
2001-2008 Taiwan n=59 66.1% 
M/ 14-
46 
Acute intoxication (n= 40); 
mechanical injury (n= 19, 
including 3 hanging and 2 
drowning); The manners of 
death were accidental (n= 
44); homicidal (n= 6); 
suicidal (n= 7); and 
undetermined (n= 2) 
Ketamine was found in 28 of these 
cases; 0.12-40.41 microg/mL 
MDMA postmortem whole blood;  
MDA ( 0.05-1.81 microg/mL) was 
found in 30 cases 
DIC, disseminated intravascular coagulation. DXM, dextromethorphan. EtOH, ethanol. F, female.  GHB, γ-Hydroxybutyric acid. M, male. MBDB, N-methyl-1,3-
benzodioxolylbutanamine. MDA, 3,4-methylenedioxyamphetamine. MDEA, N-ethyl-3,4-methylenedioxyamphetamine. MDMA, 3,4-methylenedioxy-N-methamphetamine. PMA, 
p-metoxyamphetamine. THC, ∆9-tetrahydrocannabinol. 
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Table 5. Continued. 
Reference Year Local Cases Sex/age (years)  
Cause of death/autopsy 
findings Postmortem toxicological analysis  
(Milroy 2011) 1992-2008 Sheffield, UK n=73  MDMA intoxication 
(n=17): water 
intoxication, myocardial 
necrosis, hyperpyrexia, 
etc; 
Polydrug use (n=30): 
MDMA was the main 
drug in 28 cases. The 
other principal drugs in 
these cases were MDEA 
(n=1), MBDB (n=1), 
cannabinoids (n=16), 
ethanol (n=13), heroin 
(n=11), benzodiazepines 
(n=9), amphetamine 
(n=8), antidepressants 
(n=6), methadone (n=5), 
cocaine (n=5), GHB 
(n=2).  
Trauma ( n=28) 
Homicide ( n=8), 
Vehicular collision ( 
n=10)  
Fall from height ( n=6) 
Drowning ( n=4) 
Ischaemic heart disease ( 
n=1). 
Blood MDMA concentration at 
autopsy: 0.478–53.9 mg/L in 
MDMA deaths (n=13); 0.04–41.5 
mg/L MDMA, 0.187 mg/l MDEA 
and 0.44 mg/l MBDB in mixed 
drug deaths (n = 22); and 0.035–
4.81 mg/L in traumatic deaths 
(n = 24) 
 
 
(Kaye et al. 
2009) 
2000-2005 Australia n=82 83% M/ 
17-58 
Drug toxicity (n=61): 
MDMA-only (n=17) or 
combined drug toxicity 
(n=44) 
Blood: 0.03–93.0 mg/L MDMA 
and 0.01–1.0 mg/L MDA; In 87% 
cases there were other drugs 
present (especially 
methamphetamine/ amphetamine, 
morphine, alcohol, codeine and 
benzodiazepines) 
(Gill et al. 
2002) 
2002 New York 
(USA) 
n=22 17-41 Acute intoxication 
(n=13); Mechanical 
injury (n=7); 
Combination of previous 
illness with acute 
intoxication (n=2) 
MDMA (n=22) 
Opiates and cocaine (n=7) 
(Fineschi et al. 
1999) 
1999 Italy n=2 M/19 Hyperpyrexia ,DIC MDMA (7.15 mg/L serum; 31 
mg/L urine) 
MDA (0.25 mg/L serum; 0.85 
mg/L urine) 
    M/20 Hyperpyrexia MDMA (0.18 mg/L serum; 263.13 
mg/L urine); MDA (0. 12 mg/L 
serum; 5.25 mg/L urine); MDEA 
(1.59 mg/L serum; 183.73 mg/L 
urine) 
(O'Connor et 
al. 1999) 
1999 New Zeland n=1 F/27 Cerebral edema  
(Walubo and 
Seger 1999) 
1999 USA n=1 M/53 Suicide: Hyperpyrexia 
(40.4ºC),  
Rhabdomyolysis, DIC 
MDMA (3.05 mg/L serum)  
amphetamines in urine 
(Byard et al. 
1998) 
1998 South 
Australia  
n=2 F/22 Hyperpyrexia (42.5ºC), 
DIC, Hyperkalaemia, 
Rhabdomyolysis 
Serum: 1.32 mg/L PMA and 0.3 
mg/L MDMA; high levels of MTA 
and THC 
    F/26 Cyanosis, Hyperpyrexia 
(46.1ºC), Irregular 
heartbeat, Pulmonary 
edema 
Serum: 2.2 mg/L PMA; 0.82 mg/L 
MDMA; 0.09 mg/L MTA 
(Henry and Hill 
1998) 
1998 UK n=1 M/32 Heart Failure Serum: 4.56 mg/L MDMA; 
0.36 mg/L MDA; 0.24 mg/mL 
EtOH 
(Mueller and 
Korey 1998) 
1998 USA n=1 F/20 Hyperpyrexia MDMA in serum 
DIC, disseminated intravascular coagulation. DXM, dextromethorphan. EtOH, ethanol. F, female.  GHB, γ-Hydroxybutyric acid. M, male. MBDB, N-methyl-1,3-
benzodioxolylbutanamine. MDA, 3,4-methylenedioxyamphetamine. MDEA, N-ethyl-3,4-methylenedioxyamphetamine. MDMA, 3,4-methylenedioxy-N-methamphetamine. PMA, 
p-metoxyamphetamine. THC, ∆9-tetrahydrocannabinol. 
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Table 5. Continued. 
  
Reference Year Local Cases Sex/age (years)  
Cause of death/autopsy 
findings Postmortem toxicological analysis  
(Lora-Tamayo 
et al. 1997) 
1997 Spain n=10 M/23 Hypovolemic shock Serum: 0.23 mg/L MDMA; 0.77 mg/L 
MDEA; 0.05 mg/L MDA; 
0.62 mg/L amphetamine  
    M/17 Fall from height Serum: 0.23 mg/L MDMA;  
0.10 mg/L amphetamine; 0.04 mg/L 
MDA; 0.35 mg/L MTA  
    M/32  Hit by car Serum: 0.27 mg/L MDMA; 2.47 
mg/mL EtOH  
    M/39  Sudden death at 
nightclub; Ischemic heart 
disease; Occlusion of the 
right coronary artery and 
the circumflex artery; 
stroke in the left 
ventricle 
Serum: 0.60 mg/L MDMA; 0.22 mg/L 
MDEA; 0.12 mg/L MDA; 0.22 mg/L 
amphetamine; 0.54 mg/mL EtOH 
    M/21  Car accident Serum: 0.17 mg/L MDMA; 1.07 mg/L 
MDEA; 0.18 mg/L MDA; 0.10 mg/L 
amphetamine; 0.71 mg/mL EtOH 
    M/26  Car accident Serum: 0.03 mg/L MDMA; 2.44 mg/L 
MDEA; 0.15 mg/L MDA; 0.05 mg/L 
benzoylecgonine; 0.88 mg/mL EtOH  
    M/29 Adverse reaction to 
drugs 
Serum: 4.07 mg/L MDMA; 0.49 mg/L 
MDA; 0.38 mg/L morphine; 0.1 mg/L 
alprazolam; 0.92 mg/mL EtOH  
    M/30 Acute pulmonary edema Serum: 0.98 mg/L MDMA; 0.06 mg/L 
amphetamine (in serum); 0.15 mg/L 
morphine; 0.38 mg/mL EtOH 
    M/27 Acute pulmonary edema  
Pulmonary hemorrhage 
Serum: 8 mg/L MDMA; 0.18 mg/L 
amphetamine; 1.2 mg/L MDA; 0.04 
mg/L cocaine; 0.13 mg/L 
benzoylecgonine; 0.9 mg/mL EtOH 
    M/19 Adverse reaction to 
drugs 
Serum: 0.49 mg/L MDMA; 4.32 mg/L 
MDEA; 0.29 mg/L MDA; 0.20 mg/L 
amphetamine; 1.36 mg/L dipyrone  
(Parr et al. 
1997) 
1997 Australia n=1 F/15 Hyponatraemia 
Cerebral edema 
MDMA (0.05 mg/L in serum and 430 
ng/mL in urine) 
(Coore 1996) 1996 Ireland n=1 F/18 Hyperpyrexia (43ºC) 
Kidney injury; DIC 
Rhabdomyolysis 
MDA (0.246 mg/L in serum ) 
MDMA and MDA in urine 
(Cox and 
Williams 1996) 
1996 UK n=1 M/22 Hyperpyrexia; DIC Serum: 0.43 mg/L MDMA; 0.30 mg/L 
MDEA; 0.25 mg/L MDA  
(Crifasi and 
Long 1996) 
1996 USA n=1 M/29 Accident MDMA (2.14 mg/L serum; 118.8 mg/L 
urine); MDA (< 0.25 mg/L serum; 3.86 
mg/L urine) 
(Dar and 
McBrien 1996) 
1996 USA n=1 M/17 Hyperpyrexia; 
Rhabdomyolysis; DIC 
 
(Ellis et al. 
1996) 
1996 UK n=4 F/21 Hyperpyrexia (41ºC) 
High blood pressure 
Tachycardia; Acute 
Renal failure; DIC; 
Transplant; Sepsis 
MDMA (0.11 mg/L serum ; 0.04 mg/L 
urine) 
    F/18 Progressive jaundice  
Liver failure (regular 
consumption of ecstasy) 
 
    F/36 Jaundice after 
consuming 1 tablet of 
ecstasy; Transplant; 
Sepsis 
 
    F/22 Ecstasy use for 6 months 
Jaundice; Transplant;  
Sepsis 
 
DIC, disseminated intravascular coagulation. DXM, dextromethorphan. EtOH, ethanol. F, female.  GHB, γ-Hydroxybutyric acid. M, male. MBDB, N-methyl-1,3-
benzodioxolylbutanamine. MDA, 3,4-methylenedioxyamphetamine. MDEA, N-ethyl-3,4-methylenedioxyamphetamine. MDMA, 3,4-methylenedioxy-N-methamphetamine. PMA, 
p-metoxyamphetamine. THC, ∆9-tetrahydrocannabinol. 
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Table 5. Continued. 
  
Reference Year Local Cases Sex/age (years)  
Cause of death/autopsy 
findings Postmortem toxicological analysis  
(Fineschi and 
Masti 1996) 
1996 Italy n = 1 M/20 Hyperpyrexia 
DIC 
MDMA (0.18 mg/L in serum) 
MDEA in serum 
(Milroy et al. 1996) 1996 UK n=7 M/21 Collapse in the rave 
hyperpyrexia (44ºC) 
Heat failure 
MDMA (4.2 mg/L) and 
amphetamine (1.4 mg/L) in serum  
    M/20 Collapse in club 
High blood pressure 
Hyponatraemia 
Water intoxication 
MDMA (0.04 mg/L in serum) 
    M/24 Death at the disco 
Unknown cause  
MDEA (0.187 mg/L) and 
amphetamine (0.453 mg/L) in 
serum 
 
   
M/21 Death in bed after party 
Unknown cause 
MDMA (2.1 mg/L). MDEA (3.5 
mg/L); MDA (8.5 mg/L); and 
amphetamine (0.256 mg/L) in 
serum 
    M/20 Found unconscious in 
bed; rigidity; 
hyperpyrexia (39,5ºC) 
Cerebral hypoxia 
MDMA (0.09 mg/L) and 
MDA (0.13 mg/L) in serum 
    M/25 Sudden death in the 
street 
Traces of MDMA and MDA in 
urine 
    M/23 Progressive jaundice and 
liver failure; excessive 
consumption of ecstasy 
 
(Moore et al. 1996) 1996 USA n=1 M/20 Acute intoxication with 
MDMA, cocaine and 
heroin 
MDMA (2.8 mg/L), 
benzoylecgonine (0.97 mg/L), and 
morphine (0.11 mg/L) in serum 
MDMA and MDA in urine 
(Squier et al. 1995) 1995 UK n=1 M/30 Seizures 
Hyperpyrexia 
Cerebral necrosis 
MDMA. Heroine. Amphetamine 
and EtOH in serum. 
(Forrest et al. 
1994) 
1994 UK n=1 M/21 Asphyxia 
Seizures 
MDA, MDEA and MDMA in 
serum 
(Hooft and van de 
Voorde 1994) 
1994 Belgium n=1 M/26 Road accident in an 
attempt to car surfing 
MDMA (0.63 mg/L) and 
EtOH (1.23 g/L) in serum; 
Amphetamines in urine 
(Watson et al. 
1993) 
1993 
 
UK 
 
n=1 M/16 Hyperpyrexia 
Rhabdomyolysis, DIC 
 
(Campkin and 
Davies 1992) 
1992 UK n=1 M/18 Hypotension 
Tachycardia 
Hyperpyrexia (42ºC) 
Rhabdomyolysis, DIC 
MDMA (1.26 mg/L in serum) 
(Rohrig and Prouty 
1992) 
1992 USA n=2 M/35 
 
Unknown cause MDMA (2.8 mg/L in serum) 
    F Suicide 
Depression? 
MDMA (0.58 mg/L) and diazepam 
in serum  
(Screaton et al. 
1992) 
1992  n=1 M/19 Hyperpyrexia 
Rhabdomyolysis, DIC 
 
(Henry 1992) 1992 UK n=6 M/18 Hyperpyrexia 
Cardiovascular failure 
 
    M/17 Hyperpyrexia; DIC 
Seizures 
 
    M/20 Hyperpyrexia 
Rhabdomyolysis; DIC 
 
    M/18 Hyperpyrexia 
Rhabdomyolysis; DIC 
 
    M/21 Car accident  
    M/23 Car accident  
(Chadwick et al. 
1991) 
1991 UK n=1 F/16 Hyperpyrexia; DIC MDMA (0.424 mg/L in serum) 
(Suarez and 
Riemersma 1988) 
1988 USA n=1 M/34 Heart Failure MDMA (2 mg/L in serum) 
DIC, disseminated intravascular coagulation. DXM, dextromethorphan. EtOH, ethanol. F, female.  GHB, γ-Hydroxybutyric acid. M, male. MBDB, N-methyl-1,3-
benzodioxolylbutanamine. MDA, 3,4-methylenedioxyamphetamine. MDEA, N-ethyl-3,4-methylenedioxyamphetamine. MDMA, 3,4-methylenedioxy-N-methamphetamine. PMA, 
p-metoxyamphetamine. THC, ∆9-tetrahydrocannabinol. 
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Hyperthermia can lead to serious and often fatal complications, which include 
rhabdomyolysis (Cunningham 1997; Fineschi et al. 1999; Greene et al. 2003; Henry et al. 
1992; Kendrick et al. 1977; Screaton et al. 1992), DIC (with consequent bleeding and 
widespread tissue necrosis) and acute renal failure (Carvalho et al. 2002b; Chadwick et al. 
1991; Cunningham 1997; Green et al. 2003; Holt and Moore 2001; Ishigami et al. 2003; 
Liechti et al. 2005; Terada et al. 1988). Other severe symptoms of intoxication with MDMA 
include hyperkalemia (Ravina et al. 2004), hyponatremia (Traub et al. 2002), tachycardia, 
coagulopathy, thrombocytopenia, leucocytosis, late acidosis, hypoglycaemia, pulmonary 
congestion, oedema and liver toxicity (cases of fulminant hepatitis and hepatic necrosis) 
(Chadwick et al. 1991; Dowling et al. 1987; Henry et al. 1992; Kendrick et al. 1977; McCann 
et al. 1996; Screaton et al. 1992; Terada et al. 1988; Traub et al. 2002). Other potentially fatal 
neurological effects include subarachnoid haemorrhage, intracranial haemorrhage, cerebral 
infarction and cerebral thrombosis. These complications may result from hypertension, 
cerebral angiitis or dehydration associated with the ingestion of MDMA (McCann et al. 1996; 
Milroy et al. 1996; Rutty and Milroy 1997). The necrosis of the liver and heart tissue was also 
observed in post-mortem studies (Milroy et al. 1996; Rutty and Milroy 1997). 
The most worrisome long-term toxic effect of MDMA is neurotoxicity (Boot et al. 
2000; Capela et al. 2009; Dafters et al. 1999; Gerra et al. 2000; Gerra et al. 1998; Gouzoulis-
Mayfrank and Daumann 2006b; Green et al. 2003; McCann et al. 1999a; McCann et al. 2000; 
McCann et al. 1999b; McCann et al. 1994; McCann et al. 2005; Price et al. 1989; Reneman et 
al. 2001; Reneman et al. 2002; Ricaurte et al. 1990; Ricaurte et al. 2000; Semple et al. 1999), 
an effect that appears to be reversible after a long period of abstinence, although some 
damages seem to persist (Gouzoulis-Mayfrank and Daumann 2006b). Chronic use of MDMA 
has also been associated with persistent sleeping problems (Allen et al. 1993), various 
psychopathological problems, including eating disorders (Schifano et al. 1998) and cardiac 
(Brody et al. 1998; Screaton et al. 1992) and renal impairment (Carvalho et al. 2002b; 
Cunningham 1997; Holt and Moore 2001; Ishigami et al. 2003; Liechti et al. 2005).  
Toxicity is therefore diffuse and, among the target organs of MDMA toxicity, the liver 
is of special concern because it not only suffers from the detrimental actions of MDMA itself, 
but also from the metabolic bioactivation processes that render this organ particularly 
vulnerable to the toxicity of MDMA and many other amphetamines. 
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1.5.3. Liver toxicity 
 
MDMA is among the most common causes of drug-induced liver failure, accounting for up to 
20% of all cases in young patients (Andreu et al. 1998; Carvalho et al. 2012; Carvalho et al. 
2010). This drug was even described as the second most common cause of liver injury (after 
EtOH) in young people admitted to intensive care units (Andreu et al. 1998; Carvalho et al. 
2012; Carvalho et al. 2010; Jones and Simpson 1999), but it is believed that several cases of 
MDMA-elicited liver failure are not correlated to the drug intake. In fact, the highly variable 
interval between exposure and the onset of the symptoms (from a few days to 2 or 3 weeks) 
hamper the recognition of the aetiological agent involved (Brncic et al. 2006; Carvalho et al. 
2012; Carvalho et al. 2010; Henry 1992; Nunez et al. 2002; Shulgin and Nichols 1978).  
Notwithstanding, multiple cases of hepatotoxicity mediated by MDMA have been 
described (Andreu et al. 1998; Brncic et al. 2006; Coore 1996; de Man et al. 1993; Dykhuizen 
et al. 1995; Fidler et al. 1996; Henry et al. 1992; Khakoo et al. 1995; Roques et al. 1998) and 
were subject of several reviews (Aknine 2004; Antolino-Lobo et al. 2011b; Carvalho et al. 
2010; Jones and Simpson 1999). Toxic liver effects are characterized by distinct patterns, 
ranging from asymptomatic hepatic injury (only denoted by the altered liver function tests), 
mild benign forms (Dykhuizen et al. 1995; Ellis et al. 1996), serious liver dysfunction with 
loss of liver parenchyma, as a result of extensive and/or focal hepatic necrosis (Henry et al. 
1992; Milroy et al. 1996; Sano et al. 2009) and, in worst cases, to fulminant liver failure 
(Brauer et al. 1997; Caballero et al. 2002; Dykhuizen et al. 1995; Ellis et al. 1996; Fineschi et 
al. 1999; Garbino et al. 2001; Henry et al. 1992; Khakoo et al. 1995; Liechti et al. 2005; 
Milroy 1999; Milroy et al. 1996; Varela-Rey et al. 1999) that can be fatal or require liver 
transplantation (Brauer et al. 1997; Caballero et al. 2002; Carvalho et al. 2012; Carvalho et al. 
2010; Ellis et al. 1996; Lange-Brock et al. 2002). After exposure to MDMA, the liver 
architecture can show dramatic modifications mainly due to necrosis accompanied by an 
acute inflammatory reaction, particularly in the cases accompanied by hyperpyrexia 
(Carvalho et al. 2012; Carvalho et al. 2010; Ellis et al. 1996; Fidler et al. 1996). 
Microvesicular fatty changes may be present, with the portal tracts being expanded by 
oedema and inflammatory infiltrates (Andreu et al. 1998; Milroy et al. 1996).  
This multiplicity of MDMA-induced hepatotoxic manifestations suggests different 
mechanisms of pathogenesis (Andreu et al. 1998; Brauer et al. 1997; Carvalho et al. 2012; 
Carvalho et al. 2010; Henry et al. 1992; Jones and Simpson 1999; Milroy et al. 1996; Schwab 
et al. 1999). Further complicating this scenario, is the fact that the severity of the symptoms 
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and injuries previously mentioned do not link with the chronicity of exposure nor to the dose 
of drug consumed (Andreu et al. 1998; Dykhuizen et al. 1995; Garbino et al. 2001). In some 
cases, the damage occurs after the ingestion of a small amount of drug and cases of fulminant 
acute hepatitis have been described after the ingestion of a single tablet of MDMA 
(Dykhuizen et al. 1995; Ellis et al. 1996; Garbino et al. 2001; Henry et al. 1992). In other 
cases, liver injury appears as a consequence of chronic MDMA use (de Man et al. 1993; 
Fidler et al. 1996). Repeated or/and prolonged exposures appear to increase the extent of liver 
damage, suggesting the possible involvement of immune mechanisms (Carvalho et al. 2012; 
Carvalho et al. 2010; Jones and Simpson 1999). Also, chronic use of MDMA can lead to the 
development of progressive liver fibrosis (Carvalho et al. 2012; Carvalho et al. 2010; Khakoo 
et al. 1995; Varela-Rey et al. 1999). 
For all the presented reasons, MDMA hepatocellular toxicity is characterized by its 
random occurrence, with unpredictable severity (Brncic et al. 2006; Carvalho et al. 2012; 
Carvalho et al. 2010). A brief overview of the mechanisms involved is presented below, with 
some of particular interest to the experimental work herein presented being discussed with 
further detail in the discussion section of the thesis. 
 
 
1.5.3.1.Putative mechanisms underlying MDMA-elicited 
hepatotoxicity 
 
The mechanisms through which the intoxications occur are complex and have not been 
completely elucidated but it is acknowledge the high probably of a multifactorial origin being 
at play. Carvalho et al. (2012; 2010) extensively reviewed the multiple pathways that have 
been proposed to explain the liver damage induced by ecstasy. Among others, these effects 
have been attributed to: (i) idiosyncratic reactions (Henry et al. 1992), (ii) the action of 
MDMA and/or its metabolites either by a direct toxic action, or indirectly through the release 
of endogenous catecholamines, (iii) induction of oxidative stress, (iv) hyperthermia (Andreu 
et al. 1998), (v) changes in liver blood flow, (vi) apoptosis, (vii) hypersensitivity/ 
inflammation mechanisms (Andreu et al. 1998), (viii) circulatory collapse and hypoxic 
damage (Mustafa et al. 1985), and also (ix) to the impact of other substances ingested with 
MDMA (Milroy et al. 1996; Parrott 2004a), etc. 
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1.5.3.1.1. Oxidative stress 
 
The generation of ROS and/or RNS and the subsequent oxidative/nitrosative stress is inherent 
to several mechanisms underlying MDMA-induced hepatocellular toxicity (Beitia et al. 1999; 
Beitia et al. 2000; Carvalho et al. 2002a; Cerretani et al. 2011; Custodio et al. 2010; Darvesh 
et al. 2005; Gow et al. 2004; Johnson et al. 2002; Moon et al. 2008; Ninkovic et al. 2004; 
Pacher et al. 2007; Zheng and Laverty 1998), such as hyperthermia, oxidative metabolism of 
MDMA and released catecholamines, mitochondrial impairment, and immune responses. 
With the ability to disrupt cellular homeostasis and produce cellular death, oxidative stress 
biomarkers were considered of particular interest and included in the experimental tasks of 
this thesis. 
 
 
1.5.3.1.2. Altered release of biogenic catecholamines and 
oxidative metabolism  
 
The altered release of biogenic catecholamines and its consequent oxidative metabolism plays 
a role in MDMA hepatotoxicity. The activation of α-adrenergic receptors located in the 
hepatocytes by endogenous catecholamines, which are released due to MDMA action, can 
result in decreased levels of GSH (James et al. 1983; Sies and Graf 1985), increased 
mitochondrial respiration and increased concentration of intracellular free calcium (Pontes 
2009; Taylor et al. 1983). Liver injury can also result from the oxidative metabolism of these 
catecholamines, mostly metabolized by MAO and COMT (Carvalho et al. 2012; Hoffman and 
Lefkowitz 1996; Lefkowitz et al. 1996; Pontes 2009). On the other hand, when the metabolic 
pathways become saturated or inhibited by MDMA (Leonardi and Azmitia 1994), 
catecholamines can undergo auto-oxidation with formation of highly reactive species, 
including reactive metabolites, ROS and RNS, with the ability to trigger intracellular 
oxidative stress (Bindoli et al. 1992; Bindoli et al. 1989; Carvalho et al. 2012; Pontes 2009). 
The oxidation of the catecholamines (Bindoli et al. 1992; Bindoli et al. 1989) begins with the 
oxidation of the catechol group into a semiquinone form, which rapidly oxidizes into a 
quinone (Figure 3). The reaction of the oxidation products of the catecholamines with 
cysteine and GSH results in the formation of adducts with high reactivity and potentially 
cytotoxic (Bindoli et al. 1992). Once the cell is depleted from endogenous defence 
mechanisms, including enzymatic and non-enzymatic antioxidants, it can enter into a death 
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process either by necrosis or apoptosis, depending mostly on its energetic status (Carvalho et 
al. 2012; Pontes 2009). 
 
 
1.5.3.1.3. Mitochondrial disruption 
 
Mitochondria are preferential sites for ROS/RNS production, and, consequently, vital targets 
of oxidative/nitrosative stress. It is argued that MDMA and/or its reactive metabolites 
(especially the quinones) disrupt mitochondrial functionality (Burrows et al. 2000; Carvalho 
et al. 2004b; Fisher et al. 2007; Miller et al. 1997; Montiel-Duarte et al. 2004; Moon et al. 
2008; Nakagawa et al. 2009) by directly inhibiting the activities of mitochondrial complexes 
I, II, IV, and V (Alves et al. 2009; Moon et al. 2008) or by inactivating various mitochondrial 
proteins, as already demonstrated with cytochrome c (cyt c) (Fisher et al. 2007), which is 
likely to contribute to mitochondrial dysfunction (Carvalho et al. 2012; Pontes 2009). It is 
possible that concurrent production of peroxynitrite (ONOO·-) after MDMA exposure leads 
to the oxidative modifications of some mitochondrial complex proteins, resulting in their 
inhibition (Cardoso et al. 1999; Murray et al. 2003). Interruption of the mitochondrial electron 
transport chain would lead to increased ROS leakage (Amacher 2005; Begriche et al. 2006; 
Lin and Beal 2006; Moon et al. 2008), which in turn, may also cause mitochondrial 
dysfunction (Brown and Yamamoto 2003). Mitochondrial dysfunction was also evaluated in 
the experimental work of this thesis. 
 
 
1.5.3.1.4. Hyperthermia 
 
In vitro studies have shown that the elevation of incubation temperature, aiming at simulating 
the MDMA-induced hyperthermia, enhances the hepatotoxic effects of MDMA, particularly 
those closely related to oxidative stress (Carvalho et al. 2001; Carvalho et al. 2002a; Pontes et 
al. 2010; Pontes et al. 2008a; Pontes et al. 2008b; Pourahmad et al. 2010; Santos-Marques et 
al. 2006). In several of the reported human intoxications where liver damage occurred the 
intoxicated individuals presented increased body temperature (Table 5). For any mechanistic 
evaluation of MDMA-induced toxicity the influence of hyperthermia has to be necessarily 
addressed. 
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Figure 3. Metabolism of catecholamines and their autoxidation process. Catecholamines-o-quinones are 
unstable and by deprotonation of the amino group, can endure a nucleophilic attack at the nitrogen, resulting in 
the formation of leucoaminochrome (1,4-intramolecular cyclization). The leucoaminochrome is oxidized 
forming the respective aminochrome. The speed of this metabolic process depends on the substituent groups of 
catecholamines being, therefore, variable for different catecholamines (dopamine <α-methyldopamine 
<noradrenaline <N-methyl-α-methyldopamine <adrenaline) (Chavdarian et al. 1978). The increase of 
catecholamine-o-quinones lifetime subsequently increases the likelihood for exerting intracellular oxidative 
damage. Aminochromes are chemically unstable and may undergo intramolecular rearrangements (with 
formation of dihydroxyindoles which polymerize yielding dark, insoluble melanin-like pigments), oxidations 
and reductions, regenerating leucoaminochromes. The reduction of aminochromes may occur in the presence of 
antioxidants, such as glutathione, yielding highly reactive intermediate semiquinones (Bindoli et al. 1992). The 
reactivity of quinones and aminochromes formed during these oxidation processes are directly related to their 
ability to enter in redox cycles with consequent formation of ROS and RNS. Adapted from Carmo (2007). 
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1.5.3.1.5. Metabolic bioactivation of MDMA 
 
The metabolic pathways of MDMA that were previously described provide many possibilities 
for inducing cellular damage. Several in vitro studies have demonstrated the toxicity of 
MDMA metabolites and have been extensively reviewed (Carvalho et al. 2012; Green et al. 
2003; Pontes 2009). These in vitro and in vivo studies showed that metabolic bioactivation 
plays an important role in the MDMA toxic expression not only in the liver (Carvalho et al. 
2004a; Carvalho et al. 2004b), but also in neurons (Capela et al. 2006; Gollamudi et al. 1989; 
Mueller et al. 2009; Patel et al. 1991), kidney (Carvalho et al. 2002b) and heart (Carvalho et 
al. 2004c).  
 
 
1.5.3.1.6. Immune responses and inflammation 
 
Another pathway that has been suggested to play a role in the onset of MDMA-induced liver 
injury is linked to adverse immune responses, since activated Kupffer cells (KC) and 
infiltrated inflammatory cells (lymphocytes, neutrophils, and eosinophils) have been found in 
the liver after fatal MDMA intoxications (Andreu et al. 1998; Antolino-Lobo et al. 2011b; 
Ellis et al. 1996; Khakoo et al. 1995; Schwab et al. 1999). Additionally, MDMA has been 
shown to induce a transient immune dysfunction (declining the number of T helper 
lymphocytes CD4 +, increasing the number of natural killer cells (NK), and activating nuclear 
factor kappa B (NF-κB), a transcription factor involved in the activation of response genes to 
inflammatory stimuli (Chen and Shi 2002; Montiel-Duarte et al. 2004; Pacifici et al. 2000; 
Pacifici et al. 2001a; Pacifici et al. 1999; Pacifici et al. 2002; Tiangco et al. 2005). Oxidative 
stress is also believed to play a distinct role in the development of such mechanisms. 
 
 
1.5.3.1.7. Genetic polymorphisms of MDMA abusers 
 
Polymorphisms of genes coding for proteins involved in the pharmacokinetics and 
pharmacodynamics of MDMA may help explain the fact that some individuals can consume 
MDMA regularly without apparent damage, while others die or experience severe toxic 
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reactions with sporadic or low-dose consumptions (Carmo 2007; Carvalho et al. 2012; 
Carvalho et al. 2010; Pontes 2009; Wolff et al. 1995).  
It has already been described that genetic polymorphisms affect the toxicity profile of 
MDMA due to alterations on expression and/or activity of CYP450 (CYP1A2, CYP2B6, 
CYP2D6, CYP3A4) (Ingelman-Sundberg 2004; Parkinson et al. 2004), COMT (Mattay et al. 
2003; McLeod et al. 1994; Weinshilboum et al. 1999), UDP-glucuronosyltransferase (UGT) 
(Felton and Malfatti 2006; Miners et al. 2002), sulfotransferase (SULT) (Nagata and 
Yamazoe 2000), 5-HT receptor (Masellis et al. 1995), DA receptor (Cichon et al. 2000; 
Cravchik and Gejman 1999; Li et al. 2004; Persico et al. 1996; Steen et al. 1997), serotonin 
transporter (SERT) (Lesch and Gutknecht 2005; Reneman et al. 2006; Roiser et al. 2005; 
Roiser et al. 2006), among others (Carmo 2007; Carvalho et al. 2012; Carvalho et al. 2010; 
Pontes 2009). 
 
 
1.2.1.1.1. Induction of apoptosis 
 
As mentioned before, cellular death mechanisms are mostly decided by the energetic status of 
the cell. Despite the main clinically significant toxic features of amphetamines in general, 
including hyperthermia and hepatic failure, correlate with histopathological demonstration of 
liver necrosis (Brauer et al. 1997; Garbino et al. 2001; Ibranyi and Schonleber 2003; Kamijo 
et al. 2002; Marinkovic et al. 2011; Sano et al. 2009), there are plenty of data in the literature 
supporting that also apoptotic pathways are involved in MDMA-induced liver toxicity 
(Cerretani et al. 2011; Montiel-Duarte et al. 2004; Montiel-Duarte et al. 2002; Upreti et al. 
2011). The apoptotic pathways of cellular death were also included in the experimental work 
of the thesis when mechanistic evaluations were performed. 
 
 
1.2.1.1.1. Co-exposure with other substances 
 
As can be easily concluded from what has been presented so far, the type and severity of 
MDMA-induced hepatotoxicity is influenced by assorted factors. These features, when 
combined with the heterogeneity of substances included in ecstasy tablets or the drugs that are 
inadvertently or intentionally co-ingested by abusers (to extend and exacerbate the stimulating 
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effect or to alleviate the undesired ones) increase the risk for developing toxicity and 
complicate the determination of the circumstances involved in MDMA intoxications 
(Carvalho et al. 2012; Cole and Sumnall 2003; Gowing et al. 2001; Mohamed et al. 2011). 
Given the importance of this subject for the work herein presented, the detrimental 
consequences originated by the co-exposure of MDMA and other substances will be 
extensively debated in section 2 of the introduction. 
 
 
1.2.1.2.Factors affecting liver toxicity induced by MDMA  
1.2.1.2.1. Dose ingested 
 
The ingested dose of MDMA impacts on its biological/toxicological effects, particularly due 
to the phenomenon of MDMA self-induced metabolic inhibition. Pro-social effects, 
propensity to addiction, ‘hangover’ effects, disorientation, hallucinations and other side 
effects are known to increase in a dose-depend fashion (Chesher 1990; Ho et al. 2001; 
Plessinger 1998; Solowij et al. 1992). But as already noted, it is not only the amount of 
MDMA ingested on each single occasion that accounts for the toxicity of the drug. The 
frequency of administration was shown to highly impact the hyperthermic effect, hyperkinetic 
responses, long-lasting serotonergic deficits, tachyphylaxis, psychological disorders, and 
tolerance induced by the drug (Dafters 1995; Green et al. 2004; Mechan et al. 2006; Schifano 
et al. 1998; Solowij et al. 1992). 
 
 
1.2.1.2.2. Ambient settings 
 
Despite the existence of some sporadic episodes providing compelling evidence of a direct 
toxic action of MDMA regardless of the circumstances of its use (Bedford-Russell et al. 1992; 
Chang et al. 2005; Eifinger et al. 2008; Hall et al. 1996), environmental conditions of misuse 
venues greatly affect MDMA-induced toxicity (Bellis et al. 2002; Parrott 2004b). In fact, 
MDMA abuse in hot, crowded environments, with loud repetitive electronic music and 
prolonged physical exertion, seems to exacerbate the toxicity of the drug mainly because high 
temperature increases MDMA toxicity (Capela et al. 2007; Capela et al. 2006; Carvalho et al. 
2002a; Fineschi et al. 1999; Malberg and Seiden 1998; O'Shea et al. 2006). Several in vivo 
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studies provide evidence that the effects of MDMA on body temperature are dependent on 
ambient temperature (Banks et al. 2007; Carvalho et al. 2002a; Gordon et al. 1991; Green et 
al. 2005; Malberg and Seiden 1998; Sanchez et al. 2004; Von Huben et al. 2007). When 
administered to rats at high ambient temperatures, MDMA causes hyperthermia by increasing 
heat production in brown adipose tissue and reducing heat loss due to peripheral 
vasoconstriction. Conversely, when administered to rats in a cold environment, MDMA 
causes hypothermia by inhibiting brown adipose tissue thermogenesis and due to the tail 
artery vasoconstriction caused by the cold (Rusyniak et al. 2008). Furthermore, high ambient 
temperatures increased the number of MDMA self-administrations by rats, appearing to affect 
both the social and reinforcing effects of MDMA (Chesher 1990; Cornish et al. 2003). 
Loud noise has been associated with an increase in MDMA-induced neurotoxicity 
(Walubo and Seger 1999). Noise can also exacerbate myocardium damage, rhabdomyolysis, 
by causing ultra-structural changes on mitochondria of cardiac muscle (Gesi et al. 2002a; Gesi 
et al. 2002b). Stress causes an increase in MDMA brain concentrations (Johnson et al. 2004) 
and increases psychostimulant self-administration (Piazza and Le Moal 1996). Aggregation 
potentiates the acute effects of MDMA (Fantegrossi et al. 2003; Parrott 2004b), and increases 
addictive behaviours (Meyer et al. 2002b) raising concern due to the frequently overcrowded 
consumption settings. Physical activity also contributes to the worsening of MDMA acute 
toxicity (Parrott 2004b), probably by increasing heat production and, thus, contributing to 
hyperthermia (Miller and O'Callaghan 1995). Also, the excessive water intake can lead to 
hyponatremia resulting in cerebral oedema (Cole and Sumnall 2003; Finch et al. 1996; 
Wilkins 1996). 
 
 
1.2.1.2.3. Abuser features 
 
Several factors inherent to ecstasy misusers determine the risks associated with drug 
consumption. Among the features of consumers that may impact MDMA toxicity are age 
(Broening et al. 1994; Broening et al. 1995; Marchesini et al. 1988; Morley-Fletcher et al. 
2004; Parkinson et al. 2004; Schmucker 2005; Sotaniemi et al. 1997; Wiley et al. 2008; 
Wynne et al. 1989), ethnicity (Clatts et al. 2005; Ingelman-Sundberg et al. 1999; Ompad et al. 
2005; Parkinson et al. 2004; Relling et al. 1992; Wu et al. 2006a), gender (Kawas et al. 1997; 
Liechti et al. 2001; McCann et al. 1994; Parkinson et al. 2004; Relling et al. 1992; Reneman 
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et al. 2001; Sherlock et al. 1999; Swaab and Fliers 1985; Vistisen et al. 1991; Wyeth et al. 
2009), sexual orientation (Degenhardt 2005; Parsons et al. 2006), and physiological and 
pathophysiological individual conditions (e.g. pregnancy, hypo/hyperthyroidism, liver and 
renal deficiencies, infectious and inflammatory pathologies, heart pathology, diabetes mellitus 
and obesity), as these characteristics determine individual 
pharmacokinetics/pharmacodynamics, therefore, impacting the pharmacological/toxicological 
profile of the drug, and also influences consumption patterns. 
 
 
2. MDMA multiple-drug consumption patterns – Interaction with other 
substances 
 
Ecstasy misusers repeatedly abuse several drugs simultaneously, combining legal and illegal 
substances to modulate the expected effects of MDMA (Carvalho et al. 2012; Drugs 2004; 
Pontes 2009; Schifano et al. 1998). Studies on the progression of drug use revealed that the 
recreational use of MDMA is usually preceded by legal drugs (EtOH and nicotine), followed 
by cannabis, and later by other illicit drugs, including other amphetamines (Pedersen and 
Skrondal 1999; Pontes 2009). A recent study observed that polydrug abuse is more frequent 
with the initiation of ‘heavier’ drugs, including MDMA, when compared to alcohol, tobacco 
or cannabis (Olthuis et al. 2013). Also, a direct correlation seems to exist between the 
frequency of ecstasy usage and the propensity of individuals to consume other illicit drugs, 
such as cocaine, amphetamines, LSD, hallucinogenic psilocybin mushrooms, ketamine, 
gamma-hydroxybutyrate (GHB) (Ho et al. 2001; Mendes and Lomba 2008; Mohamed et al. 
2011; Scholey et al. 2004). Frequently, the abusers notice a decrease in the drug acute effects 
after continued use (pharmacodynamic tolerance), increasing the propensity for the use of 
other psychoactive substances or drug cocktails aiming at accomplishing the desired pleasant 
experiences (Merrill 1996; Parrott 2001; Peroutka et al. 1988). 
This polydrug abuse pattern is one the most serious confounding factors when 
evaluating MDMA toxicity, as it hampers the correlation of toxicological events with one 
specific drug (Cole and Sumnall 2003; Gouzoulis-Mayfrank and Daumann 2006a). In fact, 
unique and unpredictable reactions can be produced from the joint action of MDMA and other 
substances in the body, greatly aggravating the associated health risks (Carvalho et al. 2012). 
Nevertheless, the understanding of the toxicity and the investigation of potential 
neurobehavioral, pharmacodynamic and/or pharmacokinetic drug–drug interactions between 
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MDMA and other recreational or therapeutic agents has received rather little attention, and 
most of the information on the topic is inferred from clinical cases (human reports from 
emergency room visits) and from preclinical in vitro studies (Carvalho et al. 2012; Mohamed 
et al. 2011). 
Behavioural and neurobiological interactions are the most frequently reported by the 
abusers. They usually deliberately engage in polydrug abuse patterns aiming at heightening 
social and psychological experiences, or at mitigating aversive physiological effects 
(Mohamed et al. 2011). 
Pharmacokinetic interactions may arise when a particular compound interferes with 
absorption, distribution, metabolism and/or excretion of the drug. For instance, P-glycoprotein 
(Pgp) is an ubiquitous ATP-dependent efflux transporter that eliminates a wide variety of 
xenobiotics from the cells (Ketabi-Kiyanvash et al. 2003). Pgp inhibitors (e.g. ritonavir or 
paroxetine) are able to improve the bioavailability of MDMA and other amphetaminic 
analogues (e.g. 3,4-methylenedioxy-N-ethylamphetamine or MDE, p-methoxyamphetamine 
or PMA), by reducing their renal elimination and by increasing their levels in the brain 
(through a decrease in the blood-brain barrier clearance) leading to severe adverse effects 
(Ketabi-Kiyanvash et al. 2003; Pontes 2009). Also, drugs that are metabolized by, or disturb 
the CYP450 complex (by inducing or inhibiting the isoforms involved in MDMA 
metabolism) are prone to interact with MDMA pharmacokinetics. For instance, an increase in 
MDMA plasma concentrations due to reduced hepatic metabolism is likely to occur. 
Therefore, also potential toxicodynamic interactions are expected when a competitive 
inhibitor of CYP2D6 is co-ingested with MDMA (Mohamed et al. 2011; Oesterheld et al. 
2004). Examples of these drugs include fluoxetine, paroxetine, cocaine (Mohamed et al. 2011; 
Ramamoorthy et al. 2002), other amphetamine analogues (Mohamed et al. 2011; Wu et al. 
1997), and haloperidol metabolites (Mohamed et al. 2011; Shin et al. 2001). The simultaneous 
ingestion of drugs that additionally inhibit other CYP450 isoforms (e.g., CYP3A4) will 
further induce an even more marked effect on MDMA concentrations. Also, the self-
inhibition of CYP2D6 by MDMA at high concentrations might disproportionately increase 
the levels of the co-administered drugs, triggering toxicity phenomena (delaTorre et al. 
2000a). Of particular concern is the fact that several substrates of CYP2D6 display a narrow 
safety window (e.g. some tricyclic antidepressants, antiarrhythmics, β-blockers, 
antipsychotics and tramadol). Thus, notorious adverse reactions with MDMA can worryingly 
be anticipated (Carvalho et al. 2012). 
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Pharmacodynamic interactions occur when other substances with similar or opposite 
mechanisms of action are present (Carvalho et al. 2012). It is well known that MDMA 
promotes serotonergic, dopaminergic and noradrenergic actions (Lyles and Cadet 2003). The 
most disturbing effect that may arise from the simultaneous ingestion of pro-serotonergic 
drugs and MDMA is the serotonergic syndrome, whose effects include sweating, fever, 
tremors, hyperreflexia, agitation, and myoclonus and that can be fatal (Sternbach 1991). 
Cocaine, theophylline, caffeine LSD, and other amphetamines are drugs able to aggravate 
these MDMA effects (Carvalho et al. 2012; Greene et al. 2008; Oesterheld et al. 2004). But 
also some prescribed pro-serotonergic pharmaceuticals (e.g., anticholinergics, antidepressants, 
tramadol, lithium, salicylates, DXM, etc.), compounds inadvertently ingested in the diet, 
contaminants of the tablets of MDMA (e.g., d-AMP, MDA, METH) (Teter and Guthrie 
2001), drugs used intentionally to enhance the effects of MDMA (e.g., cocaine, DXM) 
(Ramamoorthy et al. 2002) or to decrease the undesirable ones (e.g., EtOH, benzodiazepines, 
sildenafil, 5-hydroxytryptophan) (Breslau 2002; Copeland et al. 2006; Winstock et al. 2001a) 
may render individual more susceptible to MDMA pharmacodynamic complications 
(Carvalho et al. 2012; Oesterheld et al. 2004). 
Some drugs can simultaneously act as sympathomimetic/ serotonergic/ dopaminergic 
agents and as CYP2D6 inhibitors, thus having the potential to cause pharmacodynamic and 
pharmacokinetic interactions with unpredictable consequences (Carvalho et al. 2012; 
Oesterheld et al. 2004). 
 
 
2.1. Therapeutic drugs 
 
As noted above, a popular practice among ecstasy abusers is to consume medications or 
dietary supplements to strengthen the ‘drug high’ or counteract some of the undesired ‘come 
down’ effects of MDMA, such as depression and insomnia. Pilgrim et al. (2011) reviewed the 
MDMA-related fatalities occurred in Victoria, between 2002 and 2008 and found that 41% 
cases involved the concomitant use of MDMA with pharmaceuticals. There are abundant data 
in the literature concerning MDMA interactions with therapeutic drugs regimens, that have 
been reviewed elsewhere (Carvalho et al. 2012; Copeland et al. 2006; Mohamed et al. 2011). 
The most common drugs intentionally used with MDMA are benzodiazepines and sildenafil, 
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followed by MAO inhibitors (MAOI) and selective serotonin reuptake inhibitors (SSRI) 
(Carvalho et al. 2012; Copeland et al. 2006). 
Benzodiazepines enhance the effect of the neurotransmitter gamma-aminobutyric acid 
(GABA), resulting in central nervous system inhibition properties. Due to their sedative, 
anxiolytic, anticonvulsant, and muscle relaxant effects, these drugs are a first-line strategy 
employed to control the sympathomimetic effects of amphetamines (Derlet et al. 1990; 
Nisijima et al. 2003). Notwithstanding, chlordiazepoxide potentiates amphetamine-induced 
hyperactivity (Carvalho et al. 2012; Kelly et al. 2009). Starcevic and Sicaja (2007) proposed 
that dual intoxication with amphetamine and benzodiazepine enhances the toxic effects on 
cardiac tissue and coronary arteries, resulting in larger myocardial injury. Enhanced CYP3A 
inhibition was also noted in rat liver microsomes co-incubated with MDMA and clozapine 
(Antolino-Lobo et al. 2011a). 
Ecstasy abusers combine MDMA and sildenafil (a combination known as ‘sextasy’) to 
enhance the sexual experience (Breslau 2002). There are data demonstrating that sildenafil 
produces a long-lasting neuroprotective effect against MDMA-induced 5-HT deficits, 
apparently due to the increased expression of manganese superoxide dismutase (MnSOD) and 
a subsequent reduced susceptibility to the oxidative stress caused by MDMA (Puerta et al. 
2012). 
 Antidepressants are used by ecstasy abusers to enhance and prolong the drug ‘high’, to 
counteract the ‘come down’ stage, and for sleeping aid (Copeland et al. 2006). The 
antidepressants most commonly used in combination with ecstasy are SSRIs (e.g., citalopram, 
fluoxetine, paroxetine, sertraline) and MAOIs (e.g., phenelzine, moclobemide) (Carvalho et 
al. 2012), both promoting an increase of the neurotransmitters in the synaptic cleft. 
SSRIs can rise MDMA plasma levels increasing the potential for toxicodynamic acute 
reactions (Carvalho et al. 2012), but can also promote beneficial effects regarding the long-
term cellular damage, by decreasing the formation of MDMA toxic metabolites (Rietjens et 
al. 2012) through CYP2D6 inhibition such as is the case of fluoxetine (Ramamoorthy et al. 
2002). Also, clinical effects (e.g. blood pressure, heart rate, body temperature) and positive 
subjective effects can be reduced, possibly due to a pharmacodynamic interaction at the SERT 
(Rietjens et al. 2012). This reduction in MDMA subjective effects may in turn lead users to 
consume higher doses of MDMA, to achieve the desired effects, thus exposing themselves to 
potentially lethal toxic risks (Farre et al. 2007). 
 The MAOIs most frequently involved in lethal MDMA poisonings are those with 
greater selectivity for MAO-A, such as moclobemide (Vuori et al. 2003) and clorgyline 
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(Carvalho et al. 2012). MAOIs are likely to potentiate pharmacodynamic interactions with 
MDMA in humans (delaTorre et al. 2004a; Kaskey 1992; Smilkstein et al. 1987) and the most 
worrisome effect is the induction of the 5-HT syndrome (Pilgrim et al. 2010; Pilgrim et al. 
2011; Pilgrim et al. 2012; Scorza et al. 1999; Vuori et al. 2003). Selective MAO-B inhibitors 
(e.g., selegiline, L-deprenyl), on the contrary, appear to confer some protection against 
MDMA-induced neurotoxicity by several mechanisms (Carvalho et al. 2012; Pontes 2009) 
including: (i) decreasing the depletion of 5-HT in the brain (Sprague and Nichols 1995), (ii) 
decreasing the formation of reactive species resulting from the MAO-B metabolism of the 
released catecholamines (Hrometz et al. 2004), and consequently, (iii) decreasing of lipid 
peroxidation (Sprague and Nichols 1995), and of (iv) mitochondrial oxidative damage (Alves 
et al. 2007). 
The most serious cases of serotonergic syndrome seem to occur when the drugs block 
both 5-HT reuptake and MAO metabolic degradation pathways, greatly increasing the 5-HT 
levels in the synaptic cleft. 
 
 
2.2. Interaction with food 
 
Several constituents of the diet may affect the CYP450 isoenzymes (Ioannides 1999; 
Parkinson et al. 2004), potentially raising the risk for pharmacokinetic interactions with 
MDMA. The induction of these enzymes may be especially problematic due to the expected 
increase in metabolic bioactivation. Also the unpredictable effect of food xenobiotics present 
in the diet (e.g. mycotoxins, dioxins, products generated during food processing and food 
additives, such as growth promoting hormones and pesticides) on the activity of the CYP450 
and, therefore, on MDMA pharmacokinetics should not be neglected (Ioannides 1999; Pontes 
2009). 
 
 
2.3. Contaminants and adulterants of ecstasy pills 
 
Most studies on the content and purity profile of pills sold as ecstasy so far conducted (Cheng 
et al. 2003; Parrott 2004a; Sherlock et al. 1999; Stoové et al. 2006; Tanner-Smith 2006) lead 
to the same conclusions (Carvalho et al. 2012; Pontes 2009): (i) not all the tablets contain 
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MDMA and some have a completely different drug (Baggott et al. 2000; Cheng et al. 2003; 
Giroud et al. 1997; Sherlock et al. 1999; Tanner-Smith 2006); (ii) the MDMA content of 
ecstasy tablets differs greatly even within the same batch (Giroud et al. 1997; Sherlock et al. 
1999; Tanner-Smith 2006), (iii) the majority of the pills present inert substances/excipients in 
their composition (Carvalho et al. 2012; Giroud et al. 1997), and (iv) many pills contain other 
stimulants in addition to MDMA (e.g., 4-MTA, ketamine, caffeine, ephedrine, LSD, among 
many others) (Baggott et al. 2000 633; Cheng et al. 2003; Drugs 2004; Giroud et al. 1997; 
Parrott 2004a; Tanner-Smith 2006). Several relevant studies provide compelling evidence that 
extremely harmful and unpredictable reactions on consumers do occur due to such 
combinations (De Letter et al. 2006; Schifano et al. 2003). 
 
 
2.3.1. Products derived from chemical synthesis 
 
While in certain batches there is no evidence of the presence of compounds derived from the 
synthesis process (Parrott 2004a 126; Pontes 2009; Schifano 2000), reagents, intermediates 
and by-products of synthesis have already been found in seized tablets (Cheng et al. 2006). 
The presence of these impurities is worrisome from a toxicological perspective as they may 
also have inherent severe toxicity (Table 6). 
 
Table 6. Potential toxicity derived from precursors, intermediates, and by-products of MDMA chemical 
synthesis. Adapted from Pontes et al. (2009). 
 
Compound Putative effect 
Starting materials 
MDA MDMA addictive toxicodynamic and toxicokinetic effects 
(Crean et al. 2006) 
 
Saphrol and analogues Potential carcinogenicity in humans by forming adducts with 
DNA (Phillips 1994) 
 
Tetrahydrofuran (THF) Hepatocellular dysfunction at high doses (Moody 1991) 
Inhibition of some CYP450 isoenzymes (mainly CYP2E1) 
(Moody 1991) 
 
Methanol Metabolic acidosis and inhibition of cell respiration due to 
accumulation of formic acid that may decrease the half-life of 
MDMA by increasing urinary excretion (Lanigan 2001) 
 
N-methylformamide Hepatoxicity (Clagett-Carr et al. 1988) 
 
Pyridine (Cheng et al. 2006) Induction of CYP2E1 
Hepatotoxicity and nephrotoxicity 
Intermediates of synthesis 
1,3-bis-(3,4-methylenedioxyphenyl)-2-propanamine  
N-formyl-1,3-bis(3,4-methylenedioxyphenyl)-prop-2-ylamine 
Inhibition of monoamine transporters with similar intensity to 
MDMA (Pifl et al. 2005) 
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2.3.2. Other substances 
 
Apart from synthesis several other substances have been found as contaminants of ecstasy 
pills. These include caffeine, DXM, amphetamine derivatives, among others. 
Caffeine exposure results not only from contamination of the pills (Brunt et al. 2012; 
Klingler et al. 2005; Morefield et al. 2011; Vogels et al. 2009), but also from the ingestion of 
caffeine-rich drinks including, tea, coffee, coke, and non-alcoholic energy beverages that are 
consumed to reduce drowsiness and fatigue (Carvalho et al. 2012). While caffeine is 
considered safe at low doses (Daly and Fredholm 1998) it can exacerbate the acute MDMA 
toxicity and has been shown to increase mortality after acute administration of MDMA 
(Carvalho et al. 2012; Derlet et al. 1992; McNamara et al. 2006; Vanattou-Saifoudine et al. 
2012b). The involved mechanisms and associated effects were reviewed by Vanattou-
Saifoudine et al. (2012b) and included: (i) potentiation of serotonergic toxicity (Camarasa et 
al. 2006; McNamara et al. 2006; Sprague et al. 1998), (ii) increased MDMA-induced release 
of DA (Carvalho et al. 2012; Okada et al. 1997; Vanattou-Saifoudine et al. 2011) and 
enhanced intracellular response mediated by D1 receptor signalling pathway (Vanattou-
Saifoudine et al. 2012a), (iii) increased body temperature (McNamara et al. 2006; Vanattou-
Saifoudine et al. 2010a; Vanattou-Saifoudine et al. 2010b), (iv) increased MDMA-induced 
locomotor activity (Camarasa et al. 2006), (v) anorectic effects (Camarasa et al. 2006; 
McNamara et al. 2006) and (vi) profound and persistent tachycardia, (McNamara et al. 2007; 
Vanattou-Saifoudine et al. 2010b; Vanattou-Saifoudine et al. 2012b). Notwithstanding, recent 
studies suggest that chronic caffeine consumption at low doses exerts anti-inflammatory 
effects and prevents MDMA-induced neuroinflammation, as it completely prevented MDMA-
induced glial activation without inducing physiological or behavioural alterations (Ruiz-
Medina et al. 2012). Caffeine can also interfere with MDMA pharmacokinetics, as shown in 
vitro by the enhanced permeation through intestinal Caco-2 cells (Kuwayama et al. 2007), and 
in vivo with increases in the area under the plasma concentration-time curve (AUC) of 
MDMA in rats (Kuwayama et al. 2007). 
DXM is an antitussive cough suppressant that has been found in the constitution of 
ecstasy tablets at doses considerably higher than the usual therapeutic dose of this drug 
(Pontes 2009). It has been responsible for severe and even fatal intoxications 
(http://metro.co.uk/2011/07/07/a-level-student-kate-mclaughlin-killed-by-mix-of-ecstasy-and-
cough-medicine-70133/) since it potentiates the serotonergic effects of MDMA (Baggott et al. 
General introduction 
49 
 
2000; Kamei et al. 1992; Urbain et al. 2008) and competes for the CYP2D6 metabolic 
pathways (Delaforge et al. 1999). 
Paracetamol has been found in ecstasy tablets but not at hazardous doses (generally 
less than 200 mg per tablet) (Sherlock et al. 1999). The CYP450-catalysed metabolism of 
paracetamol results in formation hepatotoxic metabolites that can deplete GSH (similar to 
MDMA) and exacerbate liver injury (Plaisance 2000; Pontes 2009).  
Some pharmacologically inert excipients can also be intentionally included in the pills. 
For example, sodium bicarbonate causes an alkalinisation of the excretion fluids (e.g., urine, 
sweat) leading to a delay in MDMA clearance (Carvalho et al. 2012) and prolonging its 
effects. 
Among the drugs of abuse that most often appear in ecstasy pills, the least frequent 
seem to be cocaine, heroin and other opioids, since the inclusion of these ingredients in the 
tablets is not an economical benefit to manufacturers (Pontes 2009; Sherlock et al. 1999). 
 On the contrary, the presence of amphetamine analogues is very common in ecstasy 
pills in addition to MDMA (Barrett et al. 2005; Carvalho et al. 2012). Some may arise in 
ecstasy tablets as precursor of the MDMA synthesis, but in most cases these drugs are 
intentionally included in the composition of the tablets to enhance the effects of the drug 
(Kalasinsky et al. 2004). The consequences of such interactions will be further discussed in 
section 2.4.11 with greater detail. 
 
 
2.4. Intentional co-ingestion of other recreational drugs 
 
As already mentioned, ecstasy abusers frequently ingest other recreational drugs of abuse 
along with MDMA (Drugs 2004; Schifano et al. 1998). Scholey et al. (2004) reported that the 
abuse practices of MDMA misusers include LSD (60%), psilocybin (56%), and opiates 
(23%). But other studies disclosed the tendency for the use of other illicit drugs, such as 
ketamine (9%), GHB (7%), and psilocybin-containing ‘magic mushrooms’ (4%) (Ho et al. 
2001; Mohamed et al. 2011). Compelling evidence on polydrug abuse reported by ecstasy 
misusers are compiled in Table 1. 
 Among the drugs that are legally consumed, tobacco and EtOH are the most 
frequently reported by MDMA abusers (Carvalho et al. 2012). 
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2.4.1. Tobacco 
 
Ecstasy consumers have a high prevalence of smoking. Roughly 90% of American 
adolescents using MDMA consume tobacco (Martins et al. 2008; Mohamed et al. 2011), as do 
approximately 64% of drug-using university students in Canada (Barrett et al. 2006).  
Pharmacokinetic interactions between some of the constituents of tobacco and MDMA 
are expected due to the potent CYP450 (mainly, CYP1A2 and CYP2E1) and UGT induction 
by the polycyclic aromatic hydrocarbons (e.g., benzo [a] pyrene) and other pyrolysis products 
(Benowitz 2008; Carvalho et al. 2012; Parkinson et al. 2004). Also, nicotine per se induces 
CYP2E1 in vivo and inhibits CYP2A6 in vitro (Benowitz 2008). 
Pharmacodinamically, it was hypothesised that nicotine-mediated DA release may 
facilitate MDMA reinforcement response (Mohamed et al. 2011). Also due to the high 
affinity of MDMA for receptors containing β2 subunits (such as the nicotinic receptors) 
(Picciotto et al. 1998) MDMA can modulate nicotine addiction (Chipana et al. 2008; Pontes 
2009). Nicotine can relieve the negative effects of MDMA (Parrott 2005) and MDMA can, in 
turn, reduce the irritability and anxiety associated with the decrease of nicotine levels during 
cigarette abstinence (Parrott 1999). 
 
 
2.4.2. Ethanol (EtOH) 
 
One of the substances consumed more frequently with MDMA is EtOH (Barrett et al. 2006; 
Barrett et al. 2005; Breen et al. 2006; Carvalho et al. 2012; Lora-Tamayo et al. 2004; 
Mohamed et al. 2011; Riley et al. 2001; Winstock et al. 2001a), since it is legal and easily 
accessible in most countries (Lora-Tamayo et al. 2004; Scholey et al. 2004). Mohamed et al. 
(2009) comprehensively reviewed MDMA/EtOH interactions in humans and rodents. 
Relevant pharmacodynamic interactions may arise from the EtOH ability to counteract 
MDMA effects due to its GABAergic actions (Carvalho et al. 2012; delaTorre et al. 2004a). 
On the other hand, both drugs can produce serotonergic and dopaminergic effects, provoking 
detrimental effects at various levels including, muscular, neurologic (Izco et al. 2007), 
endocrine, immune (Pacifici et al. 2001b), cardiovascular, hepatic (Pontes et al. 2008a; Pontes 
et al. 2008b), and renal (Carvalho et al. 2012). 
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Pharmacokinetically, EtOH affects several CYP450 isoenzymes (Busby et al. 1999) 
and it can increase MDMA blood levels (Hernandez-Lopez et al. 2002; Mohamed et al. 2011; 
Oesterheld et al. 2004; Ramaekers and Kuypers 2006) probably due to the inhibition of 
MDMA metabolism (Ben Hamida et al. 2007). However, controversial in vitro studies also 
reported that EtOH increased the metabolism of MDMA to 4-hydroxy-3-
methoxymethamphetamine (HMA) and MDA in a temperature-dependent fashion, in a 
pathway mediated, at least partially, by CYP3A and CYP2E1 (Pontes et al. 2010). 
 
 
2.4.3. ∆9-tetrahydrocannabinol (THC; cannabis) 
 
The vast majority of ecstasy consumers use cannabis derivatives more or less regularly, 
before starting the consumption of MDMA and continue to consume these products 
simultaneously with MDMA (Carvalho et al. 2012; Parrott et al. 2007; Pontes 2009; Reid et 
al. 2007; Rodgers 2000; Scholey et al. 2004; Turner et al. 2003). The combination of these 
drugs has already been linked to a fatal outcome (Diffley et al. 2012). 
The actions of MDMA and ∆9-tetrahydrocannabinol (THC), the main psychoactive 
component of cannabis, converge to a common mechanism that modulates the efflux of DA 
(Robledo et al. 2007). Nevertheless, due to their antioxidant, anti-inflammatory and anti-
excitatory properties (Gouzoulis-Mayfrank and Daumann 2006a; Morley et al. 2004b; Pacifici 
et al. 2007) THC seems to protect the deleterious effects of oxidation due to the excess of DA 
(Chipana et al. 2008). A study conducted in rats showed that THC prevented the hyperthermia 
and decreased the 5-HT depletion induced by prolonged consumption of MDMA (Morley et 
al. 2004b). However, the use of larger doses is associated with several psychobiological 
problems that can disappear after a period of abstinence of both drugs (Milani et al. 2005). 
Several detrimental effects have been observed in cannabis and MDMA users including, 
psychological problems (depression, psychosis, demotivation, increased impulsivity, anxiety), 
cognitive impairment (attention, memory, learning, verbal fluency, processing speed and 
manual acuity deficits) and other neuropsychobiologic disorders (sleep disorders, sexual 
dysfunction, reduced immunocompetence, somatic complaints, obsessive-compulsive patterns 
and psychotic behaviour) (Dafters et al. 2004; Gouzoulis-Mayfrank and Daumann 2006a; 
Pacifici et al. 2007; Parrott 2006; Young et al. 2005). 
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Additionally, since THC is metabolized by CYP3A4 and CYP2C9, pharmacokinetic 
interactions between MDMA and cannabis may arise (Carvalho et al. 2012; Matsunaga et al. 
2000). An extensive review on MDMA/THC interactions was conducted by Mohamed et al. 
(2011). 
 
 
2.4.4. Cocaine 
 
The combination between cocaine and MDMA (the so-called ‘bumping up’ or ‘cloud mind’) 
is often adopted with the intent of intensifying the desired psychostimulant effects (Daza-
Losada et al. 2008). 
Although the affinity and action of cocaine and MDMA for the different monoamine 
transporters is not comparable either in humans or in rodents (Han and Gu 2006), both drugs 
share pharmacodynamic mechanisms (cocaine also elevates the synaptic levels of DA, 5-HT 
and NA) (Daza-Losada et al. 2008), so pharmacodynamic interactions may be expected 
(Carvalho et al. 2012). Both substances induce a rise in body temperature that is dependent on 
the environment temperature (Ansah et al. 1996; Gonzalez 1993). Concurrent administration 
of MDMA/cocaine produces locomotor activation and enhances dopaminergic responses in 
rats to a greater extent than administration of either drug alone (Panos and Baker 2010). A 
recent study demonstrated that MDMA increases cocaine reward in male adolescents 
(Starosciak et al. 2012). Repeated administration of MDMA to rats increases the cocaine-
induced release of DA, suggesting that MDMA can alter the vulnerability to develop cocaine 
dependence and abuse (Morgan et al. 1997).  
Cocaine was demonstrated to inhibit in vitro the metabolism of MDMA 
(Ramamoorthy et al. 2002; Shen et al. 2007). Thus, substantial increases on the 
concentrations of MDMA may be attained when the drugs are co-ingested. 
 
 
2.4.5. Lysergic acid diethylamide (LSD) 
 
LSD is one of the most potent hallucinogens, widely used all over the world (Golub et al. 
2001; Schiff 2006). Its combination with MDMA is called candyflipping or XL on the streets, 
and has reached high prevalence in the last decade (Carvalho et al. 2012; Pontes 2009; Wish 
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et al. 2006), as supported by a few reports (Licht et al. 2012; Miller and Gold 1994; Millman 
and Beeder 1994). 
The pharmacodynamic interactions between these drugs seem to result from the 
increased levels of synaptic 5-HT, which activates the receptors involved in the stimulating 
properties of LSD and MDMA (Schechter 1998). Because the acute toxic effects of LSD 
include cardiovascular symptoms (tachycardia, hypertension), renal failure and 
rhabdomyolysis (Berrens et al. 2010; Schiff 2006), the toxic response of MDMA might be 
aggravated when the drugs are co-ingested. 
As LSD metabolism appears to involve CYP2D6 (Yu 2008), it can be expected that 
the drug interferes with MDMA pharmacokinetics by altering the blood levels of the drug. 
 
 
2.4.6. γ-Hydroxybutyric acid (GHB, liquid ecstasy) 
 
GHB is an endogenous inhibitory neurotransmitter (Bessman and Fishbein 1963) often sold 
as a recreational drug in form of powder, which dissolves in water (Freese et al. 2002). Its 
unpleasant taste is often masked with alcohol, which increases the potent hypnotic/sedative 
effects of GHB (Gahlinger 2004). GHB carries the ‘street’ names liquid ecstasy or liquid X, as 
it produces MDMA-like effects including, euphoria, reduced anxiety, enhanced social 
interactions, disinhibition (Doyon 2001), progressing to amnesia (Gahlinger 2004), deep 
sedation, coma and even death (Drasbek et al. 2006). It is often used as a ‘rape drug’. 
Neurochemically, GHB and MDMA have counteracting mechanisms since GHB 
inhibits DA release and increases the availability of 5-hydroxytryptophan (the precursor of 5-
HT), thus potentiating presynaptic 5-HT turnover (Mohamed et al. 2011). So, the concurrent 
administration of GHB has allegedly the ability of attenuating dysphoric or unpleasant 
‘comedown’ after-effects of MDMA (Carvalho et al. 2012; Uys and Niesink 2005). Van 
Nieuwenhuijzen et al. (2010) showed that combined MDMA and GHB were responsible for 
MDMA-like deficits in memory and social behavior and that the combination causes long-
term neuro-adaptation in the hypothalamic oxytocin system, probably related to the long-term 
social interaction deficits caused by both drugs (van Nieuwenhuijzen et al. 2010). 
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2.4.7. Ketamine  
 
Ketamine is a derivative of 1-(1-phenylcyclohexyl)piperidine (PCP, phencyclidine) 
anaesthetic used in human and veterinary medicine, with analgesic, hallucinogenic and 
dissociative properties – characterised by a sense of detachment from the physical body and 
the external world (White et al. 1982; Wolff and Winstock 2006). Recreationally, ketamine is 
often snorted (known as K, Super K, Special K, Vitamin K, Green, Mean Green, kat-kit, Keets, 
super acid, cat valiums and Jet) but is also marketed to be smoked or ingested (as a liquid, 
powder or capsules) (Pontes 2009; Wolff et al. 1995). Ketamine has been identified in ecstasy 
tablets known as ‘strawberry milkshake’ and ‘white lightning’ in dosages ranging from 185 to 
197 mg and the effects elicited by the drug (immobility, hallucinations, among others) often 
surprises consumers that expect empathy and euphoria (Pontes 2009; Winstock et al. 2001b; 
Wolff et al. 1995). 
Ketamine has the ability to inhibit the reuptake of NA, DA and 5-HT in a dose-
dependent manner, thus having a sympathomimetic action (Nishimura et al. 1998), that may 
account for the pharmacodynamic interactions with MDMA. In fact, the risk of over-
stimulation of the heart is a potentially fatal consequence of combining ketamine with 
amphetamines, and the symptoms associated with ketamine overdose include, hyperactivity, 
anxiety, chest pain, palpitations, tachycardia, hyperthermia and, in more severe cases, 
rhabdomyolysis (Gill and Stajic 2000; Jansen 1993; Wolff and Winstock 2006). Any of these 
effects can add to those caused by MDMA, increasing toxicity (Pontes 2009). 
Besides pharmacodynamic interactions ketamine also has the potential to cause 
pharmacokinetic interactions, since most of the drug is metabolized by CYP2B6 (Carvalho et 
al. 2012; Hijazi and Boulieu 2002; Yanagihara et al. 2001). On the other hand, ketamine 
inhibited in vitro the uptake and permeation of MDMA through the epithelial cells of the 
ileum (Kuwayama et al. 2007), showing the potential to reduce MDMA absorption at the 
intestinal level (Carvalho et al. 2012). 
 
 
2.4.8. Ephedrine 
 
Ephedrine is found in Ephedra vulgaris natural (Ma-Huang or Herbal ecstasy). It causes the 
release of NO and, to a lesser extent, the release of DA and 5-HT (Rothman et al. 2001). 
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Ephedrine promotes thermogenic, sympathomimetic, and pro-dopaminergic effects and it is 
therefore likely to interact with MDMA and increase its addictive and toxic potential 
(Carvalho et al. 2012; Chen et al. 2004; Pontes 2009; Soni et al. 2004; Yates et al. 2000). The 
metabolism of ephedrine may be responsible for a pharmacokinetic interaction with MDMA 
(Soni et al. 2004), since both drugs compete for the same metabolic pathways (Carvalho et al. 
2012). 
 
 
2.4.9. Opiates and derivatives 
 
Heroin and MDMA are often combined to favour the stimulant effects of MDMA and ease 
the ‘come down’ associated with ecstasy intake (Gervin et al. 2001; Gervin et al. 1998), but 
this combination was already linked to fatal outcomes (Gerevich et al. 2000). 
It is possible that the serotonergic effects of MDMA may be enhanced by heroin 
(Oesterheld et al. 2004) elevating the risk for the 5-HT syndrome to occur. Compan et al. 
(2003) showed that the opioid antagonist naloxone suppressed the hyperlocomotor effects of 
MDMA in mice. Also modifications in the opioid system may negatively influence the abuse 
potential of MDMA (Bilsky et al. 1991; Daza-Losada et al. 2008; Mohamed et al. 2011; Reid 
et al. 1996). 
 
 
2.4.10. Psilocybin-containing mushrooms (‘magic mushrooms’) 
 
Some mushrooms have hallucinogenic properties due to its psychoactive indole alkaloids 
content (colloquially, shrooms or magic mushrooms). The effects of psilocybin mushrooms 
come from psilocybin that is converted by hydrolysis to its active metabolite, psilocin, which 
is responsible for the psychedelic effects (Passie et al. 2002). 
Psilocybin/psilocin has sympathomimetic serotonergic and dopaminergic effects 
(binding with high affinity to presynaptic 5-HT2A receptors and, to a lesser extent, to 5-HT1A 
receptors) (Passie et al. 2002). This sympathomimetic action also leads to (Passie et al. 2002; 
Pontes 2009) DA D2 receptors activation. Therefore, psilocybin/psilocin have great potential 
for pharmacodynamically interacting with MDMA (Carvalho et al. 2012). 
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2.4.11. Amphetaminic stimulants 
 
In addition to the amphetamines that are present in ecstasy pills, the interaction of MDMA 
with other amphetamines also occurs when these are intentionally co-ingested to modulate the 
effects of MDMA. The combined ingestion of MDMA and other amphetaminic analogues 
(MDA, d-AMP, 3,4-methylenedioxy-N-ethylamphetamine or MDEA and PMA) has already 
been linked to the onset of fatal poisonings, usually accompanied by hyperthermia and DIC. 
De Letter and collaborators (2001) described eight severe intoxications, one with a fatal 
outcome, involving the highly toxic 4-MTA. This drug is frequently found contaminating or 
substituting MDMA in clandestine ecstasy pills, along with other amphetamines. Also PMA, 
METH and d-AMP were identified in toxic/lethal amounts at postmortem analysis of six 
fatalities caused by the intake of tablets marketed as ecstasy (Byard et al. 1998). Since these 
drugs share biokinetic and pharmacologic pathways, the potential for interaction is very high. 
The study of the possible interactions between MDMA and three other amphetamines 
in this polydrug abuse context, and the mechanisms involved, is the major purpose of the 
experimental work of the current dissertation. For this reason, in the following sections, the 
main pharmacokinetic and pharmacodynamic properties of our test drugs, METH, d-AMP 
and 4-MTA will be discussed in greater detail. 
 
 
2.4.11.1. Amphetamine (AMP) and methamphetamine 
(METH) 
 
d-AMP, the dextrorotatory stereoisomer of the prototype of this group of drugs, and METH 
(speed, ice, crystal, crank), the N-methylated analogue of AMP, are abused worldwide due to 
their euphoric and powerful stimulant properties. Epidemiological evidence reveals that 
METH abuse rates are greater than those of d-AMP (SAMHSA 2009) possibly due to the 
presence of the methyl group that makes METH more lipophilic (therefore more potent). 
Also, because its synthesis is cheaper and easier, this drug is more readily available compared 
to d-AMP. Recreational METH abuse allegedly involves larger doses and routes of 
administration that produce a more rapid onset of effects (users often begin with intranasal or 
oral use and progress to intravenous use and, occasionally smoking) (Simon et al. 2002). Both 
drugs are approved in several countries to treat similar medical conditions, being d-AMP one 
of the most frequently prescribed medications for the treatment of attention deficit disorder, 
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and narcolepsy. Despite METH being usually perceived to have a greater abuse potential, 
findings from behavioral studies indicate that, at equivalent doses, both drugs produced 
similar discriminative stimulus effects in rats (Kuhn et al. 1974), and are self-administered by 
rhesus monkeys and rats at similar rates (Balster and Schuster 1973; Yokel and Pickens 
1973). Kirkpatrick et al. (2012) compared intranasal METH and d-AMP self-administration 
and concluded that both produced a similar dose-related profile of effects in humans, which 
supports their equivalence for abuse potential. 
 
 
2.4.11.1.1. Pharmacokinetics 
 
Generally, amphetamines have high oral bioavailability, high volume of distribution, low 
plasma protein binding (usually less than 20%) and both renal and hepatic elimination 
(Carvalho et al. 2012). Amphetamine is usually consumed orally as the S-(+)-enantiomer (d-
AMP) while METH can be used orally, intravenously, snorted, vapor inhaled, or smoked as 
S-(+)-METH hydrochloride salt. Following administration, peak METH concentrations occur 
in 1.5-3.5 hours (depending on the route of administration) and the mean elimination half-life 
is 10 hours (Mendelson et al. 2006). The bioavailability varies between 67-90% (smoked > 
snorted > oral) (Cook et al. 1993). Amphetamine blood concentration peaks at 4 hours after 
ingestion. The distribution of AMP and METH is similar and is purportedly independent of 
the administration route (Carvalho et al. 2012). Volkow and co-workers (2010) proved that 
after intravenous administration the highest uptake occurred in lungs (22%), liver (23%) and 
in brain (10%). Of forensic relevance, the drugs have been shown to accumulate in saliva, 
hair, and nails. The main metabolic reaction of METH is the N-demethylation into AMP (Lin 
et al. 1997). The metabolic pathways described for METH and AMP are presented in Figure 
4. These drugs are metabolized to a lower extent than MDMA, and the urinary levels of the 
unchanged drugs are accordingly much higher (approximately up to 50% eliminated without 
biotransformation) (de la Torre et al. 2004). There is wide variability in the elimination half-
life of amphetamines, since it is, to a great extent, dependent on urine pH (de la Torre et al. 
2004). About 15% of METH is eliminated in the urine as 4-hydroxymetamphetamine and 
10% as AMP (Cook et al. 1993). 
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Figure 4. Metabolic pathways of amphetamine and methamphetamine. METH is (i) N-demethylated to 
AMP and (ii) 4-hydroxylated to 4-hydroxymethamphetamine by CYP2D6. AMP is metabolized mainly through 
(i) N-deamination and oxidation into the corresponding benzoic acid derivatives that are further conjugated with 
glycine and excreted as the corresponding hippuric acids and (ii) 4-hydroxylation of the aromatic ring, 
generating 4-hydroxyamphetamine, followed by conjugation of the phenol group with sulfate or glucuronic acid. 
ß-oxidation of the side chain leads to the formation of norephedrine that is oxidized in the aromatic ring into 
hydroxynorephedrine. Amphetamine N-deamination seems to be catalyzed by CYP450 isoenzymes of the 
CYP2C subfamily, whereas CYP2D6 is involved in the hydroxylation of the aromatic ring. Adapted from 
Carvalho et al. (2012).  
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2.4.11.1.2. Pharmacology 
 
Similar to MDMA and the other ring-substituted amphetamine derivatives, there is plenty of 
evidence, both experimental and clinical, that METH and AMP act by increasing the release 
of the monoamine neurotransmitters (DA, NA and 5-HT) from their respective axon terminals 
either by (i) redistributing catecholamines from the synaptic vesicles to the cytosol and by (ii) 
reversing the transport of the neurotransmitter through plasma membrane transporters. 
However, the affinity of these drugs for different monoamine transporters differ. Some 
amphetamines, such as MDMA and 4-MTA, preferentially inhibit the reuptake and stimulate 
the release of 5-HT, while others, such as METH and d-Amp, preferentially inhibit the 
reuptake and stimulate the release of DA. There is also evidence that METH and d-Amp can 
increase the cytosolic levels of monoamines by inhibiting the activity of MAO, as well as by 
increasing the activity and expression of the DA-synthesizing enzyme, tyrosine hydroxylase 
(Sulzer et al. 2005). S-(+)-METH and S-(+)-d-Amp stereoisomers are generally associated 
with more potent physiological effects. 
 
 
1.2.1.1.1. Toxicity 
 
The addition of a methyl group in METH has a major influence on the neurotoxicity of the 
drug. By virtue of its higher lyphofily, METH allegedly crosses the blood-brain barrier more 
readily. Also, the duration of its effect is longer. 
METH and d-Amp use has been related to several clinical, neurological, and 
psychiatric problems. The main toxic effects occur at the nervous system level (primarily 
affecting the dopaminergic system). The initial feeling of physically and mentally enhanced 
powers following METH/AMP use can quickly deteriorate with high doses or chronic use, 
resulting in emotional lability, confusion, paranoia, hallucinations, delirium, anxiety, mood 
disorders, behavioural disinhibition, agitation, psychosis, deterioration in memory and 
learning capacity, psychomotor slowdown, and problems in processing information (Schep et 
al. 2010). Some of these psychiatric symptoms are similar to those of schizophrenia. It is 
proposed that these neurotoxic effects are a result of i) chronic methamphetamine use, ii) a 
severe acute selective decrease in the various dopaminergic markers in various cerebral 
structures, and iii) major changes in cerebral blood flow (Schep et al. 2010). Cerebrovascular 
accidents due to hemorrhage or vasospasm, cerebral edema, and cerebral vasculitis are very 
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common features of METH/AMP intoxications. Also, cardiovascular effetcs are a major 
reason of concern, and a frequent cause of death and they include chest pain, palpitations, 
myocardial infarctions, hypertension, necrosis, and ischemia. Significant hypotension with 
bradycardia and metabolic acidosis were seen in massive amphetamine overdoses (Schep et 
al. 2010). Dyspnea and breath impairment are frequently associated with amphetamines 
intake. Necrotizing angiitis with arterial aneurysms were observed in the kidney, liver, and 
pancreas, in METH drug abusers. Amphetamine-induced seizures seem to occur as isolated 
events or associated with hyperthermia, coma, muscle hyperactivity, metabolic acidosis, 
secondary rhabdomyolysis, renal failure, or shock . 
 
 
1.2.1.2.4-Methylthioamphetamine (4-MTA) 
 
4-Methylthioamphetamine (4-MTA), also known as p-methylthioamphetamine (p-MTA), 1-
(4-methylthiophenyl)-2-aminopropane, and α-methyl-4-methylthiophenylethylamine was 
firstly synthesized in 1963 as a potential anorectic agent. In 1992, David Nichols and 
colleagues (Purdue University) synthesized this molecule again, this time aiming at obtaining 
new molecules pharmacologically active in the treatment of depression. During the late 
1990s, 4-MTA emerged on the streets as a drug of abuse. Tablets containing 4-MTA were 
first seized in Europe in 1997, with the street name flatliners (nickname adopted by virtue of 
the flat half-scored white pills), 5-S, MK and Golden Eagle (Groombridge 1998; Poortman 
and Lock 1999). They were usually marketed as ecstasy. 4-MTA rapidly became a major 
cause of concern due to the several deaths linked to its consumption and to its high risk of 
severe side effects. Tablets sold on the illicit market revealed a 4-MTA content ranging 
between 100-140 mg/tablet (Elliott 2000; Poortman and Lock 1999). 
 
 
1.2.1.2.1. Pharmacokinetics 
 
In 2000, Elliott (2000) analyzed perimortem and postmortem blood specimens in a fatal case 
involving 4-MTA. The results indicated the presence of two possible metabolites of 4-MTA, 
presumably a sulfoxide and a hydroxyl derivative. The results also suggested that there is 
little difference in the concentration of 4-MTA in perimortem and postmortem femoral blood, 
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as can be observed in Table 7. This could indicate that 4-MTA may not undergo significant 
postmortem redistribution and may have a relatively low volume of distribution (Elliott 2000). 
Later, Elliott (2001) reported, for the first time, data regarding the possible 
pharmacokinetics of 4-MTA in humans. The author studied three intoxication cases 
implicating 4-MTA, in which the patients survived. In all three cases other amphetamines, 
such as d-AMP, MDMA and pseudoephedrine, were present (Elliott 2001). In all three cases 
there was a relatively low concentration of MDMA and/or amphetamine in the plasma, 
compared to 4-MTA (table 7). Presumed metabolites were also detected, with compounds 
identified as being 4-MTA sulphoxide and hydroxy-MTA. In one patient the 4-MTA 
concentration was determined in a series of plasma samples (table 7) and this allowed the 
estimation of a presumptive half-life of approximately 7 h (Elliott 2001).  
De Letter et al (2001) reported a case study involving one fatal and seven survived 
cases of intoxication with 4-MTA (table 7). In this study they observed that, similar to what 
happens with other amphetamines in which the urinary excretion is pH-dependent, the 
individuals with the lowest urinary pH showed the highest urinary 4-MTA levels (De Letter et 
al. 2001). Decaestecker and colleagues (2001) performed a detailed distribution study by 
measuring 4-MTA levels in various tissues and fluids samples after autopsy in the fatal 
outcome case (Decaestecker et al. 2001). The drug suffered postmortem diffusion from the 
liver (30.8 mg/kg) and lungs (16.6 mg/kg) to the cardiac atriums (7.9 mg/L) via the vascular 
pathway. The lungs showed levels that were almost 3 times higher than those in the peripheral 
blood. Also, 4-MTA levels in liver and bile (36.4 mg/L) were 6-7 times higher than the 
peripheral blood concentration (5.23 mg/L collected from the femoralis vein) (Decaestecker et 
al. 2001). Given the significant 4-MTA levels attained in the liver and the bile, it seems likely 
that 4-MTA is eliminated by excretion via the bile. On the contrary, 4-MTA cardiac and 
skeletal muscle levels were similar to peripheral blood concentrations, denoting that the drug 
does not tend to concentrate in these tissues. It was also suggested a certain accumulation of 
4-MTA in red blood cells. As the brain is the most worrisome target organ, 4-MTA levels in 
the various lobes of the brain and the brainstem (ranging between 31.7 mg/kg and 36.5 
mg/kg) were high and in line with the aforementioned toxicity expectations. 
Carmo et al. (2002) investigated the metabolic profile of 4-MTA after acute 
administration to Charles-River CD1 mice. Their results showed that 4-MTA was partially 
metabolized with the parent compound and its respective metabolites being excreted in urine. 
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Table 7. Concentrations of 4-MTA found at non-fatal and fatal intoxications. 
 
 4-MTA urine concentration 4-MTA blood concentration 4-MTA liver concentration Study Reference 
Number 
of pills  Post-mortem  Post-mortem Post-mortem   
   0.760 µg/L (admission) 
0.280 µg/L (after 7 h; also 
detected 40 µg/L MDMA and 
250 µg/L d-AMP) 
0.144 µg/L (after 14 h) 
0.154 µg/L (after 17 h; also 
detected 20 µg/L MDMA and 
110 µg/L d-AMP) 
  Human non fatal intoxication‡ (Elliott 2001) 
   0.131 µg/L (after 16.5 h; also 
detected 20 µg/L MDMA and 
50 µg/L d-AMP) 
  Human non fatal intoxication‡ (Elliott 2001) 
   0.189 µg/L (also detected 60 
µg/L MDMA and 20 µg/L d-
AMP) 
  Human non fatal intoxication‡ (Elliott 2001) 
7-8  87.2 mg/L 4.3 mg/L 4.6 mg/L †  Human fatal intoxication (Elliott 2000) 
≥ 6  100 mg/L 
(also 1.2 
mg/L 
MDMA) 
 8.38 mg/L 30 mg/L Human fatal intoxication& (De Letter et al. 2001) 
2 10 mg/L  0.63 mg/L   Human non fatal intoxication& (De Letter et al. 2001) 
1 4 mg/L  1.08 mg/L   Human non fatal intoxication& (De Letter et al. 2001) 
1 8 mg/L  2.08 mg/L   Human non fatal intoxication& (De Letter et al. 2001) 
1 or 1.5 4 mg/L  1.93 mg/L   Human non fatal intoxication& (De Letter et al. 2001) 
3, 5 or 6 40 mg/L  1.26 mg/L   Human non fatal intoxication& (De Letter et al. 2001) 
≥ 2 32 mg/L  0.43 mg/L   Human non fatal intoxication& (De Letter et al. 2001) 
      Human non fatal intoxication& (De Letter et al. 2001) 
    1,500 mg/L §   (Poortman and Lock 
1999) 
 
‡ At the time of specimen collection the patient was in a serious clinical condition requiring ventilation and sedation after suffering convulsions. 
& Positive for tetrahydrocannabinoic acid. The 4-MTA pills, weighing 345 mg, contained 97 mg 4-MTA. 
† Blood specimens from the femoral vein. 
§ Levels of d-AMP in the blood sample were 1,500 mg/L. 
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In addition to β-hydroxylated isomers and 4-methylthiobenzoic acid metabolites, they 
observed the presence of a third hydroxylated metabolite resulting from either aromatic 
hydroxylation or hydroxylation on the methylthio group. These metabolic pathways are 
similar to those of d-AMP and many of its derivatives (Caldwell 1980; Foster et al. 1993; 
Staack and Maurer 2005). In another study using primary hepatocytes of different animal 
species (monkey, dog, rabbit, rat, and mouse) and three male human donors (Carmo et al. 
2004), they observed that 4-MTA was not extensively metabolised by the hepatocytes 
obtained from all the species examined. The main metabolite was identified as 4-
methylthiobenzoic acid which, for the first time was described as a human metabolite. 
Similarly to what was observed in the in vivo study (Carmo et al. 2002), two β-hydroxylated 
isomers (4-methylthiophenylpropanolamine and 4-methylthiocathine) metabolites were 
observed. However, the authors concluded that those compounds and another 4-MTA 
sulfoxide metabolite could be formed spontaneously without the interference of hepatic 
metabolism. 
After investigating the urine samples (collected 8–15 h after reported ingestion) of five 
individuals taking 1-5 pills of 4-MTA, Ewald et al. (2005) identified four metabolites and 
postulated the metabolic routes presented in Figure 5. The metabolites: ring hydroxy 4-MTA, 
β-hydroxy 4-MTA and 4-methylthiobenzoic acid had already been identified by Carmo et al. 
(Carmo et al. 2002; Carmo et al. 2004). The two isomers of the ß-hydroxy metabolite that 
were detected by Carmo et al. (2004) in hepatocytes, could not be detected, maybe due to low 
urine concentrations. In addition, in this study 4-MTA sulfoxide was also identified as a 
probable artifact. As the peak of the deamino-hydroxy metabolite was more abundant in urine 
after hydrolysis with glucuronidase and arylsulfatase, it was concluded that it is partly 
excreted as glucuronide and/or sulfate. The presented study revealed that 4-MTA was poorly 
metabolized by humans. Therefore, the drug screening in case of intoxication should focus on 
the parent compound. 
Carmo et al. (2007) tested in an in vitro model whether CYP2D6 as well as CYP3A4 
could influence the susceptibility to the toxicity of 4-MTA. Their results showed that the 
expression of wild type CYP2D6*1 greatly enhanced the susceptibility to the cytotoxic effects 
of 4-MTA compared to the cells devoid of CYP-dependent enzymatic activity. Toxicity in 
cells expressing CYP2D6*1 was also higher compared to the cells expressing the low activity 
alleles CYP2D6*2 and CYP2D6*9. In contrast to CYP2D6, the CYP3A4 isoenzyme did not 
enhance 4-MTA toxicity.   
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Figure 5. Proposed pathways by Ewald and co-workers (2005) for the phase I metabolism of 4-
MTA in humans. 4-MTA suffers oxidative deamination to the corresponding deamino-oxo 
metabolite (1-[4-(methylthio)-phenyl]propan-2-one), followed by reduction to the corresponding 
alcohol deamino-hydroxy 4-MTA (1-[4-(methylthio)phenyl]propan-2-ol) or degradation of the side 
chain to 4-methylthiobenzoic acid; ring hydroxylation to a phenolic structure ((2-aminopropyl)-
(methylthio)phenol) and β–hydroxylation of the side chain to 4-methylthionorephedrine or ß-hydroxy 
4-MTA (2-amino-1-[4-(methylthio)phenyl]-propan-1-ol). The deamino-hydroxy metabolite is partly 
excreted as glucuronide and/or sulfate. 
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These data indicate that metabolism may play a role in the toxic effects of the drug. 
However, since the drug is metabolised in vivo to a relatively low extent it may not 
significantly modify the toxicity of the drug. 
 
 
1.2.1.1.1. Pharmacology 
 
There is no systematic data available on the neuropsychological effects of 4-MTA in man, 
however limited animal data suggests effects similar to the entactogen class of compounds 
such as MDMA (Kavanagh et al. 1999). 4-MTA is indeed a potent, selective, serotonin 
releaser and uptake inhibitor, apparently devoid of serotonin neurotoxic effects (Huang et al. 
1992; Scorza et al. 1999). In rats, 4-MTA caused a dose-dependent serotonin release but had 
no long-term serotonin depleting effects in frontal cortex, hippocampus and striatum at 
behaviorally relevant doses (Huang et al. 1992). With regard to the inhibition of the neuronal 
serotonin uptake 4-MTA was about six times more potent than MDMA (Huang et al. 1992; 
Murphy et al. 2002). The pro-serotoninergic activity of the drug was responsible for a dose-
dependent increased secretion of several hormones including, oxytocin, corticosterone and 
renin, in rats (Li et al. 1996). 
4-MTA has also a high MAO-A inhibitory capacity, being a more potent inhibitor than 
the other amphetamine derivatives (Scorza et al. 1999). This property was deemed responsible 
for the cytotoxicity elicited by 4-MTA in RCHT cells derived from adult rat hypothalamus 
due to the consequent increase in the intracellular concentration of dopamine that is further 
autoxidised into the respective aminochrome with simultaneous production of reactive oxygen 
species (Hurtado-Guzman et al. 2002). Additionally, MAO-A inhibition might be responsible 
for the much higher and sustained effect on the release of serotonin, which is observed with 
administration of 4-MTA (Scorza et al. 1999). As this is not an immediate effect it may also 
explain why there is a delay in producing the maximum stimulating effect desired by drug 
abusers. There is a likely possibility that potentially deleterious drug-drug interactions with 
other MAO inhibitors may occur through the potentiation of the serotonin syndrome. The 
drug also proved to be relatively inert as a catecholaminergic agent (the capacity of inhibition 
of the uptake of DA and NE by 4-MTA is two and five times, respectively, lower than that of 
MDMA) (Huang et al. 1992). 
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Carmo et al. (2003) suggested that the 4-MTA-induced hyperthermia might be highly 
influenced by the catecholaminergic and serotonergic receptor activation and the MAO 
activity as, in mice, the blockade of the 5-HT receptors with methysergide and the MAO 
inhibition with pargyline resulted in the potentiation of the 4-MTA-induced hyperthermic 
effect. Also, the blockade of the α1-adrenergic receptors with prazosin completely reverted the 
4-MTA-induced hyperthermia while with the β-adrenergic receptor blocker propranolol this 
reversal was not complete (Carmo et al. 2003). 
 
 
1.2.1.1.2. Toxicity 
 
Users have noted that 4-MTA produces a greater ‘high’ and has a delayed reaction compared 
to other ecstasy pills. The slow onset of the effects of the drug (up to 2 h) may encourage 
abusers to administer further doses assuming that the first dose was inadequate, which can 
result in accidental overdose and possible death (Elliott 2001). In fact, 4-MTA was involved 
in several fatal and non-fatal intoxication cases in the United Kingdom, Netherlands, France 
and Belgium (De Letter et al. 2001; Decaestecker et al. 2001; Elliott 2000; Elliott 2001; 
EMCDDA 1999; Poortman and Lock 1999). Most of the 4-MTA fatal and non-fatal 
intoxications involved additional drugs such as MDMA, caffeine, cannabis, other 
amphetamines, methadone and alcohol (de Boer et al. 1999; De Letter et al. 2001; Elliott 
2001; EMCDDA 1999; Poortman and Lock 1999). Based on the data obtained from those 
intoxications, Elliott (2001) suggested that moderate toxicity may be associated with plasma 
4-MTA concentrations of between 0.20 and 0.60 mg/L, severe toxicity with concentrations 
above 0.60mg/L, and death with concentrations above 1.50mg/L 
It is suspected that the toxicity of 4-MTA is related to the serotonin syndrome. The 
side-effects of 4-MTA are mainly related to the sympathicomimetic overstimulation and 
include tachycardia, tremors, palpitations, diaphoresis, paraesthesias, trismus and bruxism, 
agitation and insomnia (De Letter et al. 2001). Fatal cardiac arrhythmia and respiratory failure 
are considered probable causes of death (De Letter et al. 2001; EMCDDA 1999). The 
intoxication reports point to a stronger and prolonged effect than that caused by MDMA, and 
4-MTA also appears associated with serious unpleasant effects, including nausea, nystagmus, 
hyperthermia, glaucoma, thirst, tremors, confusion, memory loss, seizures, respiratory 
depression and increased heart rate (De Letter et al. 2001; Elliott 2000; EMCDDA 1999). De 
General introduction 
 
 67
Boer et al. (1999) reported a patient who suffered from amnesia during a 2-week period 
following the ingestion of a single pill. 
Custodio et al. (2010) studied the involvement of mitochondria in 4-MTA-induced 
hepatotoxicity and observed that 4-MTA (from 0.025 up to 0.1mM) was more potent than 
MDMA (from 0.2 up to 0.5mM) in decreasing the sensitivity of rat liver mitochondria to 
mitochondrial permeability transition. However, higher concentrations of 4-MTA (from 0.5 
up to 2mM) were highly toxic to mitochondria. 4-MTA simultaneously increased H2O2 
production in a MAO-dependent way, and uncoupled and inhibited mitochondrial respiration. 
In contrast, MDMA had only limited or no effects on these mitochondrial parameters 
(Custodio et al. 2010). 
 
 
1.2.1.2.Combination effects between amphetamine derivatives 
 
All amphetamines with phenylisopropylamine structure are inhibitors of CYP2D6 (Lin et al. 
1997), their potency being dependent on the presence of substituent functional groups (Pontes 
2009; Wu et al. 1997). The simultaneous ingestion of MDMA and other amphetamines will 
probably lead to increased MDMA plasma concentrations, thereby, increasing the risk of 
acute toxicity (Hashimoto et al. 1993). Also, the intestinal absorption of compounds with 
amine moieties, such as the amphetamines, are regulated by a common transport system. 
Therefore, amphetamine-type stimulants present in ecstasy tablets, such as AMP, METH, 
MDEA and MDA may inhibit the uptake of MDMA via ileum epithelial cells, delaying its 
intestinal absorption (Kuwayama et al. 2007; Pontes 2009). 
Pharmacodynamic interactions may arise as a result of combining MDMA with other 
amphetaminic congeners, as these drugs are also neurotoxic affecting the dopaminergic and 
serotonergic pathways through mechanisms that are similar to those of MDMA (Gouzoulis-
Mayfrank and Daumann 2006a; Seiden and Sabol 1996). Thus, the co-consumption of 
MDMA and other amphetaminic stimulants can increase serotonergic neurotoxicity and also 
the toxic effects on the dopaminergic system induced by MDMA (Gouzoulis-Mayfrank and 
Daumann 2006a). For instance, MDMA/PMA combination induces functional changes in 5-
HT neurotransmission (Mohamed et al. 2011). MDA, by itself, increases blood pressure, 
induces bradycardia and locomotor activity, and is more potent than MDMA in activating α1D, 
α
 2A and α1A receptors (Bexis and Docherty 2006; Pontes 2009). Additionally, it is also 
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capable of inducing hyperthermia (Crean et al. 2006; Pontes 2009). d-AMP also induces an 
hyperthermic response that is dependent on ambient temperature (Hamida et al. 2008). In 
spite of some differences in the effects on the thermoregulatory system of MDMA and d-
AMP or its derivatives (Jaehne et al. 2005), an increased risk for hyperthermia is expected 
when these drugs are co-ingested. 
Also, the reinforcing, physiological, and subjective effects of MDMA in humans are 
similar to those of d-AMP (Tancer and Johanson 2003). MDMA pretreatment increases the 
locomotor stimulant effect of d-AMP in rats (Callaway and Geyer 1992). Garcia-Ratés et al. 
demonstrated that METH and MDMA have affinity for, and can interact with, nicotinic 
acetylcholine receptors, inducing their up-regulation, especially when higher doses are used. 
Such effects may have a role in METH- and MDMA-induced neurotoxicity, cholinergic 
neurotransmission, and in processes related with addiction and dependence (Garcia-Rates et 
al. 2007). Also, if the relative proportion of dopaminergic amphetamines in the pills is higher, 
the addictive potential of these pills will probably be increased (Carvalho et al. 2012; Garcia-
Rates et al. 2007). In rats, pre-exposure to MDMA delays the initial acquisition of 
amphetamine self-administration and encourages amphetamine-seeking behaviour along with 
MDMA-induced hyperactivity (Morley et al. 2004a). Yet, pre-treatment with MDMA 
diminishes self-administration of METH (Clemens et al. 2006). MDMA itself does not have a 
high potential to disturb the dopaminergic system, but the increase in DA produced by the 
other congeners leads to feelings of self-confidence, energy, sexual stimulation and euphoria 
and is also responsible for the addictive potential (Pontes 2009). It was also demonstrated, in 
rats, that the MDMA/METH combination may produce adverse neurochemical and 
behavioural effects (euphoric and pro-social effects) (Clemens et al. 2007b) and marked 
monoamine depletion (Clemens et al. 2004) that are greater than those observed with similar 
doses of each drug administered separately. However, these differences seem to disappear 
with a chronic consumption pattern (Clemens et al. 2007a). Other authors reported that, in 
humans, regular use of combined MDMA/METH cause severe long-term cognitive, 
behavioural, and neurological changes (Brecht and von Mayrhauser 2002; Reneman et al. 
2002). This enhanced neurotoxicity may be caused by oxidative stress mechanisms that arise 
after exhaustion of the endogenous free-radical scavenging processes (Hanson et al. 2004). 
Recently, new amphetamine derivatives that are not controlled in many countries and 
are easily available, mainly through the Internet, have raised concern. These so-called ‘legal 
highs’ are mainly constituted of cathinone derivatives and include mephedrone, methylone, 
methedrone, and buthylone, among others. Because they share similar structures and 
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mechanisms of action with the classical amphetamines, there are increasing numbers of case 
reports involving intoxications also with these drugs (Carvalho et al. 2012). 
 
 
3. Evaluation of mixture effects in terms of additivity, antagonisms or 
synergisms – comparison of the accuracy of prediction models 
 
As outlined above, the threshold levels of amphetamines capable of causing severe 
detrimental health effects in humans are controversial and widely discussed (Milroy 2011). 
Unfortunately, low-dose and, often, first time exposures to MDMA are recurrently associated 
with severe and life-threatening accidental intoxications. The incongruence between 
concentrations of drug found in the serum and/or tissues of intoxicated abusers and the toxic 
effects elicited by these drugs, are one of the main arguments in support of the hypothesis that 
other factors might be at play to justify the risk posed by amphetamines to humans. 
Reported misuse settings show that abusers ingest multiple substances concurrently 
(Barrett et al. 2006; Mohamed et al. 2011; Wu et al. 2006a). Along with the intentional intake 
of several types of drugs (alcohol, tobacco, cannabis, other amphetamines, etc.), inadvertent 
consumption of multiple substances often occurs, for instance, due to contaminants frequently 
present in ecstasy tablets (Morefield et al. 2011; Pavlaki et al. 2011) or as a part of prescribed 
therapies. It is, therefore, conceivable that a number of these drugs may act together to 
produce effects of different magnitude to those induced by the individual drugs alone. 
In fact, polydrug abuse is one of the most relevant, yet poorly understood factors in 
evaluating MDMA toxicity and has been pointed out as one of the putative justifications for 
the unpredictability of its effects. It is possible that the combination with other chemicals will 
exacerbate the severity and/or widen the range of the toxic effects of the drug, resulting in 
serious and potentially lethal intoxications (De Letter et al. 2006; Verschraagen et al. 2007). 
Evaluating the effects of mixtures of MDMA and other substances is paramount in 
order to elucidate the realistic risks associated with ecstasy abuse. Notwithstanding, it has 
long been highlighted that there is still a lack of information regarding the toxicity and 
lethality of drugs in co-administration, as most efforts have been put into studying isolated, 
single substances. In recent years, some attempts to improve the understanding of mixture 
effects have been made (Clemens et al. 2005; Clemens et al. 2007b; Clemens et al. 2004; 
Dumont et al. 2009; Pontes et al. 2008b; van Nieuwenhuijzen et al. 2010). However, much of 
the published literature on the subject shows that the theoretical basis for mixture analysis is 
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poorly understood in the field (Pontes et al. 2008b; Schechter 1998). For this reason, many of 
the studies tend to be ill-conceived, and often lead to erroneous conclusions (Kortenkamp and 
Altenburger 1998). Some authors have fuelled the belief that synergisms between drugs need 
to be evoked to prove enhanced toxic risks associated with mixture exposures (Pontes et al. 
2008b; Robledo et al. 2007; Schechter 1998). Although the effective demonstration of 
synergisms will unequivocally always heighten concerns about health risks, the possible 
implications of apparently less spectacular additive combination effects have not received 
adequate attention (Charles et al. 2002). In our opinion, the persistent seek for synergisms in 
an attempt to justify deleterious consequences is inadequate and unhelpful, and the lack of 
synergisms may lead many to assume that it indicates ‘no risk’, as ‘mere’ additive 
combinations are not relevant to the observed toxicity. 
 
 
3.1. Defining additivity 
 
From a realistic point of view, the direct testing of all the hypothetical combinations of drugs 
is unfeasible. Thus, predictive approaches that permit the mixture assessment are 
exceptionally important. Hence, in order to correctly assess combination effects of chemicals, 
it is crucial to formulate a hypothesis about the expected effect of the mixture. This 
hypothesis (‘null-hypothesis’) provides the necessary basis for evaluating mixture effects in 
terms of synergy or antagonism. An appropriate reference point for such analyses is the 
expectation that joint effects are the result of purely additive interactions of all mixture 
components (Berenbaum 1989; Kortenkamp 2007). 
It is often understand that the effects of a mixture of drugs may be smaller or greater 
than the sum of the individual effects of all mixture components. However, from this premise 
it is often assumed that expectations of joint effects are obtainable by straightforwardly 
calculating the arithmetic sum of all individual effects. As recognized by Kortenkamp (2007), 
the fallacy of this assumption is evident: ‘when we consider, for example, 10 agents, each of 
which provokes 15% of a certain response. The anticipation that the resulting joint effect 
should be 10 x 15 % = 150% turns out to be biologically impossible if the maximally 
inducible effect can only be 100%’. This misconception is based on the predictive model of 
effect summation (ES) and has been highlighted in several works of experts in the field of 
mixture toxicology (Berenbaum 1981; Kortenkamp and Altenburger 1998). In the ES model 
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the effects of the individual compounds are added up to predict the global effect of the 
mixture. Unfortunately, this approach is not valid with chemicals that produce sigmoidal 
concentration–response curves (as it is the case of the majority of chemicals) and is only 
applicable to linear concentration–response curves. The ES concept is all too often mistakenly 
used, leading to very erroneous conclusions. Such an example is a publication by Arnold et al 
(1996) in Science. The authors claimed to see strong synergistic effects with binary mixtures 
of weak estrogens. However, there were severe issues with their work, including the fact that 
they used the ES model to predict their additive effects. These strong mixture effects could 
not be repeated by other researchers, and when it was shown that the paper was incredibly 
flawed, it had to be retracted from the journal. 
Consequently, reliable approaches are required to provide consistent computations of 
mixture effects, and those should be able to consider saturation effects at high effect levels, 
this way avoiding inconsistent expectations of supramaximal joint effects, such as in the 
example described above. 
 
 
3.2. Models for calculating additivity expectations 
 
The assessment of the combination effects in terms of synergy, antagonism and additivity, 
relies on the accurate prediction of the expected effects of a mixture. There is much debate on 
how additive effects should be calculated. All too often, mixture effects have been assessed 
without explicit reference to additive expectations, or even these expectations were 
inaccurately set (Arnold et al. 1997; Soto et al. 1994). 
Despite a number of reviews on the topic have developed few methods to assess 
combination effects (Berenbaum 1985; Berenbaum 1989; Greco et al. 1995), the main 
adversity encountered when evaluating mixture effects based on individual responses of 
mixture components, relies on validating the most accurate model from the vast assortment of 
models seeking to precisely estimate these joint effects. 
Thus, how can the expected effect of a mixture be defined? 
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3.2.1. Concentration addition (CA) 
 
The first and most frequently acknowledged model to predict additive effects has been put 
forward by Loewe and Muischnek (1926) based on the work of Fraser (1872). This approach, 
known as concentration addition (CA) or dose addition, rests on the assumption that the 
components of a mixture act in a similar way, i.e. produce the same toxic effect in the same 
target organ via the same mechanism of action. So, if two agents share the same shape and 
slope for their concentration-response curves and differ only in potency, then it can be said 
that they act as a dilution of each other if combined together. Consequently, each compound 
in the mixture can be replaced by an equi-effective concentration of another, without 
diminishing the overall mixture effect. By implication, this means that every mixture 
component contributes to the overall combination effect in proportion to its concentration, 
even below zero effect levels. This model has been further developed and described by 
Berenbaum (1985; 1989) and have been widely accepted by a number of scientists within the 
field. 
CA can be mathematically expressed by: 
 
=	 ci
ECi
= 1


                (equation 1) 
 
Where n is the number of mixture components, ECi is the concentration of the mixture 
component i that provokes an effect E of known magnitude when applied singly, and ci is the 
concentration of the respective component in the mixture. Every quotient (ci/ECi), which has 
been termed toxic unit (Sprague 1970), gives the concentration of a compound in the mixture 
scaled for its relative toxicity. If the sum of each fraction equals 1, then CA holds true and the 
joint effect can then be called additive. The mixture components act as dilutions of the same 
compound. 
Equation 1 can be applied to calculate a mixture concentration that produces a defined 
effect, when the ECi of the individual mixture components and their relative abundance in the 
mixture are known. The concentration ci of agent i in the mixture is related to the total 
mixture concentration by: 
 
ci = pi × ECmix               (equation 2) 
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Where pi is the fraction of chemical i in the total mixture concentration ECmix that is 
required to produce effect E. Substitution of ci in equation 2 gives: 
 
=	 (pi × ECmix)
ECi


               (equation 3) 
 
And rearranging yields: 
 
=	 (pi × ECmix)
ECi


               (equation 3) 
 
Equation 4 allows the calculation of the concentration ECmix of a mixture that 
provokes an effect E of defined magnitude, provided we have knowledge of the mixture 
composition and of the concentration of each mixture component that, on its own, produces 
effect E. By repeating this calculation for a large range of different effects, it is possible to 
construct a concentration-response relationship that describes the expected additive effects of 
the mixture. The effect concentrations ECi of the single agents are calculated using the best-
fit regression model inverse formulae of the concentration–response models of the single 
mixture components. 
It is assumed that chemicals with the same molecular target site have similar slopes 
(Berenbaum 1989; Gennings et al. 2005; Greco et al. 1995). The importance of the 
assumptions of CA concerning both the degree of similarity of site of action and the similarity 
of slope has been debated since the introduction of the model (Berenbaum 1989; Greco et al. 
1995; McCarty and Borgert 2006). 
 
 
3.2.2. Independent Action (IA) 
 
It is unanimous that CA is a suitable and valid concept for the prediction of mixture effects of 
similarly acting agents (Altenburger et al. 2000 ), whether it is applicable to mixtures of 
agents that show differing modes of action is the topic of a long-standing controversy 
(Berenbaum 1985) and is vehemently refuted by some experts (Pöch 1993). 
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The concept of independen action (IA) or Bliss independence was first developed by 
Bliss (1939) and has also been referred to as joint independent action (Plackett and Hewlett 
1948), response addition and effect multiplication (Colby 1967). This concept, that has been 
successfully applied to the assessment of mixtures when the components produce the same 
toxic effect but via dissimilar mechanisms of action (Backhaus et al. 2000a; Backhaus et al. 
2004a), is based on the idea of probabilistic independence (Greco et al. 1995). IA rests on the 
assumption that the effects of the individual mixture constituents are independent from one 
another, so each component of a mixture acts in a way that does not interfere with the others, 
but all contribute to the overall effect. Therefore, the relative effect of a chemical remains 
unchanged in the presence of another compound (Faust et al. 2001). For example, substance 
A acts in the presence of substance B as it would in the absence of substance B. This implies 
that the action of substance A is independent and not influenced by substance B.  
This concept assumes that mixture effects are the result of interactions of individual 
mixture constituents with different targets of a biological system. Thus, chemicals that are 
present below ‘zero effect’ levels are not expected to contribute to the total mixture effect. 
The model of IA allows calculating the predicted effects ECmix of a mixture of known 
composition by using: 
 
ECmix = 1 −
1 − ci


               (equation 5) 
 
Where, E(ci) is the effect E produced by compound i at concentration c, when applied 
singly. IA is a probabilistic model, i.e., E(ci) is a fraction of a maximal possible effect that 
cannot exceed 1. 
Thus, when applying this model to measures a toxic effects, Etox(ci), a maximal effect, 
Emax, must be defined as a reference point. The effects of test drugs are expressed relative to 
that effect maximal (e.g. 100% cell killing), and this can be represented by: 
 
ci = toxcimax                (equation 6) 
 
If the concentration-response relationships of all mixture constituents i are described 
by an appropriate regression model Mi, the effect Etox(ci) can be estimated from the mean 
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effect Mi (ci) predicted by the regression model, and this modifies equation 6 in the following 
manner: 
 
toxci 	= ici    (equation 7)       and        ci = icimax     (equation 8) 
 
The overall fractional effects are given by substituting this back into equation 5 and 
gives: 
 
ECmix = 1 −
1 −icimax 


               (equation 9) 
 
By multiplying the fractional effects (equation 9) by Emax we can compare the 
predicted effects with the CA predictions: 
 
ECmix = max 1 −
1 −icimax 


                (equation 10) 
 
There are practical limitations on the accurate calculation of IA, as the effect E(ci) 
elicited by each individual mixture component at the concentration ci that it is present in the 
mixture (equation 5) must be known. This becomes more difficult with decreasing agent 
concentrations and decreasing single agent effects. 
 
 
3.2.3. Discriminating between both models 
 
In recent years, several attempts have been made to discriminate methodically between 
predictions derived from the two concepts of CA and IA (Altenburger et al. 2000 ; Backhaus 
et al. 2000a; Marques et al. 2012). 
It is generally accepted that CA would produce valid predictions for the joint effects of 
drugs that interfere with one and the same target. Conversely, the concept of IA should prove 
to be unreliable in anticipating the joint actions of these agents, as it assumes that the different 
components of a mixture cause a common integral biological effect (e.g. cell death) through 
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interaction with different molecular target sites. Thus, based on the understanding of the assay 
system utilised and the concentration-response relationships obtained, it should be fairly 
straightforward to define the more adequate prediction model.  
Notwithstanding, it often happens that CA and IA generate very identical expectations 
of additive combination effects, which cannot be distinguished from one another. Examples of 
this problem can be found in a number of reports. Payne and collaborators used these 
approaches to predict and assess the effect of mixtures of up to four environmental estrogens. 
They found that both models produced almost undistinguishable additivity predictions, when 
applied to mixtures of oestrogen receptor agonists (similarly acting agents) (Payne et al. 2000) 
and to combinations of mitogenic agents which were expected to have diverse modes of 
action (Payne et al. 2001). Takakura and co-workers (2012) investigated the cytotoxicity 
induced by two cocktails composed of two and five pesticides previously identified in the 
French diet, on human cell lines, using the neutral red uptake assay. Two fixed proportions of 
pesticides in the cocktails were used: an equimolar proportion and an exposure proportion 
based on consumption data. The two models of CA and IA gave almost identical 
concentration–response curves in all cases. Villa et al. (2012) tested on the bacterium Vibrio 
fisheri the responses to complex equitoxic mixtures of a high number of individual 
components (up to 84 individual chemicals in the mixtures) with different chemical structures 
and toxicological modes of action (narcotics, polar narcotics, herbicides, insecticides, 
fungicides). It is remarkable that neither CA or IA could be rejected in the case of 4 mixtures 
involving narcotics and polar narcotics alone, as well as in combination with pesticides, since 
the difference between the curves calculated with both models was negligible, even in the 
case of high number of chemicals. For pesticides alone and narcotics and pesticides mixture, 
the two predictions gave different results, but the difference was negligible. Also, Backhaus 
and colleagues (2004b) validated CA and IA to predict toxicities of phenylurea 
multicomponent mixtures, as the both concepts yielded identical mixture calculations. Scelfo 
et al. (2012) studied the effects of binary mixtures with both similar and dissimilarly-acting 
compounds on neuronal networks cultured on multielectrode array chips and verified that CA 
and IA were comparable in predicting additive mixture effects. Other examples for 
overlapping predictions are widely reported in the literature (Backhaus et al. 2004b; 
Cedergreen et al. 2007a; Huang et al. 2011; Ohlsson et al. 2010; Petersen and Tollefsen 
2012). 
Although the difference between the two predictive models is regularly slight or, as 
mentioned above, inexistent, CA often consistently predicts a higher toxicity effect than IA 
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(Altenburger et al. 2000 ; Backhaus et al. 2000a; Faust et al. 2003). According to Drescher 
and Boedeker (1995), the discrimination between predictions derived from CA and IA relies 
on the number of mixture components, their concentration ratio in the mixture, the slopes of 
their concentration-response functions and the regression model used to describe the 
relationships between concentrations and effects of single agents. It has been shown that, by 
increasing the number of individual mixture components, the separation between the two 
predictions will occur (Drescher and Boedeker 1995). 
The idea that all mixture components should display parallel concentration-response 
curves to formulate a prediction based on CA was first discussed by Bliss (Bliss 1939). This 
however was dropped as a requisite following revisions made by Hewlett and Plackett (1959). 
The predictions based upon IA and CA have been shown to cope well with response curves of 
varying slopes and maximal effects (Altenburger et al. 2000 ; Berenbaum 1985; Rajapakse et 
al. 2002; Silva et al. 2002). 
The slope of a concentration–response curve can only be defined either as the ratio 
between two EC-values (e.g. the EC50/EC05 ratio) or in relation to a specific concentration–
response model. Despite their mutually exclusive conceptual positions, it is accepted that CA 
and IA will compute identical toxicities if the concentration–response curves of all mixture 
components can be described by a Weibull-model with a common slope parameter of 1 (on a 
ln-transformed concentration axis) (Backhaus et al. 2004b; Brosche and Backhaus 2010). In 
this situation, an EC50/EC05 ratio corresponds to 13.5. If the ratio for the concentration–
response curves of the mixture components is lower (i.e. the steepness is higher), CA predicts 
a greater effect (i.e. a lower EC50) for the mixture than IA and vice versa (Brosche and 
Backhaus 2010). Typically, EC50/EC05 ratios seem to be substantially smaller than the critical 
threshold of 13.5 (Faust 2004; Smit et al. 2001) and consequently, CA frequently predicts a 
higher toxicity than IA in most situations, a pattern which seems to be confirmed by empirical 
evidence (Kortenkamp et al. 2009). 
 
 
3.2.4. Applicability of CA and IA to studies with similarly and 
dissimilarly acting agents 
 
The existence of both CA and IA as models for mixture risk assessment has brought about a 
great deal of discussion surrounding their appropriate applications. In the last decades, the 
reliability of both concepts has been widely evaluated. 
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From a theoretical point of view, it has often been argued that CA is a precise 
reference model for calculation of joint effects when compounds are known to have similar 
target sites. Arrhenius et al. (2004) evaluated mixtures of structurally related and similar-
acting phenylurea herbicides on two types of marine microalgal communities. Faust et al. 
(2001) performed analyses with mixtures containing 18 s-triazine herbicidals at two different 
concentration ratios in freshwater algae. Also Junghans et al. (2003b) examined mixture 
toxicity of herbicides to aquatic systems  and found that the mixture effects conformed more 
accurately to CA predictions. Parallel outcomes were obtained in several studies performed 
with mixtures of similar-acting components, in assorted fields (Cedergreen et al. 2007b; Hass 
et al. 2007; Svendsen et al. 2010). Tammer (2007) evaluated and predicted the combined 
effects of mycotoxin mixtures upon the functional activity of immune cells and observed that 
the experimental design using the concept of CA was suitable for predicting the combined 
effects of their tested mixtures. Backhaus et al. (2000b), proved that the mixture toxicity of 
quinolones is best predicted by CA. Also in the anticancer research context, much debate has 
centred on a single, appropriate model to predict combined drug effects (Berenbaum 1989; 
Greco et al. 1995). A combination of two taxanes, paclitaxel and cisplatin, has shown close 
support for CA (Levasseur et al. 1997), especially for predicting joint effects of similarly 
acting agents. Orton and her group (2012) demonstrated a good agreement between the effects 
of a mixture of eight ‘pure’ androgen receptor antagonists and the responses predicted by CA. 
A multi-component mixture composed of 16 similarly and specifically acting chemicals, 
anticipated to have a common mode of action via weak acid respiratory uncoupling of 
oxidative phosphorylation, demonstrated highly accurate mixture predictions based upon CA 
(Altenburger et al. 2000 ), and this was further supported by the work of Silva and colleagues 
(Silva et al. 2002) with endocrine disrupting agents. Xing et al. (2012) showed that the CA 
approach was an effective method for the calculation of toxicity of binary system mixtures of 
chlorophenols, commonly used as pesticides, herbicides, and disinfectants, to Daphnia 
magna. Finally, recent findings demonstrate that CA predicts well the toxicities of simple 
binary as well as a more complex 6-component mixture of crude naphthenic acids to fish liver 
cells (Tollefsen et al. 2012). All together these investigations show the potential of using the 
CA concept to obtain accurate predictions of joint mixture effects, especially in the case of 
similar-acting compounds. 
CA has also been demonstrated as well suited in to predicting mixture toxicity of 
unclearly or differently acting substances/chemicals (Backhaus et al. 2004b; Evans et al. 
2012; Zhang et al. 2010; Zhou et al. 2010) and generally it is the more conservative of the two 
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models (Altenburger et al. 1996; Faust 2004). This is very important when doing cumulative 
risk assessment. It has been reasoned that CA should be used for the assessment of every 
mixture which risk is being evaluated, independently of the mode of action of the single 
agents. It is argued that, even if the chemicals act dissimilarly and IA is more appropriately, 
CA would be more conservative predicting mixture effects for a lower concentration range 
and, therefore, more protective of the exposed population. If not much about the chemicals in 
the mixture is known is preferable to be safe than sorry. This point of view is being 
considered very seriously in the regulatory world. 
However, the results for some mixture studies of chemicals with similar overall mode 
of action have also been equivocal (Loureiro et al. 2010; Marques et al. 2012). The reasoning 
for these discrepancies may rely on the ambiguity of the interpretation of the term ‘similar 
action’. From a mechanistic point of view, ‘similar action’ has been defined to apply to agents 
with an identical binding site (Pöch 1993). ‘Similar action’ was also taken to mean that drugs 
can trigger the same toxicological response (Berenbaum 1989). Considering endpoints such as 
cell death, then this could include an extensive range of drugs. CA has, in fact, been suggested 
to be the ‘general solution’ to compute expected effects for any combination of agents without 
the need to refer to their mechanisms of action (Berenbaum 1985). Furthermore, the 
designations of site and mode of action are equivocal, as they are concentration dependent, 
with a small minority of drugs having one site or mode of action at low concentrations and 
others at higher concentrations (McCarty and Borgert 2006). Additionally, sites and modes of 
action are still undetermined for a multitude of drugs (Borgert 2004a; McCarty and Borgert 
2006).  
Conversely, experimental evidence from studies with algae (Backhaus et al. 2004a; 
Faust et al. 2003) and bacteria (Backhaus et al. 2000a), has shown that chemicals with 
specific and dissimilar modes of action are better described using IA. Work using the marine 
bacterium, V. fischeri, has shown that IA has excellent predictive power when combining 
fourteen chemicals of well-known differing mechanisms of action in bacteria (Backhaus et al. 
2000a). The alternative concept of CA resulted in an overestimation of the mixture toxicity. 
This has further been supported by algal toxicity of sixteen dissimilarly acting biocides, where 
IA proved to be superior and more accurate in predicting combined toxic effects (Faust et al. 
2003). Notwithstanding, theoretically, the applicability of IA is seriously questioned by those 
who argue that the combination of chemicals can never act independently due to the elevated 
level of integration of a living system (Gessner 1988).  
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Some authors reported controversial predictive trends, regarding the mechanism of 
action. Barata and collaborators (2006) showed that each model’s predictive abilities changed 
across endpoints. They observed that IA concept was able to predict accurately the toxicities 
of binary combinations of dissimilarly acting chemicals (metals and pyrethroid insecticides) 
when measuring mortality of Daphnia magna, whereas the CA concept did so in three 
pairings for feeding behavior response, irrespective of the chemical mode of action. 
Cedergreen and co-authors (2008) compared the two models, CA and IA to determine which 
best described data for 158 binary mixtures of chemicals which acted in different sites of 
action (primarily pesticides and pharmaceuticals), when tested in seven different test systems. 
The analyses showed that approximately 29 of the mixtures were adequately predicted only 
by IA, 16 were adequately predicted only by CA, and both models could predict the outcome 
of another 34 combinations. Approximately half of the experiments (78) could not be 
described adequately by either of the two models. This level of predictability is rather low, 
considering that, in this situation (evaluation of joint toxicity of chemicals with a different 
molecular target site) IA allegedly should provide the better fit (Cedergreen et al. 2008). A 
comment on the state of the art of mixture toxicology for endocrine disrupters (an area where 
a large amount of mixture work has been carried out) offered an identical position, 
considering CA to be the best reference model even for differently acting chemicals, for a 
range of mammalian whole organism end points (Boekelheide 2007). 
Summarizing, the CA concept has some theoretical underpinnings and some 
experimental data supporting its use for mixtures of chemicals with the same site of action. In 
contrast, IA is not as well grounded in theory, nor is it unambiguously supported by data. 
Despite CA being usually considered a somewhat conservative default approach for the 
predictive assessment of mixture toxicities in general (Berenbaum 1985), the toxicity of 
antibiotics to microbial communities might be an exception from this pattern, as the vast 
differences in sensitivity of the involved species seems to lead to extraordinary flat 
concentration–response curves (Brosche and Backhaus 2010). This is also supported by 
mixture studies with bacterial communities, in which IA systematically predicted higher 
mixture toxicities of antibiotics (Christensen et al. 2006). The results of many studies 
encourage the view that mixture toxicity outcomes on an organism level are way too complex 
to be predicted solely on the basis of the a priori knowledge of components mode of action. 
Secondary mechanisms of action, uptake kinetics, transportation, metabolism, 
compartmentalization, and excretion of the drugs are implicated and have possibly great 
impact on the joint effects (Borgert 2004a; Borgert et al. 2004; Cedergreen et al. 2008; 
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McCarty and Borgert 2006). Nevertheless, they are not considered by the predicting models. 
Large deviations from either of the reference models can, however, be used to form 
hypotheses in terms of types of interactions (Cedergreen et al. 2008). More complex, 
mechanistic approaches, which take into consideration toxicokinetics and toxicodynamics of 
the drugs would be more accurate. However, to date, there are no pragmatic and well-
implemented alternatives. Taking the limited available information of most individual 
chemicals, the models CA and IA are, at the moment, the best option. 
 
 
3.3. Relevance of synergisms and antagonisms 
 
One of the main challenges in toxicology has been to develop approaches to address whether 
combinations of drugs will interact adversely, by either enhancing toxicity or diminishing 
efficacy. Plackett and Hewlett (1952) proposed that chemicals may basically behave in two 
ways: they can have a joint action (zero-interaction) or they can interact. In the first case they 
may act through the Bliss independence criterion, based on the IA concept, or through the 
Loewe additivity model, based on the CA concept, as aforesaid. Both are ‘‘non-interaction’’ 
models assuming that, in combination, drug effects are simply additive, and are neither infra- 
nor supra-additive. In the second case, the effects of the interaction may be antagonistic or 
synergistic. 
Antagonism is largely defined as a type of ‘interaction’ in which compounds produce 
lower toxicity when combined than would be expected by their actions separately. 
Accordingly, greater amounts of drugs are needed to yield exactly the same effect when the 
substances are present together than would be predicted from their individual effects. 
Synergism is the converse, i.e., higher effect produced, or less drug required, than predicted.  
The concept ‘predicted’ is of utmost importance in these designations, as the 
classification demands a comparison of the observed effect with the effect predicted for the 
mixture. As the interactions (synergism and antagonism) cannot be directly tested, they are 
deduced from experimental results that deviate from a model of non-interaction. 
One of the main motivations for mixture evaluation is to address the concern that 
hazard expectations for single drugs might grossly undervalue toxicity due to the potential for 
synergism between mixture components. Indeed, the anticipation of synergism has been used 
to raise fears about toxicity of a range of distinct mixtures. Concerns apart, a synergistic 
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interaction can also be particularly convenient when it confers therapeutic advantages. For 
instance, in an effort to seek for therapeutically beneficial synergistic combinations, 
pharmaceutical and pesticide industries have spent great scientific, professional and financial 
resources. Unfortunately, these efforts have been deeply unsuccessful, as synergisms have not 
been broadly identified. Contrary to synergisms, pharmacological addition and toxicological 
antagonism are among the more common means of conferring therapeutic advantage 
(Berenbaum 1988). An argument supporting that synergisms are probably rare in the 
environment, is the fact that interactions have been mathematically shown to be more likely to 
occur in the mid-range of the concentration-response curve than at high or low extremes 
(Berenbaum 1989). But despite pharmaceuticals being used in biologically active 
concentrations (contrary to environmental contaminants often present at concentrations below 
the observable effect range), pharmacologists and toxicologists have to date, found only a few 
biologically significant synergistic interactions. 
 
 
3.4.Characterising individual and joint toxicities 
 
Human populations are inexorably exposed to a virtually infinite number of complex 
mixtures, albeit the human health risk exposure is currently assessed on the basis of toxicity 
data on individual agents. The ability to employ the previous concepts to compute the overall 
joint effects depends on the knowledge of the precise response profile of single components 
and on the exact composition of the tested mixture. 
 
 
3.4.1. Selection of the assay system 
 
For the prediction of accurate and thorough concentration-response relationship at a given 
mixture ratio, information about the concentration-response curves of all single drugs is 
required (Backhaus et al. 2000a; Berenbaum 1989). 
Recognisably, to ensure greater precision of these predictions, high reproducibility in 
the assay of choice is demanded. This has to be able to produce large amounts of highly 
reliable data for every component of the mixture, in a relatively short period of time. 
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In vivo assays are, obviously, regarded as the ‘gold standards’ in the appraisal of 
drugs toxicity, as these systems incorporate all drug pharmacokinetic aspects including 
absorption, metabolism, distribution and excretion. For this reason, in vivo confirmation of the 
in vitro actions is generally required before any considerations about an agent’s effects. 
Nevertheless, animal testing for toxicity identification is a costly, time-consuming and labour 
intensive approach, and is not pragmatic for hazard identification of large numbers of 
chemicals. Moreover, most governments have increasingly restrictive policies on the use of 
animal testing, so it is minimised when possible. Thus, alternative methods that are rapid, 
sensitive, reproducible, have higher throughput ability and are predictive of in vivo effects are 
needed (Coecke et al. 2007; Lilienblum et al. 2008). 
 
 
3.4.2. Composition of the mixture 
 
The careful selection of each component’s concentration in the mixture avoids 
disproportionate contribution of a single agent to the overall mixture effect. The so-called 
fixed ratio design (Altenburger et al. 2000 ; Backhaus et al. 2000a) has been developed to 
address this issue. In it, each component of the mixture is mixed at a fixed mixture ratio such 
as concentrations that produce x% of the maximum effect. An approach such as this is 
particularly well suited for analyzing multiple mixtures by employing the models of CA and 
IA, as it ensures that all individual components contribute equally to the overall mixture effect 
and no single agent overpowers the effect of the others. In other words, it ensures that the 
more potent components are present at lower concentrations in the mixture than less potent 
agents. It is also appropriate for proof of principle and to identify which model best describe 
the mixture effects being studied. Conversely, when studying more realistic mixtures, 
chemicals are seldom combined at equieffective concentrations. The frequently used 
alternative approach of varying the concentration of one agent while keeping the others fixed 
leads to complications in the computation of expected responses, because mixture ratios 
change continuously. As will be discussed later, this approach is well suited to characterize 
potential interactions between chemicals and identify additive, synergistic or antagonistic 
effects. As described in Chapter I, we have deviated from the fixed mixture ratio design when 
studying the potential interaction of amphetamines that could be present as contaminants in 
ecstasy pills with MDMA.   
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3.4.3. Modelling individual and mixture toxicities: nonlinear 
regression analysis 
 
All single agents and mixtures should be extensively tested using a wide range of several 
different concentrations, each with a variable set of replicates run in parallel, depending on 
the variability of the assay. The most suitable concentration-response relationship for each 
drug is often selected from a number of non-linear regression models using a best-fit 
approach, as described by Scholze and colleagues (2001). Here, a number of different models 
are fitted to the data and the one that best describes the observed effects is selected (best-fit 
criterion). Some of the regression models used for describing sigmoidal concentration-
response curves of single and combined agents are listed in Table 8.  
 
Table 8. Regression models used to calculate the concentration–response curves. 
Regression model (acronym) Function (f)a 
Logit f(x)= θmin + (θmax - θmin)/(1+exp(-θ1-θ2*log(x))) 
Generalized Logit I (GLI) f(x)= θmax *1/(1+exp(-θ1- θ2*log10(x)))^ θ3 
Generalized Logit II (GLII) f(x)= θmax * (1-1/(1+exp(θ1+ θ2*log10(x)))^ θ3) 
Gompertz f(x)= θmax  * (1-exp(-exp(θmin + θmax *(x)))) 
Probit f(x) = θmax * PAREA(θ1+ θ2*( x)) 
Langmuir f(x)= 1/( θ1+ θ2* x)^(- θ3-1) 
Logit with Box-Cox transformation f(x)= tetmax  * 1/(1+exp(-tet1- θ2*( x ^ θ3-1)/ θ3)) 
Gompertz with Box-Cox transformation f(x)= tetmax  * (1-exp(-exp(tet1+ θ2*( x ^ θ3-1)/ θ3))) 
Hill f(x)= θmin + (θmax - θmin)/((1+ x /EC50) exp(-θ2) 
Weibull f(x)=exp(−exp(θ1+θ2log10 x)) 
a
 Where θmin and θmax are the minimal and maximal observed effects, respectively; x is the concentration 
of the test agent; θ1 is the parameter for location; θ2 is the slope parameter; θ3 describes the degree of 
asymmetry around the EC50 and PAREA is the area under the normal probability distribution curve 
from infinity to x. 
 
Once dose-response relationships are obtained for each of the single agents and 
suitable fits established, the parameters from the fitted concentration-response curves of all 
single components are used to model the responses of well-defined mixtures using the two 
concepts for mixture analysis as described before, IA and CA. 
 
 
3.5. Low-Dose Mixture Effects 
 
The relevance of mixture effects at extremely low levels of individual components may be 
controversial. From a theoretically perspective, it is clear that the significance of ‘low-effect’ 
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concentrations is different, depending on the concept employed. Under the assumption of CA, 
there is no threshold concentration other than zero itself as any concentration, no matter how 
low it is, of any mixture constituent is expected to contribute to the overall mixture effect in 
an additive fashion. In contrast, IA admits that only those drugs that are present at effective 
concentrations, i.e., that cause individual effects greater than zero, will contribute to the whole 
joint effect. By other words, IA would predict a mixture effect of zero when all mixture 
constituents are present below the threshold concentration, whereas CA could predict a supra-
threshold response. Hence, the predicted joint effect of components at low effect 
concentrations will vary, depending on the value of the estimated ‘zero effect’ concentrations. 
Clearly, an exact estimation of low effect concentrations, particularly that ‘zero effect’ levels 
for IA, are required to carry out consistent mixture assessments when drugs are combined at 
low or very low amounts.  
 
 
3.5.1. Calculating low effect levels 
 
Recurrently ‘zero effect’ level, or no effect concentration (NEC), is defined as the highest 
tested concentration that produces no effect. In toxicity tests performed on animals, using a 
limited and well-defined number of test individuals, NEC is the concentration that would not 
lead to the observed end point (e.g. death) in any of the individuals tested (Villa et al. 2012). 
This definition is not feasible for tests with microorganisms (algae, bacteria), where a 
functional parameter of the population (growth, luminescence, etc.) is measured. Therefore, a 
NEC may be defined as the concentration that would not produce a response different from 
the control (Villa et al. 2012).  
It is well established that it is impossible to ascertain NECs with confidence, because 
genuine ‘zero effects’ cannot be distinguished from very small, albeit unnoticeable responses. 
The statistical approach most commonly used to deal with this uncertainty is hypothesis 
testing in which treatment responses are compared with negative controls to test the null 
hypothesis that they are drawn from the same population. If the null hypothesis is rejected, a 
multiple comparison test (e.g. Dunnett, Newman-Keuls, or Tukey test) is used to generate a 
no observed effect concentration (NOEC). Thus, a NOEC value is derived from experimental 
data by applying statistical hypothesis testing procedures to distinguish between the highest 
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tested concentration at and below which the effect is not significantly different from untreated 
controls (Van der Hoeven 1997). 
NOEC is a quite controversial concept and its use as the basis for estimating ‘zero 
effects’ has been severely criticised (Chapman 1996). It has been shown that what is 
estimated as a NOEC depends to a large degree on the biological variability of the test system 
and the number and spacing of test concentrations (Moore 1997). Often, effects below 10% of 
a maximal possible response cannot be distinguished reliably from the effects seen in 
untreated controls (Moore 1997). NOECs tend to increase the fewer concentrations tested and 
the larger the spacing between each concentration (Moore 1997). Thus, one of the major 
criticisms on the use of NOECs is the fact that this can lead to false negative results, as 
NOECs are highly dependent on the quality of the data being analysed. There is a high risk of 
overlooking real low dose effects, if the data is poorly distributed (Kortenkamp and 
Altenburger 1998). Furthermore, most of the information in the concentration-response curves 
(e.g. the slope and confidence intervals) is lost and cannot be used, for example, to estimate 
risks of different severity. In summary, NOECs define a range of concentrations where low 
effects can neither be quantified nor ruled out with certainty. 
The so-called benchmark concentrations (ECx) are increasingly viewed as an 
alternative to NOEC determinations (Chapman 1996; Faust et al. 2001; Van der Hoeven 
1997). These are estimated by interpolation from the best-fitting regression model equation of 
the individual observed effects (Moore 1997). Unlike NOECs, which are derived from 
comparisons of only two concentrations (‘treated’ versus ‘controls’), the benchmark 
concentration procedure utilizes the information contained in the entire concentration-
response curve. Moreover, one can confidently interpolate effects to untested concentrations. 
 
 
3.5.2. Combining substances at very low concentrations 
 
Risk assessment authorities provide threshold doses or concentrations of regulatory concern 
such as acceptable daily intakes (ADI) or predicted no effect concentrations (PNECs) for 
individual chemicals that are based on reference points (no observed adverse effect levels, 
NOAELs, NOECs, or benchmark doses). Exposures below these levels are usually considered 
safe. But is there adequate protection also against joint exposures, if each component is 
present below its individual threshold doses or concentrations? 
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The data reported in the literature provide evidence that low levels of individual drugs, 
far below concentrations traditionally assumed as NOECs, are suitable to contribute to the 
toxicity of the mixture, particularly those comprising a higher number of individual 
components. Silva et al. (2002) found significant mixture effects, when eight xenoestrogens 
were mixed together at levels well below their NOECs and EC01. Villa and collaborators 
(Villa et al. 2012) described that an effect of 50% had been obtained by testing a mixture 
composed of 84 chemicals, in which concentrations of individual chemicals were orders of 
magnitude lower than the traditional NOEC. Actually, for about 90% of the individual 
substances the concentration was below EC01. The results of these and other investigations 
(Faust et al. 2001; Junghans et al. 2003a) are corroborated by the theoretical assumptions of 
the CA model, as the concentrations of the chemicals, however low they are, are accounted 
for the overall mixture effect.  
Notwithstanding, Backhaus et al (2011) have shown clear mixture effects when five 
distinct pharmaceuticals and personal care products were present at their individual NOECs 
(an effect accurately predicted by IA) highlighting the fact that, even with respect to mixtures 
of chemically and functionally dissimilar compounds, possible mixture effects from low-
effect concentrations of individual compounds must be taken into consideration.  
In summary, albeit the traditional approaches may be suitable to signpost a level at 
which a drug is considered more or less ‘safe’, evidence supports that this may not be a real 
‘zero effect’ concentration, if the drugs are combined in complex mixtures. 
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PART II – OBJECTIVES OF THE THESIS 
 
From the information previously presented in the introduction section it can be concluded that 
the effects caused by the ingestion of an ecstasy pill may be influenced by a plethora of 
factors that converge in a given individual at a given moment, thus complicating the 
evaluation of the mechanisms associated with the toxic effects of the drug.  
Of particular concern are the interactions that may arise between MDMA and other 
drugs, intentionally or accidentally co-consumed, which can be potentially lethal. Polydrug 
abuse is, undoubtedly, one of the most relevant confounding factors in determining the 
toxicological potential of MDMA and several studies support the evidence that polydrug 
abuse is of serious consequence for the development of toxicity upon exposure to MDMA 
(Cole and Sumnall 2003; Schifano 2004; Schifano et al. 1998). 
From a clinical pharmacokinetic perspective, amphetamine-type drugs share many of 
their pharmacological and toxicological effects, as well as the same metabolic bioactivation 
pathways. It is, therefore, reasonable to anticipate that the co-occurrence of these stimulants 
could result in toxicities that differ from those observed when they are present individually. 
Whilst the risk of interaction between ecstasy and other drugs, including amphetamine-like 
stimulants, have been clearly pointed out, a lack of systematic information regarding the 
toxicity and lethality of drugs in simultaneous administration in the context of ecstasy abuse 
has been noticed.  
This project aimed at increasing the understanding of the toxicological interactions 
between MDMA and other amphetamine-type drugs. More specifically, the purposes of this 
work were: 
 
1. To assess whether the joint cytotoxic effects of mixtures of amphetamine-like 
substances could be accurately predicted based on the concentration-response data of 
the individual components, using the models of CA and IA. 
 
2. To classify the mixtures as additive, synergistic or antagonistic by comparing 
experimental observations with the additivity expectations according to both models. 
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3. To determine if there were significant combination effects, when the individual 
components were present in the mixture at low, ‘realistic’ concentrations, even when 
these did not produce measurable effects when tested individually. 
 
4. To improve the understanding of the mechanisms of interaction between the 
components of the mixture, especially if deviations from additivity were observed. 
Due to their recognized influence on the toxicity of amphetaminic drugs, the 
contributions of hyperthermia and metabolic bioactivation were specially considered. 
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PART III – ORIGINAL RESEARCH 
 
This section presents a detailed description of the experimental protocols, the results and their 
statistical treatment, as well as the discussion of the data within each experimental work, in 
the form of the publications that were originated or the manuscripts that were submitted for 
publication in peer-reviewed international journals listed in the Journal Citation Reports of the 
ISI Web of Knowledge. Five different studies are presented: 
 
Chapter I. The risky cocktail: what combination effects can we expect between 
ecstasy and other amphetamines? Reprinted from Archives of toxicology 87(1): 111-
122 (doi: 10.1007/s00204-012-0929-9). Copyright (2012) with kind permission of 
Springer-Verlag. 
 
Chapter II. Combination effects of amphetamines under hyperthermia – The role 
played by oxidative stress. Submitted to Journal of applied toxicology. 
 
Chapter III. Cytotoxic effects of amphetamine mixtures in primary hepatocytes 
are severely aggravated under hyperthermic conditions. Submitted to Toxicology 
in vitro. 
 
Chapter IV. Mixtures of MDMA and its major human metabolites induce 
significant toxicity to liver cells when combined at low, ineffective concentrations. 
Journal of applied toxicology. In press. Copyright (2013) with kind permission of 
Wiley-Blackwell. 
 
Chapter V. A mechanistic insight into the hepatocellular death induced by 
amphetamines, individually and in combination – The involvement of necrosis 
and apoptosis. Submitted to Archives of toxicology. 
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Abstract 
We evaluated the impact of hyperthermia on the cytotoxicity of combinations of 3,4-
methylenedioxymethamphetamine (MDMA, ecstasy) and three other amphetamines, often co-ingested with 
MDMA. With this purpose, HepG2 cells were exposed to MDMA, d-amphetamine, methamphetamine and 4-
methylthioamphetamine, individually or combined, in hyperthermia (40.5 ºC). The obtained data were 
compared with information from normothermia (37.0 ºC). Mixture additivity expectations were calculated by 
mathematical models of independent action and concentration addition (CA). To delineate the mechanism(s) 
underlying the elicited effects, a range of stress endpoints were evaluated, including quantification of reactive 
species (ROS/RNS), lipid peroxidation, GSH and GSSG, ATP, and changes on mitochondrial membrane 
potential (∆ψm). 
Our data show that, in hyperthermia, the joint effects of the amphetamines were additive and 
accurately predicted by CA. Interestingly, at 40.5 ºC, even slight increases in the concentrations of each 
drug/mixture promoted significant rises in cytotoxic effects, which quickly shifted from roughly undetectable 
to maximal mortality. Additionally, the observed increase of RNS/ROS production, decrease of GSH, and 
ATP depletion, accompanied by mitochondrial impairment were greatly exacerbated under hyperthermia 
Importantly, when equieffective cytotoxic concentrations of the mixture and individual amphetamines were 
compared for all tested stress endpoints, it was observed that the effects of the mixture did not deviate from 
those elicited by individual drug treatments, suggesting that these chemicals have a similar mode of action, 
which is not altered in combination. 
Concluding, our data indicate that mixtures of amphetamines produce deleterious effects, even when 
the individual drugs are combined at very low concentrations. These effects are strongly exacerbated in 
hyperthermia, emphasizing the potential increased risks of ecstasy intake, especially when hyperthermia 
occurs simultaneously as polydrug abuse. 
 
Keywords 
Amphetamines; Concentration addition (CA); Hepatocytes; Hyperthermia; Mixtures; Oxidative Stress. 
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Introduction 
In spite of the increasing evidence of severe and 
even fatal toxicity, 3,4-
methylenedioxymethamphetamine (MDMA, 
ecstasy) abuse is still considered by many of its 
users to be relatively ‘safe’, since the reported 
number of fatalities or severe morbidity events 
related with this drug do not appear to be 
proportional to the high frequency of misuse. 
Nevertheless, the consumption of this drug often 
results in unexpected and random severe toxicity, 
for which there is still no clear explanation 
(deLetter et al. 2004; Greene et al. 2003; Henry 
1992; O'Donohoe et al. 1998; Schifano 2004). In 
fact, the concentrations of MDMA found in human 
abusers following symptomatic and/or fatal 
intoxications vary enormously (deLetter et al. 2004; 
Sticht et al. 2003) and, consequently, threshold 
toxic concentrations or potentially lethal 
concentrations are currently unknown for this drug. 
Also, there is apparently no correlation between the 
amount or the frequency of MDMA intake and the 
severity of toxic symptoms. It is remarkably 
striking that, in some cases, MDMA-related deaths 
occur for first time users or after consumption of 
only a single tablet of ecstasy, while in other cases 
mild intoxication symptoms and full recovery 
occurred after the ingestion of up to a few dozens of 
tablets on a single occasion (Coore 1996b; deLetter 
et al. 2004; Henry et al. 1992b; Milroy et al. 1996; 
O'Donohoe et al. 1998; Ramcharan et al. 1998; 
Schifano 2004). 
Contributing to this unpredictable acute toxicity 
of MDMA is undoubtedly the frequently reported 
concomitant abuse of other substances. It is widely 
acknowledged that a number of recreational drugs, 
including other amphetamines, are often taken 
together with MDMA, either accidentally or 
deliberately (Baggott et al. 2000; Camilleri and 
Caldicott 2005; Dams et al. 2003; Greene et al. 
2008). Ecstasy pills often contain more than one 
type of these stimulants including 
methylenedioxyamphetamine (MDA), d-
amphetamine (d-AMP), 
methylenedioxyethylamphetamine (MDEA), 
methamphetamine (METH), among others 
(Camilleri and Caldicott 2005; Carvalho et al. 2012; 
Sherlock et al. 1999; Tanner-Smith 2006; Teng et 
al. 2006). Consequently, this simultaneous use of a 
wide variety of drugs can have a significant impact 
on the toxicity of MDMA, as combination and 
interactions with other chemicals can potentially 
increase the severity or broaden the range of its 
toxic effects (deLetter et al. 2006; Verschraagen et 
al. 2007) either through toxicokinetic (e.g. 
metabolic impairment) or toxicodynamic 
interactions (e.g. increased sympathomimetic and 
serotonergic effects) (Oesterheld et al. 2004). This 
issue has been recently addressed in a recent 
publication from our group that unequivocally 
demonstrated that amphetamine-like compounds 
that are known to be simultaneously abused in vivo 
(MDMA, d-AMP, METH and 4-
methylthioamphetamine, 4-MTA), were able to 
interact in vitro in an additive fashion, producing 
considerable cytotoxic mixture effects, even when 
combined at individually ineffective concentrations 
(Dias da Silva et al. 2012). 
Also, the environmental conditions in the 
recreational venues where MDMA intake regularly 
takes place have been implicated in its health-
threatening risks (Bellis et al. 2002). Effectively, it 
has been argued that MDMA toxicity may be 
strongly potentiated by the overcrowded and 
overheated environments as they exacerbate one of 
the most toxic effects of the drug, the impairment of 
thermoregulation. The thermogenic actions of 
MDMA, combined with the mentioned 
environmental conditions, as well as the excessive 
dancing and inadequate fluid intake have been 
shown to induce dramatic increases in body 
temperature, with reported values as high as 43.3 oC 
(Armenian et al. 2012; Coore 1996b; Green et al. 
2003; Henry et al. 1992b). This MDMA-induced 
hyperthermia has been associated with the most 
serious detrimental health effects of the drug. Even 
though fatalities elicited by MDMA-induced 
overheating are not very frequent high body 
temperature has been described as one of the most 
aggressive physiological consequences of 
amphetamines in acute poisonings and has been 
recurrently pointed out as a cause for life-
threatening complications, such as acute liver 
failure, rhabdomyolysis, disseminated intravascular 
coagulation, acidosis and multiple organ failure 
(Armenian et al. 2012; Henry et al. 1992a; Kalant 
2001; Kendrick et al. 1977; Patel et al. 2005; 
Screaton et al. 1992). 
One of the main target organs for MDMA 
toxicity that is especially sensitive to the 
hyperthermic effect of the drug is the liver. MDMA 
has been deemed responsible for several cases of 
acute liver failure in young people (Andreu et al. 
1998). The hepatotoxic action of MDMA stems 
from multiple interacting mechanisms that become 
exacerbated at high body temperatures. These 
mechanisms include the increased efflux of 
neurotransmitters, the oxidation of biogenic amines, 
formation of highly reactive metabolites, 
mitochondrial impairment, and apoptosis (Carvalho 
et al. 2012; Carvalho et al. 2010). Several studies 
have shown that an increase in body temperature is 
not only directly related with hepatotoxic damage 
per se, but also further exacerbates the 
amphetamines-related liver toxicity (Carvalho et al. 
1997a; Carvalho et al. 2001; Carvalho et al. 2002a; 
Pontes et al. 2008b; Skibba et al. 1991). Both in in 
vivo and in vitro study models, hyperthermic 
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conditions were shown to potentiate the hepatotoxic 
effects, namely those related with oxidative stress, 
including depletion of GSH levels, lipid 
peroxidation and loss of cell viability (Carvalho et 
al. 2012). As noted above, the severity of the 
symptoms and the hepatic lesions do not seem to 
correlate either with the duration of use or with the 
amount of drug consumed (Andreu et al. 1998; 
Dykhuizen et al. 1995; Garbino et al. 2001). In 
some cases, liver damage appeared only after 
regular use for weeks or months, but two reported 
cases of fulminant hepatitis (Coore 1996a; Ellis et 
al. 1996) and two cases of acute hepatitis 
(Dykhuizen et al. 1995; Henry et al. 1992a) have 
been reported after ingestion of a single tablet of 
ecstasy. The pathogenesis of MDMA-induced liver 
injury remains, therefore, poorly understood. 
A major challenge in elucidating such 
mechanisms is to account for complex factors like 
polydrug abuse and hyperthermia in the study 
models. As mentioned above, we have previously 
tested the combined effects of commonly abused 
amphetamines in an in vitro model using human 
hepatoma HepG2 cells. We demonstrated that, even 
when each components was present at very low 
concentrations, mixtures of these drugs had 
significant hepatotoxic effect (Dias da Silva et al. 
2012).We have now extended our previous research 
by applying  this study model to  hyperthermic  
conditions, which better reflect the physiological 
environment of the liver in an acute intoxication 
scenario, due to the thermogenic action of the drugs 
and the environmental circumstances of the abuse. 
We presently report the investigation of the 
cytotoxic effects elicited by the tested 
amphetamines, when these drugs were incubated 
individually and in combination at a temperature of 
40.5 ºC. Our observations were compared with our 
previous data, obtained under normothermia (i.e. 37 
ºC) to highlight potential changes in cytotoxicity 
associated with an increase in body temperature. 
Furthermore, in a similar way to our previous study 
(Dias da Silva et al. 2012), we tested the 
applicability of two mathematical models, 
concentration addition (CA) and independent 
action (IA), with the aim of investigating whether 
good agreement was still observed with the CA 
expectations, under the new experimental 
conditions. Finally, in order to delineate the 
mechanisms underlying the observed cytotoxicity, 
we further evaluated the involvement of several 
stress indicators in the promoted effects, namely the 
increased formation of reactive oxygen (ROS) and 
nitrogen (RNS) species, the contents of reduced 
(GSH) and oxidised (GSSG) glutathione, the loss of 
mitochondrial membrane potential (∆ψm), lipid 
peroxidation markers, and the ATP intracellular 
levels. 
Our results indicated a disturbance in the cell 
redox status and antioxidant defences, with 
consequent mitochondrial injury and energetic 
deficit that seem to play an important role in the 
observed individual and mixture effects, under 
hyperthermic settings. Of particular note, was the 
increase in the steepness of the cytotoxicity curves 
displayed by each one of these drugs individually, 
as well as in combination, at hyperthermic 
incubations, emphasizing the potential reduction of 
the ‘safety window’ of these drugs and the 
consequent increased risks for ecstasy abusers in 
the high temperature misuse scene. 
Materials and Methods 
Chemicals 
MDMA (HCl salt) was extracted and purified from 
high purity MDMA tablets that were provided by 
the Portuguese Criminal Police Department and 4-
MTA (HCl salt) was synthesized at REQUIMTE/ 
Department of Biological Sciences, Laboratory of 
Toxicology, Faculty of Pharmacy, University of 
Porto. The obtained MDMA and 4-MTA salts were 
pure and fully characterized by nuclear magnetic 
resonance (NMR) and mass spectrometry (MS) 
methodologies. d-AMP (sulfate salt) was purchased 
from Tocris Bioscience (Bristol, UK) and (+)-
METH hydrochloride was purchased from Sigma-
Aldrich, Co. (St. Louis, MO, USA). 
All chemicals were used as supplied. Stock 
solutions were prepared in ultra-purified sterile 
water and were at least 20 times more concentrated 
than the highest concentration tested to prevent 
media dilution. All stock solutions were stored at –
20 °C and subsequent dilutions were freshly 
prepared in cell culture medium before each 
experiment. A range of test concentrations were 
prepared by successive dilutions employing the 
fixed mixture ratio design, as described by 
Altenburger (2000) and Backhaus (2000a). Briefly, 
the master stock solution was serially diluted 
without changing the ratio between each 
constituent. These serial dilutions covered a broad 
range of concentrations, so that a complete 
concentration–response relationship could be 
recorded allowing robust computation of the data. 
Cell culture routine 
HepG2 cells were routinely maintained in 75 cm2 
canted-neck tissue culture flasks (Helena 
Biosciences; Gateshead, UK) in Minimum Essential 
Medium Alpha (MEM Alpha) with GlutMAXTM 
supplemented with 10% foetal bovine serum (FBS), 
1 % antibiotic (5000 U/ml penicillin, 5000 µg/ml 
streptomycin), 0.5% fungizone (250 µg/ml 
amphotericin B) and 0.0015% human transferrin (4 
mg/ml) in a humidified incubator, at 37 °C, with 
5% CO2. Cells were subcultured at approximately 
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70% confluence over a maximum of 10 passages 
and regularly tested for Mycoplasma contamination. 
All reagents used in routine cell culture, 
including 0.05% trypsin/1 mM EDTA and Hanks 
balanced salt solution (HBSS) without Ca and Mg 
were obtained from GIBCO, Invitrogen 
Corporations (Paisley, UK), unless stated 
otherwise. 
MTT reduction assay 
The protocol described previously by Dias da Silva 
et al. (2012) was used. Briefly, HepG2 cells were 
seeded onto the central 60 wells of 96-well 
microtiter plates (Falcon; BD Biosciences, Oxford, 
UK), at a density of 8 x104 cells per well. Peripheral 
wells on the plate were filled with sterile water to 
prevent evaporation and concentration of test 
solutions. Forty eight hours after seeding, the media 
was gently aspirated and the cells were incubated 
with the test drugs MDMA, METH, 4-MTA, d-
AMP individually, and with the tested mixture 
dilutions prepared in fresh culture medium, in a 
humidified air atmosphere containing 5% CO2, at 
40.5 °C. The concentrations were selected to cover 
the whole effect range, from undetectable effects 
(when compared to negative controls) to 100% 
mortality. Each individual plate included six 
replicates of negative controls (i.e., no test agents) 
and six replicates of positive controls (full media 
with 1% Triton X-100). After incubation for 48 h, 
at 40.5 °C, the medium was removed and the 
attached cells rinsed with 200 µl HBSS (pH 7.4), 
followed by the addition of fresh cell culture 
medium containing 0.25 mg/l MTT (Sigma-
Aldrich, Co.; St. Louis, USA). Plates were 
incubated at 37 °C, for 30 min. Finally, the cell 
culture medium was aspirated and the formed 
intracellular formazan crystals dissolved in 100% 
DMSO (Fisher Scientific Ltd; Loughborough, UK). 
The spectrophotometric analysis was run at 570 nm 
using a multi-well plate reader (Labsystems 
Multiskan, Basingstoke, UK). To reduce inter-
experimental variability, data were normalized 
plate-by-plate as described elsewhere (Rajapakse et 
al. 2004), with all data scaled between 0 (negative 
controls) and 1 (positive controls). Data were 
obtained from at least five independent 
experiments, with each test plate containing six 
replicates of eight increasing concentrations of the 
tested individual drugs and mixtures. 
Regression modelling 
The normalised MTT data were fitted to the 
dosimetric logit model, that was chosen based on a 
statistical goodness-of-fit principle (Scholze et al. 
2001): Y= θmin + (θmax - θmin)/(1+exp(-θ1-
θ2*log(x))), where θmin and θmax are the minimal and 
maximal observed effects, respectively; x is the 
concentration of test agent; θ1 is the parameter for 
location; and θ2 is the slope parameter. 
Mixture design and prediction of combination 
effects 
The mixture ratio was chosen such that all 
chemicals were present at concentrations eliciting 
50% of their individual maximal effect (EC50) as 
determined in the MTT assay. This ensured that all 
mixture components were present at equipotent 
concentrations, thus preventing disproportionate 
contributions from any single component. The 
overall effect of the designed mixture was predicted 
using the concepts of concentration addition and 
independent action (IA), first described by Loewe 
and Muchnik (1926) and Bliss (1939), respectively. 
These concepts are based on general assumptions 
regarding the mechanisms of action of the mixture 
constituents and their details have been discussed 
elsewhere (Kortenkamp 2007). Briefly, the concept 
of CA is based on the assumption that the mixture 
constituents have similar modes of action, which 
means that any component can be replaced partially 
or totally with another without changing the overall 
mixture effect (Backhaus et al. 2000b; Silva et al. 
2011). This means that each individual component 
contributes to the global joint effect by acting in 
proportion to its concentration, even at 
concentrations producing no effect. The IA 
alternative approach better describes combination 
effects of drugs with dissimilar mechanisms of 
action with each agent interacting at differing sites 
of action (Backhaus et al. 2000a). In this case, the 
fractional response of one individual component is 
supposed to be independent from those induced by 
other components, presuming that mixture 
components present at zero effect concentrations 
will not contribute to the overall effect. The two 
models can produce very distinct expectations and, 
to our knowledge, have only been applied to 
amphetamine-like compounds in our former study 
conducted at normothermic (37 ºC) incubations 
(Dias da Silva et al. 2012). The mathematical 
derivations of prediction models (CA and IA) were 
described by Payne et al. (2000). 
Drugs challenge for mechanistic studies 
Based on the individual cytotoxicity data obtained 
in the MTT viability assay, four concentrations 
were chosen for each individual amphetamine and 
also for the mixture. The concentrations selected 
were 0.3 mM, 1 mM, 1.5 mM and 1.8 mM for 
MDMA; 0.8 mM, 1.8 mM; 2.3 mM and 3 mM for 
METH; 0.3 mM, 0.5 mM 0.7 mM and 0.9 mM for 
4-MTA; 0.8 mM, 1.7 mM, 1.9 mM and 2.2 mM for 
d-AMP; and, 0.7 mM, 1.5 mM, 2.1 mM and 3 mM 
for the mixture.  
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Table 1. Concentration of each individual amphetamine at the tested mixture concentrations. 
 
 
Tested mixture 
concentration 0.7 mM 1.5 mM 2.1 mM 3.0 mM 
Individual concentration present 
in the mixture (mM) 
MDMA 0.186 0.399 0.559 0.798 
METH 0.270 0.578 0.810 1.156 
4-MTA 0.069 0.149 0.208 0.298 
d-AMP 0.174 0.374 0.523 0.747 
 
These concentrations were selected to cover a 
wide cytotoxic effect range. Although they are 
generally higher than those found in human 
abusers, which are usually in the low micromolar 
range (Garcia-Repetto et al. 2003), they can still be 
considered physiologically relevant since blood 
concentrations found in victims of MDMA-related 
fatal intoxications can be as high as 13.5 mg/L 
(approximately 70 µM) (deLetter et al. 2004; 
deLetter et al. 2006). In such cases the autopsy 
findings have shown that the tissue levels of the 
drug can be much higher (Garcia-Repetto et al. 
2003; Sticht et al. 2003), up to 18 times higher than 
blood concentrations in the liver (deLetter et al. 
2006) and 30 times higher in the brain (Garcia-
Repetto et al. 2003). Moreover, these 
concentrations found at autopsy are probably lower 
than the peak concentrations that are expected to 
occur after drug intake, especially in the cases 
where the victims are submitted to emergency-care 
treatments to control the intoxications. 
Table 1 presents the individual concentrations 
of each amphetamine at different tested mixture 
concentrations. Incubations were conducted both 
under normothermic (37 ºC) and hyperthermic 
(40.5 ºC) conditions. The following biochemical 
endpoints were determined. 
ROS and RNS 
The intracellular ROS and RNS production was 
monitored by means of 2',7'-
dichlorodihydrofluorescein diacetate (DCFH-DA), 
a lipophilic sensitive probe that readily penetrates 
the cells producing 2',7'-dichlorodihydrofluorescein 
(DCFH) after hydrolysis, that further reacts with 
intracellular ROS and RNS, including the hydroxyl 
radical and hydrogen peroxide, generating green 
fluorescent 2',7'-dichlorofluorescein (DCF), which 
is polar and trapped within the cells (Rao et al. 
1992; Smith and Weidemann 1993). 
For this determination, 8 x104 cells per well were 
seeded onto 96-well black plates (Greiner 
CELLSTAR® from Sigma) and allowed to attach 
for 24 h. On the day of the experiment, the cells 
were rinsed twice with HBSS and pre-incubated 
with 10 µM DCFH-DA (Sigma) for 30 min, at 37 
°C. DCFH-DA was stored in an opaque airtight 
container at –20 °C. As DCFH-DA is a non water-
soluble powder, it was initially prepared as a 4 mM 
stock solution in DMSO (Merck) and made up to 
the final concentration in fresh culture media 
(ensuring that the final concentration of DMSO did 
not exceed 0.5%) immediately before each 
experiment. The cells were then rinsed twice with 
HBSS and incubated with 200 µl/well of each test 
concentration of MDMA, METH, 4-MTA, d-AMP 
and mixture dilutions prepared in fresh medium at 
either 37 ºC or 40.5 ºC. A blank (no cells) and a 
negative control (no test drugs) were also included 
in the plate. After a 24 h treatment period, 
fluorescence was recorded at 37 °C, on a 
fluorescence microplate reader (FLUOstar Optima, 
BMG Labtech GmbH) set to 485 nm excitation and 
530 nm emission. The data obtained for the 
individual drug and mixture treatments were 
normalized to negative controls on a plate-by-plate 
basis and presented as fold increase over control 
conditions at 37 ºC or 40.5 ºC. This normalization 
is required to minimize the variability between 
plates and between independent experiments and 
has been extensively described elsewhere 
(Rajapakse et al., 2004). 
GSH and GSSG 
The cellular GSH and GSSG levels were 
determined by the DTNB–GSSG reductase 
recycling assay, as described before (Anderson 
1985), with some adaptations. Briefly, 2 x106 cells 
were seeded onto 10 cm2 petri dishes and allowed 
to attach for 24 h. On the day of the experiment, the 
media was gently aspirated and the cells were 
incubated with each test concentration of MDMA, 
METH, 4-MTA, d-AMP, and mixture dilutions, 
prepared in fresh medium, at either 37 ºC or 40.5 
ºC. Twenty-four hours after cell treatment, the cells 
were rinsed twice with HBSS and 
scrapped/precipitated with 5% perchloric acid 
(HClO4, w/v). After centrifugation for 5 min at 
16,000g (at 4 °C), the supernatants were collected 
and kept frozen at –80 °C until further 
quantification, and the pellet was used for protein 
quantification. The thawed acidic supernatant was 
neutralized with an equal volume of 0.76 M 
potassium bicarbonate (KHCO3) and centrifuged 
for 5 min at 16,000g (at 4 °C). Total glutathione 
(tGSH) was determined by transferring, in 
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triplicate, 100 µl of the neutralized supernatants, 
standards, or blank (5% HClO4, w/v) to a 96-well 
plate, followed by the addition of 65 µl of freshly 
prepared reagent containing 0.24 mM NADPH and 
1.3 mM 5,5-dithio-bis(2-nitrobenzoic acid) 
(DTNB) in phosphate buffer (71.5 mM Na2HPO4, 
71.5 mM NaH2PO4 and 0.63 mM EDTA, pH 7.5). 
The plates were then incubated for 15 min, at 30 
°C, in a microplate reader (SPECTRAmax 340PC 
ROM v3.13, Molecular Devices, US), prior to the 
addition of 40 µl per well of a freshly prepared 10 
IU/ml glutathione reductase solution (Sigma) in 
phosphate buffer. The stoichiometric formation of 
5-thio-2-nitrobenzoic acid (TNB) was followed 
every 10 sec for 3 min at 415 nm (at 30 °C), and 
compared to a standard curve performed for all 
readings. For the determination of GSSG, 10 µl of 
2-vinylpyridine were added to 200 µl aliquots of 
the acidic supernatants and mixed continuously for 
1 h (at 0 °C) for derivatization of the sulfhydryl 
groups (SH). GSSG was then measured as 
described for total glutathione. The molar reduced 
glutathione (redGSH) content was calculated by 
subtracting the GSSG from the total glutathione 
values (redGSH = tGSH −2x GSSG). The results 
were normalized to the total protein amount, and 
the final results were expressed as nmol GSH or 
GSSG.mg-1 protein. 
Protein determination 
Protein was quantified by the Bradford assay 
(Bradford 1976). The absorbance measurement was 
taken at 595 nm using a multi-well plate reader 
(Labsystems Multiskan, Basingstoke, UK) and was 
compared with a bovine serum albumin (BSA, 
Sigma) standard curve to assess protein amount. 
ATP content 
Cellular ATP levels can be rapidly detected through 
a bioluminescent luciferase-based assay. Luciferase 
catalyses the formation of light from the reaction of 
ATP and luciferin. For this determination, 2 x106 
cells were seeded onto 10 cm2 petri dishes to obtain 
confluent monolayers 24 h later. On the day of the 
experiment, the media was gently aspirated and the 
cells were incubated with each test concentration of 
MDMA, METH, 4-MTA, d-AMP and mixture 
dilutions prepared in fresh medium at either 37 ºC 
or 40.5 ºC. After 24 h, the cells were rinsed twice 
with HBSS and scrapped/precipitated with 5% 
HClO4 (w/v). After centrifugation for 5 min at 
16,000g (at 4 °C), the supernatants were collected 
and kept frozen at –80 °C until quantification, and 
the pellet was used for protein quantification. The 
thawed acidic supernatant was neutralized with an 
equal volume of 0.76 M KHCO3 and centrifuged 
for 5 min at 16,000g (at 4 °C). The ATP contents 
were then measured in triplicate in 96-well white 
plates (Greiner CELLSTAR® from Sigma), using a 
luciferin/luciferase bioluminescence ATP 
determination kit (Invitrogen) and following the 
manufacturer instructions. The emitted light 
intensity was determined by using a luminescence 
microplate reader (FLUOstar Optima, BMG 
Labtech GmbH) and compared to a standard curve 
performed within each experiment. The results 
were normalized to the total protein amount, and 
the final results were expressed as nmol ATP.mg-1 
protein. 
Lipid peroxidation 
The extent of lipid peroxidation, which can be 
related with the formation of malondialdehyde 
(MDA) after the hydrolysis of polyunsaturated fatty 
acids, was measured by the thiobarbituric acid 
reactive substances (TBARS) assay (Buege and 
Aust 1978), with some variations from the original 
protocol. Briefly, 1 x106 cells were seeded onto 6-
well plates and allowed to attach for 24 h. On the 
day of the experiment, the media was gently 
aspirated and the cells were incubated with each 
test concentration of MDMA, METH, 4-MTA, d-
AMP and mixture dilutions prepared in fresh cell 
culture medium at either 37 ºC or 40.5 ºC. 
Following a 24 h incubation period, the cells were 
scrapped with 250 µl HBSS and precipitated with 
500 µl of 10% trichloroacetic acid (TCA, w/v). The 
mixture was incubated on ice for 30 min before 
centrifugation at 16,000 g, for 10 min (at 4 oC). 
Aliquots of 500 µl of the supernatants were added 
to an equal volume of 1% thiobarbituric acid 
solution (TBA, w/v in distilled water). The mixture 
was heated for 10 min at 80-95 oC and allowed to 
cool down to room temperature. The absorbance 
readings were performed at 535 nm using a multi-
well plate reader (Labsystems Multiskan, 
Basingstoke, UK). TBARS were expressed as 
MDA equivalents per milligram of protein after 
calculation with the extinction coefficient of 1.56 
x105 M−1 cm−1 (Buege and Aust 1978). 
Mitochondrial integrity 
Assessment of mitochondrial integrity was 
performed by measuring the tetramethylrhodamine 
ethyl ester perchlorate (TMRE) inclusion. TMRE is 
a cell permeable fluorescent dye that specifically 
stains live mitochondria, and accumulates in 
proportion to mitochondrial membrane potential 
(∆ψm) (Scaduto and Grotyohann 1999). For this 
determination, 8 x104 HepG2 cells were seeded 
onto 96-well black plates (Greiner CELLSTAR® 
from Sigma). After 24 h, the media was gently 
aspirated and the cells were incubated with each 
test concentration of MDMA, METH, 4-MTA, d-
AMP, and mixture dilutions prepared in fresh 
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medium at either 37 ºC or 40.5 ºC. At the end of the 
24 h incubation period, the cells were rinsed twice 
with HBSS and incubated at 37 °C with 100 ul of 2 
µM TMRE (Sigma), for 30 min. As TMRE is a non 
water-soluble powder, a 2 mM stock solution was 
initially prepared in DMSO (Merck) and stored in 
the dark. The final 2 µM concentration was 
prepared in fresh culture media, shortly before 
usage (the final concentration of DMSO did not 
exceed 0.5%). Afterwards, the media was gently 
aspirated and replaced by 0.2% BSA in HBSS. 
Fluorescence was measured at 37 °C on a 
fluorescence microplate reader (FLUOstar Optima, 
BMG Labtech GmbH) set to 544 nm excitation and 
590 nm emission. The data obtained for the 
individual drug and mixture treatments were 
normalized on a plate-by-plate basis to the values 
of the respective controls and calculated as the 
percentage of control conditions at 37 ºC or 40.5 
ºC. This normalization is required to minimize the 
variability among the individual plate readings and 
between independent experiments (Rajapakse et al., 
2004). 
Statistical analysis 
The cytotoxicity data from the MTT reduction 
assay were obtained from at least five independent 
experiments and fitted to the logit regression. The 
results were presented including the 95 % 
confidence intervals (CI) of the mean values. For 
the biochemical assays, results are presented as 
mean ± standard error of the mean (SEM) from at 
least four independent experiments. Normality of 
the data distribution was assessed by the 
Kolmogorov–Smirnov normality test. Statistical 
comparisons were performed by one-way analysis 
of variance (ANOVA) followed by the Tukey’s 
multiple comparison test. The control values (raw 
data) obtained for hyperthermic and normothermic 
incubations in the determination of ROS and RNS 
and mitochondrial integrity assays were compared 
by the Student's unpaired t-test for identification of 
potential effects on these endpoints of the increase 
in temperature alone. Significance was accepted at 
p < 0.05. All statistical calculations were performed 
using GraphPad Prism software, version 5.01 
(GraphPad Software, San Diego, CA). 
Results 
The cytotoxicity of amphetamines is significantly 
exacerbated under hyperthermia 
A comprehensive concentration–response analysis 
of all single drugs was carried out under 
hyperthermic conditions by incubating the cells at 
40.5 ºC with the test drugs over a wide 
concentration range. In the MTT assay, all the 
tested drugs yielded reproducible concentration-
dependent cytotoxic effects. The data were 
produced on five different occasions, using 
independently prepared serial dilutions of all 
chemicals and an excellent agreement between 
experiments was consistently noted. The mortality 
curves for each of the tested amphetamines, 
including the upper and lower 95% confidence 
intervals (CI), are displayed in figure 1. A summary 
of the parameters of the best-fit regressions is 
provided in table 2. 
For all the tested drugs, complete lethality 
curves were obtained that significantly differed in 
their slope and EC50 values, as shown in figure 1. 
MDMA (EC50 1.77 mM) and d-AMP (EC50 1.66 
mM) showed comparable potencies. A considerably 
lower median effect concentration was obtained for 
4-MTA (EC50 0.66 mM) that showed the highest 
potency, whilst METH was the least potent drug 
tested (EC50 2.97 mM). 
For the sake of comparison, our previously 
reported data obtained under similar experimental 
conditions, but with the incubations performed 
under normothermia (i.e. 37 ºC) (Dias da Silva et 
al. 2012) were also included in figure 1. The EC50 
values obtained under hyperthermic circumstances 
were lower than those obtained at a physiological 
incubation temperature (Dias da Silva et al. 2012): 
MDMA EC50 2.23 mM at 37 ºC versus 1.77 mM at 
40.5 ºC; METH EC50 5.26 mM at 37 ºC versus 2.97 
mM at 40.5 ºC; 4-MTA EC50 0.74 mM at 37 ºC 
versus 0.66 mM at 40.5 ºC; and d-AMP EC50 2.42 
mM at 37 ºC versus 1.66 mM at 40.5 ºC, thus 
indicating an increase in toxicity at the higher 
incubation temperature that was observed for all 
tested amphetamines with a remarkable difference 
noted for METH. 
By comparing the slopes of the regression 
models at hyperthermic incubations with those 
achieved at normothermic incubations, it became 
clear that the curves obtained at 40.5 °C were 
significantly steeper than those at 37 °C, and that 
very small increases in the concentration of each 
test drug provoked much greater increases in cell 
mortality than what could be observed at 37 ºC 
(figure 1). These results indicate that increasing the 
incubation temperature to values that mimic the 
target-organ temperatures expected to occur in vivo, 
in an intoxication scenario (Armenian et al. 2012; 
Henry et al. 1992b) has a strong impact on the 
cytotoxic profile of the test drugs, with very similar 
concentrations inducing effects that can quickly 
shift from roughly undetectable to high mortality 
levels. 
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Figure 1. Concentration–response curves obtained with the MTT reduction cytotoxicity assay for all four individual amphetamine 
mixture components, in HepG2 cells after 48 h incubations at 40.5 °C. The open circles represent data from five independent 
experiments for MDMA, METH, 4-MTA and d-AMP, following 48 h incubations. The red solid lines represent the regression model (logit) 
and the dashed red lines represent the corresponding 95% CI. The dashed blue lines represent the previously reported data obtained under 
similar experimental conditions when incubations were performed at normothermic (37 ºC) conditions (Dias da Silva et al. 2012). 
 
Table 2. Logit parameters for the test amphetaminic agents in the MTT reduction assay, at 40.5 °C. 
 
Drug 
Estimated parameters for the best-fit regression model of 
each individual agent 
EC50 (mM) Relative proportion in mixture (%) 
ᶿ1 ᶿ2 
MDMA -4.42E+00 1.78E+01 1.77E+00 20.94 
METH -9.74E+00 2.38E+01 2.97E+00 49.39 
4-MTA 6.12E+00 3.39E+01 6.60E-01 6.96 
d-AMP -5.20E+00 2.37E+01 1.66E+00 22.71 
Mixture -9.84E+00 2.94E+01 2.06E+00 100 
 
Amphetamines interact with each other to 
produce significant additive effects at 
hyperthermic incubations 
Based on the individual information of the single 
agents, the mathematical models CA and IA were 
applied to predict the additive mixture effects of the 
four amphetamines for the complete concentration–
response range. The computed data yielded well-
discriminated predictions, enabling a good 
validation of the most suitable model in predicting 
the joint effects of amphetamines, under 
hyperthermic conditions (figure 2). We then tested 
the mixture experimentally. As formerly described 
in the mixture design used in this study, the 4 drugs 
were combined in proportion to their EC50, such 
that they were present in the mixture at 
equieffective concentrations. The composition of 
the mixture analysed in the experimental studies is 
provided in table 2.  
As shown in figure 2, the slope for each 
prediction model was similar. However, the curve 
according to CA was shifted to lower 
concentrations, assuming greater combination 
effects than with the IA model. 
When the mixture was experimentally tested, 
the obtained data revealed low variability and the 
observed responses were well estimated by CA, up 
to concentrations producing 50% mortality. 
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Figure 2. Predicted and observed effects obtained with the MTT reduction cytotoxicity assay for an equipotent mixture of MDMA, 
METH, 4-MTA and d-AMP in HepG2 cells, after 48 h incubations at 40.5 °C. Best-fit of observed mixture effects (black solid line) is 
from six independent experiments, with dashed black lines indicating the 95% CI. Predicted effects were calculated using the models of 
concentration addition (CA; solid red line), and independent action (IA; dashed blue line). Dotted green lines indicate the EC50 of predicted 
and experimentally observed concentration–response curves: observed mixture effect - EC50 2.06 mM; CA - EC50 1.91 mM; and IA - EC50 
5.14 mM. 
 
The EC50 value of the experimentally tested 
mixture was 2.06 mM and the estimated value 
according to CA was 1.91 mM, proving good 
prediction power. On the other hand, IA predicted a 
much higher EC50 value of 5.14 mM, clearly 
underestimating the mixture effects and proving 
inappropriateness to predict the joint effects of 
amphetamines under our experimental conditions. 
At concentrations higher than the EC50, the curve 
obtained with the experimental data deviated from 
CA, with a minimal shift to the right, suggesting a 
potential slight antagonism. 
Amphetamines, individually and in combination, 
generate reactive species in a concentration- and 
temperature-dependent manner 
Following environmental stress, such as that 
elicited by cytotoxic agents or overheating, some 
cellular redox modifications may happen through 
the production of peroxides and free radicals. 
Nonetheless, the cells contain complex antioxidant 
defense mechanisms to counteract the risk of 
oxidative injury. When the generation of reactive 
species (RNS/ROS) exceeds the capability of the 
cell machinery to scavenge and detoxify the 
reactive intermediates, oxidative stress arises with 
the damage of vital cellular structures, such as 
nucleic acids, proteins, and lipids (Powers and 
Lennon 1999). The existing literature suggests that 
oxidative burst is implicated in the cytotoxicity 
elicited by amphetamine derivatives (Barbosa et al. 
2012; Carvalho et al. 2002a; Cerretani et al. 2011). 
So, in order to elucidate the mechanisms underlying 
the observed hepatotoxicity in the MTT assay, we 
examined the involvement of oxidative/nitrosative 
stress in the effects of the tested chemicals. As 
shown in figure 3, the DCFH assay revealed that 24 
h after normothermic incubations, all 4 drug 
treatments significantly increased the formation of 
reactive species in a concentration-depend manner, 
being 4-MTA the most effective. These effects 
were significantly potentiated when the drugs and 
the mixtures were incubated at 40.5 oC (figure 3). 
Significant differences in the ROS and RNS 
intracellular levels were also observed (p<0.05) 
between control incubations at 37 ºC (39939 ± 8096 
fluorescence units) and at 40.5 ºC (43768 ± 13045 
fluorescence units), showing that an increase in 
temperature had an impact on ROS and RNS 
formation per se. 
With the aim of directly comparing the 
individual potencies of each drug at 40.5 ºC, as well 
as the effects of the individual chemicals with those 
of the mixture, we focused on the effects elicited by 
the individual EC50 under hyperthermia, i.e., those 
concentrations that elicited 50% cell death in the 
MTT assay. These concentrations were: 1.8 mM for 
MDMA, 3.0 mM for METH, 1.7 mM d-AMP, 0.7 
mM 4-MTA and 2.1 mM for the mixture. The 
obtained data show that, at these equieffective 
cytotoxic concentrations, MDMA and METH 
induced a similar effect in ROS/RNS increase over 
controls (2.25 ± 0.08 and 2.50 ± 0.09, respectively), 
while d-AMP and 4-MTA proved to be much more 
potent, inducing 3.72 ± 0.11 and 3.86 ± 0.08 fold 
increases, respectively. The mixture exhibited an 
intermediate response yielding a 3.01 ± 0.08 fold 
increase over control values. 
 
 
 
Chapter II 
 118 
 
Figure 3. Effect of MDMA (A), METH (B), 4-MTA (C), d-AMP (D) and mixture (E) on reactive species (ROS and RNS) production 
in HepG2 cells, after 24 h incubations at 37 ◦C (white bars) or 40.5 ◦C (black bars). Results represent the mean ± SEM of the 
fluorescence emitted when 2’,7’-dichlorodihydrofluorescein (DCFH) reacts with ROS and RNS and were normalized to the control 
(fluorescence of non-treated cells was set to 1). Data are from at least 4 independent experiments, run in triplicate. Statistical comparisons 
were made by one-way ANOVA followed by the Tukey’s multiple comparison post hoc test. **p<0.01, *** p<0.001, compared with 
control at 37 ◦C; xx p<0.01, xxx p<0.001, compared with control at 40.5 ◦C; ###p<0.001, compared with the same concentration at 37 ◦C. 
 
Amphetamines, individually and in combination, 
induce a concentration-dependent decrease in 
reduced and total intracellular glutathione, an 
effect that is exacerbated at hyperthermic 
incubations 
The presence of GSH in the cytosol and aqueous 
compartments of mitochondria is essential to 
counteract the detrimental effects of free radicals in 
the cell. This tripeptide has several antioxidant 
functions, including the scavenging of a variety of 
radicals and the reduction of a diversity of cellular 
antioxidants. Acting as a co-substrate of glutathione 
peroxidase (GPx) it contributes to the elimination 
of H2O2 and other peroxides. By donating a pair of 
hydrogen ions, GSH is oxidized into GSSG and the 
regeneration into GSH is catalyzed by glutathione 
reductase (GR) using NADPH as the reducing 
substrate (Meister 1995). 
As depicted in figure 4, the results from our study 
on GSH and GSSG intracellular levels indicate that 
there were no significant alterations in the 
intracellular levels of glutathione disulfide between 
the control incubations at 37 ºC (6.78 ± 0.36 nmol 
GSSG/mg protein) and at 40.5 ºC (5.84 ± 0.40 nmol 
GSSG/mg protein). Also, no significant differences 
were observed in GSSG levels for any of the drug 
incubations at both incubation temperatures. These 
observations were expected, as GSSG in the liver is 
maintained at very low levels to keep the 
intracellular ratio of GSH/GSSG high and minimize 
GSSG toxicity (Kretzschmar et al. 1992). 
After the disulfide production, the cells excrete 
GSSG to the extracellular space (Leier et al. 1996). 
A significant decline in reduced GSH, and 
consequently, in the total glutathione levels (tGSH), 
was observed in a concentration-dependent fashion, 
when HepG2 cells were incubated with the test 
drugs at 37 oC (figure 4A). In fact, significant 
decreases from control values (97.9 ± 7.5 nmol 
tGSH/mg protein) were observed for all drugs and 
for the mixture. These effects were significantly 
exacerbated at 40.5 ºC incubations, as can be seen 
in figure 4 (B). For all test drugs and the mixture, 
tGSH levels were significantly lower than those 
obtained with the same concentrations at 37 ºC 
incubations, including the control incubations (78.7 
± 4.1 nmol tGSH/mg protein, p<0.05 versus control 
at 37 ºC).  
At EC50 in the MTT assay (40.5 ºC), METH 
induced the smallest decrease in tGSH levels to 
37.4 ± 1.8 nmol tGSH/mg protein. The drugs 
MDMA and 4-MTA displayed very similar 
potencies, with MDMA inducing a decrease in 
tGSH levels to 10.2 ± 0.9 nmol tGSH/mg protein 
and 4-MTA down to 11.5 ± 1.6 nmol tGSH/mg 
protein. Both d-AMP and the mixture exhibited an 
intermediate effect by inducing a decrease down to 
13.6 ± 1.1 nmol tGSH/mg protein and 14.1 ± 3.5 
nmol tGSH/mg protein, respectively. 
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Figure 4. Effect of MDMA, METH, 
4-MTA, d-AMP, and mixture on 
the total glutathione (tGSH), 
reduced glutathione (redGSH) and 
glutathione disulfide (GSSG) 
contents in HepG2 cells, after 24 h 
incubations at 37 ◦C (A) or 40.5 ◦C 
(B). Results represent the mean ± 
SEM and are from at least five 
independent experiments, run at least 
in triplicate. Statistical comparisons 
were made by one-way ANOVA 
followed by the Tukey’s multiple 
comparison post hoc test. *p<0.05, 
**p<0.01, *** p<0.001, compared 
with control at 37 ◦C; x p<0.05, xx 
p<0.01, xxx p<0.001, compared with 
control at 40.5 ◦C; ###p<0.001, 
compared with the same 
concentration at 37 ºC. 
 
 
Amphetamines, individually and in combination, 
altered the intracellular energetic status, 
particularly at hyperthermic incubations 
ATP, the key intermediate for energy exchange, is 
considered the ‘primary energy currency’ in living 
cells (Knowles 1980). ATP serves as a means for 
storing energy and its break down, with consequent 
energy release, is engaged in a variety of cellular 
activities, including cellular energetics, metabolic 
regulation and signalling. Since all cells require 
ATP to remain alive and carry out their specific 
function and, because ATP is transiently depressed 
by many forms of cellular stress, its levels reflect 
the functional integrity of viable cells.  
The observed changes in intracellular ATP 
levels are presented in figure 5. 
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Figure 5. Effect of MDMA (A), METH (B), 4-MTA (C), d-AMP (D) and mixture (E) on ATP intracellular content in HepG2 cells, 
after 24 h incubations at 37 ◦C (dark solid line) or 40.5 ◦C (dashed red line). Results represent the mean ± SEM and are from at least 
four independent experiments, run in triplicate. Statistical comparisons were made by one-way ANOVA followed by the Tukey’s multiple 
comparison post hoc test. *p<0.05, **p<0.01, ***p<0.001, compared with control at 37 ◦C; x p<0.05, xx p<0.01, xxx p<0.001, compared 
with control at 40.5 ◦C; #p<0.05, ##p<0.01, ###p<0.001, compared with the same concentration in normothermia. 
 
Control values were 24.23 ± 0.30 nmol 
ATP/mg protein and 18.62 ± 0.50 nmol ATP/mg 
protein at 37 ºC and 40.5 ºC incubations, 
respectively (p<0.01 versus control at 37 ºC). At 37 
ºC, significant decreases in ATP intracellular levels 
were observed for 4-MTA, d-AMP and mixture 
incubations with all tested concentrations. Smaller, 
but still significant ATP decreases could also be 
observed for MDMA and METH incubations. 
At median cytotoxic effect concentrations 
(EC50 values in the MTT assay) tested at 40.5 ºC, 4-
MTA significantly decreased the ATP cellular 
levels (3.0 ± 0.8 nmol ATP/ mg protein) and was 
the most potent drug, while higher values were 
observed for MDMA and METH (7.9 ± 1.0 nmol 
ATP/ mg protein and 12.0 ± 0.9 nmol ATP/ mg 
protein, respectively). Intermediate values were 
obtained for d-AMP (4.8 ± 0.7 nmol ATP/ mg 
protein) and mixture (4.7 ± 1.1 nmol ATP/ mg 
protein). 
Amphetamines did not induce lipid peroxidation 
in HepG2 cells, neither at normothermic nor 
hyperthermic incubations 
Due to their high reactivity, free radicals can 
interact with the lipids of cell membranes, resulting 
in their oxidative degradation, a process known as 
lipid peroxidation, which can result in destruction 
of the cell membrane. The end-products of lipid 
peroxidation, such as malonildialdehyde (MDA), 
are also injurious and can react with intracellular 
targets including DNA, forming adducts (Marnett 
1999). 
After 24 h of incubations at 37 ºC and at 40.5 
ºC no detectable signs of modification in the 
formation of MDA (data not shown), a general 
indicator of the decomposition of polyunsaturated 
fatty acids, were observed for any of the tested 
concentrations of the amphetamines and the 
mixture as determined by the TBARS assay. 
Mitochondrial function of HepG2 cells is 
severely affected by amphetamines incubation, 
individually and in combination, at 40.5 ºC 
∆ψm is crucial for maintaining the physiological 
function of the mitochondrial respiratory chain, a 
process responsible for ATP generation. A 
significant loss of ∆ψm impairs oxidative 
phosphorylation, depleting cells of energy and 
inducing cell death. Therefore, the determination of 
∆ψm by the TMRE mitochondrial inclusion assay 
provides important information about the 
mitochondrial function and the physiological status 
of the cell.  
When incubated at 37 ºC, the cells suffered 
∆ψm dissipation only at the highest concentration 
tested (down to 89.2 ± 2.3% of control for 1.8 mM 
MDMA, 36.8 ± 5.5% of control for 0.9 mM 4-
MTA, 69.8 ± 2.7% of control for 2.2 mM d-AMP, 
and 48.9 ± 8.5% of control for 3 mM mixture) 
(figure 6). 
Mitochondrial damage was significantly 
aggravated under hyperthermic conditions, as 
significant differences were observed in response to 
lower concentrations of the tested drugs. 
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Figure 6. Effect of MDMA (A), METH (B), 4-MTA (C), d-AMP (D) and mixture (E) on the amount of tetramethylrhodamine ethyl 
ester (TMRE) incorporated within the mitochondria as a measure of mitochondrial membrane integrity, after 24 h incubations at 
37 ◦C (white bars) or 40.5 ◦C (black bars). Data are expressed in percentage of control at 37 ◦C or 40.5 ◦C (fluorescence of non-treated 
cells set to 100%) and represented as the mean ± SEM. Results were obtained from four independent experiments run in six replicates. 
Statistical comparisons were made by one-way ANOVA followed by the Tukey’s multiple comparison post hoc test. *p<0.05, *** 
p<0.001, compared with control at 37 ◦C; x p<0.05, xxx p<0.001, compared with control at 40.5 ◦C; ###p<0.001, compared with the same 
concentration in normothermia. 
 
 
At 40.5 ºC and for the highest concentrations 
tested, the following values were observed: 72.9 ± 
4.3% of control for 1.8 mM MDMA; 31.8 ± 4.1% 
of control for 0.9 mM 4-MTA; 27.4 ± 1.6% of 
control for 2.2 mM d-AMP; and 23.8 ± 2.6% of 
control for 3 mM mixture). No significant 
differences were identified (p>0.05) between 
control incubations at 37 ºC (45875 ± 11516 
fluorescence units) and at 40.5 ºC (47364 ± 14120 
fluorescence units) highlighting that an increase in 
temperature in the absence of amphetamine 
treatment had no impact on mitochondrial function. 
For the 50% effective concentrations in the 
MTT assay, the results show that MDMA and d-
AMP were the least effective in generating 
significant mitochondrial disruption (with decreases 
in TMRE inclusion down to 72.9 ± 4.3% of control 
and 69.8 ± 6.3% of control, respectively). 
Notwithstanding, 4-MTA and the four-component 
mixture were able to produce greater effects (down 
to 32.6 ± 3.5% of control and 34.0 ± 1.1% of 
control, respectively). METH, by itself, did not 
have a significant effect on ∆ψm, since no changes 
in TMRE inclusion in relation to control values 
were detected at 37 ºC or 40.5 ºC incubations for 
any of the tested concentrations of the drug. 
Discussion 
Remarkable interindividual differences in the 
toxicity of amphetamine-like drugs, including 
MDMA, have been reported (Carmo et al. 2004; 
Carmo et al. 2005; deLetter et al. 2004; Henry et al. 
1992a; O'Donohoe et al. 1998). However, it is still 
unclear why, under similar circumstances, the 
consumption of this drug can either induce no 
noticeable clinical symptoms or result in life-
threatening and lethal complications, even when the 
drug is taken in relatively small amounts (1 or 2 
tablets on a single occasion) (Coore 1996b; Mueller 
and Korey 1998). Among the most probable 
contributing factors that have been put forward to 
explain these random toxicity events are the 
concomitant intake of other drugs and the hot, 
crowded, dance clubs conditions which can 
enhance the thermogenic actions of amphetamines 
(Green et al. 2004). Understanding the influence of 
drug combinations and environmental factors on 
ecstasy toxicity, as well as clarifying the 
mechanisms involved in their toxicological effects 
is, therefore, crucial to predict and consequently 
prevent random toxicity events. 
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Nevertheless, only a scarce number of studies 
has so far addressed the investigation of the 
putative interactions between amphetamines in 
mixture (Clemens et al. 2007; Clemens et al. 2005; 
Clemens et al. 2004). Also, these studies are often 
impaired by the lack of adequate study models that 
can accurately reflect the human situation and bring 
together factors, such as combination effects and 
hyperthermia. In recently published work, Dias da 
Silva and colleagues (2012) were able to 
demonstrate that in an in vitro model using 
immortalized human hepatoma HepG2 cells, four 
amphetamines that are frequently co-ingested in 
ecstasy pills (4-MTA, d-AMP and METH and 
MDMA) act together to produce significant 
cytotoxic mixture effects, even when combined at 
very low, ineffective concentrations (Dias da Silva 
et al. 2012). This work clearly demonstrated that 
potentially harmful interactions among 
amphetamines can be expected when these drugs 
are taken concomitantly.  
In the present study, we took this approach one 
step further and showed, for the first time, that the 
same four amphetamines act together to produce 
significant mixture effects, and that these effects are 
further exacerbated when the temperature is raised 
from physiological (37oC) to hyperthermic (40.5 
oC) levels. An example of these observations can be 
provided by using the concentration of the four-
component mixture that prompts 50% of effect 
(EC50 2.9 mM). At this concentration (37oC), all 
four individual components were present in the 
mixture at concentrations that individually yielded 
effects indistinguishable from controls (below 6% 
of maximal responses). Yet, when combined, they 
were able to induce 50% of cell mortality, 
indicating a significant additive mixture effect. 
Strikingly, when this same concentration (2.9 mM) 
of the same mixture was tested in the same in vitro 
system, but at a temperature of 40.5 ºC, it induced 
97.7% mortality, substantiating an astonishing 
exacerbation of toxicity. Thus, this mixture effect 
that was significant at 37 ºC was greatly 
exacerbated under hyperthermic settings. 
In terms of our ability to predict mixture 
toxicity in hyperthermia, of note was the excellent 
discrimination achieved between the expectations 
according to CA and IA at 40.5 ºC, which allowed 
an accurate determination of the model that better 
described the experimental outcomes. Similarly to 
what was observed at 37 oC, the model of CA 
provided accurate estimations of amphetamine 
combination effects at 40.5 oC, proving that the 
tested chemicals acted together in an additive 
fashion (Dias da Silva et al. 2012). Since the CA 
model assumes that all our mixture components 
operate in a similar manner and that each individual 
drug contributes to the overall mixture effect in 
proportion to its concentration, we can expect that 
the same overall effect will be observed if one 
constituent were totally or partially replaced by an 
equieffective concentration of another drug. As a 
consequence, significant mixture effects can occur 
even when the drugs are mixed at individually 
ineffective concentrations. It is, therefore, plausible 
that low levels of amphetamines present in ecstasy 
pills can produce adverse effects by virtue of its 
additive mixture effects.  
In spite of the excellent agreement between CA 
and experimental data, a very slight deviation from 
additivity was detected at higher effect 
concentrations, indicating a weak antagonism. This 
was also previously observed with incubations at 37 
ºC and was attributed to a possible metabolic 
interaction since at higher mixture concentrations 
an increase in the metabolic conversion into MDA, 
a metabolite that retains pharmacological action but 
is less cytotoxic than MDMA (Carvalho et al. 
2002b; Johnson et al. 1988), was observed (Dias da 
Silva et al. 2012). Yet, this hypothesis awaits 
experimental confirmation, since additional factors 
may be involved such as the availability of the 
drugs at the binding sites, or unspecific serum 
protein binding that may be altered due to the 
combination of the mixture components. 
The inappropriateness of the IA model for the 
assessment of the joint effects of these drugs in the 
MTT assay was shown by the model’s significant 
underestimation of the experimentally observed 
mixture toxicity. This further suggests that there is, 
in fact, a similarity in the way in which these agents 
lead to HepG2 cell death. Accordingly, an overall 
analysis of our data on the oxidative stress, 
energetic status, and mitochondrial dysfunction of 
hepatocytes exposed to the drugs either individually 
or in mixture showed that, for all evaluated 
parameters, the mixture exhibited a similar 
response profile when compared with the individual 
drug treatments. 
A remarkable feature of the cytotoxicity curves 
obtained at 40.5 ºC was the steepness of the 
concentration–response relationships for all drugs, 
meaning that, in the linear part of the curve, very 
small increases in the concentrations of the test 
chemicals elicited substantial increases in 
cytotoxicity and, consequently, the differences 
between concentrations inducing no noticeable 
effects and those leading to significant toxicity 
were extremely small. This was not observed when 
the incubation temperature was set at 37 oC, 
suggesting that this was a temperature-related 
event. Consequently, it could be hypothesized that, 
in an in vivo situation, the ‘safety window’ of these 
drugs would become narrower and the associated 
hazards increased under hyperthermia.  
Our data also agrees well with previous studies 
that have provided experimental support for the 
influence of hyperthermia in the severity of the 
cytotoxic effects that MDMA produces in the target 
organs, namely in the liver (Carvalho et al. 2001; 
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Carvalho et al. 2002a; Pontes et al. 2010; Pontes et 
al. 2008a). It has been postulated that hyperthermia 
per se induces a pro-oxidant state (Flanagan et al. 
1998; Skibba et al. 1991) that may aggravate the 
oxidant effects of amphetamines (Carvalho et al. 
2001; Carvalho et al. 2002a; Pontes et al. 2010; 
Pontes et al. 2008a) and that amphetamines, 
directly or through the production of reactive 
metabolites, are able to disturb the pro-
oxidant/antioxidant cellular status, in favour of the 
first, in several systems (Barbosa et al. 2012; 
Carvalho et al. 2004; Cerretani et al. 2011). Our 
data support such mechanistic interactions, given 
that our results revealed a concentration-dependent 
generation of ROS/RNS and a significant decrease 
in GSH intracellular levels, when HepG2 cells were 
exposed to the test amphetamines both individually 
and in combination. Hepatotoxicity provoked by 
hyperthermia has been previously linked to lipid 
peroxidative damage as a consequence of oxidative 
stress (Skibba et al. 1991; Skibba et al. 1990) and 
was observed in freshly isolated rat hepatocytes 
incubated with amphetamines (Carvalho et al. 
1997a; Carvalho et al. 2001), but we did not 
observe this end-effect of oxidative stress. In 
addition, we did not observe an intracellular change 
in GSSG levels since, once formed, it is extruded to 
the extracellular medium (Leier et al. 1996). It 
cannot be, therefore, excluded that the observed 
decrease in tGSH and reduced GSH levels result at 
least partially from the loss due to the high 
reactivity of the amphetamine metabolites that can 
conjugate with GSH (Bindoli et al. 1992; Carvalho 
et al. 1997b; Hiramatsu et al. 1990) and not only 
from oxidation into GSSG. 
Overall, all the tested stress endpoints were 
greatly intensified when the incubation temperature 
was increased. Accordingly, the effect of 
hyperthermia was particularly notorious in the 
dramatic depletion of intracellular stores of ATP 
that was observed for the amphetamines 
individually, as well as in combination. The 
consequent mitochondrial dysfunction was also 
confirmed by the loss in ∆ψm, at 40.5 oC. The 
similarities between the magnitude of effects 
elicited by the amphetamines alone and combined 
suggest a similarity in the mechanism of action of 
the individual drugs, which is maintained in a 
mixture setting. In other words, as the 
concentrations tested were equieffective in terms of 
cytotoxicity and for this endpoint additivity was 
confirmed, a similar equieffectiveness for the 
remaining endpoints, suggests the drugs still act in 
a similar way and the mixture remains additive. On 
the other hand, it is important to highlight that the 
individual concentrations of the drugs in the 
mixture are much lower than those required to 
produce the same effect when tested individually. 
As an example, the 1.5 mM concentration of the 
mixture for which significant effects were noted in 
the majority of the tested endpoints (both at 
normothermia and hyperthermia), contains 0.399 
mM MDMA, 0.578 mM METH, 0.149 mM 4-
MTA, and 0.374 d-AMP. At these individual 
concentrations, no effect would be noted. These 
data demonstrates that the simultaneous drug abuse 
under hyperthermia can induce toxic effects that are 
much higher than those that could be anticipated 
based on the individual actions of the drugs. 
Concluding, our study brings experimental 
support to the concerns raised by the amphetamine 
polydrug abuse especially when body temperature 
is increased, either due to the thermogenic action of 
the drug or due to the influence of high 
environmental temperatures, or both 
simultaneously. Taking into account the potential 
impact of each (hyperthermia and joint effects) 
individually, severely increased toxicity might be 
anticipated in the corresponding misuse scene, but 
the combination of both has the potential to 
dramatically aggravate the severity of the 
intoxications. For accurate in vivo extrapolations 
further investigation is required but an alarming 
picture of the potential risks of ecstasy abuse is 
already exposed. 
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Abstract 
Amphetamine consumers are often, deliberately or not, polydrug abusers. Predicting combination effects based 
on concentration–response analysis of individual components has revealed to be a valid strategy for accurate 
toxicological assessment of mixtures. We previously reported that the deleterious joint effects of 3,4-
methylenedioxymethamphetamine (MDMA, ecstasy) and three other often co-ingested amphetamines 
(methamphetamine, 4-methylthyoamphetamine and d-amphetamine) could be predicted by concentration 
addition (CA) model in HepG2 cells. We sought to further evaluate the relevance of these findings by extending 
these studies to a primary cell model that more closely mimics in vivo situation. 
Detailed cytotoxic information of the four individual amphetamines on primary rat hepatocytes was recorded 
by the MTT assay, under physiological (37 oC) and hyperthermic (40.5 oC) conditions. The latter simulates the 
rise in body temperature induced by amphetamines intake. Mixture expectations were calculated using the CA 
and independent action (IA) models. 
Combined effects were accurately predicted by CA, while IA underestimated the observed toxicity. 
Incubation at 40.5 ºC further aggravated the cytotoxic effects. Our findings provide evidence of the increased 
risks associated with the abuse of amphetamine mixtures, especially under hyperthermia, and emphasize the 
need to increase the awareness of misinformed users who believe these drugs are safe. 
 
Keywords 
Amphetamine-related toxicity; Primary hepatocytes; Polydrug abuse; Concentration addition (CA); Independent 
action (IA); Hyperthermia. 
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Introduction 
Reports of acute intoxications related with 
amphetamine abuse have been increasing in recent 
years (De Letter et al., 2004; De Letter et al., 2001; 
Lin et al., 2011; Papaseit et al., 2012; Sano et al., 
2009; Schifano, 2004; Vanden Eede et al., 2012). In 
view of the random nature of the toxic effects of 
3,4-methylenedioxymethamphetamine (MDMA, 
ecstasy) in ecstasy abusers (Milroy, 2011) and the 
large discrepancy between the blood concentrations 
found in intoxicated individuals and the magnitude 
of the induced toxicity (Coore, 1996; Milroy et al., 
1996; Ramcharan et al., 1998), possible health risks 
based solely on exposure to the drug are difficult to 
explain. Consequently, it is plausible that other 
factors must be at play. 
One of the aspects that have been highlighted 
as a potential justification to these inconsistencies is 
the polydrug intake frequently associated with 
misuse contexts (Carvalho et al., 2012; Carvalho et 
al., 2010; Mohamed et al., 2011a). Often, 
uninformed abusers are encouraged to ingest 
several drugs in combinations with the aim of 
maximizing the desired effects or ameliorating the 
unpleasant ones. Also, inadvertent ingestion of 
therapeutic drugs and contaminants or adulterants 
present in ecstasy party pills is frequent (Schifano, 
2004). Since MDMA consumers are exposed to a 
plethora of other drugs, including other 
amphetamines (Camilleri et al., 2005; Sherlock et 
al., 1999; Tanner-Smith, 2006; Teng et al., 2006), 
which are often involved in fatal intoxications 
(Carvalho et al., 2012; Carvalho et al., 2010; 
Mohamed et al., 2011a), the toxicological impact of 
combined effects of these drugs needs to be 
considered. 
Despite putative interactions being of particular 
concern and, requiring examination, particularly 
because they can be lethal, in vivo investigation of 
the multitude of conceivable mixtures is often 
hampered by ethical, economical, or practical 
aspects. Recurrently, risk assessment strategies rely 
on quantitatively estimations of joint effects of 
substances that are based on the knowledge of 
individual mixture constituents. In effect, two 
reference concepts broadly employed for predicting 
mixture outcomes can be distinguished: the Loewe 
additivity or concentration addition (CA), 
originally introduced by Loewe and Muschnik 
(1926); and independent action (IA), also known as 
response addition, or Bliss independence, 
developed by Bliss (1939). 
The first model, CA, is based on the principle 
that the components of a certain mixture have a 
common site/mechanism of action (Dias da Silva et 
al., 2013; Silva et al., 2002). It is based on the 
assumption that, if all mixture components act in a 
similar way, then the same mixture effect can be 
obtained by replacing one chemical, entirely or in 
part, by a portion, with the same effectiveness, of 
another. Conversely, the competing approach, IA, 
relies on the assumption that the compounds of a 
given mixture act independently, by acting in 
different molecular targets and having different 
modes of action (Backhaus et al., 2000). 
In order to evaluate the mixture effects of 
amphetamines that are often taken concomitantly 
by ecstasy abusers, we have previously studied, in 
the immortalised hepatocarcinoma HepG2 cell line 
(Dias da Silva et al., 2013), the cytotoxic effect of 
MDMA in combination with three other 
amphetamines, commonly found in ecstasy tablets: 
methamphetamine (METH), 4-
methylthyoamphetamine (4-MTA) and d-
amphetamine (d-Amp) (Camilleri et al., 2005; 
Sherlock et al., 1999; Tanner-Smith, 2006; Teng et 
al., 2006). In this in vitro system, we showed that 
CA provided accurate expectations of the mixture 
effects of amphetamines and revealed that these 
drugs acted together in an additive fashion to 
produce significant effects, even when combined at 
very low levels (Dias da Silva et al., 2013). 
Although it is recognizable that an accurate 
investigation of drug interactions based on the 
assessment of mixture effects would ideally rely on 
the integrated use of in vivo and in vitro systems, 
the extensive concentration–response descriptions 
that are required for these studies are currently only 
feasible at reasonable cost with in vitro assays, that 
provide high through-put testing with minimum 
biologic variability and maximum reproducibility. 
To further investigate the relevance of these 
findings and overcome some of the limitations of 
previously used human hepatoma HepG2 cell 
model, we have now extended our previous 
investigations to an in vitro model that more closely 
mimics the in vivo situation, the rat primary 
hepatocyte, and compared these two cellular 
models. 
Amphetamines intake is associated with an 
increase in body temperature (Greene et al., 2003) 
due to the drugs’ thermogenic actions, which are 
further aggravated by the crowded, hot 
environments where drug abuse often takes place 
(Henry et al., 1992a). This hyperthermia has been 
associated with some of the toxic events linked to 
ecstasy use, including acute liver failure, 
rhabdomyolysis, and disseminated intravascular 
coagulation (Armenian et al., 2012; Henry et al., 
1992b; Kalant, 2001; Kendrick et al., 1977; Patel et 
al., 2005; Screaton et al., 1992). Consequently, we 
set out to also evaluate the impact of raised 
temperature on the toxicity of our test 
amphetamines by incubating the primary 
hepatocytes with the drugs both alone and in 
combination at a temperature of 40.5 ºC. This 
aimed at mimicking the hyperthermic state of the 
Chapter III 
131 
 
liver, which can occur in a real intoxication 
scenario. 
Materials and Methods 
Test drugs 
4-Methylthioamphetamine hydrochloride (racemic 
mixture) was kindly gifted by Doctor David 
Nichols (Purdue University, West Lafayette, IN). 
3,4-Methylenodioxymethamphetamine 
hydrochloride was extracted and purified from high 
purity MDMA tablets provided by the Portuguese 
Criminal Police Department at REQUIMTE/ 
Department of Biological Sciences, Laboratory of 
Toxicology, Faculty of Pharmacy, University of 
Porto. The obtained salt was pure and fully 
characterized by nuclear magnetic resonance 
(NMR) and mass spectrometry (MS) 
methodologies. d-Amphetamine (d-AMP) sulfate) 
was purchased from Tocris Bioscience (Bristol, 
UK) and (+)-METH hydrochloride (98% purity) 
was purchased from Sigma-Aldrich (St. Louis, MO, 
USA). All chemicals used were of analytical grade 
and were employed as supplied. Master stock 
solutions of all amphetamines and mixtures were 
prepared in ultra-pure sterile water and were at least 
20 times more concentrated than the highest 
concentration tested, to prevent media dilution. All 
stock solutions were preserved at –20 °C and 
subsequent dilutions were freshly prepared in cell 
culture media before each experiment. 
Primary culture of cryopreserved rat 
hepatocytes 
High quality plateable cryopreserved male Wistar 
rat hepatocytes were purchased from Invitrogen 
Corporations (Paisley, UK). The vials were thawed 
in a water bath at 37 oC, until ice disappeared and 
the hepatocyte suspension was gently transferred 
into 45 ml of thawing/plating medium containing 
Williams’ medium E (1x) without L-glutamine and 
phenol red, supplemented with 5% fetal bovine 
serum (FBS), 10 µM dexamethasone solution in 
DMSO, 100 U/mL penicillin-streptomycin, 4 mg/L 
bovine insulin, 1% GlutaMAX™ 100x and 15 mM 
HEPES pH 7.4. After centrifuging cells at room 
temperature at 55 x g for 3 min, the supernatant was 
carefully aspirated and the pellet gently 
resuspended in approximately 5 ml of the 
thawing/plating medium. The viability of the 
isolated hepatocytes was estimated by the trypan 
blue exclusion test and was always greater than 
80%. Subsequently, a suspension containing 0.5 x 
106 viable cells/ml was prepared in thawing/plating 
medium and seeded onto the central 60 wells of 
collagen-coated clear 96-well culture plates at a 
density of 8 x 104 viable cells/cm2. The peripheral 
wells were filled with sterile water to prevent media 
evaporation. The cells were incubated at 37 oC in a 
humidified atmosphere containing 5% CO2/95% 
air, for cell adhesion. After 4-6 h the medium was 
replaced and the cells incubated overnight at 37 oC 
in the maintenance medium containing Williams’ 
medium E (1x) without L-glutamine, phenol red or 
FBS, and supplemented with 10 µM 
dexamethasone solution in DMSO, 50 U/mL 
penicillin-streptomycin, 1% ITS+ (insulin, 
transferrin, selenium complex, BSA, linoleic acid), 
1% GlutaMAX™ 100x and 15 mM HEPES pH 
7.4pH 7.4. The experiments were carried out 24 h 
later. 
The MTT reduction viability assay 
The mitochondrial reductases of viable cells reduce 
the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT) dye to purple formazan 
crystals that are spectrophotometrically quantified 
to produce a measure of cell viability (Mosmann, 
1983). The protocol described by Dias da Silva et 
al. (2013) was followed with some modifications. 
Briefly, 24 h after cell seeding, the maintenance 
media was gently aspirated and the cells were 
incubated for 48 h, at 37 oC or 40.5 oC with the 
selected concentrations of MDMA, METH, 4-
MTA, d-AMP or mixture, prepared in fresh cell 
maintenance medium. Each individual plate 
included six replicates of negative controls (i.e., no 
test agents) and three replicates of positive controls 
(full media with 1%Triton X-100). To obtain 
complete concentration–response, a broad range of 
concentrations was tested for each individual drug 
and for the mixture, at least in triplicate, in a 
minimum of three independent experiments. After 
48 h, the incubation medium was removed and the 
attached cells rinsed with 200 µL HBSS (pH 7.4), 
followed by the addition of fresh maintenance 
medium containing 0.5 mg/L MTT. The cells were 
incubated at 37 °C in a humidified environment, 
with 5% CO2/95% air atmosphere, for 3 h. Finally, 
the cell culture medium was removed and the 
formed insoluble formazan crystals dissolved in 
100% DMSO. The spectrophotometric analysis was 
run at 570 nm using a multi-well plate reader 
(Labsystems Multiskan, Basingstoke, UK). To 
reduce inter-experimental variability, data were 
normalized on a plate-by-plate basis and scaled 
between 0% (negative controls) and 100% effect 
(positive controls). Results from at least three 
independent experiments were graphically 
presented as the percentage of cell death versus 
concentration (mM). 
Regression modelling 
Scatter plots of normalized cellular mortality values 
(effect) versus log concentration were constructed 
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and analysed through the best-fit approach (Scholze 
et al., 2001). For each individual data set, the model 
that best fitted the experimental values was selected 
from a range of nine different two or three-
parametric nonlinear regression models (including 
the commonly used probit, Gompertz, and Hill 
models). This selection was accomplished on the 
basis of the sum of absolute errors and an analysis 
of residues, performed on the specialised software 
program NLREG – Nonlinear Regression, version 
5.4 (Phillip H. Sherrod, USA). In the present study, 
the generalised logit function was employed, as 
described by Dias da Silva et al. (2012). 
 
 
 
Table 1. Parameters derived from nonlinear fits of single agent concentration–response data to the asymmetric logit function, in the 
MTT reduction assay, at normothermic conditions, 37 oC (Figure 1). These parameters were used to compute the predicted mixture effect 
curves shown in Figure 4. 
 
Compound Tested concentration 
range (mM) 
Estimated parameters for the best-fit regression model 
Fraction in the mixture 
θ11 θ22 θmax3 
MDMA 6.64E-02 – 1.7E+01 -5.18E+00 1.28E+01 1.04E+02 2.82E-01 
METH 6.64E-02 – 1.7E+01 -1.06E+01 1.75E+01 1.03E+02 4.52E-01 
4-MTA 9.76E-03  – 2.5E+00 0 6.23E+00 2.06E+01 1.07E+02 5.52E-02 
d-Amp 3.91E-02 – 1.0E+01 -4.36E+00 1.58E+01 1.02E+02 2.11E-01 
Mixture 4.29E-02 – 1.1E+01 -3.64E+00 1.35E+01 1.00E+02 1.00E+00 
1Location parameter of the Logit function. 2Slope parameter. 3Maximal effect, expressed as corrected % cell death 
 
Table 2. Parameters derived from nonlinear fits of single agent concentration–response data to the asymmetric logit function, in the 
MTT reduction assay, at hyperthermic conditions, 40.5 oC (Figure 2). These parameters were used to compute the predicted mixture effect 
curves shown in Figure 4. 
 
Compound Tested concentration range (mM) 
Estimated parameters for the best-fit regression model 
Fraction in the 
mixture 
θ11 θ22 θmax3 
MDMA 9.07E-02 – 10E+01 1.36E+00 7.67E+00 9.98E+01 2.10E-01 
METH 9.07E-02 – 10E+01 -1.37E+00 8.64E+00 9.69E+01 4.62E-01 
4-MTA 1.17E-02 – 1.5E+00 1.10E+01 1.96E+01 9.62E+01 8.72E-02 
d-Amp 7.25E-02 – 8E+00 2.07E+00 1.69E+01 9.58E+01 2.41E-01 
Mixture 6.35E-02 – 7E+00 6.24E+00 3.70E+01 9.61E+01 1.00E+00 
 
1Location parameter of the Logit function. 2Slope parameter. 3Maximal effect, expressed as corrected % cell death 
Table 3. Comparison between median effect concentrations (EC50a) obtained in HepG2 cells and primary rat hepatocytes, using the 
MTT reduction assay, at hyperthermic (40.5 oC) and normothermic (37 oC) conditions. 
 
Compound 
Primary rat hepatocytes HepG2 cells 
37 oC 40.5 oC 37 
oC 
(Dias da Silva et al., 2013) 
40.5 oC 
(Dias da Silva et al., 2012) 
MDMA 2.50E+00 6.66E-01 2.23E+00 1.77E+00 
METH 4.01E+00 1.47E+00 5.26E+00 2.97E+00 
4-MTA 4.90E-01 2.76E-01 7.40E-01 6.60E-01 
d-Amp 1.87E+00 7.63E-01 2.41E+00 1.66E+00 
Mixture 1.87E+00 6.81E-01 2.90E+00 2.06E+00 
a I.e., concentration yielding 50% of the maximal effect in the MTT assay 
 
 
A summary of the logit parameters for the best-fit 
regression model of each individual agent are 
presented for normothermic (Table 1) and for 
hyperthermic (Table 2) incubations. 
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Figure 1. Mortality induced by MDMA, METH, 4-MTA, and d-Amp 48 h after incubation with primary rat hepatocytes, at 37 oC. 
Cellular mortality data as evaluated by the MTT reduction assay following 48 h incubations of primary rat hepatocytes to MDMA, 
METH, 4-MTA, and d-Amp. Data were fitted to the logit function represented by the solid blue line. Dashed blue lines show the 95% 
confidence interval belt of the fit. Data were normalized to negative (untreated) and positive (1%Triton X-100) controls. The results were 
obtained from four independent experiments where a range of different concentrations of each drug was tested in series of three to six 
replicates. The dashed red line represents the cytotoxicity curves of the substances towards the human hepatoma HepG2 cell line under 
the same experimental setting (Dias da Silva et al., 2013). 
 
Mixture design 
All chemicals were combined in proportion to the 
concentration producing 50% of the maximal effect 
in the MTT assay (EC50), calculated by 
interpolation from the best-fit regression model for 
each tested agent. The estimated median effect 
concentrations for the best-fit regression model of 
each individual agent are presented in Table 3, for 
hyperthermic and normothermic incubations.By 
using this design, it was ensured that all mixture 
components were present at equipotent 
concentrations in the mixture, so that no single drug 
contributed excessively and disproportionately to 
the overall mixture effect. For this purpose, a 
master solution of the mixture containing all the 
individual components in proportion to the EC50 
was prepared. A range of test concentrations was 
obtained through serial dilutions by employing the 
fixed mixture ratio design (Altenburger et al., 
2000), so that the ratio between each constituent 
was kept constant. This mixture design was selected 
with the aim of exploring the predictability of 
combination effects in primary rat hepatocytes, 
under our experimental conditions. In other words, 
the mixture tested here is intended as a proof of 
concept. If the observed effects meet the 
expectations, the applicability of the concept will be 
possibly extended to other potential mixture ratios, 
as observed formerly (Dias da Silva et al., 2013). 
Predicting combination effects 
After exhaustive characterization of the 
concentration–response curves of the single agents, 
the effects of the mixture were predicted assuming 
additive joint responses. The expected effects were 
calculated using the CA and IA approaches, as 
reported by Payne et al. (Payne et al., 2000) and 
used as a reference for the assessment of 
combination effects in terms of synergisms (if the 
observed effects are greater than additive 
predictions), additivity (if the experimental mixture 
outcomes equal the prediction), and antagonism (if 
the experimental joint effects fall short of 
additivity). 
Statistical analysis 
Nonlinear regression analysis was carried out using 
the best-fit approach and results were presented as 
the best estimate of the mean effects. 
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Figure 2. Regression models for the mortality of all four amphetamines, individually and combined 48 h after incubation with 
primary rat hepatocytes, at 37 oC (A) and at 40.5 oC (B). The black solid and dashed lines are the mean and 95% confidence interval of 
the mean responses of the individual drugs, respectively. The numbering of the drugs is as follows: 1: MDMA, 2: METH, 3: 4-MTA, 4: d-
Amp. The red solid and dashed lines are the mean and 95% confidence interval of the mean responses of the mixture, respectively. 
 
Statistical uncertainties were expressed as the 95% 
confidence intervals (CI) and differences between 
the best fits were deemed statistically significant 
when their corresponding CI belts did not overlap. 
Additionally, comparisons between HepG2 cells 
and primary hepatocytes curve parameters for 
maximal effects, slope and location (θmax, θ1 and θ2, 
respectively) were performed using the extra sum-
of-squares F test. p values lower than 0.05 were 
considered statistically significant. Nonlinear curve 
fitting and all statistical calculations were 
performed using GraphPad Prism software, version 
5.01 (GraphPad Software, San Diego California, 
USA). 
Results 
4-MTA and METH were the most and the least 
potent amphetamines, respectively, eliciting 
cytotoxicity in primary rat hepatocytes, at a 
physiological incubation temperature (37 oC). 
In order to accurately estimate the effects of a 
mixture with well-defined composition, detailed 
and reliable information on the individual responses 
of each of the constituents is required. Therefore, a 
comprehensive range of concentrations was tested 
for all test substances to describe the complete 
response range (from 0 to 100% effect), for the 
MTT cytotoxicity assay. 
Figure 1 shows the cytotoxicity curves obtained for 
the single substances, at a physiological incubation 
temperature (37 oC). 
Table 1 provides the individual curve 
parameters for all the tested drugs, including slope, 
and maximal effects at the same temperature. 
Median effect concentrations (EC50) are displayed 
in Table 3. The regression lines of all substances 
were similar in shape and slope, but exhibited 
different individual potencies (Fig. 2). For example, 
d-AMP potency (EC50 1.87 mM) was 
approximately 4 times lower than that of the most 
potent tested amphetamine, 4-MTA (EC50 0.49 
mM), and over 2 times higher than that of METH 
(EC50 4.01 mM), the least cytotoxic of the four 
tested amphetamines. MDMA exhibited an EC50 of 
2.50 mM.  
Primary rat hepatocytes are more sensitive to 
the detrimental effects of MDMA, METH, 4-
MTA, d-AMP, when incubated under 
hyperthermic conditions (40.5 oC) then under 
physiological circumstances (37 oC) 
Figure 3 depicts the scattergrams and nonlinear 
regression models (blue solid lines), including the 
95% confidence intervals for the mean effects 
(dashed blue lines), when primary hepatocytes were 
incubated with the four tested amphetamines, under 
hyperthermic conditions (incubation temperature of 
40.5 oC). 
As previously noted with the incubations 
performed at 37 ºC, under this new temperature 
setting, the MTT assay proved to be a rapid and 
sensitive method, yielding reproducible results with 
minimum variability, for all the tested drugs (Fig. 
3). Table 2 provides the individual curve 
parameters, including slope and maximal effects. 
The median effect concentrations (EC50) are shown 
in Table 3. The comparison between the calculated 
median effects (Fig. 2) shows that METH is the 
least potent cytotoxic amphetamine tested (EC50 
1.47 mM) while 4-MTA is the most potent (EC50 
0.28 mM). MDMA and d-Amp showed 
intermediate median effect concentrations (EC50 
0.67 mM and 0.76 mM, respectively). 
Amphetamines act in an additive fashion in 
primary rat hepatocytes 
Assessments of combination effects in terms of 
synergisms, antagonisms, or additivity critically 
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depend on the determination of the expected effect 
of a given mixture. After thoroughly characterising 
the concentration–effect relationships of the 
individual agents in terms of shape, slope, and 
maximal effects, the CA and IA mathematical 
models were applied for quantitatively modelling 
the expected effects of an equimolar mixture of 
MDMA, METH, 4-MTA, and d-Amp. As depicted 
in Fig. 4, the two additive assumptions, CA and IA, 
produced very distinct expectations. This good 
discrimination between both models allowed the 
correct evaluation of which of the concepts best 
described the amphetamines mixture effects. The 
CA model estimated stronger effects, predicting 
EC50 values of 1.98 mM and 0.74 mM for 
normothermic and hyperthermic incubations, 
respectively, while the median effect concentrations 
estimated by IA were 7.14 mM for normothermic 
(Fig. 4A) and 2.28 mM for hyperthermic 
incubations (Fig. 4B).  
The experimental mixture testing, confirmed that 
the CA model was the best suited for predicting 
mixture effects at both incubation temperatures, as 
this model was able to prediction accurately the 
responses over the entire range of effect levels. 
Experimentally obtained EC50 values provided in 
Table 3 (1.87 mM for normothermia and 0.68 mM 
for hyperthermia) agreed with those calculated 
using the CA approach. Conversely, the 
independent action concept clearly underestimated 
the mixture toxicity. 
 
 
 
Figure 3. Mortality induced by MDMA, METH, 4-MTA, and d-Amp 48 h after incubation with primary rat hepatocytes, at 40.5 oC. 
Data obtained with the MTT reduction assay were from three independent experiments where several different concentrations of MDMA, 
METH, 4-MTA, and d-Amp were tested in series of three to six replicates. Mean effects (lethality) were fitted to the logit function 
represented by the solid blue line. Dashed blue lines show the 95% confidence interval belt of the fit. Data were normalized to negative 
(untreated) and positive (1%Triton X-100) controls. The dashed red line represents the cytotoxicity curves of the substances towards the 
human hepatoma HepG2 cell line, under the same experimental setting (Dias da Silva et al., 2012). 
 
Discussion 
Remarkable inter-individual differences in the 
susceptibility to the toxic effects of MDMA and 
other amphetamines have been noted on several 
occasions (De Letter et al., 2004; Henry et al., 
1992a; O'Donohoe et al., 1998). The plasma or 
target-organ concentrations of the drugs often fail to 
explain the random, severe and sometimes lethal 
intoxications that often occur after ecstasy use 
(Greene et al., 2003). Polydrug abuse, either due to 
unintentional ingestion of impure ecstasy tablets, or 
deliberately aimed at increasing the desired effects 
of the drugs is thought to be, at least partially, 
responsible for these unexpected intoxication 
events (Schifano, 2004).  
Assessing the risk associated with the ingestion 
of drug mixtures is a challenge often hampered by 
the immense number of possible combinations and 
their permanent change in quality and quantity 
within the organism, due to metabolism and 
transport mechanisms, among others (Borgert, 
2004). 
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Figure 4. Predicted and observed cytotoxic effects of a mixture of MDMA, METH, 4-MTA, and d-Amp, obtained with the MTT 
assay after 48h incubations of primary rat hepatocytes, at either 37 oC (A) or 40.5 oC (B). The individual components were mixed in 
proportion to their EC50 values calculated from the best-fit regression model for each individually tested drug (Table 3). On the basis of the 
single drug concentration–response relationships (Fig. 1 and 2, for the physiological and hyperthermic settings, respectively), additive 
combination effects were predicted using the models of concentration addition, given by the solid line labelled CA, and independent 
action, as represented by the dashed line, labelled IA. Data were from at least three independent experiments where different concentrations 
were tested in six replicates. 
 
We have previously tested the combination 
effects of four different amphetamines that are 
known to be simultaneously abused, using the 
human hepatoma HepG2 cell line. In the mentioned 
study, we found significant additive effects, even at 
very low levels of the individual substances, which 
can potentially explain the severe effects that can 
arise when these are ingested concomitantly (Dias 
da Silva et al., 2013). In the present study we 
extended these previous investigations to an in vitro 
model that is known to be more representative of 
the in vivo situation, cultured primary hepatocytes 
(Donato et al., 2008; Hengstler et al., 2000a; 
Hengstler et al., 2000b). 
Due to the thermogenic action of the drugs 
combined with high ambient temperatures, the body 
temperature of intoxicated individuals is often 
increased. This phenomenon has also been 
suggested as potentially linked to the unexpected 
effects of amphetamines (Carvalho et al., 2012). 
Consequently, we also investigated the impact of 
raising the incubation temperature to levels that 
mimic the hyperthermic state induced by these 
drugs on their joint cytotoxic effects. 
With the work presented here, we have shown 
that the tested MDMA, 4-MTA, d-AMP and METH 
amphetamines have joint effects in primary rat 
hepatocytes. These effects were observed for both 
incubations temperatures, but the overall 
cytotoxicity was severely increased when the drugs 
were incubated at 40.5 ºC, both individually and in 
combination. Our data, therefore, supports that 
hyperthermia can greatly aggravate the harmful 
effects attributed to polydrug abuse. These results 
agree well with those previously obtained with the 
immortalized HepG2 cells (Dias da Silva et al., 
2012; Dias da Silva et al., 2013). 
In spite of the acknowledged importance in 
assessing the effects of mixtures in this field, 
research has focused predominantly on the activity 
of single drugs and the few mixture studies 
conducted so far have suffered from inadequate 
theoretical and conceptual foundations, that have 
led some authors to claim synergisms even when no 
references to the expected mixture outcomes were 
provided (McNamara et al., 2006; Mohamed et al., 
2011b; Pontes et al., 2008; Schechter, 1998; Young 
et al., 2005). We have now demonstrated that in 
primary hepatocytes these four amphetamines 
interact in an additive manner and therefore, based 
on CA postulations, significant toxicity is expected 
to occur when the amphetamines are mixed at 
individual ineffective concentrations, as shown 
before with the HepG2 cells (Dias da Silva et al., 
2013). The in vivo relevance of such interactions 
can be clearly demonstrated by several reports of 
human intoxications involving MDMA and other 
amphetamines (Dams et al., 2003; Felgate et al., 
1998; Fineschi et al., 1996; Johansen et al., 2003). 
From a pharmacokinetic perspective, the four 
tested amphetamines share pharmacological and 
toxicological mechanisms and also the same 
metabolic bioactivation routes. Therefore, we 
anticipated that the CA model would more 
accurately predict the mixture effects than the IA 
model. In effect, despite only few studies 
employing both concepts in a comparative manner 
for mixture toxicity prediction be available, there is 
a clear understanding that CA concept is most 
appropriately used for mixtures constituted by 
similar agents while the contrary occurs with IA 
(Kortenkamp, 2007). Our data corroborated these 
assumptions, given that the CA model provided the 
best estimates, with EC50 values that were very 
close to those experimentally observed both at 37 
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ºC and 40.5 ºC. This suggests that equal overall 
effects will be promoted in case one drug is 
replaced by an equieffective concentration of 
another one. Should this prove to be true, 
amphetaminic agents, when present in mixtures, 
may act together additively even when each 
component is present at concentrations that 
individually produce no noticeable effects. In this 
case, it may not be necessary to invoke synergisms 
to elucidate how low, ostensibly irrelevant, levels 
of drug present in illicit formulations may produce 
significant effects as mixtures. 
Conversely, marked deviations between IA 
predictions and observations were identified. For 
both mixtures (37 oC and 40.5 oC), this model 
vastly underestimated the mixture cytotoxic effects 
proving to be an inappropriate concept to model 
combination effects of these substances. 
By comparing these results in primary rat 
hepatocytes with those produced in HepG2 cells 
under the same experimental settings (data 
published previously by our group (Dias da Silva et 
al., 2013)), we observed no significant differences 
(p >0.05), for all the treatments, at 37 oC. In spite of 
the similarity in terms of shape and position, the 
corresponding curves obtained from experiments in 
HepG2 cells (Dias da Silva et al., 2013) are 
somewhat shallower (lower slopes) (Fig. 1), which, 
in some cases, can be translated into median effects 
slightly different from those seen with primary cells 
(Table 3). Notwithstanding this good agreement 
between the effects in primary and immortalised 
cells at physiological temperature, the cytotoxic 
effects were significantly aggravated in the primary 
hepatocytes compared to the HepG2 cells at 40.5 
ºC. Effectively, a significantly lower cytotoxic 
effect was observed for all the treatments in the 
HepG2 cells (p <0.0001) as shown by the 
remarkable rightwards shift of the lethality curves 
(Figure 3) and by the significantly higher calculated 
EC50 values (Table 3), suggesting that, under 
hyperthermic conditions, the primary hepatocytes 
may be more susceptible than HepG2 to the toxicity 
of the tested amphetamines, both individually and 
mixed. These differences may be explained by the 
changes in drug metabolism that are expected to 
occur under a hyperthermic state and to which the 
primary hepatocytes would naturally display a 
higher susceptibility compared to the HepG2 cells. 
In fact, it is recognized that improved metabolic 
efficiency occurs when the rat liver is subjected to 
heat stress (40 oC and 42 oC) (Li et al., 2012). The 
role of the hepatic bioactivation of amphetamines in 
toxicity has been extensively studied and it is 
known to greatly contribute to the in vivo toxicity 
of these drugs in rodent experimental models as 
well as and in humans (de la Torre et al., 2004; 
Easton et al., 2003; Gollamudi et al., 1989; Jones et 
al., 2005). The oxidative metabolites that are 
produced in the liver are highly reactive and 
generate ROS and RNS, inducing an oxidative 
stress that is extremely damaging for the cell 
(Antolino-Lobo et al., 2011; Barbosa et al., 2012; 
Carvalho et al., 2012; Carvalho et al., 2010; de la 
Torre et al., 2004). Admitting that primary cells are 
metabolically more competent than cell lines, they 
might be susceptible to higher toxicity when 
exposed to substances that are metabolised into 
more harmful derivatives than the parent 
compound. Whether an increased production of 
these metabolites and their deleterious effects 
occurs in these primary hepatocytes in vitro system 
needs further experimental confirmation. 
Human hepatoma cell lines, such as the HepG2 
cells, are highly differentiated, exhibit numerous 
genotypic qualities of the liver cells from which 
they are derived and retain many of the biochemical 
synthesis pathways (Sassa et al., 1987). 
Nonetheless, in general, continuous cell lines 
(tumour or artificially immortalized) express a 
limited range of phase I enzymes and UDP-
glucuronosyl transferases found in hepatic tissue 
and, in spite of preserving some metabolic 
functions, the enzyme activity may show variability 
with increasing number of cell passages (Donato et 
al., 2008; Gerets et al., 2012; Westerink et al., 
2007; Xu et al., 2004), becoming less 
representative of the in vivo situation. The 
accumulation of successive replicative-related 
variations also introduces variability in the original 
cellular background. Using primary hepatocytes 
substantially overcomes these limitations. In spite 
of the additional costs, limited life span, and the 
complexity of the cell isolation and culture 
techniques (Madan et al., 2003) the use of primary 
hepatocytes is clearly advantageous over the 
immortalized cell lines when metabolism is thought 
to contribute to the toxic effects, such as in the 
amphetamines case. The use of more complex 
systems, including in vivo experimental models will 
undoubtedly bring additional confidence in what 
concerns the extrapolation from rat to human 
hepatocytes and from the in vitro to the in vivo 
situation. 
In conclusion, the additive effects of 
amphetamines that are often ingested 
simultaneously raise concern about the detrimental 
effects that are expected to occur even if the drugs 
are mixed at low concentrations that would 
individually produce no effect. Also, a dramatic 
increase in toxicity can occur if body temperature 
increases. These data provides experimental 
evidence supporting that the severity of the 
intoxications is not reflected by the blood and tissue 
concentrations of these drugs and mixture effects 
must be taken into account. Accurate risk 
assessment of these drugs of abuse is strengthened 
by these powerful prediction tools. Knowledge on 
the nature of such interactions is of utmost 
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importance for increasing the awareness of the risks 
associated with simultaneous amphetamine abuse. 
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Abstract 
Hepatic injury following 3,4-methylenedioxymethamphetamine (MDMA; Ecstasy) intoxications is highly 
unpredictable and does not seem to correlate with either dosage or frequency of use. The mechanisms 
involved include the metabolic bioactivation of the drug and the hyperthermic state of the liver triggered by its 
thermogenic action and exacerbated by the environmental circumstances of the abuse at hot and crowded 
venues. We therefore became interested in understanding the interaction between ecstasy and its metabolites 
generated in vivo as misusers are always exposed to mixtures of parent drug and metabolites. 
With this purpose, HEPG2 cells were incubated with MDMA and its main human metabolites 3,4-
methylenedioxyamphetamine (MDA), α-methyldopamine (α-MeDA), and N-methyl-α-methyldopamine (N-
Me-α-MeDA), individually and in mixture, at normal (37 oC) and hyperthermic (40.5 oC) conditions. After 
48h, viability was assessed by the MTT assay. The extensive concentration–response analysis performed with 
single drugs was used to predict joint effects by using the well-founded models of concentration addition 
(CA) and independent action.  
Experimental testing revealed that mixture effects conformed to CA, for both temperature settings. 
Additionally, substantial combination effects were attained even when each substance was present at low 
concentrations that individually produced unnoticeable effects. Hyperthermic incubations dramatically 
increased the toxicity of the tested drug and metabolites, both individually and in mixture. These outcomes 
suggest that the MDMA metabolism has hazard implications to liver cells even when metabolites are found in 
low concentrations, as they contribute additively to the overall toxicological effect. 
 
Keywords 
3,4-methylenedioxymethamphetamine (MDMA; Ecstasy); Metabolites; Mixture effects; Hyperthermia; 
Concentration addition (CA); Independent Action (IA). 
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Introduction 
The recreational use of the ring-substituted 
amphetamine derivative 3,4-
methylenedioxymethamphetamine (MDMA, 
ecstasy) has been recognized as one of the most 
significant trends in drug abuse over the past 
decades. Acting as a potent releaser and/or reuptake 
inhibitor of presynaptic serotonin, dopamine, and 
noradrenaline (Capela et al., 2009; de la Torre et al., 
2004a; de la Torre et al., 2004b; Green et al., 2003) 
it induces intense feelings of euphoria, friendliness, 
comfort, intimacy, pleasure, empathy, and 
hyperactivity (Parrott, 2001). This psychoactive 
drug is commonly misrepresented among its young 
users as being safe. However, the number of 
ecstasy-related deaths and emergency department 
visits for overdose and unexpected reactions seem 
to have peaked in the last decade (CDC, 2010; Sano 
et al., 2009). Severe acute toxic effects associated 
with MDMA abuse are, in part, related to its 
pharmacological actions and include multiorganic 
failure, severe hyperthermia, tachycardia, 
hypertension, myocardial ischemia, psychosis, 
cerebral haemorrhage, and the serotonin syndrome 
(increased muscle rigidity, hyperreflexia, and 
hyperthermia), which can ultimately lead to death 
(Brauer et al., 1997; de la Torre et al., 2004b; 
Greene et al., 2003; Henry et al., 1992; Jones and 
Simpson, 1999; Schwab et al., 1999). Among these, 
an increase in reported cases of acute and chronic 
hepatic injury secondary to ecstasy intake has been 
noticed (Andreu et al., 1998; De Carlis et al., 2001; 
Ellis et al., 1996; Sano et al., 2009). These effects 
do not rely on dosage and may occur with the 
administration of a single dose or only after 
repeated use (Coore, 1996; Dykhuizen et al., 1995; 
Ellis et al., 1996; Henry et al., 1992). The produced 
hepatic lesions range from benign forms similar to 
viral hepatitis (Carvalho et al., 2010; Dykhuizen et 
al., 1995; Ellis et al., 1996) to extensive necrosis 
causing severe acute hepatic failure that require 
hepatic transplantation (Carvalho et al., 2010; Ellis 
et al., 1996; Henry et al., 1992; Milroy et al., 1996). 
The mechanisms that have been proposed to 
explain these hepatotoxic effects induced by 
MDMA are diverse and include the increased 
release of endogenous catecholamines, metabolic 
bioactivation, oxidative stress, liver blood flow 
changes, immunological mechanisms and 
hyperthermia.  
MDMA interferes with thermoregulation and 
the hyperthermia induced by ingestion of the drug 
can be greatly exacerbated by the hyperactivity and 
physical exertion of the user, as well as the crowded 
overheated settings of nightclubs or dance parties, 
where its consumption often occurs (Henry et al., 
1992). These factors combined can induce 
significant increases in body temperature, with 
temperatures as high as 43 ºC having been reported 
(Green et al., 2003). Hyperthermia is, consequently, 
considered one of the potentially lethal 
consequences of MDMA acute intoxications and 
has been implicated in MDMA-induced 
hepatotoxicity through the induction of deleterious 
oxidative stress (Jones and Simpson, 1999). The 
hepatocellular damage observed in MDMA 
intoxication cases is, in several aspects, similar to 
that produced by hyperthermic injury to isolated 
hepatocytes (Santos-Marques et al., 2006). 
Moreover, incubation of freshly isolated 
hepatocytes with MDMA under hyperthermic 
conditions has been shown to further increase the 
cellular mortality and aggravate toxicity, 
particularly oxidative stress biomarkers, including 
decreased GSH levels and lipid peroxidation 
(Carvalho et al., 2001). 
There is also increasing evidence that the acute 
effects of MDMA intoxications do not correlate 
entirely with MDMA plasma concentrations 
(Carvalho et al., 2012; Greene et al., 2003), 
suggesting the involvement of the metabolic 
bioactivation of the drug (Fig. 1). 
N-dealkylation of MDMA leads to the 
formation of the corresponding primary amine 3,4-
methylenedioxyamphetamine (MDA or love) which 
retains pharmacological action (Johnson et al., 
1988) and has also been extensively used as a 
recreational drug of abuse. MDMA and MDA 
hepatic oxidative metabolism consists mainly of 
demethylenation into the highly reactive catechol 
metabolites N-methyl-α-methyldopamine (N-Me-α-
MeDA) and α-methyldopamine (α-MeDA) that are 
o-methylated by catechol-o-methyltransferease 
and/or conjugated with glucoronide or sulphate 
prior to excretion (de la Torre et al., 2004a; de la 
Torre et al., 2000; Lim and Foltz, 1989; Maurer et 
al., 2000). Both N-Me-α-MeDA and α-MeDA can 
be further oxidized into the corresponding ortho-
quinones. These highly redox-active molecules can 
enter a redox cycling with their semiquinone 
radicals, leading to the generation of reactive 
species of oxygen (ROS) and nitrogen (RNS) 
(Bolton et al., 2000; Remiao et al., 2004). Parallel 
side-chain degradation pathway leads to the 
formation of oxidatively deaminated metabolites 
(Lim and Foltz, 1988) that are excreted as their 
benzoic derivatives (hippuric acids) (Maurer, 1996; 
Maurer et al., 2000). 
The aforementioned oxidative metabolites have 
been implicated in the mechanisms underlying the 
toxic effects of MDMA (Capela et al., 2006; 
Carvalho et al., 2002; Carvalho et al., 2004a; 
Carvalho et al., 2004b; Carvalho et al., 2004c; 
Easton et al., 2003; Escobedo et al., 2005; Forsling 
et al., 2002; Gollamudi et al., 1989; Hartung et al., 
2002; Jones et al., 2005). 
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Figure 1. Proposed mechanisms for oxidative 3,4-methylenedioxymethamphetamine (MDMA) metabolism into hepatotoxic 
metabolites. MDMA and MDA are o-demethylenated, predominantly by cytochrome P450 2D6 (CYP2D6) in humans, to N-methyl-a-
methyldopamine (N-Me-a-MeDA) and α-methyldopamine (α-MeDA). N-Me-α-MeDA can be subsequently N-demethylated to give α-
MeDA through CYP2D and 2B isoforms. Both reactive catechols are readily oxidized to the corresponding ortho-quinones, highly redox-
active molecules that can enter a redox cycling with their semiquinone radicals leading to the injury of cellular components through the 
generation of pro-oxidant reactive species (ROS and RNS), conjugate with glutathione (GSH), or further oxidize into aminochromes 
through cyclization and polymerize leading to melanin type polymers. Adapted from (Carmo et al., 2006). 
 
In vitro studies using freshly isolated rat 
hepatocytes have shown that the toxicity of the 
metabolites was much higher than MDMA under 
the same experimental settings (Carvalho et al., 
2004a; Carvalho et al., 2004b). This metabolic 
bioactivation of MDMA is particularly significant 
in the liver, where MDMA is extensively 
metabolized, with approximately 80% of the 
ingested dose being excreted after hepatic 
metabolism (de la Torre et al., 2004b). In spite of 
the abundance of in vitro evidence, the in vivo 
relevance of the metabolic bioactivation of MDMA 
in the development of hepatotoxicity is still a matter 
of debate. Extrapolation of these in vitro findings to 
the in vivo situation has often been limited by the 
relatively high concentrations of the metabolites 
that are tested in vitro. However, a few in vivo 
studies have already provided evidence on the role 
of MDMA oxidative metabolism on neurotoxicity 
(Easton et al., 2003; Gollamudi et al., 1989; Jones 
et al., 2005). 
In the liver, due to the potential MDMA 
bioactivation, it is possible that the metabolites 
contribute to the overall toxicity of the drug by 
acting together with MDMA. However, to our 
knowledge, this hypothesis has not been addressed 
yet. With the present investigation we aimed at 
evaluating the contribution of the metabolites to the 
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hepatotoxicity of MDMA by studying their effects 
when mixed with the parent compound.  
To better understand the putative interactions 
between MDMA and its metabolites generated in 
vivo we used a previously developed study model 
that compares the applicability of two well-
established mathematical models for the calculation 
of expected additive mixture effects (Pavlaki et al., 
2011; Payne et al., 2000; Rajapakse et al., 2001; 
Silva et al., 2002): concentration addition (CA) and 
independent action (IA). Concentration addition is 
usually applied to mixtures of substances that exert 
their effects through similar modes of action, while 
independent action is usually suitable to predict 
additive responses of combinations of drugs with 
diverse modes of action. It is in relation to the 
additivity expectations given by these models that 
combination effects are evaluated in terms of 
synergisms (when the experimentally observed 
effects are greater than the additivity expectations) 
or antagonisms (when the experimentally observed 
effects fall short of the additivity expectations) 
(Kortenkamp, 2007). These models also enable 
investigating the potential for significant joint 
effects to occur, even when the components are 
mixed at low physiologically relevant 
concentrations. We have previously successfully 
applied these models for predicting, in 
immortalized hepatoma HEPG2 cells, the joint 
toxic effects of amphetaminic drugs often found as 
low-level contaminants in street drugs offered as 
ecstasy (Dias da Silva et al., 2012). Given the 
influence of hyperthermia on the outcome of the 
hepatotoxic effects, the interaction between MDMA 
and metabolites was also tested in this system under 
hyperthermic incubation conditions. 
Materials and Methods 
Test drugs 
MDMA (HCl salt) was extracted and purified from 
high purity MDMA tablets provided by the 
Portuguese Criminal Police Department, at 
REQUIMTE/ Toxicology Laboratory, Biological 
Sciences Department of the Faculty of Pharmacy, 
University of Porto. MDA (HCl salt) was 
synthesized in the Organic Chemistry Department 
of the Faculty of Pharmacy, University of Porto. 
The obtained salts were purified and fully 
characterized by nuclear magnetic resonance 
(NMR) and mass spectrometry (MS) 
methodologies. Synthesis of N-Me-α-Me-DA (HBr 
salt) and α-MeDA (HBr salt) was prepared 
following the procedure of Borgman et al. (1974), 
at REQUIMTE/CQFB, Chemistry Department, 
Faculty of Science and Technology, Universidade 
Nova de Lisboa, as described by Capela et al. 
(2006). 
Master stock solutions of all amphetamines and 
the mixture were prepared in deionised sterile water 
and were at least 20 times more concentrated than 
the highest concentration tested. Subsequent serial 
dilutions were freshly prepared before each 
experiment. All solutions were stored at –20 oC, 
protected from light. 
HepG2 routine cell culture 
The human hepatocarcinoma HepG2 cell line was 
routinely maintained as previously described (Dias 
da Silva et al., 2012). Briefly, cells were cultured in 
75 cm2 flasks in minimum essential medium alpha 
(MEM alpha) supplemented with 10% heat-
inactivated FBS, 1% penicillin (5,000 
units/ml)/streptomycin (5,000 µg/ml) mixture, 1% 
fungizone and 6 µg/ml transferrin (complete culture 
medium) and incubated in a humidified atmosphere 
of 5% CO2 at 37 oC. All the cell culture reagents 
were purchased from Invitrogen Corporations 
(Paisley, UK). The medium was changed every 3 
days. When cells reached 70% confluence, cells 
were detached by trypsinization and subcultured 
over a maximum of 10 passages. HepG2 cells were 
routinely tested for Mycoplasma contamination. 
For the MTT assay, 80,000 cells were seeded 
onto the central 60 wells of 96-well plates in order 
to obtain confluent monolayers within two days. 
Peripheral wells on the plate were filled with sterile 
water to avoid evaporation of the treatment 
solutions. On the day of the experiment, the seeding 
media was gently aspirated and the cells exposed to 
eight different concentrations per plate (six 
replicates each) of MDMA, MDA, N-Me-α-Me-
DA, α-MeDA, and mixture solution, prepared in 
fresh culture medium, for 48 h, at 37 oC or 40.5 oC. 
Each individual plate also included six replicates of 
negative controls (i.e., no test agents) and six 
replicates of positive controls (full media with 
1%Triton X-100). A broad range of concentrations 
was tested for each individual chemical and 
mixture, in order to obtain complete and well-
described concentration-response curves. 
The MTT reduction assay 
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT) is reduced to purple 
formazan by mitochondrial reductases of living 
cells, providing a measure of the cell viability. The 
protocol described by Mosmann (1983) was 
followed with some modifications (Dias da Silva et 
al., 2012).  
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Table 1. Parameters derived from nonlinear fits (logit model) of single agent concentration–response data, in the MTT reduction 
assay, at normothermic conditions, 37 oC (Figure 2). These parameters were used to compute the predicted mixture effect curves shown 
in Figure 3. 
 
Compound Tested concentration 
range (mM) 
Estimated parameters for the best-fit regression model 
EC50 (mM) 4 EC01 (mM) 5 Fraction in the mixture 
θ1
1
 θ2
2
 θmax
3
 
MDMA 6.6E-03 – 12 -7.97E-01 2.44E+00 1.17E+02 1.62E+00 2.40 E-02 6.53E-02 
MDA 9.22E-04 – 10 -1.45E+00 1.97E+00 1.74E+02 1.88E+00 1.31E-02 3.56E-02 
α-MeDA 2.32E-03  – 5 4.03E+00 1.59E+01 9.05E+01 7.51E-01 2.91E-01 7.90E-01 
N-Me-α-MeDA 2.36E-03 – 5 1.58E+00 4.17E+00 7.05E+01 5.83E-01 4.02E-02 1.09E-01 
1Location parameter of the Logit function. 2Slope parameter. 3Maximal effect, expressed as % cell death. 4Median effect concentration, i.e., concentration yielding 50% of the maximal 
effect produced by the drug in question. 5Concentration yielding 1% of the maximal effect in the MTT assay. 
 
 
 
Table 2. Parameters derived from nonlinear fits (logit model) of single agent concentration–response data, in the MTT reduction 
assay, at hyperthermic conditions, 40.5 oC (Figure 2). These parameters were used to compute the predicted mixture effect curves shown 
in Figure 3. 
 
1Location parameter of the Logit function. 2Slope parameter. 3Maximal effect, expressed as % cell death. 4Median effect concentration, i.e., concentration yielding 50% of the maximal 
effect produced by the drug in question. 5Concentration yielding 1% of the maximal effect in the MTT assay. 
Compound Tested concentration 
range (mM) 
Estimated parameters for the best-fit regression model 
EC50 (mM) 4 EC01 (mM) 5 Fraction in the mixture 
θ1
1
 θ2
2
 θmax
3
 
MDMA 3.46E-03 – 12 -9.04E-01 4.89E+00 1.12E+02 1.39E+00 1.67E-01 3.51E-01 
MDA 8.65E-04 – 10 -7.68E-01 4.13E+00 1.10E+02 1.39E+00 1.12E-01 2.36E-01 
α-MeDA 1.17E-03  – 5 -2.08E-01 4.03E+00 1.52E+02 6.83E-01 6.41E-02 1.35E-01 
N-Me-α-MeDA 1.183E-03 – 5 1.94E+00 7.32E+00 8.99E+01 5.75E-01 1.32E-01 2.78E-01 
 
Briefly, at the selected time point, the culture 
medium was aspirated and the attached cells were 
rinsed with 200 µl HBSS, followed by the addition 
of fresh culture medium containing 0.25 mg/l MTT. 
After a 30 min incubation at 37 oC in a humidified, 
5% CO2 atmosphere, the formed intracellular 
crystals of formazan were dissolved in 100 µl 100% 
DMSO. The absorbance was measured at 570 nm, 
using a multi-well plate reader (Labsystems 
Multiskan, Basingstoke, UK). 
To reduce inter-experimental variability, data 
from each test plate were normalized and scaled 
between 0% (negative controls) and 100% of effect 
(positive controls). Single agent data were obtained 
from at least six independent experiments run in six 
replicates, and mixture samples were run in six 
replicates on at least five independent occasions. 
Results were graphically presented as percentage of 
cell death versus concentration (mM). 
Regression modelling 
Curves of normalized mortality values (effect) 
versus concentration (mM) were constructed and 
analyzed through the best-fit approach (Scholze et 
al., 2001). The final data analysis was carried out 
with the best-fit model, selected from a number of 
nonlinear regressions. In the present study, the logit 
function was employed:  
Y= θmin + (θmax - θmin)/(1+exp(-θ1-θ2*log(x))) 
where θmin and θmax are the minimal and maximal 
observed effects, respectively; x is the concentration 
of test agent; θ1 is the parameter for location; and θ2 
is the slope parameter. 
Mixture design 
All chemicals were combined in proportion to their 
EC01 (concentration producing 1% of the maximal 
inducible toxic effect in the MTT assay). Using 
these criteria, all mixture components were present 
at equipotent concentrations, ensuring that no single 
drug contributed disproportionately to the overall 
mixture effect. For this purpose, a master solution 
of mixture was prepared containing the individual 
components in proportion to the EC01 and a range 
of concentrations for testing were subsequently 
prepared by employing the fixed mixture ratio 
design (Altenburger et al., 2000). The ratio between 
each constituent was maintained. EC01 values were 
determined by interpolation from the best-fit 
regression model for each tested agent. A summary 
of the logit parameters and estimated 1% effect 
concentration for the best-fit regression model of 
each individual agent are presented for 
normothermia (Table 1) and for hyperthermia 
(Table 2). 
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Figure 2. Regression models for the mortality induced by MDMA and the 3 tested metabolites MDA, N-Me-α-Me-DA, and α-
MeDA, at normal and hyperthermic conditions, in HepG2 cells. Cellular mortality data as evaluated by the MTT reduction assay 
obtained following 48 h exposures of HepG2 cells to MDMA, MDA, α-MeDA, and N-Me-α-MeDA. Mean effects (lethality) were fitted to 
the logit function (best fit: black and red solid lines for 37 oC and 40.5 oC incubations, respectively). Dashed lines show the 95% confidence 
belt of the fit (mean responses). Responses were normalized to negative (untreated) and positive (1% Triton X-100) controls. Data were 
obtained from at least six independent experiments where fifty-eight different concentrations were tested in series of six replicates. 
Comparisons between normothermic and hyperthermic curves of each substance were made using the extra sum-of-squares F test. In all 
cases, the differences were considered statistically significant (curve p values <0.0001). 
 
Computing combination effects 
After exhaustive concentration–response analysis of 
all single agents, the effects of the mixture (with all 
chemicals combined in proportion to their EC01 
values; Table 1 and Table 2) were predicted 
assuming additive joint responses. The expected 
effects were calculated using the CA and IA 
approaches. The mathematical derivation of the 
concepts was published by Payne et al. (2000). 
Statistical analysis 
Nonlinear regression analysis was carried out using 
a best-fit approach as described by Scholze and 
colleagues (2001) and the results are presented as 
the best estimate of the mean effects. Statistical 
uncertainties are expressed as 95% confidence 
intervals (CI) and differences between the best fits 
were deemed statistically significant when their 
corresponding 95% confidence belts did not 
overlap. Additionally, comparisons between curves 
(θmax, θ1 and θ2) were also performed using the 
extra sum-of-squares F test. p values lower than 
0.05 were considered statistically significant. 
Normality of the data distribution was assessed by 
three tests (KS normality test, D’Agostino and 
Pearson omnibus normality test and Shapiro–Wilk 
normality test) and statistical comparison between 
groups was estimated using the nonparametric 
method of Kruskal–Wallis [one-way analysis of 
variance (ANOVA) on ranks] followed by Dunn’s 
post hoc test. Nonlinear curve fitting and all 
statistical calculations were performed using 
GraphPad Prism software, version 5.01 (GraphPad 
Software, San Diego California, USA). 
Results 
N-Me-α-MeDA and α-MeDA are more potent 
cytotoxic metabolites than the respective parent 
compounds MDMA and MDA 
The cytotoxic effects induced by MDMA, MDA, α-
MeDA, and N-Me-α-MeDA to the HepG2 cells 
after 48 h incubations at 37 oC and 40.5 oC are 
presented in Fig. 2, and the curve parameters are 
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listed in Table 1 and Table 2, respectively. Under 
these experimental settings all tested substances 
induced a concentration-dependent cytotoxic effect, 
as evaluated by the MTT reduction assay. The 
metabolite MDA produced an effect that was very 
similar to that observed with MDMA. Both 
substances showed very reproducible effects in all 
independent experiments and the resulting curves 
were highly consistent in terms of slope, maximal 
effect, and median effect concentrations (MDMA 
EC50 1.62 mM and 1.39 mM, MDA EC50 1.88 mM 
and 1.39 mM, at 37 oC and 40.5 oC, respectively). 
In contrast, the catechol metabolites N-Me-α-Me-
DA and α-MeDA produced effects greater than 
MDA and MDMA, both at 37 ºC and 40.5 ºC 
(curve p values <0.0001). In line with earlier 
observations (Carvalho et al., 2004c), α-MeDA was 
less potent (i.e., showed a higher median effect 
concentration) than N-Me-α-MeDA, both at 40.5 ºC 
(α-MeDA EC50 0.68 mM and N-Me-α-MeDA EC50 
0.57 mM) and 37 ºC (α-MeDA EC50 0.75 mM and 
N-Me-α-MeDA EC50 0.58 mM) in inducing cell 
death. 
For all the tested substances, incubations at 
40.5 ºC produced steeper curves with significantly 
higher slopes (p values <0.0001, when curves were 
compared for θ2) (Table 1 and Table 2) indicating a 
higher mortality variation within a smaller 
concentration range, under hyperthermic 
conditions.  
Of note, the incubations with N-Me-α-Me-DA and 
α-MeDA failed to produce a maximal lethal effect, 
i.e. maximal responses were always below those of 
the positive control. α-MeDA yielded a maximal 
effect of 90.53% at 37 ºC, while N-Me-α-MeDA 
only induced up to 70.46% and 89.9% maximal 
responses under normothermic and hyperthermic 
conditions, respectively. This is due to the turbidity 
resulting from the incubation with high 
concentrations of the catechol metabolites and has 
been previously observed in vitro (Carmo et al., 
2006; Carvalho et al., 2004c). At the higher 
concentration range, these metabolites produce 
ortho-quinones that are further oxidized in a process 
that involves an irreversible 1,4- intramolecular 
cyclization, resulting in the formation of 
aminochromes (orange-colored pigments) and 
related compounds, such as 5,6-dihydroxyindoles, 
which eventually leads to the appearance of dark-
brown or black insoluble polymers of the melanin 
type (Figure 1) (Bindoli et al., 1992; Bindoli et al., 
1989). 
In the MTT assay, the formation of these 
pigments is accounted as formazans, which 
interfere with the optical density readings and, for 
this reason, higher metabolite concentrations were 
not considered. 
CA is the most accurate model to predict 
combination effects between MDMA and its 
metabolites at normothermic and hyperthermic 
incubations 
Based on the single agent concentration–
response relationships, shown in Fig. 2, we 
calculated the predictions for an equipotent mixture 
on the basis of the EC01 of individual components, 
so that none of the constituents contributed 
disproportionately to the overall mixture effect. The 
predictions were made assuming additive 
combination effects according to the CA and IA 
models. At both incubation temperatures, the two 
models produced well-differentiated additivity 
expectations that allowed the clear identification of 
the model that better correlated with the 
experimental observations (Fig. 3). The 
experimentally observed mixture effects agreed 
perfectly with the CA estimations, as the CA 
prediction was able to model responses over the 
entire range of effect levels and the predicted CA 
curve overlapped with the 95% confidence intervals 
of the best-fit regression model for the mixture 
(Fig. 3). Conversely, IA led to a clear 
underestimation of the observed joint effects. 
Accordingly, at 37 oC, the EC50 were 0.72 mM for 
the experimentally tested mixture and 0.79 mM for 
the CA prediction curve, while a much higher EC50 
value of 1.93 mM was observed for the IA 
prediction curve (Fig. 3A). Likewise, for the 
hyperthermic incubations (40.5 oC), the 
experimental median effect concentration was 0.92 
mM for the mixture, 0.92 mM for the CA 
prediction, and 1.59 mM for the prediction derived 
from IA (Fig. 3B). 
Maximal observed lethal effects also agreed well 
with the predicted values according to the CA 
model, both at normothermic and hyperthermic 
incubations. However, as denoted above, the 
maximal responses for the α-MeDA and N-Me-α-
MeDA metabolites were below those for the 
positive controls, so that CA predictions were 
limited in their full effect range. 
Significant mixture effects are observed even 
when the drugs are combined at individually 
ineffective concentrations 
The results displayed in Fig. 4, convincingly 
demonstrate that MDMA and its metabolites act 
together to produce significant additive mixture 
effects when each chemical was present at its 
individual EC01 value (Table 1 and 2). These effects 
were accurately predicted by the CA model.  
 
 
Chapter IV 
 150 
Figure 3. Predicted and observed effects of a mixture of MDMA and the 3 tested metabolites MDA, N-Me-α-Me-DA, and α-MeDA, 
in the MTT assay in normothermic (A) and hyperthermic (B) conditions. On the basis of the single agent concentration–response 
relationships (Fig. 2), additive combination effects were predicted using the models of concentration addition (CA), given by the solid red 
line; and independent action (IA), as represented by the solid blue line. The individual components were mixed in proportion to their EC01 
values calculated from the data obtained with the single incubations (Fig. 2). The best-fit regression model (logit) for the experimental data 
obtained following 48 h of incubation with the mixture is shown by the solid black line, labelled ‘observed effect’. Black dashed lines 
represent the upper and lower 95 % CI for the regression fit. The green dotted lines show the EC50 for each response curve (A: 0.72 mM 
observed effect, 0.79 mM CA and 1.93 mM IA at 37oC; B: 0.918 mM observed effect, 0.920 mM CA and 1.59 mM mM IA at 40.5oC). 
Data are from five independent experiments with sixty-four different concentrations tested in six replicates. 
 
When tested individually at 37 ºC, 0.024 mM 
MDMA, 0.013 mM MDA, 0.29 mM α-MeDA, and 
0.04 mM N-Me-α-MeDA produced 1% cell death 
each (such an effect is within the negative control 
variation range). When mixed together (0.368 mM 
mixture total concentration) the observed cell death 
effect was significantly different from untreated 
controls, reaching a mean level of 19.85 ± 1.07 % 
cell killing, that was well estimated by the CA 
model (19.6%, Fig. 4A).  
Similarly, at 40.5 ºC, 0.167 mM MDMA, 0.112 
mM MDA, 0.064 mM α-MeDA, and 0.132 mM N-
Me-α-MeDA incubations produced an individual 
1% cell death effect while the corresponding 
mixture (0.476 mM total concentration) induced a 
significantly higher lethal effect of 17.33 ± 1.55 % 
cell death, that was also previously well estimated 
by the CA model (17% estimated cell death, Fig. 
4B). 
This demonstrates that there were substantial joint 
effects even when the test agents were combined at 
concentrations that individually yielded responses 
indistinguishable from those of untreated controls. 
Discussion 
Intoxications following MDMA abuse are 
worrisome in terms of acute and/or long lasting 
effects and are frequent causes of emergency 
department admissions (Carvalho et al., 2012). 
The toxicological actions of this drug are due to 
complex and interacting mechanisms resulting in 
remarkable interindividual differences in toxicity 
(Henry et al., 1992; O'Donohoe et al., 1998), which 
adds to the complexity and the severity of the 
intoxications and renders their treatment unspecific 
and mostly empirical. Among the putative aspects 
that may contribute for the described toxicity is 
MDMA metabolism. In humans, MDMA is 
principally cleared by hepatic metabolism, which 
results in production of redox-active metabolites 
(Antolino-Lobo et al., 2011; Carvalho et al., 2012; 
Carvalho et al., 2010; de la Torre and Farre, 2004). 
These metabolites formed in vivo may act jointly 
with the parent compound to produce an overall 
effect that can be different than that elicited by 
MDMA alone. We, therefore, investigated the 
combined effects of MDMA and its three major 
human hepatic metabolites (MDA, N-Me-α-MeDA 
and α-MeDA) in a human hepatoma cell line and 
found that together, the parent drug and its main 
metabolites significantly increase liver toxicity in 
relation to the parent compound alone, by acting in 
an additive way. We have further tested whether 
hyperthermia could aggravate these combination 
effects. Hyperthermia is a common feature of 
MDMA-induced intoxications, as it has been linked 
to the majority of the acute toxicity cases reported, 
including fatalities (Armenian et al., 2012; Coore, 
1996; Dar and McBrien, 1996; Garcia-Repetto et 
al., 2003). Also, the hot, crowded, dance club 
conditions where MDMA abuse often takes place 
are expected to enhance the thermogenic actions of 
the amphetamines, with well-known clinical 
implications (Green et al., 2004). Our data show 
that the effects of MDMA and its main metabolites 
are severely aggravated when the cells are 
incubated at a temperature of 40.5 ºC. Even more 
remarkable was the observation that, when MDMA 
and its main metabolites were combined at 
individually low ineffective concentrations, 
significant cytotoxicity occurred, independently of 
the incubation temperature. These results clearly 
support the putative contribution of metabolic 
bioactivation to the toxicity of MDMA. 
 
Chapter IV 
151 
 
 
 
Figure 4. Individual and mixture effects of MDMA and the metabolites MDA, α-MeDA and N-Me-α-MeDA mixed at their EC01 
effect level, in normothermic (A) and hyperthermic (B) conditions. CA: Concentration addition prediction. MIX: experimentally 
observed effect of 0.368 mM of mixture incubated at 37 ºC (A) and 0.476 mM of mixture incubated at 40.5 ºC (B). The individual 
concentrations of the four-mixture components in 0.368 mM of the mixture (A) were 0.024 mM MDMA, 0.013 mM MDA, 0.29 mM α-
MeDA and 0.04 mM N-Me-α-MeDA. The individual concentrations of the four-mixture components in 0.476 mM of the mixture (B) were 
0.167 mM MDMA, 0.112 mM MDA, 0.064 mM α-MeDA and 0.132 mM N-Me-α-MeDA. The dashed red line corresponds to the sum of 
the individual effects of all mixture components (4%). Data (mean results) were from five independent experiments run in six replicates. 
Error bars represent the 95% CI. Statistical comparisons were made using the Kruskal–Wallis test followed by the Dunn’s multiple 
comparison post hoc test. *** Show statistically significant differences between the mixture and all other treatments. (***p<0.001). 
 
The cytotoxicity of the oxidative metabolites 
has been previously recognized in several in vitro 
studies that have shown that the metabolic 
bioactivation of the drug has an important role in its 
neuronal (Gollamudi et al., 1989; Patel et al., 1991), 
hepatic (Carvalho et al., 2004a; Carvalho et al., 
2004b), renal (Carvalho et al., 2002), and cardiac 
(Carvalho et al., 2004c) toxicities. These studies 
have demonstrated that the cytotoxic effects of the 
metabolites, especially those of the metabolites that 
retained the catechol moiety were greatly increased 
relative to the effects of MDMA. For example, the 
oxidative MDMA metabolite N-Me-α-MeDA 
proved to be more than 100-fold more cytotoxic 
than the parent compound MDMA (Carmo et al., 
2006). The toxicity of N-Me-α-MeDA and α-MeDA 
involves the reactivity of the catechol moiety of 
these molecules that can be easily oxidized into the 
corresponding o-quinones (figure 1). These 
quinones directly react with cellular nucleophiles, 
such as sulfhydryl groups, including free cysteine, 
GSH and cysteinyl residues on proteins, rendering 
the cells more susceptible to the effects of the 
reactive compounds generated by these metabolic 
reactions. Further redox cycling occurs generating 
reactive species (ROS and RNS) and causing 
oxidative stress through the formation of oxidized 
cellular macromolecules, including lipids, proteins, 
and DNA (Bindoli et al., 1992; Bolton et al., 2000). 
N-Me-α-MeDA also depletes intracellular GSH 
(Carvalho et al., 2004b; Carvalho et al., 2004c), and 
the o-quinones can conjugate with GSH to form a 
redox-active glutathionyl adduct that is 
subsequently oxidized to a quinone thioether, 
which, after the reductive addition of a second 
molecule of GSH, yields a bis-glutathionyl 
conjugate (Hiramatsu et al., 1990; Monks et al., 
2004). Further oxidation of the o-quinones 
produces aminochromes, a late stage event of 
catecholamine oxidation (Bindoli et al., 1989). α-
Methyldopaminochrome and N-methyl-α-
methyldopaminochrome are, in turn, oxidized and 
lead to melanin type polymers with a dark 
brown/black colour (Zhang and Dryhurst, 1994). 
Accordingly, a dark brown/black turbidity occurred 
in the cell culture media of the cells incubated with 
N-Me-α-MeDA and α-MeDA, in our study. In fact, 
due to the formation of such coloured compounds 
that significantly interfered with the absorbance 
readings of the MTT assay, we could not obtain 
complete concentration-response curves after the 
individual incubations with N-Me-α-MeDA and α-
MeDA, since this was specially notorious at high 
concentrations of the metabolites. For this reason, it 
was not possible to test these highest concentrations 
in our system. The intracellular formation of such 
polymers is believed to occur only when the 
antioxidant defence system of the cell is 
significantly compromised. Additionally, N-Me-α-
MeDA, o-quinones, and the aminochromes can 
inhibit the activity of important enzymes involved 
in the cellular antioxidant defence, namely, 
glutathione reductase (GR), glutathione peroxidase 
(GPx), and glutathione S-transferase (GST) 
(Carvalho et al., 2004b; Remiao et al., 1999; 
Remiao et al., 2002). N-Me-α-MeDA also depletes 
ATP (Carvalho et al., 2004b), which combined to 
the disturbance in the thiol homeostasis, may 
contribute to mitochondrial dysfunction and 
disruption of cellular energetics. 
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As can be seen in figure 2, our results confirm 
the greater cytotoxicity of the catechol metabolites 
when compared to MDMA, with lower EC50 values 
and a left-shift in the concentration-response plots. 
On the other hand, the N-demethylated metabolite 
MDA produced very similar cytotoxic effects 
compared to the parent drug, with similar EC50 and 
slope values obtained for both substances. Other 
studies have also shown that MDA had comparable 
or even slightly lower cytotoxic effects than those 
elicited by MDMA (Carvalho et al., 2002). 
In spite of all the evidence supporting the 
cytotoxicity of MDMA metabolites, the 
confirmation of the in vivo relevance of these in 
vitro findings has been hindered due to a lack of 
adequate in vivo models that accurately distinguish 
the toxic effects caused by the parent drug from 
those of the toxic metabolites. Also, confounding 
factors including redundant metabolic pathways, 
interspecies differences in the extent of metabolite 
formation, and the relative amounts of the formed 
metabolites preclude these in vivo investigations. 
With this study model we were able to bring 
together two important features of MDMA toxicity: 
metabolic bioactivation and hyperthermia, and were 
able to demonstrate for the first time that significant 
additive joint effects occur between MDMA and its 
metabolites under circumstances that are highly 
representative of the human situation in an acute 
intoxication scenario. 
With the present data, we were able to calculate 
quantitative estimations of expected mixture effects 
that were accurately predicted by the CA model. An 
excellent discrimination achieved between the 
expectations according to CA and IA models 
allowed an accurate determination of the model that 
better described the experimental outcomes. The 
model of CA provided accurate estimations of 
combination effects proving that the tested 
chemicals acted together in an additive fashion. 
Since the CA model assumes that all our mixture 
components operate in a similar manner and that 
each individual drug contributes to the overall 
mixture effect in proportion to its concentration, we 
can expect that the same overall effect will be 
observed if one constituent were totally or partially 
replaced by an equieffective concentration of 
another. As a consequence, significant mixture 
effects can occur even when the individual test 
drugs are mixed at individually ineffective 
concentrations. This was clearly demonstrated for 
the mixture of MDMA and the metabolites, since 
when these were mixed at their individual EC01 
concentrations (that failed to produce measurable 
effects relative to untreated controls) significant 
cytotoxicity was observed. It is, therefore, plausible 
that even when low levels of metabolites are 
produced in the liver adverse effects can occur by 
virtue of these additive effects. The model of IA, on 
the other hand, proved to be inappropriate for the 
assessment of the joint effects of MDMA and its 
major metabolites. This model that describes 
combination effects of drugs with dissimilar 
mechanisms of action and/or interacting at differing 
sites of action (Backhaus et al., 2000; Faust et al., 
2003), severely underestimated the experimentally 
observed toxicity of the mixture. This suggests that 
there is a similarity in the way in which MDMA 
and its major metabolites lead to HepG2 cell death. 
However, the mechanistic interactions that explain 
these observed mixture effects await further 
investigation. 
Of note is the fact that our data agrees well 
with a previous study that recently demonstrated 
that, in HepG2 cells, four amphetamines that are 
frequently co-ingested in ecstasy pills (4-
methylthioamphetamine, d-amphetamine, 
methamphetamine, and MDMA) acted together 
producing additive cytotoxic mixture effects that 
could be accurately predicted by the CA model 
(Dias da Silva et al., 2012) whereas the IA model 
failed to produce accurate estimations of the 
cytotoxic joint effects of that mixture.  
The finding of significant additive cytotoxic 
effects when MDMA and metabolites were 
combined at low, physiologically relevant 
concentrations is of special relevance. The reported 
concentrations of MDMA found in the blood and 
tissues at autopsy after fatal intoxications vary 
enormously and range from 1.0 to 70 µM (Carvalho 
et al., 2012). In the tissues, much higher 
concentrations of the drug are achieved. For 
example, in the liver, the drug levels can be up to 
18 times higher than blood concentrations (Garcia-
Repetto et al., 2003). Very limited information is 
available on metabolite levels in human specimens. 
However, data from pharmacokinetic studies 
obtained with volunteers after the ingestion of 
relatively small doses of MDMA, revealed that the 
maximal N-Me-α-MeDA plasma concentrations are 
similar to those attained by MDMA (Segura et al., 
2001). 
A limitation to our prediction analysis was the 
production of an incomplete cytotoxicity 
concentration-response curve for N-Me-α-MeDA 
(both at normothermia and hyperthermia) and α-
MeDA (at normothermia), since maximal effects 
could not be recorded due to the absorbance 
interference of the pigments produced by the 
metabolites incubations. Due to the mathematical 
features of CA, this concept cannot be applied to 
effect levels that exceed the maximal effect of the 
chemical with the shortest (most incomplete) 
concentration-response curve (Silva et al 2007). 
However this had no significant impact on the 
accuracy of the estimation achieved by this model 
and our ability to compare it with experimental 
outcomes in the work reported here. 
An important point to consider is the possibility 
that MDMA could be metabolized into the tested 
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mixture components by the HepG2 cells, with 
consequent changes in the contributions of 
individual agents to the overall mixture effect, as 
these cells retain a certain metabolic activity 
regarding the main cytochrome P450 isoenzymes 
involved in the hepatic metabolism of these 
metabolites (CYP2D6 for the catechols and 
CYP2B6 for MDA) (Donato et al., 2008). 
However, we did not observe any deviation from 
additivity, indicating that such putative metabolic 
interactions are probably not contributing to the 
observed effects. 
Conclusions 
Overall, we have shown, for the first time, that 
MDMA and its three major hepatic metabolites act 
in an additive manner producing joint effects that 
were accurately predicted by the concentration 
addition model. As such, when mixed at 
individually ineffective concentrations, significant 
cytotoxicity is produced. This was clearly 
demonstrated both at normothermic and 
hyperthermic incubations experimentally 
suggesting that, at physiologically relevant 
conditions, the metabolic bioactivation greatly 
contributes to the liver toxicity of the drug in 
intoxicated individuals. This is also a strong 
reminder that when concentrations of MDMA are 
evaluated in plasma of intoxicated individuals, 
these largely underestimate the overall exposure of 
cells to the toxic mixture of MDMA and its 
metabolites. Whether such additive combination 
effects between the parent drug and metabolites 
also occur in more complex experimental models 
deserves further investigation. 
Abbreviations 
CA, Concentration addition; CI, Confidence 
interval; EC01, Concentration producing 1% of the 
maximally inducible effect in the MTT assay; EC50, 
Concentration producing 50% of the maximally 
inducible effect in the MTT assay; IA, Independent 
Action; MDA, 3,4-Methylenedioxyamphetamine; 
Love; MDMA, 3,4-
methylenedioxymethamphetamine; Ecstasy; α-
MeDA, α-Methyldopamine; MTT, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide; N-Me-α-MeDA, N-methyl-α-
methyldopamine; RNS, Reactive species of 
nitrogen; ROS, Reactive species of oxygen. 
Acknowledgements 
The authors would like to kindly thank Dr Paula 
Sério Branco and Dr Luísa Maria Ferreira  
(REQUIMTE/CQFB (Centro de Química Fina e 
Biotecnologia), Chemistry Department, Faculty of 
Science and Technology, Universidade Nova de 
Lisboa, Portugal) for the synthesis of N-Me-α-Me-
DA (HBr salt) and α-MeDA (HBr salt). 
This work was supported by the Portuguese 
Research Council Fundação para a Ciência e para a 
Tecnologia (FCT) through the grants PEst-
C/EQB/LA0006/2011 and SFRH/BD/45617/2008. 
References 
Altenburger, R., Backhaus, T., Boedeker, W., Faust, M., Scholze, 
M., Grimme, L.H., 2000. Predictability of the toxicity of 
multiple chemical mixtures to Vibrio fischeri: Mixtures 
composed of similarly acting chemicals. Environmental 
Toxicology and Chemistry 19, 2341-2347. 
Andreu, V., Mas, A., Bruguera, M., Salmeron, J.M., Moreno, V., 
Nogue, S., Rodes, J., 1998. Ecstasy: a common cause of 
severe acute hepatotoxicity. Journal of hepatology 29, 394-
397. 
Antolino-Lobo, I., Meulenbelt, J., van den Berg, M., van 
Duursen, M.B., 2011. A mechanistic insight into 3,4-
methylenedioxymethamphetamine (‘ecstasy’)-mediated 
hepatotoxicity. The Veterinary quarterly 31, 193-205. 
Armenian, P., Mamantov, T.M., Tsutaoka, B.T., Gerona, R.R., 
Silman, E.F., Wu, A.H., Olson, K.R., 2012. Multiple MDMA 
(Ecstasy) Overdoses at a Rave Event: A Case Series. Journal 
of intensive care medicine. 
Backhaus, T., Altenburger, R., Boedeker, W., Faust, M., Scholze, 
M., Grimme, L.H., 2000. Predictability of the toxicity of a 
multiple mixture of dissimilarly acting chemicals to Vibrio 
fischeri. Environmental Toxicology and Chemistry 19, 2348-
2356. 
Bindoli, A., Rigobello, M.P., Deeble, D.J., 1992. Biochemical and 
toxicological properties of the oxidation products of 
catecholamines. Free radical biology & medicine 13, 391-405. 
Bindoli, A., Rigobello, M.P., Galzigna, L., 1989. Toxicity of 
aminochromes. Toxicology letters 48, 3-20. 
Bolton, J.L., Trush, M.A., Penning, T.M., Dryhurst, G., Monks, 
T.J., 2000. Role of quinones in toxicology. Chemical research 
in toxicology 13, 135-160. 
Borgman, R.J., Baylor, M.R., McPhillips, J.J., Stitzel, R.E., 1974. 
Alpha-methyldopamine derivatives. Synthesis and 
pharmacology. Journal of medicinal chemistry 17, 427-430. 
Brauer, R.B., Heidecke, C.D., Nathrath, W., Beckurts, K.T., 
Vorwald, P., Zilker, T.R., Schweigart, U., Holscher, A.H., 
Siewert, J.R., 1997. Liver transplantation for the treatment 
of fulminant hepatic failure induced by the ingestion of 
ecstasy. Transplant international : official journal of the 
European Society for Organ Transplantation 10, 229-233. 
Capela, J.P., Carmo, H., Remiao, F., Bastos, M.L., Meisel, A., 
Carvalho, F., 2009. Molecular and cellular mechanisms of 
ecstasy-induced neurotoxicity: an overview. Molecular 
neurobiology 39, 210-271. 
Capela, J.P., Meisel, A., Abreu, A.R., Branco, P.S., Ferreira, 
L.M., Lobo, A.M., Remiao, F., Bastos, M.L., Carvalho, F., 
2006. Neurotoxicity of Ecstasy metabolites in rat cortical 
neurons, and influence of hyperthermia. The Journal of 
pharmacology and experimental therapeutics 316, 53-61. 
Carmo, H., Brulport, M., Hermes, M., Oesch, F., Silva, R., 
Ferreira, L.M., Branco, P.S., Boer, D., Remiao, F., Carvalho, 
F., Schon, M.R., Krebsfaenger, N., Doehmer, J., Bastos Mde, 
L., Hengstler, J.G., 2006. Influence of CYP2D6 
polymorphism on 3,4-methylenedioxymethamphetamine 
('Ecstasy') cytotoxicity. Pharmacogenetics and genomics 16, 
789-799. 
Carvalho, M., Carmo, H., Costa, V.M., Capela, J.P., Pontes, H., 
Remiao, F., Carvalho, F., Bastos, M.D., 2012. Toxicity of 
amphetamines: an update. Archives of toxicology. 
Carvalho, M., Carvalho, F., Bastos, M.L., 2001. Is hyperthermia 
the triggering factor for hepatotoxicity induced by 3,4-
methylenedioxymethamphetamine (ecstasy)? An in vitro 
Chapter IV 
 154 
study using freshly isolated mouse hepatocytes. Archives of 
toxicology 74, 789-793. 
Carvalho, M., Hawksworth, G., Milhazes, N., Borges, F., Monks, 
T.J., Fernandes, E., Carvalho, F., Bastos, M.L., 2002. Role of 
metabolites in MDMA (ecstasy)-induced nephrotoxicity: an 
in vitro study using rat and human renal proximal tubular 
cells. Archives of toxicology 76, 581-588. 
Carvalho, M., Milhazes, N., Remiao, F., Borges, F., Fernandes, 
E., Amado, F., Monks, T.J., Carvalho, F., Bastos, M.L., 
2004a. Hepatotoxicity of 3,4-methylenedioxyamphetamine 
and alpha-methyldopamine in isolated rat hepatocytes: 
formation of glutathione conjugates. Archives of toxicology 
78, 16-24. 
Carvalho, M., Pontes, H., Remiao, F., Bastos, M.L., Carvalho, F., 
2010. Mechanisms underlying the hepatotoxic effects of 
ecstasy. Current pharmaceutical biotechnology 11, 476-495. 
Carvalho, M., Remiao, F., Milhazes, N., Borges, F., Fernandes, 
E., Carvalho, F., Bastos, M.L., 2004b. The toxicity of N-
methyl-alpha-methyldopamine to freshly isolated rat 
hepatocytes is prevented by ascorbic acid and N-
acetylcysteine. Toxicology 200, 193-203. 
Carvalho, M., Remiao, F., Milhazes, N., Borges, F., Fernandes, 
E., Monteiro Mdo, C., Goncalves, M.J., Seabra, V., Amado, 
F., Carvalho, F., Bastos, M.L., 2004c. Metabolism is required 
for the expression of ecstasy-induced cardiotoxicity in vitro. 
Chemical research in toxicology 17, 623-632. 
CDC, 2010. Ecstasy overdoses at a New Year's Eve rave--Los 
Angeles, California, 2010. MMWR Morbidity and mortality 
weekly report 59, 677-681. 
Coore, J.R., 1996. A fatal trip with ecstasy: a case of 3,4-
methylenedioxymethamphetamine/3,4- 
methylenedioxyamphetamine toxicity. J R Soc Med 89, 51P-
52P. 
Dar, K.J., McBrien, M.E., 1996. MDMA induced hyperthermia: 
report of a fatality and review of current therapy. Intensive 
Care Med 22, 995-996. 
De Carlis, L., De Gasperi, A., Slim, A.O., Giacomoni, A., Corti, 
A., Mazza, E., Di Benedetto, F., Lauterio, A., Arcieri, K., 
Maione, G., Rondinara, G.F., Forti, D., 2001. Liver 
transplantation for ecstasy-induced fulminant hepatic 
failure. Transplantation proceedings 33, 2743-2744. 
de la Torre, R., Farre, M., 2004. Neurotoxicity of MDMA 
(ecstasy): the limitations of scaling from animals to humans. 
Trends in pharmacological sciences 25, 505-508. 
de la Torre, R., Farre, M., Navarro, M., Pacifici, R., Zuccaro, P., 
Pichini, S., 2004a. Clinical pharmacokinetics of amfetamine 
and related substances: monitoring in conventional and non-
conventional matrices. Clin Pharmacokinet 43, 157-185. 
de la Torre, R., Farre, M., Ortuno, J., Mas, M., Brenneisen, R., 
Roset, P.N., Segura, J., Cami, J., 2000. Non-linear 
pharmacokinetics of MDMA ('ecstasy') in humans. British 
journal of clinical pharmacology 49, 104-109. 
de la Torre, R., Farre, M., Roset, P.N., Pizarro, N., Abanades, S., 
Segura, M., Segura, J., Cami, J., 2004b. Human 
pharmacology of MDMA: pharmacokinetics, metabolism, 
and disposition. Ther Drug Monit 26, 137-144. 
Dias da Silva, D., Carmo, H., Silva, E., 2012. The risky cocktail: 
what combination effects can we expect between ecstasy and 
other amphetamines? Archives of toxicology. 
Donato, M.T., Lahoz, A., Castell, J.V., Gomez-Lechon, M.J., 
2008. Cell lines: a tool for in vitro drug metabolism studies. 
Current drug metabolism 9, 1-11. 
Dykhuizen, R.S., Brunt, P.W., Atkinson, P., Simpson, J.G., 
Smith, C.C., 1995. Ecstasy induced hepatitis mimicking viral 
hepatitis. Gut 36, 939-941. 
Easton, N., Fry, J., O'Shea, E., Watkins, A., Kingston, S., 
Marsden, C.A., 2003. Synthesis, in vitro formation, and 
behavioural effects of glutathione regioisomers of alpha-
methyldopamine with relevance to MDA and MDMA 
(ecstasy). Brain research 987, 144-154. 
Ellis, A.J., Wendon, J.A., Portmann, B., Williams, R., 1996. 
Acute liver damage and ecstasy ingestion. Gut 38, 454-458. 
Escobedo, I., O'Shea, E., Orio, L., Sanchez, V., Segura, M., de la 
Torre, R., Farre, M., Green, A.R., Colado, M.I., 2005. A 
comparative study on the acute and long-term effects of 
MDMA and 3,4-dihydroxymethamphetamine (HHMA) on 
brain monoamine levels after i.p. or striatal administration 
in mice. British journal of pharmacology 144, 231-241. 
Faust, M., Altenburger, R., Backhaus, T., Blanck, H., Boedeker, 
W., Gramatica, P., Hamer, V., Scholze, M., Vighi, M., 
Grimme, L.H., 2003. Joint algal toxicity of 16 dissimilarly 
acting chemicals is predictable by the concept of independent 
action. Aquat Toxicol 63, 43-63. 
Forsling, M.L., Fallon, J.K., Shah, D., Tilbrook, G.S., Cowan, 
D.A., Kicman, A.T., Hutt, A.J., 2002. The effect of 3,4-
methylenedioxymethamphetamine (MDMA, 'ecstasy') and its 
metabolites on neurohypophysial hormone release from the 
isolated rat hypothalamus. British journal of pharmacology 
135, 649-656. 
Garcia-Repetto, R., Moreno, E., Soriano, T., Jurado, C., 
Gimenez, M.P., Menendez, M., 2003. Tissue concentrations 
of MDMA and its metabolite MDA in three fatal cases of 
overdose. Forensic Sci Int 135, 110-114. 
Gollamudi, R., Ali, S.F., Lipe, G., Newport, G., Webb, P., Lopez, 
M., Leakey, J.E., Kolta, M., Slikker, W., Jr., 1989. Influence 
of inducers and inhibitors on the metabolism in vitro and 
neurochemical effects in vivo of MDMA. Neurotoxicology 10, 
455-466. 
Green, A.R., Mechan, A.O., Elliott, J.M., O'Shea, E., Colado, 
M.I., 2003. The pharmacology and clinical pharmacology of 
3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’). 
Pharmacological reviews 55, 463-508. 
Green, A.R., O'Shea, E., Colado, M.I., 2004. A review of the 
mechanisms involved in the acute MDMA (ecstasy)-induced 
hyperthermic response. Eur J Pharmacol 500, 3-13. 
Greene, S.L., Dargan, P.I., O'Connor, N., Jones, A.L., Kerins, 
M., 2003. Multiple toxicity from 3,4-
methylenedioxymethamphetamine (‘ecstasy’). The American 
journal of emergency medicine 21, 121-124. 
Hartung, T.K., Schofield, E., Short, A.I., Parr, M.J., Henry, J.A., 
2002. Hyponatraemic states following 3,4-
methylenedioxymethamphetamine (MDMA, 'ecstasy') 
ingestion. QJM : monthly journal of the Association of 
Physicians 95, 431-437. 
Henry, J.A., Jeffreys, K.J., Dawling, S., 1992. Toxicity and deaths 
from 3,4-methylenedioxymethamphetamine (‘ecstasy’). 
Lancet 340, 384-387. 
Hiramatsu, M., Kumagai, Y., Unger, S.E., Cho, A.K., 1990. 
Metabolism of methylenedioxymethamphetamine: formation 
of dihydroxymethamphetamine and a quinone identified as 
its glutathione adduct. The Journal of pharmacology and 
experimental therapeutics 254, 521-527. 
Johnson, M., Letter, A.A., Merchant, K., Hanson, G.R., Gibb, 
J.W., 1988. Effects of 3,4-methylenedioxyamphetamine and 
3,4-methylenedioxymethamphetamine isomers on central 
serotonergic, dopaminergic and nigral neurotensin systems 
of the rat. The Journal of pharmacology and experimental 
therapeutics 244, 977-982. 
Jones, A.L., Simpson, K.J., 1999. Review article: mechanisms 
and management of hepatotoxicity in ecstasy (MDMA) and 
amphetamine intoxications. Alimentary pharmacology & 
therapeutics 13, 129-133. 
Jones, D.C., Duvauchelle, C., Ikegami, A., Olsen, C.M., Lau, S.S., 
de la Torre, R., Monks, T.J., 2005. Serotonergic neurotoxic 
metabolites of ecstasy identified in rat brain. The Journal of 
pharmacology and experimental therapeutics 313, 422-431. 
Kortenkamp, A., 2007. Ten years of mixing cocktails: a review of 
combination effects of endocrine-disrupting chemicals. 
Environmental health perspectives 115 Suppl 1, 98-105. 
Lim, H.K., Foltz, R.L., 1988. In vivo and in vitro metabolism of 
3,4-(methylenedioxy)methamphetamine in the rat: 
identification of metabolites using an ion trap detector. 
Chemical research in toxicology 1, 370-378. 
Lim, H.K., Foltz, R.L., 1989. Identification of metabolites of 3,4-
(methylenedioxy)methamphetamine in human urine. 
Chemical research in toxicology 2, 142-143. 
Maurer, H.H., 1996. On the metabolism and the toxicological 
analysis of methylenedioxyphenylalkylamine designer drugs 
by gas chromatography-mass spectrometry. Ther Drug 
Monit 18, 465-470. 
Maurer, H.H., Bickeboeller-Friedrich, J., Kraemer, T., Peters, 
F.T., 2000. Toxicokinetics and analytical toxicology of 
Chapter IV 
155 
 
amphetamine-derived designer drugs ('Ecstasy'). Toxicology 
letters 112-113, 133-142. 
Milroy, C.M., Clark, J.C., Forrest, A.R., 1996. Pathology of 
deaths associated with ‘ecstasy’ and ‘eve’ misuse. Journal of 
clinical pathology 49, 149-153. 
Monks, T.J., Jones, D.C., Bai, F., Lau, S.S., 2004. The role of 
metabolism in 3,4-(+)-methylenedioxyamphetamine and 3,4-
(+)-methylenedioxymethamphetamine (ecstasy) toxicity. 
Ther Drug Monit 26, 132-136. 
Mosmann, T., 1983. Rapid colorimetric assay for cellular growth 
and survival: application to proliferation and cytotoxicity 
assays. Journal of immunological methods 65, 55-63. 
O'Donohoe, A., O'Flynn, K., Shields, K., Hawi, Z., Gill, M., 1998. 
MDMA toxicity: no evidence for a major influence of 
metabolic genotype at CYP2D6. Addict Biol 3, 309-314. 
Parrott, A.C., 2001. Human psychopharmacology of Ecstasy 
(MDMA): a review of 15 years of empirical research. Hum 
Psychopharmacol 16, 557-577. 
Parrott, A.C., 2004. Is ecstasy MDMA? A review of the 
proportion of ecstasy tablets containing MDMA, their dosage 
levels, and the changing perceptions of purity. 
Psychopharmacology (Berl) 173, 234-241. 
Patel, N., Kumagai, Y., Unger, S.E., Fukuto, J.M., Cho, A.K., 
1991. Transformation of dopamine and alpha-
methyldopamine by NG108-15 cells: formation of thiol 
adducts. Chemical research in toxicology 4, 421-426. 
Pavlaki, M.D., Pereira, R., Loureiro, S., Soares, A.M., 2011. 
Effects of binary mixtures on the life traits of Daphnia 
magna. Ecotoxicology and environmental safety 74, 99-110. 
Payne, J., Rajapakse, N., Wilkins, M., Kortenkamp, A., 2000. 
Prediction and assessment of the effects of mixtures of four 
xenoestrogens. Environmental health perspectives 108, 983-
987. 
Rajapakse, N., Ong, D., Kortenkamp, A., 2001. Defining the 
impact of weakly estrogenic chemicals on the action of 
steroidal estrogens. Toxicological sciences : an official 
journal of the Society of Toxicology 60, 296-304. 
Remiao, F., Carmo, H., Carvalho, F.D., Bastos, M.L., 1999. 
Inhibition of Glutathione Reductase by Isoproterenol 
Oxidation Products. J Enzyme Inhib 15, 47-61. 
Remiao, F., Carvalho, M., Carmo, H., Carvalho, F., Bastos, M.L., 
2002. Cu2+-induced isoproterenol oxidation into 
isoprenochrome in adult rat calcium-tolerant 
cardiomyocytes. Chemical research in toxicology 15, 861-869. 
Remiao, F., Rettori, D., Han, D., Carvalho, F., Bastos, M.L., 
Cadenas, E., 2004. Leucoisoprenochrome-o-semiquinone 
formation in freshly isolated adult rat cardiomyocytes. 
Chemical research in toxicology 17, 1584-1590. 
Sano, R., Hasuike, T., Nakano, M., Kominato, Y., Itoh, H., 2009. 
A fatal case of myocardial damage due to misuse of the 
‘designer drug’ MDMA. Leg Med (Tokyo) 11, 294-297. 
Santos-Marques, M.J., Carvalho, F., Sousa, C., Remiao, F., 
Vitorino, R., Amado, F., Ferreira, R., Duarte, J.A., de 
Lourdes Bastos, M., 2006. Cytotoxicity and cell signalling 
induced by continuous mild hyperthermia in freshly isolated 
mouse hepatocytes. Toxicology 224, 210-218. 
Scholze, M., Boedeker, W., Faust, M., Backhaus, T., 
Altenburger, R., Grimme, L.H., 2001. A general best-fit 
method for concentration-response curves and the estimation 
of low-effect concentrations. Environmental toxicology and 
chemistry / SETAC 20, 448-457. 
Schwab, M., Seyringer, E., Brauer, R.B., Hellinger, A., Griese, 
E.U., 1999. Fatal MDMA intoxication. Lancet 353, 593-594. 
Segura, M., Ortuno, J., Farre, M., McLure, J.A., Pujadas, M., 
Pizarro, N., Llebaria, A., Joglar, J., Roset, P.N., Segura, J., 
de La Torre, R., 2001. 3,4-Dihydroxymethamphetamine 
(HHMA). A major in vivo 3,4-
methylenedioxymethamphetamine (MDMA) metabolite in 
humans. Chemical research in toxicology 14, 1203-1208. 
Silva, E., Rajapakse, N., Kortenkamp, A., 2002. Something from 
‘nothing’--eight weak estrogenic chemicals combined at 
concentrations below NOECs produce significant mixture 
effects. Environmental science & technology 36, 1751-1756. 
Zhang, F., Dryhurst, G., 1994. Effects of L-cysteine on the 
oxidation chemistry of dopamine: new reaction pathways of 
potential relevance to idiopathic Parkinson's disease. Journal 
of medicinal chemistry 37, 1084-1098 
  156
 157 
  
 
 
 
 
 
 
 
 
 
 
 
Chapter V. A mechanistic insight into the hepatocellular death induced by 
amphetamines, individually and in combination – The involvement of necrosis 
and apoptosis. 
 
 
Submitted to Archives of toxicology.  
  158 
  
 159 
An insight into the hepatocellular death induced by 
amphetamines, individually and in combination – The 
involvement of necrosis and apoptosis 
 
DIANA DIAS DA SILVA1,2, 3*, HELENA CARMO2, ADAM LYNCH3 AND ELISABETE SILVA3 
 
1
 Faculdade de Medicina, Universidade do Porto. 4200-319 Porto, Portugal. 2 REQUIMTE (Rede de Química e Tecnologia), Laboratório de 
Toxicologia, Departamento de Ciências Biológicas, Faculdade de Farmácia, Universidade do Porto, 4050-313 Porto, Portugal. 3Institute for 
the Environment, Brunel University. Uxbridge, Middlesex UB8 3PH, United Kingdom,  
 
* Correspondence should be addressed to: Diana Dias da Silva. REQUIMTE (Rede de Química e Tecnologia), Laboratório de Toxicologia, 
Departamento de Ciências Biológicas, Faculdade de Farmácia, Universidade do Porto, Rua de Jorge Viterbo Ferreira n.º 228, 4050-313 
Porto, Portugal; e-mail: diana.dds@gmail.com. 
 
Abstract 
The liver is a vulnerable target for amphetamine toxicity, but the hepatotoxicity mechanisms involved remain 
poorly understood. The purpose of the current research was to characterize the mode of death elicited by four 
amphetamines and to evaluate whether their combination triggered the same mechanisms in immortalised 
human HepG2 cells. 
The obtained data revealed a time- and temperature-dependent mortality of HepG2 cells exposed to 3,4-
methylenedioxymethamphetamine (MDMA, ecstasy; 1.3 mM), methamphetamine (3 mM), 4-
methylthioamphetamine (0.5 mM) and d-amphetamine (1.7 mM), alone or combined (1.6 mM mixture). At 
physiological temperature (37 oC) 24 h-exposures caused HepG2 death preferentially by apoptosis, while a 
rise to 40.5 oC favoured necrosis. ATP levels remained unaltered when the drugs where tested at 
normothermia, but incubation at 40.5 oC provoked marked ATP depletion for all treatments. Further 
investigations on the apoptotic mechanisms triggered by the drugs (alone or combined) showed a decline in 
BCL-2 and BCL-XL mRNA levels, with concurrent upregulation of BAX, BIM, PUMA and BID genes. 
Elevation of Bax, cleaved Bid, Puma, Bak and Bim protein levels was also seen. To the best of our 
knowledge, Puma, Bim and Bak have never been linked with the toxicity induced by amphetamines. Time-
dependent caspase-3/-7 activation, but not mitochondrial membrane potential (∆ψm) disruption also mediated 
amphetamine-induced apoptosis. The cell dismantling was confirmed by PARP proteolysis. 
Overall, for all evaluated parameters, no relevant differences were detected between individual 
amphetamines and the mixture (all tested at equieffective cytotoxic concentrations), suggesting that the mode 
of action of the amphetamines in combination does not deviate from the mode of action of the drugs 
individually, when eliciting HepG2 cell death. 
 
Keywords 
3,4-Methylenedioxymethamphetamine (ecstasy, MDMA); Amphetamine-related toxicity; Hepatocytes; 
Combination effects; Apoptosis; Necrosis. 
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Introduction 
It has been widely recognised that 3,4-
methylenedioxymethamphetamine (MDMA, 
Ecstasy,) is hepatotoxic to humans, in spite of this 
toxicity being random and associated with variable 
clinical outcomes, ranging from asymptomatic 
elevation of hepatic enzymes (ALT, AST, alkaline 
phosphatase) to lethal liver failure (Andreu et al. 
1998; Dykhuizen et al. 1995; Ellis et al. 1996; 
Henry et al. 1992; Khakoo et al. 1995). The 
underlying mechanisms are not yet fully 
understood, but a plethora of factors have been 
proposed to justify these effects, including 
hyperthermia, drug-drug interactions from polydrug 
abuse, altered efflux of neurotransmitters, oxidation 
of biogenic amines, mitochondrial function 
impairment, direct effect of reactive metabolites, 
immune responses and activation of apoptotic 
pathways (Antolino-Lobo et al. 2011; Carvalho et 
al. 2012; Carvalho et al. 2010). 
Results from previous studies from our group 
have supported the fact that hepatotoxicity can be 
exacerbated by the combination of MDMA with 
other amphetamines, which are either intentionally 
ingested or present in ecstasy pills as contaminants, 
even for combinations at concentrations that 
individually produce no detectable effects (Dias da 
Silva et al. 2013). In addition, we have shown that 
temperatures higher than those physiologically 
normal, such as those reached in vivo after 
amphetamine intake, further enhance the 
hepatotoxicity of amphetamines, as well as of their 
mixtures (Dias da Silva et al. 2012). 
The hepatotoxicity of amphetamines has been 
associated with an increase in apoptosis and the 
mechanisms involved in this effect include a 
decrease in the levels of anti-apoptotic genes and 
related proteins, such as Bcl-2 and Bcl-XL (De 
Miglio et al. 2000; Jayanthi et al. 2001; Montiel-
Duarte et al. 2002; Upreti et al. 2011), an 
overexpression of pro-apoptotic factors, like Bax 
and Bad (De Miglio et al. 2000; Genc et al. 2003; 
Jayanthi et al. 2001), Bid (Cerretani et al. 2011; 
Jayanthi et al. 2001) and p53 (De Miglio et al. 
2000), the  release of cytochrome c (cyt c) 
(Beauvais et al. 2011; Montiel-Duarte et al. 2002), 
SMAC/DIABLO (Cerretani et al. 2011) and 
apoptosis inducing factor (AIF) from the 
mitochondria, the activation of caspase-3 (Montiel-
Duarte et al. 2002), the proteolysis of poly(ADP-
ribose)polymerase (PARP) (Montiel-Duarte et al. 
2002), the condensation of nuclei chromatin 
(Montiel-Duarte et al. 2002) and the accumulation 
of oligonucleosomal fragments in cytoplasm 
(Montiel-Duarte et al. 2002). Upreti et al. (2011) 
also demonstrated that MDMA activates c-Jun N-
terminal protein kinase and p38 kinase. These 
protein kinases phosphorylate the anti-apoptotic 
Bcl-2 protein, so, indirectly, their activation may 
promote apoptosis in MDMA-exposed tissues. 
Conversely, numerous clinical hepatotoxic 
descriptions of amphetamines correlate with 
morphological evidence of acute necrosis, rather 
than apoptosis, particularly in cases of intoxicated 
patients, who died or required liver transplantations 
(Brauer et al. 1997; Garbino et al. 2001; Ibranyi and 
Schonleber 2003; Kamijo et al. 2002). 
It is clear from the aforementioned studies that 
the relative contribution of apoptosis and/or 
necrosis to amphetamine-induced liver injury 
remains controversial, as evidence for both types of 
cell death has been reported in hepatocytes. In 
addition to the uncertainties surrounding the precise 
mechanisms of cytotoxic action of individual 
amphetamines is the question of whether the mode 
of action of these drugs remains unaltered when 
they are combined. Does the simple combination of 
these drugs impact on the mode of cell death? 
Furthermore, taking into account the substantial 
increase in body temperature that often occurs with 
amphetamine abuse, would the mechanism of cell 
death, for both the individual and the mixed 
amphetamines, also be affected in a hyperthermic 
situation? 
In order to address these questions and provide 
new insights into the putative mechanisms 
underlying the cytotoxicity linked to amphetamine 
intoxications, the present study attempted to 
delineate the mechanisms of cell death under 
normothermic (37 oC) and hyperthermic (40.5 oC) 
conditions caused by MDMA, methamphetamine 
(METH), 4-methylthioamphetamine (4-MTA), d-
amphetamine (d-AMP), and their mixture in HepG2 
cells. For that, we evaluated the mode of HepG2 
cell death (apoptosis or necrosis) and the cellular 
energetic status. Additionally, the relative mRNA 
expressions of BCL-2, BCL-XL, BAX, BIM, BAD, 
PUMA and BID, as well as levels of PARP/cleaved 
PARP, Bak, Puma, Bim (EL, S and L isoforms), 
Bid/cleaved Bid and Bax proteins were assessed at 
37 oC (the temperature condition showing higher 
apoptosis rates). Ultimately, and since the tested 
drugs induced differential expression of anti- and 
proapoptotic BCL-2 family members, we tested 
mitochondrial permeability impairment. 
Overall, a better understanding of the cellular 
and molecular mechanisms involved in 
amphetamine toxicity should help to generate more 
adequate therapeutic approaches to lessen the long-
term consequences of amphetamine use. 
Materials and Methods 
Test Drugs 
All chemicals used were of analytical grade. d-
AMP (sulphate salt) was purchased from Tocris 
Bioscience (Bristol, UK) and (+)-METH 
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hydrochloride (98% purity) was purchased from 
Sigma-Aldrich, Co. (St. Louis, MO, USA). MDMA 
(HCl salt) was extracted and purified from high 
purity MDMA tablets provided by the Portuguese 
Criminal Police Department, at REQUIMTE/ 
Toxicology Laboratory, Biological Sciences 
Department of Faculty of Pharmacy, University of 
Porto. The obtained salts were purified and fully 
characterized by nuclear magnetic resonance 
(NMR) and mass spectrometry (MS) 
methodologies. 4-MTA hydrochloride (racemic 
mixture) was generously provided by Dr David 
Nichols (Purdue University, West Lafayette, IN). 
All chemicals were used as supplied. Stock 
solutions were prepared in ultra purified water and 
kept at –20 °C. Dilutions were freshly prepared 
before each experiment and were at least 20 times 
more concentrated than the highest concentration 
tested, so that media dilution was avoided. 
 
Table 1. Tested drug concentrations and composition of the tested mixture. Adapted from Dias da Silva et al. (2013). 
 
 
Compound MDMA METH 4-MTA d-AMP Mixture 
EC50 (mM)a 2.23 5.260 0.741 2.42 2.90 
Fraction in the mixture (%) 20.90 49.40 6.96 22.70 100 
EC25 (mM)b 1.3  3.0 0.5 1.7 1.6c 
aThe EC50 were used to design the mixture, and to determine the ratio between the individual components of the equipotent mixture. 
b
 Correspond to the concentrations tested in this study. 
c
 1.6 mM of mixture is constituted by 334 µM MDMA, 790 µM METH, 113 µM 4-MTA and 363 µM d-AMP. 
 
 
HepG2 cells culture 
HepG2 cells were kindly provided by Dr Maryam 
Modarai from UCL School of Pharmacy, London, 
UK. HepG2 cells were routinely maintained in 75 
cm2 canted-neck tissue culture flasks (Helena 
Biosciences; Gateshead, UK) in Minimum Essential 
Medium Alpha (MEM Alpha) with GlutMAX 
supplemented with 10% fetal bovine serum (FBS), 
1% antibiotic (5,000 U/ml penicillin, 5,000 µg/ml 
streptomycin), 0.5% fungizone (250 µg/ml 
amphotericin B) and 0.0015% human transferrin (4 
mg/ml) in a humidified incubator, at 37 °C, with 
5% CO2. Cells were sub-cultured at approximately 
70% confluence over a maximum of 10 passages 
and regularly tested negative for Mycoplasma. All 
the reagents used in routine cell culture including 
0.05% trypsin/1 mM EDTA and Hanks balanced 
salt solution (HBSS) without Ca and Mg were 
obtained from GIBCO, Invitrogen Corporations 
(Paisley, UK), unless stated otherwise. 
Mixture design 
The tested mixture was planned as described before 
(Dias da Silva et al. 2013). The composition of the 
mixture was based on parameters derived from 
previous experimental studies, using the 
tetrazolium-based (MTT) viability assay (Dias da 
Silva et al. 2013) and is shown in Table 1. The ratio 
between the four amphetamines was based on the 
concentrations eliciting 50% of the maximal 
mortality in the MTT assay (EC50), after 48h 
incubations at 37 ºC. This mixture design ensures 
that all mixture components are present at 
equipotent concentrations, thus preventing non-
proportional individual contributions. 
 
Drug treatments 
In a previous study, we evaluated the cytotoxic 
effects of the mixture shown in Table 1 using the 
MTT assay and demonstrated that all four 
amphetaminic mixture components acted in an 
additive way to induce the overall mixture effect. 
Also, as the toxicity of the mixture could be 
accurately predicted by the mathematical model of 
concentration addition, it was suggested that all 
tested drugs acted via a similar mechanism of 
action (Dias da Silva et al. 2013). In the work 
presented here, it was important to select test 
concentrations (of individual amphetamines and 
mixture) that produced an equal level of cell death, 
i.e. were equipotents. In doing so, we ensured an 
easy and direct comparison between individual 
drugs and their mixture in the outcomes evaluated. 
Based on the additivity interactions shown 
previously, it is expected that all chemicals will 
have the same mechanism of action and therefore 
the equipotency of all tested drugs, as well as the 
mixture should be maintained in all studied 
endpoints. A deviation from those will suggest a 
difference in mechanism of action, rather than a 
difference in potency. 
Consequently, the individual drugs and mixture 
were tested at concentrations that induced 25% of 
the maximum effect observed in the MTT reduction 
assay (EC25), i.e. 1.3 mM MDMA, 3 mM METH, 
0.5 mM 4-MTA, 1.7 mM d-AMP and 1.6 mM 
mixture (Dias da Silva et al. 2013) (Table 1). This 
effect level was selected as it corresponds to some 
degree of toxicity by moderately decreasing cell 
metabolic competence/viability, allowing the 
assessment of mechanisms of action and avoiding 
high levels of mortality. 
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Neutral red uptake for cell viability assessment 
The neutral red (NR) viability assay, originally used 
by De Renzis and Schechtman (1973), is based on 
the ability of viable cells to incorporate and 
subsequently retain the supravital dye neutral red 
(3-amino-m-dimethylamino-2-methylphenazine 
hydrochloride; Sigma-Aldrich). This weak cationic 
compound readily penetrates the cellular membrane 
and accumulates in the lysosomes (lower pH) by 
binding the matrix through its anionic sites. 
Modifications of cell surface or delicate lysosomal 
membrane determine lysosomal fragility that 
become permanent, with consequent decreased in 
the dye uptake (Borenfreund and Puerner 1985). 
8x104 cells were seeded per well on the 96-well 
plates and allowed to attach. After 24h, the culture 
medium was replaced by treatment solutions (six 
replicates), freshly prepared in cell culture medium. 
Each plate also included a negative control. After 
the incubation periods (6h, 12h, 24h and 48h), at 37 
oC (physiological temperature) or 40.5 oC 
(hyperthermic conditions), the culture medium was 
removed and the plate was rinsed with HBSS. 100 
µl medium containing neutral red (50 µg/ml) was 
added to each well. After 2 h of incubation at 37 oC, 
the medium was removed and the plate was rinsed 
twice with HBSS. Then, 200µl lysis solution, 
containing 1% glacial acetic acid, 50% ethanol and 
49% H2O, was added to each well, and shaken for 
15 minutes in the dark. The absorbance (Abs) of the 
coloured solution was measured with a multi-well 
plate reader (Labsystems Multiskan, Multisoft 
Primary EIA V.1.3-0, Basingstoke, UK) at 540 nm, 
and is directly correlated to the number of cells with 
an intact membrane and unimpaired lysosomal 
activity (Borenfreund and Puerner 1985). 
 
ImageStream multispectral imaging flow 
cytometry 
Flow cytometry is a technique with great sensitivity 
and accuracy that allows discrimination between 
cellular populations based on parameters such as 
cell size, complexity, and fluorescence (usually 
derived from antibodies labelling specific cellular 
structures). In order to distinguish between live, 
necrotic, and early and late apoptotic cells, the 
combination propidium iodide (PI)/ fluorescein 
labelled Annexin V (AnV-FITC) was used. 
Annexin V (AnV) is a Ca2+-dependent protein with 
high affinity for phosphatidylserine (PS), a 
phospholipid component that is usually held on the 
inner layer of cell membrane by the enzyme 
flippase. When cells undergo apoptosis, PS is no 
longer constrained to the cytosolic side of the 
membrane, becoming exposed to the outer leaflet, 
where proapoptotic agents (highly conjugated with 
Ca2+) readily and irreversibly bind to PS (Vermes et 
al. 1995). In contrast, PI enters the cell and stains 
the nucleus, after the membrane becomes 
permeable. Late apoptotic and necrotic cells 
(nonviable) promptly stain with PI (Vermes et al. 
2000; Vermes et al. 1995). In late apoptotic cells, 
this is a consequence of the increased permeability 
instigated by nuclear pores, permitting the entrance 
of large molecules to the nucleus, such cationic 
nucleotide-binding dyes (Faleiro and Lazebnik 
2000). In necrotic cells, mitochondrial disruption 
leads to the impairment of nuclear membrane 
integrity (Kroemer et al. 1998). After entering the 
cells, PI passes through the disrupted nuclear 
membrane and intercalates between the double-
stranded DNA, causing red fluorescence in the 
nucleus (Vermes et al. 2000; Vermes et al. 1995). 
Cells with intact plasma membranes (viable and 
early apoptotic cells) exclude PI.  
To characterize the type of cell death elicited 
by amphetamines, isolated or in mixture, on HepG2 
cells, and evaluate the influence of temperature and 
time of exposure, 1x106 cells were seeded onto 10 
cm2 petri dishes and left to attach for 24 h. Then, 
the cells were exposed to the test solutions and 
incubated at 37 oC or at 40.5 oC, for 24 h or 48h. At 
the end of the treatment periods, the cells were 
rinsed twice with HBSS and trypsinized for 5 min 
with 300 µl 0.05% Trypsin-EDTA, at 37 °C. The 
cell culture media was kept and processed since 
adherent cells undergoing apoptosis may detach 
from the culture surface. Cells were washed in cold 
HBSS at 500 x g for 5 min (pre-cooled centrifuge, 
at 4 oC) and the supernatant was discarded. The cell 
pellet was resuspended in approximately 100 µl of 
1x annexin-binding buffer (BD Pharmigena. 
Oxford, UK). Cell counting was carried out using a 
Neubauer chamber and the density of the cell 
suspension determined. Final cell density was then 
adjusted to ~1x107 cells per ml. The samples were 
stained with 5 µl of AnV-FITC and 5 µl PI (BD 
Pharmigena. Oxford, UK). After gently vortexing, 
cells were incubated for 15 min, at room 
temperature (RT, 25°C), in the dark. All the cell 
preparation procedures were carried out with care to 
maintain cellular integrity. The samples were 
placed on ice and the analysis was performed 
within 1 h on the ImageStream multispectral 
imaging flow cytometer (Amnis Corporation, 
Seattle, WA). The system provides both 
photometric and morphometric classifications, as it 
enables visualization of individual cells passing 
through the flow chamber, offering additional 
information regarding morphology and spatial 
distribution of each cell. At least 5-10 x 104 images 
were collected for each sample and images were 
divided into four sub-groups: live cells (unstained), 
cells at early apoptotic state (stained with AnV-
FITC), cells at late apoptotic state (stained by both 
AnV-FITC and PI) and necrotic cells (stained with 
PI). Debris, including cell dublets and clumps, was 
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eliminated from the data as the machine gates 
around only single cells for analysis. A non-treated 
sample was divided into 3 tubes corresponding to 
negative control (AnV−/PI−), AnV-positive control 
(AnV+/PI−) and PI-positive control (AnV−/PI+) 
groups, which were used for compensation. 
Acquired results were processed using the 
ImageStream Data Analysis and Exploration 
Software (IDEAS 5.0). 
ATP content 
Cellular ATP levels can be rapidly detected through 
a bioluminescent luciferase-based assay, since 
luciferase catalyses the formation of light from the 
reaction of ATP and luciferin. Briefly, 1x106 cells 
were seeded onto 10 cm2 petri dishes to obtain 
confluent monolayers 24 h later. On the day of the 
experiment, the media was gently aspirated and the 
cells were incubated for 24 h with MDMA, METH, 
4-MTA, d-AMP and mixture dilutions prepared in 
fresh medium, at 37 ºC or at 40.5 ºC. Then, the cells 
were rinsed twice with HBSS and scrapped/ 
precipitated with 5% perchloric acid (HClO4, w/v). 
After centrifugation for 5 min at 16,000 x g (4 °C), 
the supernatants were kept frozen at –80 °C until 
further quantification. The pellet was used for 
protein quantification. The thawed acidic 
supernatant was neutralized with an optimised 
equal volume of 0.76 M potassium bicarbonate 
(KHCO3) and centrifuged for 5 min at 16,000 x g (4 
°C). The ATP contents were measured in triplicate 
in 96-well white plates (Greiner CELLSTAR® from 
Sigma), using an ATP determination kit (Invitrogen 
Corporations) following the manufacturer 
instructions. ATP levels are linearly related to the 
emitted light intensity that was determined by using 
a luminescence microplate reader (FLUOstar 
Optima, BMG Labtech GmbH) and compared to a 
standard curve performed with each experiment. 
The results were normalized to the total protein 
amount, and the final results were expressed as 
nmol ATP.mg-1 protein. 
Protein determination 
Protein was quantified through the Bradford assay 
(Bradford 1976). The absorbance measurements 
were taken at 595 nm using a multi-well plate 
reader (Labsystems Multiskan, Basingstoke, UK) 
and were compared with a bovine serum albumin 
(BSA, Sigma) standard curve to assess protein 
amount. 
Cell treatment for RNA isolation 
HepG2 cells were seeded at a density of 1x106 cells 
per 10 cm2 petri dish and grown for 24 h. The cell  
culture media was then replaced by selected 
dilutions of MDMA, METH, 4-MTA, d-AMP and 
mixture. Non-treated cells were used as controls. 
Following the dosing period (1 h, 4 h, 8 h, 16 h, 24 
h and 48 h at 37 ºC), the cells were harvested by the 
addition of 300 µl 0.05% trypsin-EDTA and 
incubated at 37 °C for 5 min. The cell suspension 
was centrifuged at 500 x g for 5 min and the 
supernatant was removed. The pellet was 
immediately frozen in liquid nitrogen and stored at 
−80 °C until further use for RNA isolation. 
Isolation and quantification of total RNA 
Total RNA was isolated from cell suspensions 
using the Nucleospin RNA II kit (Macherey-Nagel, 
Abgene, Epson, UK) following the manufacturer 
instructions and the obtained RNA pellets were 
solubilised in RNAse/DNAse free water to prevent 
traces of genomic contamination. The concentration 
and purity of the final preparations were determined 
after measuring the absorbances at 230 nm, 260 nm 
and 280 nm, by calculating the 260/230 and 
260/280 absorbance ratios, respectively (NanoDrop 
1000-v3.7 spectrophotometer, Thermo Fisher 
Scientific). 
Reverse transcription 
Approximately 2.5 µg of total RNA was reverse 
transcribed into cDNA using the following 
protocol: 7 µl 5x RT buffer (Promega, 
Southampton, UK), 4 µl 10 mM dNTP mix (Agilent 
Technologies), 1 µl RNAse inhibitor (Promega), 1 
µl hexamer random primers (Invitrogen), 2.5 µg 
RNA and 15 µl of RNAse/DNAse free water 
(Sigma-Aldrich) were mixed and heated at 62 °C 
for 10 min. The samples were then cooled on ice for 
2 minutes before adding 2 µl M-MLV Reverse 
Transcriptase (Promega). The reaction was then 
allowed to proceed for another 90 min at 42 °C. 
The reverse transcribed products were stored at −80 
°C until further use. 
Primer design and quantitative real-time PCR 
(qPCR) 
Primers for qPCR were designed using Beacon 
designer 5.1 software (Premier Biosoft 
International, Palo Alto USA), and purchased as 
high quality, purified OliGold Primers from 
Eurogentec Ltd (Hampshire, UK). The sequences of 
the primers used are presented in Table 2. 
cDNA was used in qPCR reactions performed 
on the iCycler iQ qPCR detection system with the 
iCycler v3.1. Software (Bio-Rad Laboratories, 
Hertfordshire, UK). 
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Table 2. Oligonucleotide primer sequences for real-time PCR. 
 
 
Gene Genebank accession 
number Primer Sequence Conc. (nM) Prod. length (bp) 
β-ACTIN X00351 Forward 5′-TCAGCAAGCAGGAGTATG-3′ 300 97 
 
 Reverse 5′-GTCAAGAAAGGGTGTAACG-3′   
GAPD NM_002046 Forward 5′-TCTCTGCTCCTCCTGTTC-3′ 900 120 
 
 Reverse 5′-GCCCAATACGACCAAATCC-3′   
HPRT1 M31642 Forward 5’-CCTTGGTCAGGCAGTATAATCC-3′ 100 135 
 
 Reverse 5′-GGGCATATCCTACAACAAACTTG-3′   
BCL-2 EU287875 Forward 5′-CCTGGTGGACAACATC-3’ 100 160 
 
 Reverse 5′- GAGCAGAGTCTTCAGAG-3’   
BCL-xL BT007208 Forward 5′- TGAACAGGTAGTGAATGAAC-3’ 100 105 
 
 Reverse 5′-TCCTTGTCTACGCTTTCC-3’   
BAX BC014175 Forward 5′- CCTCCTCTCCTACTTTGG-3’ 150 103 
 
 Reverse 5′-GCCTCAGCCCATCTTC-3’   
BIM O43521 Forward 5′- GCCACTACCACCACTTG-3’ 150 84 
 
 Reverse 5′-GCAGCGAACCGAATACC-3’   
BAD BT006678 Forward 5′-GATGAGTGACGAGTTTGTG-3’ 150 133 
 
 Reverse 5′-GCCCAAGTTCCGATCC-3’   
PUMA AF354654 Forward 5′-AGGCGATTGCGATTGG-3’ 150 107 
 
 Reverse 5′-CCCTGCTCTGGTTTG-3’   
BID AY005151 Forward 5′-GTGAACCAGGAGTGAGTC-3’ 200 112 
 
 Reverse 5′-AAGCCAAACACCAGTAGC-3’   
 
 
For a total volume of 20 µl per reaction, 0.8 µl 
cDNA and 10 µl 1x iQ SYBR Green Supermix 
(Bio-Rad) were mixed with 9.2 µl of an adequate 
dilution of forward and reverse primers mixture (1 
µM stock) in a 96-well low profile PCR plate (Bio-
rad). Optimised primer concentrations are listed in 
Table 2. Melting curves were generated for every 
primer pair following every qPCR reaction, to 
ensure that a single amplification product was 
obtained. Amplification was optimised for each 
gene with regard to temperature, and primer and 
template concentration (data not shown). PCR 
conditions were considered optimized when PCR 
efficiency ranged between 98 and 100%. Relative 
quantification was performed using the comparative 
threshold cycle method. GAPDH, HPRT1 and β-
ACTIN were tested as internal controls (reference 
genes). As neither gene's expression changed with 
the treatments, HPRT1 was used to normalize gene 
expression throughout. 
Data analysis for qPCR 
Expression data were analysed in terms of relative 
quantification. HPRT1 was used as reference gene. 
Data were normalized and relatively compared to 
the control group according to the ∆∆Ct model with 
the following formulas (Livak and Schmittgen 
2001): 
∆Ct = Ct (target gene) – Ct (reference gene) 
 
∆∆Ct = ∆Ct(treatment group) – mean ∆Ct(control group) 
 
The expression ratio of the treatments 
compared to the controls is expected as 2−∆∆Ct. 
Results were displayed as fold increase over 
controls standardized such that values obtained in 
controls were set to 1. 
Immunoblotting 
HepG2 cells were seeded at a density of 1x106 cells 
per 10 cm2 petri dish and cultured for 24 h. Then, 
cells were incubated with the test drugs for 24 h 
(PARP/cleaved PARP detection) or 12 h (all other 
proteins), at 37 oC. After the incubation period, 
HepG2 cells were lysed by incubating for 20 min 
with a freshly prepared ice-cold Laemmli sample 
buffer, containing: 62 mM Tris-HCl (pH 6.8), 2% 
(w/v) sodium dodecyl sulphate (SDS), 10% 
glycerol, 5% β-mercaptoethanol, 1 mM 
phenylmethylsulfonyl fluoride (PMSF), 1:100 
Protease Inhibitor Cocktail (Sigma) (Laemmli 
1970). Cells were harvested from the petri dishes 
with a rubber scraper and transferred to pre-chilled 
tubes. Lysates were boiled at 95 oC for 10 minutes 
and pulsed spun. Equal amounts of whole-cell 
lysates (25-40 µg of total protein) were loaded onto 
9-12% polyacrylamide gels and submitted to 
sodium dodecylsulfate polyacrylamide gel 
electrophoresis (SDS-PAGE).At the end of each 
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run, proteins were electrophoretically transferred 
from the gels onto nitrocellulose membranes (GE 
Healthcare, Buckinghamshire, UK) at 40 V for 1 h, 
at RT, using a transfer buffer containing 25 mM 
Tris, 190 mM glycine, 0.1% (w/v) SDS and 20% 
(v/v) methanol. After blotting, non-specific binding 
was blocked by soaking the membranes in 20mM 
Tris-base, 0.1 M NaCl, 0.1% (v/v) Tween-20, pH 8 
(TBS-T buffer) containing 5% non-fat dry milk and 
incubated for 1 h. Afterwards, the membranes were 
washed three times for 5 min, with 15 ml TBS-T 
buffer. They were then incubated overnight at 4 °C 
with rabbit polyclonal anti-Puma antibody (Cell 
Signaling Technology, Inc.; 1:1000 in 5% w/v 
BSA/TBS-T); rabbit monoclonal anti-Bak antibody 
(Cell Signaling Technology, Inc.; 1:1000 in 5% w/v 
BSA/TBS-T); and rabbit monoclonal anti-Bax 
antibody (Cell Signaling Technology, Inc.; 1:1000 
in 5% w/v BSA/TBS-T). Rabbit polyclonal anti-Bid 
antibody (Cell Signaling Technology, Inc.; 1:1000 
in 5% w/v nonfat dry milk/TBS-T) was employed 
for detection of both full length (22 kDa) and 
cleaved large fragment (15 kDa) of human Bid; 
whereas levels of total Bim (EL, L and S isoforms) 
protein were analysed with rabbit monoclonal anti-
Bim antibody (1:1000 in 5% w/v BSA /TBS-T). 
Rabbit polyclonal anti-PARP antibody was used for 
detection of endogenous levels of full length PARP 
(116 kDa), as well as the large fragment (89 kDa) 
of PARP resulting from caspase cleavage (Cell 
Signaling Technology, Inc.; 1:1000 in 5% w/v 
nonfat dry milk/TBS-T). Thereafter, the membranes 
were washed 3 times for 5 min with TBS-T buffer. 
After washing, the membranes were incubated with 
secondary horseradish peroxidase (HRP)-
conjugated anti-rabbit IgG (Cell Signaling 
Technology, Inc.), diluted 1:3000 in 5% w/v non-
fat dry milk /TBS-T, for 1 h at RT. Finally, the 
membranes were washed again following the 
procedure described above. Detection of bound 
antibodies was carried out using the enhanced 
chemiluminescence (ECL) system, consisting of the 
incubation of the membranes for 1 min with the 
ECL buffer (Trisma-HCL 100 mM, pH 8.5) 
supplemented with 250 mM luminol (Avocado 
Research Chemicals, Lancashire, UK), 90 mM 
cumaric acid (Sigma) and hydrogen peroxide 
(H2O2, Sigma). The luminescent signal was 
captured by ChemiDoc XRS System (Bio-Rad). To 
ensure that the exact same amount of protein was 
evenly loaded into the SDS-acrylamide gels, the 
membranes were stripped of the antibody and re-
probed with anti-β-Actin antibody (Cell Signaling 
Technology, Inc.; 1:1000 in 5% w/v BSA/TBS-T). 
Stripping and re-probing of membranes 
Membranes were incubated at 50 °C with stripping 
buffer (0.5 M Tris-HCl (pH 6.8), 20% SDS, 0.8% 
β-mercaptoethanol) for 45 min with gentle 
agitation. The blots were then rinsed with TBS-T, 
re-blocked and re-probed with anti-β-Actin 
antibody as described above. 
Mitochondrial integrity by TMRE inclusion 
Assessment of mitochondrial integrity was 
evaluated by measuring the tetramethylrhodamine 
ethyl ester (TMRE) inclusion. TMRE is a cell 
permeable fluorescent dye that specifically stains 
viable mitochondria, being accumulated in 
proportion to mitochondrial membrane potential 
(∆ψm) (Scaduto and Grotyohann 1999). Briefly, 8 x 
104 HepG2 cells were seeded onto 96-well black 
plates (Greiner CELLSTAR® from Sigma). After 
24 h, the media was gently aspirated and the cells 
were exposed to MDMA, METH, 4-MTA, d-AMP, 
as well as mixture solutions prepared in fresh 
medium at 37 ºC or at 40.5 ºC. At the end of the 24 
h treatment period, cells were rinsed twice with 
HBSS and incubated at 37 °C with 100 µl of 2 µM 
TMRE (Sigma), for 30 min. As TMRE is a non 
water-soluble powder, a 2 mM stock solution was 
initially prepared in DMSO (Merck) and stored in 
the dark. The final 2 µM concentration was 
prepared in fresh culture media, shortly before 
usage (the final concentration of DMSO did not 
exceed 0.5%). Afterwards, the media was gently 
aspirated and replaced by 0.2% BSA in HBSS. 
Fluorescence was measured at 37 °C on a 
fluorescence microplate reader (FLUOstar Optima, 
BMG Labtech GmbH) set to 544 nm excitation and 
590 nm emission wavelengths. The data obtained 
for the individual drug and mixture treatments were 
normalized on a plate-by-plate basis to the values of 
the respective controls and calculated as the 
percentage of control conditions at 37 ºC or 40.5 
ºC. This normalization is required to minimize the 
variability among the individual plate readings and 
has been extensively described elsewhere 
(Rajapakse et al. 2004). 
Measurement of caspase-3/7 activity 
Caspase-3/7 activation assay was performed using a 
Caspase-Glo 3/7 assay kit according to the 
manufacturer’s instructions (Promega, 
Southampton, UK). Briefly, HepG2 cells were 
seeded onto Greiner Bio-One CELLSTAR® 96-
well white plates (Fisher, UK) at a density of 104 
cells/well. After 24 h, the cells were exposed to the 
4 tested amphetamines, individually or in mixture at 
37 ºC. Each plate also included a blank (medium 
alone), a negative control (untreated cells) and a 
positive control (15 µM Mitomycin C, MMC, 
derived from Streptomyces caespitosus, Sigma-
Aldrich). 
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Figure 1. Time-course of HepG2 cell death, as indicated by NR lysosomal inclusion, after exposure to MDMA (A), METH (B), 4-
MTA (C) and d-AMP (D), individually or in mixture (E), at 37 oC (white bars) or 40.5 oC (black bars). The compounds were tested at 
concentrations that induce 25% of the maximum effect observed in the MTT reduction assay (EC25), i.e. 1.3 mM MDMA, 3 mM METH, 
0.5 mM 4-MTA, 1.7 mM d-AMP and 1.6 mM mixture (Dias da Silva et al. 2013). Results presented as mean ± SEM are from five 
independent experiments, run in six replicates. Statistical comparisons were made by Kruskal–Wallis test followed by the Dunn’s post hoc 
test. *p<0.05, **p<0.01 ***p<0.001 show statistically significant differences versus controls at 37 ◦C. ×p<0.05, ××p<0.01 and 
×××p<0.001, indicate significant differences versus controls at 40.5 ◦C. #p<0.05, ##p<0.01 and ###p<0.001 show statistically significant 
differences versus 37 oC. +p<0.05 indicates differences between individual treatments and the mixture at same incubation time and 
temperature. 
 
All the treatments were run at least in triplicate. 
Following the dosing period (1 h, 4 h, 8 h, 16 h, 24 
h, 36 h and 48 h), Caspase-Glo 3/7 reagent was 
added to each well. The plate was then incubated in 
the dark at RT, for 1 h and the luminescence was 
measured with a multiwell plate-reading 
luminometer (FLUOstar Optima, BMG Labtech 
GmbH). Luminescence is proportional to the 
amount of caspase activity present. 
Sulforhodamine B Assay 
As the different treatments and time points may 
influence the cellular density per well in the 
Caspase 3/7 assay, the Sulforhodamine B (SRB, 
Sigma-Aldrich) assay was run in parallel for each 
treatment and used for normalization of the cell 
number. Briefly, after the testing periods, the assay 
was finished by placing a clear 96-well plate on ice, 
for 1 min. After gently removing the experimental 
media, the cells were fixed with 200 µl of 10% 
trichloroacetic acid, for 20 min and rinsed 5 times 
with tap water. After air-drying, 50 µl 4% SRB was 
added to each well and incubated for 10 min. The 
cells were then washed with 1% acetic acid until the 
solution ran clear, to remove unbound dye. After 
air-drying in the dark, the bound dye was 
solubilised with 100 µl of 10 mM Tris solution (pH 
10.5). Absorbances were measured at 510 nm, 
directly in the plate, using a multi-well plate reader 
(Labsystems Multiskan, Basingstoke, UK). The 
data obtained was correlated with the cell number 
of each well by means of a calibration curve 
previously plotted. 
Statistical analysis 
All assays were performed in at least four 
independent experiments (with exception of the 
cytometry assay performed in two) and SD values 
were always < 10%. Data achieved were expressed 
as mean ± SEM (standard error of the mean). All 
statistical calculations were performed using the 
GraphPad Prism version 5.0a for Mac OS X 
(GraphPad Software, San Diego California, USA). 
Normality of the data distribution was assessed by 
three tests (Kolmogorov–Smirnov normality test, 
D’Agostino and Pearson omnibus normality test 
and Shapiro–Wilk normality test). The control 
values (raw data) obtained for hyperthermic and 
normothermic incubations in the determination of 
the mitochondrial integrity were compared by the 
Student's unpaired t-test in order to investigate 
potential effects associated with the increase of 
temperature alone. All the other statistical 
comparisons were estimated by the nonparametric 
method of Kruskal–Wallis [one-way analysis of 
variance (ANOVA) on ranks] followed by the 
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Dunn’s multiple comparison test. p values lower 
than 0.05 were considered statistically significant. 
Results 
Viability assessment by NR lysosomal uptake 
In order to corroborate the previously published 
cytotoxicity of MDMA, METH, 4-MTA, d-Amp 
and mixture in HepG2 cells (Dias da Silva et al. 
2013) and confirm that the concentrations selected 
were in fact equieffective and corresponded to 25% 
toxicity effects, we evaluated the viability of 
HepG2 cells in response to the amphetamines and 
their mixture in the NR lysosomal uptake assay. 
The data presented in Fig. 1 (white bars) indicate a 
time-dependent increase in cytotoxicity, when the 
HepG2 cells were exposed at 37 oC to the 4 tested 
amphetamines, alone or combined. At 37 ºC, the 
observed cytotoxicity in the NR assay only reached 
significance (p<0.001) when the cells were 
incubated for 48 h, with the exception of MDMA 
and 4-MTA. Conversely, when the incubation 
temperature was raised to 40.5 oC, all the drugs 
(alone or combined) induced effects significantly 
different to controls (p<0.001), for all exposure 
periods. 
Overall, we observed that, at 48 h, under 
normothermia (the temperature used to determine 
the equieffective cytotoxic concentrations in the 
MTT assay) the cytotoxicty determined by the NR 
assay showed effect levels that were similar to 
those obtained in the MTT, confirming that, at the 
selected concentrations, the cytotoxic effect of the 
individual amphetamines and mixture is similar. 
Accordingly, no substantial disparities were 
observed when comparing responses elicited by 
individual amphetamines with those obtained from 
the mixture. The noted exceptions were for MDMA 
(at 40.5 ºC after 48 h, p<0.05) and METH (at 37 ºC 
after 24 h, p<0.05). 
Differential contributions of necrosis and 
apoptosis to HepG2 cell death elicited by 
amphetamines 
To investigate which mechanisms mediate the 
cytotoxic effects of the four amphetamines and their 
combination we analysed, by flow cytometry, the 
preponderance of apoptosis and necrosis to the 
observed hepatocyte death. HepG2 cells had been 
exposed to individual and combined drugs at 
different time points (24 h and 48 h) and different 
temperatures (37 oC and 40.5 oC). After incubation, 
the cells were stained with AnV-FITC and PI and 
evaluated using the ImageStream multispectral flow 
cytometer (Amnis Corporation, Seattle, WA). On 
the ImageStream, each cell was concomitantly 
imaged in dark field (488 nm laser side-scatter), 
green fluorescence (500–550 nm, annexin V 
channel), orange fluorescence (550–600 nm, PI 
channel), and bright field (660–720 nm). Based on 
the total intensities of AnV-FITC and PI staining as 
well as morphological features, the cells were 
grouped into live (AnV−/PI−), early apoptotic 
(AnV+/PI−), late apoptotic (AnV+/PI+) and 
necrotic (AnV−/PI+) populations (Fig. 2A).  
Of note, is the fact that positive ANV/PI double 
staining is not always specific to cells in late stages 
of apoptosis and may also be present in cells 
undergoing necrosis, so they cannot be 
distinguished based solely on fluorescence 
descriptions. A unique aspect of the ImageStream 
flow cytometry system is that it allows visual 
examination of the images taken, allowing the 
differentiation between advanced apoptotic and 
necrotic populations, based on their specific 
morphology. Cells in late apoptosis exhibit 
shrunken, irregular shape and condensed 
(pyknosis), fragmented nuclei (karyorrhexis). 
Necrotic cells are larger, with large, 
unfragmented nuclei that uniformly stain with PI. 
Additionally, apoptotic cells exhibit lower bright 
field intensity and greater granularity compared to 
necrotic cells (Fig. 2A). 
Another exclusive quality of data obtained with 
the ImageStream system is that each data point on 
the scatter graph can be directly related to the image 
of the contributing cell (Fig. 2B).  After 
categorizing live, early apoptotic, late apoptotic and 
necrotic populations using fluorescence intensities, 
the identities of cell populations were confirmed 
using this ‘virtual cell sorting’ function (George et 
al. 2004) of the IDEAS data analysis software that 
analyses the data from the ImageStream, by 
inspecting the bright field, fluorescence, and dark 
field (laser side-scatter) imagery obtained from 
each cell. These population gates were adjusted 
based on the morphology of cells, permitting better 
resolution of necrotic from late apoptotic cells. 
Figure 3 depicts the relative amounts (% of cell 
population) of live, early apoptotic, late apoptotic 
and necrotic HepG2 cells at the time of the staining. 
The vast majority of untreated cells (negative 
controls) cultivated at 37 oC were viable after 24 h 
exposures (75.5 ± 0.6%). Usually, the mortality in 
the controls is not as high (up to 15%). The 
reasoning for the relatively elevated amount of cells 
undergoing cell death processes might be related 
with the basal levels within the cell line population, 
the after-staining waiting time before measurement, 
or the damage to the plasma membrane caused 
during the preparation procedures, which could 
have occurred, despite all the care taken during 
technique execution. 
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Figure 2. Imaging flow cytometry-based cellular classification according to fluorescent staining and morphological examination 
of HepG2 cells using ImageStream multispectral flow cytometer (Amnis Corporation, Seattle, WA). A. Morphological examination 
of HepG2 cells classified into live (AnV−/PI−), early apoptotic (AnV+/PI−), late apoptotic (AnV+/PI+) and necrotic (AnV−/PI+) cells 
based on staining profile. B. Representative analysis of gated cells to show procedure for classification. PI = Propidium iodide; AnV = 
Annexin V; Composite image = an overlay of AnV, PI, and bright field. 
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Figure 3. Effect of both temperature (37 oC or 40.5 oC) and incubation time (24h or 48h) on AnV/PI staining of HepG2 cells after 
exposure to MDMA, METH, 4-MTA and d-AMP, individually or in mixture. The treatments were tested at concentrations that induced 
25% of the maximum cytotoxic effect observed in the MTT reduction assay (EC25), i.e. 1.3 mM MDMA, 3 mM METH, 0.5 mM 4-MTA, 1.7 
mM d-AMP and 1.6 mM mixture (Dias da Silva et al. 2013). HepG2 population was separated into live (AnV−/PI−), early apoptotic 
(AnV+/PI−), late apoptotic (AnV+/PI+), and necrotic cells (AnV−/PI+), according to cellular staining with AnV-FITC and PI and cell 
morphology. Results are mean ± SEM from two independent experiments, run in triplicate. Statistical comparisons were made by using 
Kruskal–Wallis test followed by the Dunn’s post hoc test. *p<0.05, **p<0.01, ***p<0.001 show statistically significant differences versus 
controls at the same incubation time and temperature. ×p<0.05, ××p<0.01 represent statistical comparisons between individual drugs and the 
mixture at the same incubation time and temperature. #p<0.05, ###p<0.01 and ###p<0.001 show statistical comparison versus the 37 oC 
incubation temperature. ++p<0.01 and +++p<0.001, represent statistically significant differences versus the 24h incubation time. 
 
 
The viable fraction in controls slightly 
decreased with the increase of the temperature to 
40.5 oC (68.4 ± 2.8% at 24 h) and time of 
incubation to 48 h (70.75 ± 5.15% at 37 oC), 
reaching the highest drop when cells were 
incubated at 40.5 oC for 48 h (57.15 ± 0.35%). The 
number of living cells suffered a substantial decline 
when HepG2 cells were treated with all the 
amphetamines, alone or combined (p<0.05 versus 
control). Analysis of cell populations revealed that 
the distribution of the cells between the population 
sets (live, early apoptotic, late apoptotic, and 
necrotic cells) varies with temperature and 
incubation time. An overall evaluation indicated 
that, at 37 oC, with the increase of incubation time 
from 24 h to 48 h, there is a decrease in cell 
viability that is mostly counterbalanced by an 
increase in cells in early and/or late stages of 
apoptosis; while at 40.5 oC the decrease in cell 
viability predominantly gives place to a slight rise 
in the late apoptosis population. A more obvious 
tendency exists regarding the temperature 
increment from 37 oC to 40.5 oC as, along with the 
decrease of cell viability, there is a noteworthy 
expansion in the number of cells undergoing 
necrosis, what is clearly observed for all treatments 
(p<0.05), for both 24 h and 48 h incubations. 
In general, no significant differences were detected 
when HepG2 cells were exposed to amphetamines 
individually or in mixture. Notwithstanding, some 
exceptions occurred at 37 oC, with early apoptosis 
more evident in the mixture relative to the MDMA 
and METH individual incubations after 24h, and 
late apoptosis less evident in the mixture relative to 
the individual MDMA, METH, and 4-MTA 
individual treatments at 48h incubations. This 
indicates that, although these drugs lead to the same 
cytotoxic outcome, the underlying mechanisms may 
slightly differ. 
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Figure 4. Effect of MDMA, METH, 4-MTA, d-AMP 
and the mixture on ATP intracellular storages in 
HepG2 cells, at 37 ◦C (white bars) or 40.5 ◦C (black 
bars), after 24 h exposure. HepG2 cells were exposed to 
amphetamines, for 24h, at the following equieffective 
concentrations (EC25 MTT Assay, after 48h at 37 ºC): 1.3 mM 
MDMA, 3 mM METH, 0.5 mM 4-MTA, 1.7 mM d-AMP 
and 1.6 mM mixture (Dias da Silva et al. 2013). Results 
from at least four independent experiments are presented 
as mean ± SEM. Statistical comparisons were made by 
using Kruskal–Wallis test followed by the Dunn’s post 
hoc test. *p<0.05, **p<0.01, ***p<0.001 represent 
statistical differences versus controls within the same 
incubation temperature (37 oC or 40.5 oC). #p<0.05, 
###p<0.01 and ###p<0.001 show statistical comparison 
between different incubation temperatures. 
 
 
 
Intracellular energetic levels 
Research evidence indicates that the cell death fate, 
either by apoptosis or necrosis, is a condition 
determined by intracellular ATP levels, as 
apoptosis is an extremely controlled phenomena 
involving a number of energy-dependent processes, 
such as enzymatic hydrolysis (e.g. caspase 
activation), chromatin condensation, contraction 
and membrane blebbing (Eguchi et al. 1997; 
Zamaraeva et al. 2005). 
Results displayed in Fig. 4 suggest there were 
no significant differences in cellular ATP between 
controls and drug treatments, when HepG2 cells 
were exposed at normothermia (37 oC). 
Nonetheless, the increase in the temperature of 
incubation to 40.5 oC prompted significant 
alterations in energy storages for all amphetaminic 
exposures (p<0.05). No statistically significant 
differences were observed between mixture and the 
drugs alone under the same temperature conditions. 
Expression profiles of BCL-2 family genes 
Our results revealed that apoptosis plays a highly 
significant role in the mechanism of cell death 
provoked by the amphetamines in HepG2 cells, 
particularly at a physiological temperature (37 oC). 
With the aim of exploring the specific pathways 
responsible for initiating apoptosis in the presence 
of the test substances, early intracellular events 
linked to apoptotic phenomena, such as the 
regulation of pro and antiapoptotic factors, were 
studied under the same experimental settings. 
BCL-2 is a family of interrelated proteins that 
regulate mitochondrial or intrinsic pathway of 
apoptosis via its proapoptotic and prosurvival 
(antiapoptotic) members. BCL-2 factors are also 
involved in the enhancement of the extrinsic death 
receptor pathway. So far, approximately 20 BCL-2 
family members have been identified and are 
classically divided into three subfamilies: Bcl-2 
pro-survival subfamily (including Bcl-2 and Bcl-
xL), Bax-like pro-apoptotic subfamily (comprises 
Bax and Bak), and BH3-only pro-apoptotic 
subfamily. These proteins are crucial controllers of 
the permeabilization of the outer membrane of the 
mitochondria, which promotes the release of cyt c 
and other apoptotic factors to the cytosol, activating 
the downstream effector caspase-3/-7 cascade. 
As this is considered an irreversible point in the 
programmed cell death, these proteins play a 
pivotal role in deciding whether a cell lives or dies.  
Pro- and antiapoptotic BCL-2 members may be 
regulated by mechanisms other than post-
translation alterations. So, to avoid harmful actions 
in viable cells, constitutively active proapoptotic 
regulators are transcriptionally silent, but in 
response to selected death stimuli transcription is 
initiated. To ascertain to what extent proapoptotic 
and antiapoptotic BCL-2 family regulators may 
account for triggering apoptosis in HepG2 cells, 
after exposure to amphetamines, the expression of 
some apoptosis-regulating genes was investigated 
by qPCR. BCL-2 family genes were found to be 
differentially expressed in HepG2 cells after 
incubation with equieffective cytotoxic 
concentrations of individual and combined 
amphetamines at 37 oC, particularly after 8 h 
exposures (Fig. 5). In fact, this was the earliest 
incubation period, which exhibited statistically 
significant differences, despite several time points 
(1 h, 4 h, 8 h, 16 h, 24 h and 48 h) having been 
tested (data not shown). As shown in Fig. 5, a 
remarkable down-regulation of the antiapoptotic 
BCL-2 and BCL-XL genes was observed for all the 
treatments (p<0.001). 
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Figure 5. Gene expression of proapoptotic and antiapoptotic regulators involved in HepG2 cell death, elicited by individual and 
combined amphetamines. qPCR analysis of BCL-2, BCL-XL, BAX, BIM, BAD, PUMA and BID mRNA levels was performed after 
incubation of HepG2 cells at 37 oC, for 8 h with 1.3 mM MDMA, 3 mM METH, 0.5 mM 4-MTA, 1.7 mM D-AMP and 1.6 mM of mixture 
(concentrations inducing 25% of the maximum effect observed in the MTT reduction assay, EC25) (Dias da Silva et al. 2013). Expression of 
each gene was normalized to HPRT1 (reference gene) and compared to the control group, according to the 2−∆∆Ct model. Control values were 
set to 1 (dashed red line), so values higher than 1 are indicative of up-regulation and values lower than 1 reveal down-regulation. Results are 
at least from four independent experiments and are given as mean ± SEM. Statistical comparisons were made using Kruskal–Wallis test 
followed by the Dunn’s post hoc test. *p<0.05, **p<0.01, ***p<0.001 show statistically significant differences versus controls. ×p<0.05 
indicates significant differences between treatments with individual drugs and the mixture. 
 
Accordingly, a significant increase in the 
expression rates of the genes coding for 
proapoptotic factors, BAX, BIM, PUMA and BID 
was also found, with slight variations among the 
different drugs (Fig. 5). No alteration in the 
expression pattern of BAD was detected, with the 
exception of HepG2 cells exposed to MDMA 
(p<0.05). Individual and mixture results revealed 
great concordance, as no significant differences 
were observed; with exception of BAX in MDMA-
treated cells (p<0.05). 
Protein expression analysis 
In order to confirm at the protein level the increased 
expressions observed at the gene level, the amount 
of proapoptotic BCL-2 family markers were 
investigated, after 12 h treatments by 
immunoblotting. Results showed an increase in the 
levels of proapoptotic Puma, Bim, Bid and Bax 
proteins in HepG2 cells, when these were treated 
with the test amphetamines. Similarly, an increase 
in Bak levels in relation to those present in 
untreated controls, was also observed for all 
treatments (Fig. 6). Nuclear PARP, a protein 
involved in DNA repair, is one of the main 
cleavage targets of caspase-3 and caspase-7 in vivo 
(Fig. 5). PARP inactivation has been proposed to 
prevent depletion of ATP, which is thought to be 
required for the latest events of apoptosis. Our data 
suggest that, at 24 h, there are signs of PARP 
cleavage, as given by the reduction in the intensity 
of the PARP (116 kDa) band and the presence of an 
89 kDa fragment (corresponding to the cleaved 
protein), particularly evident in MDMA and d-
AMP cases (Fig. 6). 
Mitochondrial integrity assessed by TMRE 
inclusion 
The mitochondria has been shown to play a major 
role in apoptosis by mediating and propagating 
death signals originated from the inside (intrinsic 
apoptotic pathway) or outside (extrinsic apoptotic 
pathway) of the cell.  
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Figure 6. Immunoblotting analysis of the effect of MDMA, METH, 4-MTA, d-AMP and their mixture on the expression of 
proapoptotic markers. Western blotting of poly (ADP-ribose) polymerase (PARP)/cleaved PARP, Bak, Puma, Bim (EL, S and L 
isoforms), Bid/cleaved Bid and Bax protein expressions performed after incubation of HepG2 cells at 37 oC, for 24 h (PARP/cleaved PARP) 
or 12 h (all other proteins), with 1.3 mM MDMA, 3 mM METH, 0.5 mM 4-MTA, 1.7 mM d-AMP and 1.6 mM mixture (concentrations 
inducing 25% of the maximum effect observed in the MTT reduction assay, EC25) (Dias da Silva et al. 2013). β-Actin was used as an 
internal loading control. 
 
Most apoptotic events involve the dissipation of the 
mitochondrial inner transmembrane potential 
(∆ψm), which is crucial for maintaining the 
physiological function of the mitochondrial 
respiratory chain. A significant loss in ∆ψm impairs 
oxidative phosphorylation, which depletes the cells 
of energy and promotes the release of apoptotic 
factors, with subsequent death. Therefore, the ∆ψm 
can provide important information about the 
mitochondrial function and the physiological status 
of the cell.  
Our data on the accumulation of TMRE inside 
HepG2 cells exposed to test amphetamines for 24 h 
revealed only slight, insignificant (p>0.05) declines 
in ∆ψm, when incubations were carried out at 37 oC 
(Fig. 7). However, considerable deviations from 
controls were obtained in hyperthermic conditions 
(p<0.01), as observed by the decline in TMRE 
mitochondrial inclusion, indicating significant 
mitochondrial impairment. 
No significant differences were identified (p>0.05) 
between control incubations at 37 ºC (40702 ± 
12264 fluorescence units) and at 40.5 ºC (44255 ± 
10562 fluorescence units), showing that the 
increase in temperature alone had no impact on 
∆ψm. Moreover, at 40.5 oC, mixture results 
presented relevant dissimilarities from those 
obtained with MDMA, METH and 4-MTA 
(p<0.05). At the other tested conditions, no 
significant differences were observed between 
individual and combined drugs. 
Measurement of caspase-3/-7 activity 
As noted before, programmed cell death can be 
triggered by the activation of cell surface death 
receptors (extrinsic apoptosis pathways) or in 
response to signals instigated from inside the cell 
(intrinsic apoptosis pathways). Nonetheless, the 
signals of such diverse sources seem to ultimately 
converge to activate common downstream 
mechanisms, specifically the apoptosis executioner 
caspase cascade. Among effector caspases that are 
proteolytically activated are the caspase-3 and -7, 
two cysteine-aspartic acid proteases that, following 
activation, cleave a specific set of protein 
substrates, including procaspases themselves and 
PARP, resulting in the spreading of apoptotic death 
stimulus and eventually in the execution of cell 
suicide. The purpose of the current determination 
was to define the contribution of caspase-3/7 
activity to the extent of observed cell death and 
identify the onset and peak of this molecular event 
for each treatment, in order to identify possible 
differences between the mechanisms underlying the 
cytotoxicity of individual and combined 
amphetamines. 
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Figure 7. Effect of MDMA, METH, 4-MTA, d-AMP and mixture on mitochondrial membrane potential in HepG2 cells, at 37 ◦C 
(white bars) or 40.5 ◦C (black bars). HepG2 cells were exposed to amphetamines, for 24 h, at the following equieffective concentrations 
(EC25 MTT Assay): 1.3 mM MDMA, 3 mM METH, 0.5 mM 4-MTA, 1.7 mM d-AMP and 1.6 mM mixture (Dias da Silva et al. 2013). Shown 
are the mean ± SEM from four independent experiments, with six replicates each, expressed as percentage of controls (fluorescence of non-
treated cells) for 37 oC or 40.5 oC incubations. The red dashed line indicates the control values, set to 100%. Statistical comparisons were 
made using the Kruskal–Wallis test followed by Dunn’s post hoc test. *p<0.05, **p<0.01, ***p<0.001 show statistically significant 
differences versus controls, at the same incubation temperature. ×p<0.05, ××p<0.01 indicate differences between the individual treatments 
and the mixture, at the same incubation temperature. #p<0.05, ###p<0.01 and ###p<0.001 show statistical differences versus 37 oC 
incubations. 
 
As observed in Fig. 8, MDMA and METH 
induced a short, but significant increase in enzyme 
activity from 8-16 h of incubation (maximal effects 
of 1.34 ± 0.14 fold increase and 1.36 ± 0.21 fold 
increase, respectively), which remained more or 
less constant after 16 h of exposure (p<0.001). 
Earlier and more pronounced effects were observed 
when HepG2 cells were exposed to 4-MTA and to 
d-AMP, as significant effects were seen as early as 
1h (4-MTA) and 4h (d-AMP) of incubation. A peak 
in the effects of these drugs was achieved at 16 h 
(5.08 ± 0.36 fold increase) and 24 h (3.91 ± 0.69 
fold increase), for 4-MTA and d-AMP, 
respectively.  
There were no statistically significant 
differences between the mixture and all other 
treatments, for any of the incubation periods. In 
fact, mixture effects were clearly seen at 8 h of 
treatment (p<0.05) and seem to lie between all 
individual responses, being more pronounced at 16 
h (2.16 ± 0.40 fold increase). 
Discussion 
Years of clinical and experimental evidence have 
demonstrated hepatotoxicity after amphetamine 
exposure in human abusers and laboratory animals 
(Andreu et al. 1998; Beitia et al. 1999; Brncic et al. 
2006; Khakoo et al. 1995; Montiel-Duarte et al. 
2002). Accordingly, our in vitro findings in the 
human hepatoma HepG2 cell line indicate that all 
tested amphetamines and their combination 
promote time-(6 h – 48 h) and temperature-(37 oC 
and 40.5 oC) dependent mortality, when evaluated 
by the NR reuptake assay. Under normothermic 
conditions, the NR assay demonstrated similar 
sensitivity to the MTT reduction assay, which was 
used in previous studies to assess cytotoxicity at 
48h (Dias da Silva et al. 2013). 
Several lines of investigation suggest that either 
necrosis or apoptosis mediate the reported 
amphetamine-related toxicity. Previous reports have 
shown that amphetamine designer drugs can induce 
apoptosis in human serotonergic JAR cells 
(Simantov and Tauber 1997), rat cortical neurons 
(Cunha-Oliveira et al. 2006; Stumm et al. 1999; 
Warren et al. 2007), immortalized mesencephalic 
neurons (Cadet et al. 1997; Kanthasamy et al. 
2006), rat cerebellar granule cells (Jimenez et al. 
2004), striatal glutamic acid decarboxylase (GAD)-
containing neurons (Jayanthi et al. 2004), and in 
mice striatal dopaminergic neurons (Krasnova et al. 
2005; Zhu et al. 2005), among others. Capela et al. 
(2012) have additionally demonstrated MDMA-
induced programmed neuronal death, involving 
both the mitochondria machinery and the extrinsic 
cell death pathway in primary cultures of 
hippocampus obtained from rat embryos. 
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Figure 8. Time-course of caspase-3/-7 activation in HepG2 cells exposed to MDMA (A), METH (B), 4-MTA (C), d-AMP (D), 
individually and in combination (E). The compounds were tested at concentrations that induce 25% of the maximum effect observed 
in the MTT reduction assay (EC25), i.e. 1.3 mM MDMA, 3 mM METH, 0.5 mM 4-MTA, 1.7 mM d-AMP and 1.6 mM mixture (Dias da 
Silva et al. 2013). Caspase-3/-7 activation was measured using a caspase-Glo 3/7 assay kit (Promega) after 1h, 4h, 8h, 16h, 24h, 36h or 
48h of incubation, at 37 oC. Results are from five independent experiments performed in six replicates and are presented as mean ± 
SEM. Control values are set to 0 (dashed red line). Statistical comparisons were made using the Kruskal–Wallis test followed by 
Dunn’s post hoc test. *p<0.05, **p<0.01, ***p<0.001 show statistically significant differences versus controls. 
 
 
Albeit the neuronal system being the most 
widely studied, apoptosis has also been 
demonstrated in cultured hepatic stellate cells 
(Montiel-Duarte et al. 2004; Montiel-Duarte et al. 
2002) and in freshly isolated rat hepatocytes 
exposed to amphetamines (Montiel-Duarte et al. 
2002). Conversely, post-mortem reports of 
intoxicated abusers describe cases of human livers 
exhibiting clear necrotic effects, from foci of 
individual necrotic cells to massive hepatic necrosis 
(Milroy et al. 1996), which seems to indicate that 
apoptosis is not the only mechanism of cell death 
attributed to amphetamines. In addition to liver 
necrosis, which is accompanied by fatty 
degeneration and inflammation, Sano et al. (2009) 
have also observed small foci of myocyte necrosis 
providing further evidence of the extension of this 
cell death process to other organ systems. 
A classical definition of necrosis, based on 
morphological criteria, presumes an unregulated 
phenomenon involving damage of membrane 
integrity, cellular disruption and swelling of 
cytoplasmic organelles; whereas apoptosis is 
characterized by organised plasma membrane 
blebbing, cell shrinkage and typical modifications 
of nuclear morphology, such as chromatin 
condensation and fragmentation. 
With the current investigation, we expected to 
provide new insights into the putative mechanisms 
underlying the reported cellular death observed here 
and in previous studies (Dias da Silva et al. 2012; 
Dias da Silva et al. 2013), under physiological and 
hyperthermic settings. Additionally, we expected to 
provide new understandings of the way 
amphetamines work when in combination. 
Effectively, a few studies aimed at establishing the 
type of interaction between these four agents have 
already been carried out (Dias da Silva et al. 2012; 
Dias da Silva et al. 2013), and support the 
conviction that amphetamines act in a similar way 
to prompt the overall mixture cytotoxicity. 
However, the mechanisms underlying such additive 
interactions are yet to be fully understood. 
We, therefore, evaluated the rate of necrosis vs. 
apoptosis in HepG2 cells following incubation with 
these drugs, under different time and temperature 
conditions. Our findings indicate that in the absence 
of heat stress (37 oC), HepG2 cells preferentially 
exhibited death with apoptotic characteristics. The 
extent of hepatocellular apoptosis is dependent on 
the duration of exposure to the tested drugs, being 
more pronounced after 48 h incubations. Apoptosis 
is a highly effective cell-suicide program, which 
entails the orchestrated interplay of a range of 
promoter and suppressor agents belonging to the 
BCL-2 family. The results presented herein clearly 
shown the significant downregulation of BCL-2 and 
BCL-XL gene expressions in response to 
amphetamine treatment. Other authors have already 
reported a differential expression of these 
antiapoptotic markers in the rat liver after exposure 
to MDMA (Cerretani et al. 2011; Montiel-Duarte et 
al. 2002; Upreti et al. 2011) and d-AMP (De Miglio 
et al. 2000), but this correlation was never reported 
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for hepatotoxicity provoked by METH and 4-MTA, 
nor for amphetamine combinations. 
The proteins encoded by these antiapoptotic 
genes have the role of preventing the activation of a 
proteolytic caspase cascade that condemns cells to 
death, through direct interactions with the 
proapoptotic members (Cory et al. 2003; Garcia-
Saez 2012; Gross et al. 1999). Indeed, it had 
become evident that it is the imbalance between the 
opposing BCL-2 family members, in favor of 
proapoptotic regulators, rather than the proteins 
themselves, that controls the release of downstream 
effector caspases. 
In accordance with results obtained in other 
cellular systems for METH (Genc et al. 2003; 
Pereira et al. 2006; Shao et al. 2012) and d-AMP 
(De Miglio et al. 2000; Krasnova et al. 2005), anti-
survival Bax was found to be differentially 
expressed in HepG2 cells after amphetamine 
treatment. Notwithstanding, as far as we know, this 
is the first study reporting Bax overexpression 
induced by MDMA and 4-MTA. Also, this is the 
first time that an association between Bak 
overexpression and apoptosis have been reported 
for our test drugs. It is conceivable that in our 
cellular model, upon a death stimulus, Bax, which 
is present in the cell in the form of cytosolic 
monomers, translocates to the mitochondria. Once 
there, Bax and Bak, the latter being constitutively 
bound to the outer membrane, suffer 
conformational changes, integrate into the 
membrane and oligomerize (Nechushtan et al. 
2001). The formed oligomers are alleged to 
provoke the permeabilization of the outer 
mitochondrial membrane, permitting the release of 
several crucial pro-death factors from the 
mitochondrial intermembrane space into the 
cytoplasm, which in turn activates the effector 
caspase-3 and -7 that execute apoptosis (Susin et al. 
1999; Verhagen and Vaux 2002). 
Under normal cell conditions, the BH3-only 
regulators (e.g., Bid, Bim and Puma) have no 
activity or exist only at residual levels. Upon 
stimuli, like the one induced by amphetamines, they 
are transcriptionally upregulated (similarly to what 
was observed with Bim, Bad, Puma and Bid) or 
activated by post-translational modifications, such 
as dephosphorylation, subcellular translocation, or 
proteolysis (as with Bim and Bid). To the best of 
our knowledge, Puma and Bim have never been 
linked with the toxicity induced by amphetamines. 
Increased Bad has been associated with apoptosis 
induced by METH in mouse neocortex (Jayanthi et 
al. 2001) and rat striatum (Beauvais et al. 2011);and 
upregulation of Bid has been reported in MDMA-
rat liver exposed to MDMA (Cerretani et al. 2011) 
and in mouse brain exposed to METH (Deng et al. 
2007; Jayanthi et al. 2001) but not in hepatocytes. 
When activated, these proteins govern apoptosis 
either directly activating Bax/Bak or neutralizing 
the role of prosurvival members, such as Bcl-2, 
Bcl-xL. 
In the particular case of Bid, it was observed 
that its expression was increased at both transcript 
and protein levels. This p22 protein is generally 
confined to the cytosol of the cell in an inactive 
form. When activated, caspase-8 mediates the 
cleavage of Bid into one major p15 and two minor 
p13 and p11 fragments, and leads to the 
translocation of the p15 truncated form (tBid) to the 
mitochondrial outer membrane (Li et al. 1998; Luo 
et al. 1998; Yin et al. 1999). The translocation of 
tBid is associated with cyt c efflux from the 
mitochondria, due to Bax/Bak oligomerization. 
Since the apical caspase-8 is activated by cell 
surface death receptors, such as Fas and tumor 
necrosis factor (TNF), it is plausible that extrinsic 
signalling pathways mediate, at least in part, 
apoptotic responses triggered by amphetamines in 
HepG2 hepatocytes. Supporting this possibility are 
the results presented by Capela and co-workers 
(2012) that demonstrated programmed cell death of 
primary cultures of hippocampal neurons exposed 
to amphetamine derivatives, an effect involving 
receptor stimulation, caspase-8 activation, 
significant increase in AIF and release of cyt c to 
the cytoplasm. 
Our results seem to indicate that apoptosis 
induced by amphetamines in HepG2 occurred 
primarily through extrinsic and/or mitochondrial 
pathways. This was further confirmed by the 
observed activation of caspases-3 and-7 and 
cleavage of cellular components, like PARP, in the 
presence of the test substances. We did not detect 
any disruption of mitochondrial membrane 
potential when HepG2 cells were exposed to 
amphetamines, at 37 oC. Notwithstanding, the 
importance of mitochondrial dysfunction in 
hepatocyte programmed death is unclear. Despite 
the loss of ∆ψm being allegedly an early apoptotic 
event, there is emerging evidence advocating that 
this may not be the case. Depending on the cell 
system under investigation and the apoptotic 
stimuli, the loss of ∆ψm may not be required for cyt 
c release (Ly et al. 2003). These inconsistencies 
may also be attributed to the distinct abilities of 
fluorochromes to accurately discriminate changes in 
∆ψm. 
From our results, it was also clear that the 
increase in temperature (from 37 oC to 40.5 oC) 
rendered cells more vulnerable to necrosis, for both 
time conditions (24 h and 48 h). This suggests that 
is there is a change in the mode of cell death with 
the increase in temperature. At physiological 
temperature, amphetamines led preferentially to 
apoptosis, but under hyperthermia, cellular death 
was mostly due to necrosis and not apoptosis. This 
observation indicates that a 3.5 oC increment was 
sufficiently detrimental to provoke premature death 
of HepG2 cells by necrosis, even in controls, 
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advocating that hyperthermia per se is deleterious 
enough to trigger necrotic pathways. The 
vulnerability of the cells exposed at hyperthermia 
was further exacerbated with the exposure to 
amphetamines, as necrosis was greatly enlarged in 
the treatment groups in comparison to controls. 
Necrotic effects were additionally enhanced with 
the widening of drug exposure period (from 24 h to 
48 h). 
Intracellular ATP levels corroborate these 
results. Although energy contents slightly decrease 
in HepG2 cells treated with amphetamines at 37 oC, 
the ATP decline only presented statistically 
substantial differences (p<0.05) when cells where 
exposed at 40.5 oC. Actually, as observed in this 
study, when temperature was set to physiological 
conditions (37 oC), cells exposed to amphetamines 
preferentially died by apoptosis. This programmed 
process is highly regulated and requires energy for 
a number of ATP dependent stages (Richter et al. 
1996; Zamaraeva et al. 2005), such as caspase 
activation (Li et al. 1997), chromatin condensation 
(Kass et al. 1996), and blebbing (Barros et al. 
2003). On the other hand, it has been proven that 
the exhaustion of ATP cellular storages redirects 
the type of death from apoptosis to necrosis (Leist 
et al. 1997; Nicotera et al. 1998). This is in 
agreement with our results, considering that 
hyperthermia (40.5 oC) per se was capable of 
reducing cellular ATP and that this effect was 
further exacerbated in the presence of 
amphetamines. 
Apoptosis is a physiologically occurring 
programmed and targeted way of cell death that 
normally provides benefits to the organism. In 
contrast, despite investigation suggesting that 
necrosis occurrence and progression might be 
tightly controlled (Golstein and Kroemer 2007; 
Proskuryakov et al. 2003), it almost always implies 
negative consequences. Contrary to apoptosis, in 
which apoptotic bodies containing cytosol, 
condensed nuclear material, and organelles are 
ultimately engulfed by phagocytes without causing 
any damage; cells undergoing necrosis suffer early 
plasma membrane rupture, loss of selective 
permeability, dilatation of cytoplasmic organelles, 
particularly mitochondria, and uncontrolled leakage 
of cellular contents into the extracellular space. 
This results in injury of neighbouring cells and 
severe inflammatory reaction in the corresponding 
tissue, which could become chronic and cause 
irreparable damage. Given the fact that the higher 
temperature used in our experiment (40.5 oC) 
coincides with the body temperatures that 
recreational abusers may attain after ecstasy 
consumption, our results support the hypothesis that 
amphetamine-induced thermodysregulation, which 
is also exacerbated by the hot and overcrowded 
venues were consumption often occurs, is one of 
the key causes of necrosis-mediated acute liver 
failure. 
Overall, no major differences were observed 
between the independently tested amphetamines 
and their mixture for any of the investigated 
endpoints. This supports the assumption that these 
compounds, tested at equal effect concentrations, 
behave similarly and do not interact with each other 
in any unexpected way. In other words, this 
supports previous observations which showed that, 
when combined, these amphetamines act in an 
additive manner (Dias da Silva et al. 2013). 
In conclusion, the cell death mechanism 
(apoptosis or necrosis) induced by amphetamines, 
alone and in mixture, depends on both temperature 
and duration of exposure. It is possible that under 
less hostile temperature settings, psychostimulant 
amphetamines promote programmed hepatocyte 
death involving both the mitochondrial machinery, 
(through the synchronized interaction between 
BCL-2 members), and the extrinsic cell death, 
possibly by activating caspase-8. Although 
upstream mechanisms were not totally clarified, our 
results evidenced that apoptosis common pathways 
were eventually activated, after HepG2 cells 
exposure to amphetamines. Further approaches 
aimed at elucidating the involvement of the 
mitochondrial and, particularly, extrinsic receptor 
pathway should be considered in the future. We 
stress the importance of these results for an 
improved knowledge of the molecular mechanisms 
involved in amphetamines toxicity, which should 
aid in implementing novel therapeutic approaches 
with a view to avoid or attenuate the acute and/or 
chronic consequences of ecstasy misuse. 
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PART IV – GLOBAL DISCUSSION  
1. Evaluating the mixture effects of MDMA and other amphetamine designer 
drugs 
 
MDMA abuse is due to the euphoric state induced by the drug, that includes an increased 
sense of energy, emotional openness, increased capacity for introspection, empathy, reduced 
negative thoughts and reduced inhibitions (Davison and Parrott 1997; delaTorre et al. 2004a; 
Hegadoren et al. 1999; Liechti and Vollenweider 2000a; Morgan 2000; Parrott and Stuart 
1997; Peroutka et al. 1988). The perception of sounds and colours can also seem more intense 
(Davison and Parrott 1997). To obtain such effects, MDMA is rarely ingested alone (Carvalho 
et al. 2012; Mohamed et al. 2011). There is a wide variety of drugs that are used for such 
purposes. Mixtures of several amphetamine-like drugs are among the most frequently used 
drug combinations (Carvalho et al. 2012; Mohamed et al. 2011). Therefore, considering the 
high incidence of the simultaneous administration of different amphetamine-designer drugs 
(Barrett et al. 2005; Carvalho et al. 2012; Dams et al. 2003; Johansen et al. 2003; Kunsdorf-
Wnuk et al. 2005; Lin et al. 2007; Mohamed et al. 2011) and the severity of the intoxications 
that have been associated with this polydrug abuse pattern  (Dams et al. 2003; Felgate et al. 
1998; Fineschi and Masti 1996; Johansen et al. 2003; Kunsdorf-Wnuk et al. 2005; Lin et al. 
2007), the present work aimed at understanding the nature of the interactions between these 
drugs to help predict and explain their toxic effects. So far, mixture effects had been mostly 
neglected since the vast majority of the studies on the toxicity of this type of drugs addresses 
individual effects, underestimating the real risk associated with multidrug ‘cocktails’. 
MDMA toxicity is diffuse and produces a wide variety of adverse health effects. 
Long-term toxicity is particularly worrisome, due to the neurotoxic effects that can 
irreversibly damage the brain of its young users. On the other hand, acute intoxications can be 
lethal and virtually all organs are potentially affected by the detrimental actions of this drug. 
The liver is a remarkably vulnerable target for MDMA toxicity because the drug is 
extensively metabolised in this organ generating very reactive metabolites that are 
accompanied by the formation of deleterious ROS and NOS (Figure 1). Several studies have 
contributed to the characterization of the toxicity of MDMA metabolites (Barbosa et al. 2012; 
Barenys et al. 2012; Capela et al. 2006; Carvalho et al. 2002b; Carvalho et al. 2004a; 
Carvalho et al. 2004b; Carvalho et al. 2004c; Ferreira et al. 2013; Gollamudi et al. 1989; Patel 
et al. 1991), demonstrating that metabolic bioactivation plays an important role in the 
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expression of MDMA toxicity. As a consequence, clinical cases of hepatotoxicity secondary 
to ecstasy abuse have been frequently and increasingly reported. Among the most commonly 
noted symptoms are jaundice, hepatomegaly, centrilobular necrosis, hepatitis, and fibrosis 
(Aknine 2004; Brncic et al. 2006; Dykhuizen et al. 1995; Fidler et al. 1996; Garbino et al. 
2001). 
Although to different extents, other amphetamines are also metabolised in the liver 
and share many of the bioactivation pathways that have been well characterized for MDMA 
(Caldwell et al. 1972; delaTorre et al. 2000a; Ewald et al. 2005; Kraemer and Maurer 2002; 
Kuwayama et al. 2012; Shima et al. 2006). Therefore, we were particularly interested in 
studying the impact of amphetamines mixtures in liver toxicity. 
Evaluating joint toxicity is a project with immense scope. At any given instant, 
misusers are exposed to a multitude of unique mixtures, resulting both from intentional and 
unpremeditated (e.g., food, medicines) drug exposures. Also, the number and concentrations 
of individual mixture constituents are permanently fluctuating within the organism, due to, 
among others, pharmacokinetic phenomena (Borgert 2004a; Faust et al. 2003). The number of 
potential drug combinations is virtually immeasurable and makes the in vivo investigations of 
these combined effects challenging, considering both cost and ethical restrictions. To 
overcome these limitations, assessment of mixture effects often relies on high throughput in 
vitro assays that estimate joint effects based on the detailed knowledge of the toxic responses 
of the individual constituents. The choice of adequate study models and toxicity endpoints 
are, thus, crucial for the success of these investigations. We chose two complementary in vitro 
models that have been widely used to study liver toxicity: a human immortalized hepatoma 
cell line (HepG2) and primary rat hepatocytes. Human hepatoma cell lines, such as HepG2, 
are highly differentiated, exhibit numerous genotypic qualities of the liver cells from which 
they are derived and retain many of the morphological features and the metabolic pathways 
(Sassa et al. 1987). Nonetheless, in general, continuous hepatic cell lines (tumour or 
artificially immortalized) express a limited range of the phase I enzymes and UGT that are 
found in hepatic tissue. Even when the metabolic functions are preserved, the enzyme activity 
may show variability with increasing number of cell replications during cell culture, 
becoming less representative of the in in vivo situation (Donato et al. 2008; Gerets et al. 2012; 
Westerink and Schoonen 2007; Xu et al. 2004). In fact, because cell lines undergo several 
passages, they may accumulate variations introducing significant transformations relative to 
the original background. Primary rat hepatocytes on the contrary, are metabolically more 
competent, but are derived from a rodent species (Donato et al. 2008; Gerets et al. 2012; 
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Westerink and Schoonen 2007; Xu et al. 2004). Several studies proved a good correlation 
between in vitro results in primary rat, mouse and human hepatocytes and those obtained in 
vivo (Akrawi et al. 1993; Carmo 2007; deSousa et al. 1995; Kelly et al. 1992; Li et al. 1997), 
supporting that primary hepatocytes are an excellent tool in the assessment of the toxicity and 
the metabolism of drugs. This holds true also in the case of the cryopreserved cells (Bronley-
DeLancey et al. 2006; Brown et al. 2006; Carmo 2007; Carmo et al. 2004; Carmo et al. 2005; 
deSousa et al. 1999; Guillouzo et al. 1999; Hewitt et al. 2000; Koebe et al. 1999). 
Nevertheless, Carmo et al. (2004) examined the cytotoxicity and the metabolic profile of 4-
MTA in primary hepatocytes isolated from three male human donors and Sprague-Dawley 
rats, and observed that human hepatocytes are more metabolically competent (as shown by 
the increased 4-methylthiobenzoic acid formation) (Figure 5). Accordingly, comparative 
studies of metabolism performed with d-AMP and other related compounds have shown 
moderate interspecies differences (Caldwell 1980). 
When we started our investigations, all the studies conducted with amphetamines and 
their associations, including those claiming synergisms (Diffley et al. 2012; McNamara et al. 
2006; Mohamed et al. 2011; Pontes et al. 2008b; Robledo et al. 2007; Schechter 1998; Song 
et al. 2010; Vanattou-Saifoudine et al. 2012a; Vanattou-Saifoudine et al. 2011; Young et al. 
2005), were designed with neither reference to the expected additivity joint effects, nor to the 
conceptual principles, such as the CA and IA models, that are the foundation of mixture 
toxicology. This evidenced some knowledge gaps in the field, related to the application of 
fundamental concepts and approaches essential to accurately study mixtures of 
amphetamines. Thus, toxicity predictions with theoretical modelling methods represented, at 
that time, an open issue of critical urgency. 
 
 
1.1. Model appropriateness in predicting amphetamine joint effects 
 
The first part of our work with mixtures of amphetamines focused on the issue of validating 
joint assessment concepts. The first challenge was to construct a mixture where the 
combination effect predictions derived from CA and IA were sufficiently different to permit 
sound identification of the most accurate model in predicting mixture effects. To avoid the 
disproportionate contribution of a single drug to the overall mixture effect, it was imperative 
to choose concentration ratios that reflected the individual potency of each mixture 
Global discussion 
 182
component. With this purpose the first mixture to be experimentally tested included MDMA, 
METH, 4-MTA and d-AMP at concentrations corresponding to their individual EC50 values, 
i.e., the concentration that for each drug induced 50% lethality in the MTT assay in HepG2 
cells (Experimental section, Chapter 1). A fixed mixture ratio design was employed to 
produce a wide range of concentrations of this mixture. Additionally, other mixture designs 
were tested, aiming at mimicking more realistic circumstances relative to the in vivo situation. 
These included a mixture where the same individual components (MDMA, METH, 4-MTA 
and d-AMP) were mixed at individually ineffective concentrations (the EC01 value of each 
individual drug was chosen), and a third mixture where MDMA was present at a fixed 
(‘realistic’) concentration and the remaining components were changed over a wide range of 
concentrations, as would be expected if they were present as impurities in ecstasy tablets 
(Experimental section, Chapter 1). Nevertheless, we acknowledge that due to the 
overwhelming number of complex mixtures with variable compositions that could potentially 
occur in the organism after simultaneous ingestion of these drugs, even the most ‘realistic’ 
combination would suffer from a certain lack of realism. Despite not being able to mimic 
exactly the real mixtures an individual is exposed to, due to all the possible chemicals 
ingested and the impossibility of quantifying the doses ingested of each one, our approach 
was very effective at validating the system and allowing proof of concept. Furthermore, if we 
see mixture effects with these relatively simplistic mixtures, it is highly likely that similar (or 
even worse) combination effects occur in ‘real life’ scenarios. In all tested situations, these 
amphetamines acted together to generate additive effects. 
We next continued our studies by applying this experimental protocol to the HepG2 
cells incubated at a higher temperature (40.5 ºC), which mimics the hyperthermic state of the 
liver that occurs in human intoxications (Experimental section, Chapter 2). Primary rat 
hepatocytes were also tested at both physiological and hyperthermic incubation conditions 
(Experimental section, Chapter 3). All the obtained data showed notable additive effects 
between the tested amphetamine drugs. Overall, we found strong evidence that the effect of 
amphetamine mixtures can be correctly predicted based on the detailed knowledge of the 
toxicity of individual components, both in primary rat hepatocytes and in HepG2 cells, either 
at physiological (37 oC) or hyperthermic (40.5 oC) conditions, proving the applicability of the 
CA predicting model to situations similar to those occurring in humans. Although extensive 
data from other areas of toxicological interest, specially ecotoxicology, had already shown 
that the accurate modelling of the toxicity of the individual mixture constituents is critical to 
obtain good estimations of joint combined toxicity (Altenburger et al. 2000 ; Backhaus et al. 
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2000a; Faust et al. 2001; Faust et al. 2003; Scholze et al. 2001), we produced the first reports 
on the drug abuse field of research. Our group was the first to demonstrate that the responses 
of multi-component mixtures of amphetamines might be accurately anticipated by the concept 
of CA. CA computations fitted perfectly with the experimental outcomes of combinations of 
MDMA and the three other often co-ingested amphetamines (METH, 4-MTA and d-AMP). 
These results consistently indicated that severe and potentially lethal interactions among 
amphetaminic drugs are to be expected when these drugs are taken concomitantly. Our 
investigations provided sound experimental evidence supporting what is frequently observed 
with the human intoxications, i.e., increased severity and lethality of the intoxication when 
more than one amphetamine derivative is ingested (Byard et al. 1998; CDC 2010; Forrest et 
al. 1994; Kunsdorf-Wnuk et al. 2005; Liechti et al. 2005). It also explains, at least in part, 
why it is often impossible to interpret the severity of the intoxication based upon the blood 
and/or tissue levels of the drugs that are measured after the intoxication or even post-mortem 
(Milroy 2011). It is now clear that these additive mixture effects must be taken into 
consideration. To efficiently predict such effects is a powerful tool not only to understand, but 
also to prevent toxicity by making misinformed users aware of the increased risks that they 
are exposed to, when ingesting ‘amphetamine cocktails’. 
Because MDMA generates extremely reactive metabolites in vivo, these have long 
been suspected to contribute to the mechanism of toxic action of the drug (Barbosa et al. 
2012; Barenys et al. 2012; Capela et al. 2006; Carvalho et al. 2002b; Carvalho et al. 2004a; 
Carvalho et al. 2004b; Carvalho et al. 2004c; Ferreira et al. 2013; Gollamudi et al. 1989; Patel 
et al. 1991). Consequently, the concepts described above were also applied to predict joint 
effects that could occur in the liver cells after MDMA metabolism. For this purpose, and 
using the least metabolically competent in vitro model, the HepG2 cells, to minimize the 
interference of the metabolites that are produced by the cellular metabolism of MDMA, we 
incubated these cells with MDMA and its main human metabolites: MDA, α-MeDA, and N-
methyl-α-MeDA, in an attempt to mimic the in vivo bioactivation expected after MDMA 
intake (Experimental section, Chapter 4). Again, additive joint effects could be observed and 
the CA model provided the most accurate estimations of the mixture toxicity. With this set of 
experiments we, for the first time, provided experimental evidence that supported the 
hypothesis that, even when produced at low concentrations, these metabolites contribute 
significantly to the overall toxic effect of the drug (Experimental section, Chapter 4). Even if 
MDMA is the only drug involved in the intoxication, mixture effects between the parent drug 
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and its oxidative metabolites, particularly α-MeDA and N-methyl-α-MeDA, cannot be 
overlooked when hazard implications of ecstasy intake are considered. 
The ability of the drugs to elicit maximal responses (100% cell death) is an important 
criterion to obtain prediction curves that cover a suitable range of effects. For mathematical 
reasons, the concept of CA cannot predict mixture effects that exceed those of the mixture 
component with the lowest maximal effect. This issue was of special concern when 
addressing the combination toxicity of MDMA with its metabolites, since the interference 
with the optical density readings of the MTT assay that occurred at highest concentrations of 
the tested metabolites prevented obtaining full concentration-response curves that reached 
maximal effects (100% lethality). Despite incomplete additivity predictions potentially 
hindering the comparison between the competing expectation concepts (Rajapakse et al. 
2001), due to the robustness of our CA estimations and to the excellent discrimination 
achieved between both CA and IA models, we could overcome these limitations.  
It is interesting to note that in all studied cases, IA predicted a lower toxicity for the 
tested mixtures relative to CA, consistently underestimating the mixture toxicity. This 
supports the notion that the CA model is a pragmatic and realistic worst-case model, capable 
of ensuring an adequate level of protection when predicting the toxicity of amphetamines 
mixtures. This assumption agrees well to a recent opinion approved by the Scientific 
Committees of the European Commission (2012) on the toxicity of chemical mixtures. 
To a large extent, the great consistency between CA predictions and experimental 
observations could be attributed to the high reproducibility of the MTT assay. It remains to be 
seen whether the methodology employed here can be successfully applied to bioassays that 
produce less reproducible data, such as those used in more complex in vitro or even in in vivo 
systems. For practical reasons, CA and IA have been mostly applied either to biochemical in 
vitro (Ohlsson et al. 2010; Payne et al. 2001; Rajapakse et al. 2002; Rajapakse et al. 2004; 
Silva et al. 2002; Silva et al. 2011) or to unicellular in vivo (Huang et al. 2011; Villa et al. 
2012; Zhou et al. 2010) models. Due to their functional simplicity, it might be alleged that 
these models may not reflect the outcomes of more complex living systems, such as the entire 
organism (Barata et al. 2007). Notwithstanding, a few studies have contributed to our 
understanding of mixture effects at increasing levels of biological complexity (Christiansen et 
al. 2008; Correia et al. 2007; Goncalves et al. 2008). Hass et al.(2007) assessed joint effects 
of three androgen receptor antagonists (vinclozolin, flutamide and procymidone) on male 
sexual differentiation in rats after in utero and postnatal exposures. The authors found that 
effects of a mixture of similarly acting anti-androgens, which individually appears to exert 
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only small effects, may in concert induce marked responses that were predicted fairly 
accurately on the basis of the potency of the individual mixture components by using the dose 
addition concept. Christiansen and collegues (2009) investigated the effects of mixtures 
chemicals widely present in food, consumer products, and the environment in inducing 
irreversible demasculinization and malformations of sex organs among male rat offspring. In 
relation to some hallmarks of disrupted male sexual development, the combined effects were 
dose additive (Christiansen et al. 2009). Strikingly, the effect of combined exposure to the 
selected chemicals on malformations of external sex organs was synergistic, and the observed 
responses were greater than would be predicted from the toxicities of the individual chemicals 
(Christiansen et al. 2009). These outcomes are highly relevant to human risk assessment and 
evaluations that ignore the possibility of combination effects may lead to considerable 
underestimations of risks associated with exposures to chemicals that disrupt male sexual 
differentiation (Christiansen et al. 2009). An important task will be to further investigate 
whether our findings hold true for biological effects at higher levels of cellular organisation, 
e.g. at the organism level. 
Despite our success in predicting the joint effect of amphetamines, a more important 
question remained to be answered: can these mixtures produce significant effects, even when 
the individual drugs are present at low, ineffective concentrations? 
 
 
1.2. Mixture outcomes at low-effect concentrations of individual components 
 
The relevance of the in vitro investigations of the toxicity of amphetamine-like designer drugs 
of abuse has often been questioned due to the high concentrations of the test drugs that are 
necessary to produce a positive response in the cytotoxic endpoints that are most frequently 
tested. This prompted us to investigate an important hypothesis: Can amphetamines, even at 
low ineffective concentrations, act together to produce significant responses? In order to 
address this issue we measured the joint toxic action when each amphetamine was present at 
levels that individually provoked unnoticeable effects, i.e., indistinguishable from those of 
untreated controls. For this purpose, it was necessary to estimate, as accurately as possible, 
low effect concentrations of all tested agents. The EC01 was determined by interpolation to the 
best-fit cytotoxicity curve of MDMA, METH, 4-MTA and d-AMP, since this has been 
considered the most accurate approach (Scholze and Kortenkamp 2007; Silva et al. 2007). 
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Also, such low concentrations could not be tested individually, as they do not produce effects 
above the limit of detection of the assay (they could not be differentiated from controls) and 
therefore could not be associated with a measurable effect. The only way to accurately 
estimate the effects associated with such concentrations was to derive them from the fits. 
Then, a more realistic mixture was tested by adding all individual components in proportion 
to their EC01 concentrations. The observed cytotoxic effect greatly exceeded that expected by 
the simple sum of the effects of the individual components. These additive effects were, once 
again, accurately predicted by the CA model. 
Silva and co-workers (2002) tested multicomponent mixtures of eight xenoestrogens 
of environmental relevance and found that estrogenic agents are able to act together to 
produce substantial mixture effects even though each chemical was present at levels well 
below its NOEC and EC01. Also Brian et al.(2007) investigated the ecological significance of 
mixture effects at low-effect concentrations by assessing the combined effect of estrogenic 
chemicals on the reproductive performance of fish. Data from these experiments provide 
evidence of the capacity for chemicals to act together to affect reproductive performance, 
even when each component is present below the threshold of detectable effects (Brian et al. 
2007). Christiansen and collegues (2008) observed that doses of anti-androgens, which appear 
to induce no hypospadias when judged on their own, may induce a very high frequency of 
hypospadias in rats when they interact in concert with other anti-androgens. Similar to our 
findings, these results stress the great limitations of focusing on single substances rather than 
on combinations. Had we tested the chemicals alone, we would have not detected any 
measurable toxicity. Thus, when dealing with mixture exposures, the assumption that 
individual drugs constitute negligible risk when present at low, ineffective levels in humans is 
most likely inappropriate. From our data, we can anticipate that if every amphetamine 
contributes additively to the overall effect, identifying the potential risks associated with these 
multiple drug exposures becomes highly dependent on the number of the drugs present in the 
organism. 
These conclusions also emphasize that pursuing synergistic combination effects has 
been unnecessary. Instead, additive combination effects are of utmost importance and need 
urgent attention when considering the conceivable risks that amphetamines, and other drugs 
of abuse, may pose for humans (Silva et al. 2002).  
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1.3. Deviations from additivity 
 
The strengths of the CA and IA models lie mainly on their relative simplicity and consistent 
applicability in environmental and human toxicology. Yet, some relevant weaknesses must be 
noted. Firstly, these two general principles do not contemplate pharmacokinetic interactions 
between the components of the mixture. So, enhanced (synergistic) or weakened 
(antagonistic) combined effects that occur with respect to either model expectations (CA and 
IA) need to be considered independently. In our studies, a slight deviation from the CA 
prediction model was observed when the HepG2 cells were exposed towards higher mixture 
concentrations, particularly at high effect levels (Experimental section, Chapters 1 and 2). 
Because the model does not take into account potential pharmacokinetic interactions between 
chemicals it seemed plausible that the amphetamines could be competing in the mixture for 
their shared metabolic routes (Caldwell et al. 1972; Carvalho et al. 2012; delaTorre et al. 
2000a; Ewald et al. 2005; Kraemer and Maurer 2002; Kuwayama et al. 2012). Unexpectedly, 
an increase in MDA formation when MDMA was combined with the other amphetamines 
was observed, instead of the anticipated decrease in the oxidative metabolic pathways that 
remained unaltered (Experimental section, Chapter 1). Because MDA has been shown to be 
less toxic than the catechol metabolites, its increased formation could explain the 
aforementioned weak antagonistic effects. It is not possible, with the present data, to 
understand why such an increase would occur. However, one can speculate that the 
incubation period is long enough to allow for CYP induction to occur. If this is the case, then 
a preferential overexpression of CYP2B6 that catalyses the N-demethylation in detriment of 
the O-demethylenation pathway that produces the highly reactive metabolites can account for 
the observed effects. On the other hand, high concentrations of amphetamines will likely 
inhibit CYP2D6, the main CYP isoform involved in the O-demethylenation (Carvalho et al. 
2012). Yet, the accurate pharmacokinetic interactions between amphetaminic drugs are still 
not fully understood and it is possible that additional factors are involved in the deviations 
observed, thus requiring further investigation. 
Secondly, each of these concepts is based on assumptions on the primary mode of action 
of each of the components of the mixture, i.e., whether they act in a dissimilar (IA) or similar 
(CA) way, but this information is recurrently unavailable. The toxicity mechanisms of the 
studied amphetamines are still not completely understood, but even in light of the limited 
information available, identifying the similarities in the mechanisms of action of the 
components of the amphetamines’ mixture is a complex issue in practice. So how can we 
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decide whether a drug acts in a similar or dissimilar way to one another? Herein lie the 
uncertainties, as the term of similar action can be interpreted in different ways and the criteria 
used to define similar or dissimilar action of mixture components are not well defined 
(Berenbaum 1989; Greco et al. 1995). At one extreme of the spectrum of opinions, similar 
action has been suggested to be based upon each drug competitively and reversibly interacting 
with an identical molecular target site, by identical toxic intermediates – in a narrow sense we 
could say similar mechanisms (Pöch 1993). The opposite mechanistic standpoint is described 
by the view that ‘similar action’ should be taken to mean the induction of phenomenological 
similar effects, e.g. cell killing (Berenbaum 1989; Borgert et al. 2004; Faust et al. 2003). This 
particular toxicological endpoint can encompass a very broad range of chemicals being 
considered as similar.  
So, while the mechanistic basis for the selection of CA and IA for a given mixture appears 
appealing (similar vs. dissimilar action), it has not yet been established how ‘similar’ the 
actions need to be before CA can be selected as the most proper model. Mechanistic studies of 
the individual compounds and the mixtures are, therefore, needed to shed light on the 
interactions that may or may not exist at the molecular level. 
 
 
2. Understanding the mechanisms underlying the joint action of amphetamines 
 
As mentioned above, a common feature for many drugs is that they exhibit a great variety of 
pathways that can be ignited to provoke cell death. In many cases, these drugs have known 
sites of action but an exact understanding of the mechanism of action is lacking. Following on 
from our findings at both physiological and hyperthermic conditions, we have seen how 
predictions based upon CA gave consistently better reflections of the observed mixture effects 
for all tested four-component combinations of amphetamines. These empirical observations 
would suggest that these drugs work in a similar fashion. We then set out to understand the 
mechanisms underlying the observed joint effects of the amphetamines. 
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2.1. Dissecting hepatocyte death pathways 
 
An exploration of the modes of action of each individual drug and their combination was 
developed in a two-stage approach. The first was to explore whether there was a common 
activation by all single and combined drugs in the process of inducing cell death, either by 
apoptosis or necrosis. Thus, our initial question was: Are all the drugs, and their mixture, able 
to induce apoptosis/necrosis, and, if so, would this meet the similarity criterion required for 
CA? The second stage was to move towards the more restrictive definition of ‘similar action’ 
and to prove whether all drugs exhibited the same specific mechanisms of action in initiating 
apoptosis/necrosis. This was achieved by examining the cellular energetic status and the 
activation of a number of important signalling factors within the apoptotic pathway, namely, 
the relative expressions of BCL-2, BCL-XL, BAX, BIM, BAD, PUMA and BID genes. The 
levels of PARP/cleaved PARP, Bak, PUMA, Bim (EL, S and L isoforms), Bid/cleaved Bid 
and Bax were also assessed. Ultimately, and since the tested drugs induced differential 
expression of anti- and pro-apoptotic BCL-2 family members, we further tested mitochondrial 
permeability impairment. 
The relative contribution of apoptosis or necrosis to amphetamines-induced liver 
injury remains controversial, as evidence of both types of death has been described for 
hepatocytes (Cerretani et al. 2011; Kamijo et al. 2002; Marinkovic et al. 2011; Sano et al. 
2009; Upreti et al. 2011). Apoptosis is an ATP-dependent cell death program comprising 
chromatin condensation, nuclear disintegration, cell contraction, blebbing, and formation of 
apoptotic bodies enclosing nuclear or cytoplasmic material (Kerr et al. 1972). Necrosis is 
typically the consequence of an acute metabolic perturbation with ATP depletion and often 
characterized by cytoplasmic swelling, dilation of organelles, and mechanical rupture of the 
cellular membrane (Edinger and Thompson 2004). In principle, the nature and length of 
cellular damage determine if cells die by apoptosis, necrosis, or other mechanisms. In several 
circumstances, a variety of deleterious stimuli prompt apoptosis, but the same stimuli can 
trigger necrosis under more severe conditions (Pontes et al. 2008b). The outcomes of the 
present research (Experimental section, Chapter 5) revealed that the cell death mode was 
dependent upon the exposure temperature. At physiological conditions (37 oC), the elicited 
HepG2 mortality occurred preferentially by apoptosis, while at 40.5 oC cell death occurred 
mainly through necrosis (Experimental section, Chapter 5). Cell lethality was exacerbated 
with increasing incubation period that equally affected both apoptotic and necrotic cell death. 
Accordingly, the ATP intracellular stores revealed no significant alterations when drugs 
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where tested at a physiological incubation temperature, a condition that favours the 
occurrence of apoptosis, an energetic-dependent process. On the other hand, incubations at 
40.5 oC provoked a marked ATP depletion for all drug treatments. These findings suggest that 
the rise in incubation temperature rendered the cells unable to maintain cell homeostasis and, 
consequently, leading to necrosis. Due to the swelling and rupture of intracellular organelles, 
most notably the mitochondria, and ultimately, due to the plasma membrane breakdown 
accompanied by cell lysis, the cytoplasmic contents, including lysosomal enzymes, are 
released into the extracellular space. Therefore, in vivo, necrotic cell death is often associated 
with extensive tissue damage resulting in an intense inflammatory response. This has been 
corroborated by frequent reports on liver toxicity following amphetamines exposure at high 
environmental temperatures. Most of these reports denote portal and sinusoidal inflammation 
(Marinkovic et al. 2011; Sano et al. 2009), periportal and lobular necrosis (Brauer et al. 1997; 
Ibranyi and Schonleber 2003; Marinkovic et al. 2011; Sano et al. 2009), stasis (Marinkovic et 
al. 2011), intralobular haemorrhage (Marinkovic et al. 2011), increase of liver enzymes serum 
activity (Marinkovic et al. 2011), and fatty degeneration (Sano et al. 2009) accompanied by 
inflammation (Sano et al. 2009). 
The pro-apoptotic action of MDMA was already demonstrated in isolated rat 
hepatocytes (Montiel-Duarte et al. 2002) and in liver cells maintained in culture (immortal 
hepatic stellate HSC cell line) (Montiel-Duarte et al. 2004). Montiel-Duarte and co-workers 
(2002) demonstrated pro-apoptotic effects upon exposure to MDMA in freshly isolated rat 
hepatocytes and in immortalised liver cells (hepatic stellate HSC cells), as shown by 
chromatin condensation of the nuclei and accumulation of oligonucleosomal fragments in the 
cytoplasm. These observed effects correlated with decreased levels of the anti-apoptotic factor 
bcl-XL, release of cyt c from the mitochondria and activation of caspase-3 (Montiel-Duarte et 
al. 2002). MDMA induced further PARP proteolysis in HSC cells (Montiel-Duarte et al. 
2002). Additional studies from the same group attempted to scrutinize the role played by 
oxidative stress in the apoptotic response caused by MDMA on HSC cells (Montiel-Duarte et 
al. 2004). MDMA-induced apoptosis of HSC was accompanied, but not caused by oxidative 
stress (Montiel-Duarte et al. 2004). The results obtained suggest the involvement of a 
metabolic derivative of MDMA on its apoptotic process (Montiel-Duarte et al. 2004). These 
authors also observed an MDMA-induced activation of NF-κB that played a protective role 
against the apoptotic response (Montiel-Duarte et al. 2004). Also, Upreti et al. (2011) found 
that MDMA induces oxidative modification of many cytosolic proteins accompanied by 
increased oxidative stress and activation of c-Jun N-terminal protein kinase and p38 kinase. 
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Since these protein kinases phosphorylate anti-apoptotic Bcl-2 protein, their activation may 
promote apoptosis in MDMA-exposed tissues (Upreti et al. 2011). Cerretani et al. (2011) 
obtained evidence that MDMA-induced apoptosis in liver cells is accompanied by oxidative 
stress (loss of GSH homeostasis, decreases antioxidant enzyme activities, and 
lipoperoxidation). This correlation between MDMA-induced oxidative stress/apoptosis raises 
two major possibilities: (i) MDMA may prompt apoptosis by causing intracellular stress, 
and/or (ii) MDMA may increase the susceptibility to apoptosis induced by the extrinsic 
pathway (Cerretani et al. 2011). One possible mechanism for the later would be the depletion 
of GSH, which has been suggested to sensitize to tumor necrosis factor alpha (TNF-α)-
induced extrinsic cell death (Cerretani et al. 2011; Montiel-Duarte et al. 2004; Nagai et al. 
2002). In fact, Cerretani and co-authors (2011) hypothesised that the mitochondria are the 
central executioners for TNF-α-induced hepatocyte apoptosis, as supported by their 
observations of activation of pro-apoptotic (Bid, SMAC/DIABLO) and inhibition of anti-
apoptotic (NF-κB, Bcl-2) proteins (Cerretani et al. 2011). 
In the present work (Experimental section, Chapter 5) a thorough investigation of the 
apoptotic mechanisms triggered by the tested drugs (alone or in combination) showed the 
involvement of the BCL-2 superfamily members. BCL-2 is a family of interrelated proteins 
that rule mitochondrial or intrinsic pathway of apoptosis by means of the interaction of its 
proapoptotic and pro-survival members. Besides, BCL-2 members are also involved in the 
enhancement of the death signal triggered by the extrinsic death receptor pathway (mediated 
by cell surface receptors upon extracellular stimuli). So far, about 20 mammalian family 
related proteins were identified and are classically divided into three subfamilies: (i) Bcl-2 
pro-survival subfamily (including the proteins Bcl-2 and Bcl-XL), (ii) Bax-like pro-apoptotic 
subfamily (comprises Bax and Bak), and (iii) BH3-only pro-apoptotic subfamily (Garcia-Saez 
2012). These proteins are crucial controllers of the permeabilization of the outer membrane of 
mitochondria that promotes the release of cyt c and other apoptotic factors to the cytosol, 
activating the downstream effector caspase-3/-7 cascade. As this is considered an irreversible 
point in the programmed cell death, these proteins play a pivotal role in deciding whether a 
cell lives or dies.  
Our results evidenced a decline in BCL-2 and BCL-XL mRNA levels (Experimental 
section, Chapter 5). These genes code for the respective antiapoptotic proteins, Bcl-2 and Bcl-
xL, which by binding apoptotic peptidase activating factor 1 (Apaf-1), prevent its association 
with Caspase-9. In turn, this caspase, when activated by cyt c release from the mitochondria, 
activates the effector caspase cascade (Fig. 6). Conversely, death inducers (Bax, Bak and 
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BH3-only proteins) help to dissipate the membrane potential of mitochondria and therefore 
make it more permeable for cyt c release. The BH3-only family members include the p53 
upregulated modulator of apoptosis (Puma) that also plays a critical role in the p53 tumor 
suppressor pathway; Bim (which major isoforms BimEL, BimL and BimS are generated by 
alternative splicing and generally only transiently expressed during apoptosis), Bad and Bid. 
These proteins usually promote apoptosis by binding to and antagonizing anti-apoptotic Bcl-2 
family members through BH3 domain interactions. 
Synchronized with antiapoptotic transcripts downregulation, we also observed an 
upregulation of BAX, BIM, BAD (only for MDMA), PUMA and BID genes (Experimental 
section, Chapter 5). Additionally, the elevation of Bax, cleaved Bid, Puma, Bak and Bim (EL, 
S and L isoforms) at protein level was also confirmed (Experimental section, Chapter 5). 
Growing evidence suggest that Bid, a p22 protein usually confined to the cytosol of the cell as 
an inactive precursor, in response to apoptotic signalling, is cleaved by caspase-8 at internal 
Asp60 site resulting in one major p15 and two minor p13 and p11 fragments. Cleaved or 
truncated Bid (tBid) interacts with Bax, mainly present in cell cytosol, forcing it to undergo a 
conformation shift and further insert into the outer mitochondrial membrane (Fig. 6). Some 
studies indicate that p15 truncated form also translocates to the mitochondrial outer 
membrane as an integral membrane protein (Li et al. 1998; Luo et al. 1998; Yin et al. 1999). 
This induces the opening of the mitochondrial voltage-dependent anion channel or, 
alternatively, forms an oligomeric pore on mitochondrial membrane, promoting the leakage of 
apoptogenic factors, such as cyt c (Fig. 6). Translocation of tBid is also associated with cyt c 
efflux from the mitochondria, by affecting Bax/Bak oligomerization. 
Since the apical caspase-8 is activated by cell surface death receptors, such as Fas and 
TNF, it is plausible that extrinsic signalling pathway mediates, at least in part, the apoptotic 
response triggered by amphetamines in HepG2 hepatocytes. Supporting this conviction are 
the results presented by Capela and co-workers (2012) that demonstrated that caspase-8 
activation mediates programmed cell death of primary cultures of hippocampal neurons 
exposed to amphetamine derivatives. 
As noted above, some of these apoptotic markers involved in the observed HepG2 cell 
death were already described in studies addressing the toxicity mechanisms of the 
amphetamines (Beauvais et al. 2011; Cerretani et al. 2011; Chetsawang et al. 2012; Krasnova 
et al. 2005; Shao et al. 2012). However, to the best of our knowledge, we have for the first 
time linked the Puma, Bim and Bak markers to the apoptosis induced by amphetamine drugs 
of abuse.  
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Figure 6. Schematic representation of putative molecular mechanisms involved in apoptosis evoked by 
amphetamines and their combinations, in HepG2 cells. Programmed cell death can be provoked by diverse 
stimuli from inside and outside the cell. Incoming signals, such those impelled by cytotoxic drugs, recurrently 
derive from nucleus and, in most cases, encourage expression of proapoptotic BCL-2 members and suppress 
antiapoptotic BCL-2 and BCL-XL expression. The sophisticated integration of the BCL-2 family antagonic 
members governs cell death, particularly at the level of mitochondrial membrane permeability. The 
mitochondrial control by these proteins is of utmost importance as it permits the release of cytochrome c (cyt 
c) from the intermembrane space to cytosol due to formation of a channel in the outer mitochondrial 
membrane. Bax and/or Bak form the pore after tBid activation, while Bcl-2 and Bcl-XL inhibit its formation. 
The BH3-only family members, such as Puma, Bim, Bad and Bid, are vital initiators of apoptosis. They 
unleash the apoptotic cascade by inactivating the protective function of the anti-apoptopic members and by 
activating the Bax/Bak-like pro-apoptotic BCL-2 family members. Once cyt c is released into the cytosol it 
binds with apoptotic peptidase activating factor 1 (Apaf-1) and ATP, which then bind to pro-caspase-9 to form 
a caspase-activating signaling complex, known as apoptosome. The apoptosome cleaves the pro-caspase-9 to 
its active form caspase-9, which in turn activates the effector caspase-3 and -7 that execute apoptosis: 
phosphatidylserine (PS) is exposed to the outer leaflet of cytoplasmic membrane, cell shrinks, death substrates 
are cleaved (e.g., Poly (ADP-ribose) polymerase, PARP), the chromatin condenses, cellular membrane is 
blebbing and finally the cell is disintegrated into condensed membrane-enclosed assemblies, known as 
apoptotic bodies. Blue lines indicate inhibition in the pathway while brown arrows indicate activation. ATP, 
Adenosine-5'-triphosphate. 
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Additional data showed that time-dependent caspase-3/-7 activation but not 
mitochondrial membrane potential (∆ψm) disruption accompanied the observed amphetamine-
induced apoptosis. Also, cell dismantling was confirmed by the observed poly PARP 
proteolysis (Experimental section, Chapter 5).  
Considering all the parameters evaluated, no relevant differences were detected when 
cells were exposed to the equieffective concentrations of the drugs individually and in 
combination, corroborating the CA assumption that amphetamines combination effects are 
additive and that the whole mixture components acted in a similar way to prompt HepG2 cell 
death. 
These results provide a new understanding on the hepatocyte death pathways 
prompted by the tested amphetamines and show that these pathways also operate when the 
amphetamines are combined. It also became clear that cell death is highly dependent on 
temperature and time of exposure stimuli. 
 
 
2.2. Hyperthermia severely aggravates the risks associated with amphetamines 
abuse 
 
From all the experiments performed, both at physiological and hyperthermic incubation 
conditions, it can be concluded that hyperthermia is a crucial determinant of toxicity of all the 
individual and combined amphetamines. It has already been proposed that the exposure of 
hepatocytes to amphetamines under hyperthermic conditions triggers multiple cellular 
signalling pathways, leading to the disruption of cellular homeostasis that may finally 
culminate in cell death (Gabai and Sherman 2002). 
 From our studies, one of the most compelling evidences of the detrimental influence 
of high incubation temperature on the cytotoxicity of the amphetamines, both individually and 
in combination, was the increased steepness of the slopes of the concentration–response 
curves that was observed. This means that very small increases in the concentrations of each 
drug/mixture prompted cytotoxic responses that rapidly shifted from imperceptible effects to 
maximal mortality, at 40.5 ºC. Of note, several studies have shown that an increase in body 
temperature is per se directly related with hepatotoxic damage, further exacerbating the 
amphetamines-related liver toxicity (Carvalho et al. 1997; Carvalho et al. 2001; Skibba and 
Gwartney 1997; Skibba et al. 1991). Among other factors that could explain such an 
influence, metabolism may be at play. Our data shows that the toxicity elicited by 
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amphetamines under hyperthermia was significantly aggravated in the most competent 
metabolic model, the rat primary hepatocytes when compared to the HepG2 cells 
(Experimental section, Chapter 3). Overall, these data indicate that hyperthermia significantly 
narrows the ‘safety range’ of amphetamines and their mixtures, highlighting the increased 
risks that ecstasy abusers are exposed to, in the corresponding drug abuse scene. 
As noted before, MDMA-induced hyperthermia may be at least partly responsible for 
the hepatotoxicity that is observed in vivo, as liver injury is often accompanied by a 
hyperthermic state (Andreu et al. 1998; Broening et al. 1995; Chadwick et al. 1991; Coore 
1996; Gahlinger 2004; Green et al. 2003; Hall and Henry 2006; Henry et al. 1992; Malberg 
and Seiden 1998; Mallick and Bodenham 1997; Mechan et al. 2002; Milroy et al. 1996; Nash 
et al. 1988; Schmidt et al. 1990; Screaton et al. 1992; Vanden Eede et al. 2012). Also, the 
hepatocellular damage observed in cases of poisoning with MDMA is, in many aspects, 
similar to that produced by hyperthermia in isolated hepatocytes (Santos-Marques et al. 
2006). Skibba et al. (1991) studied the heat-induced hepatotoxicity by perfusing isolated rat 
livers with four solutions at different temperatures (from 37 oC to 43 oC) and observed a 
temperature-dependent increase in oxidative stress, purine catabolism and cell death rates. 
Consequently, it can be argued that oxidative stress plays a role in the toxicity linked with 
elevated temperatures.  
In vitro and in vivo studies have shown that the elevation of incubation temperature of 
isolated rat hepatocytes enhances the hepatotoxic effects of MDMA, particularly the effects 
closely related to oxidative stress, such as decrease in the levels of intracellular GSH, 
increased glutathione disulfide (GSSG) and lipid peroxidation (Beitia et al. 2000; Carvalho et 
al. 2002a; Johnson et al. 2002; Ninkovic et al. 2004). Pourahmad and collegues (2010) 
reported MDMA-induced cytotoxicity, reactive oxygen species formation, ∆ψm decline and 
lysosomal membrane leakage in isolated rat hepatocytes at physiological temperature, and 
these effects on the oxidative stress markers were further exacerbated at 41 oC. Antioxidants, 
reactive oxygen species scavengers, and inhibitors of CYP2D6 reduced all markers of 
MDMA-induced hepatocyte oxidative stress (Pourahmad et al. 2010). Carvalho et al. (2002a) 
obtained some evidence of oxidative stress (as expressed by GSH depletion, lipid 
peroxidation, decreased catalase activity, decreased glutathione peroxidase activity, 
vacuolation of the hepatocytes, presence of blood clots and loss of typical hepatic cord 
organization), after the administration of an acute intraperitoneal dose of MDMA to mice that 
were placed at a high ambient temperature (30+/-2 oC). The same authors observed that a rise 
in incubation temperature from 37 oC to 41 oC increased oxidative stress in freshly isolated 
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mouse hepatocytes, reflected by increased lipid peroxidation, GSH depletion, and consequent 
loss of cell viability (Carvalho et al. 2001). These findings together indicate that hyperthermia 
acts as a pro-oxidant aggressive condition that worsens de pro-oxidant effects of 
amphetamines. We, therefore, pursued our mechanistic studies by evaluating the ability of the 
tested amphetamines to produce oxidative damage, when tested individually and in 
combination. 
 
 
2.3. Oxidative-modifications elicited in HepG2 Cells  
 
There is overwhelming evidence supporting the role of oxidative stress in amphetamines-
induced damage. Several studies have shown the involvement of oxidative stress in 
hepatocellular toxicity induced by MDMA, in vivo and in vitro (Beitia et al. 1999; Beitia et al. 
2000; Carvalho et al. 2002a; Johnson et al. 2002). Beitia and co-workers (1999) observed a 
marked decrease in the intracellular levels of GSH and cellular bioenergetics on isolated rat 
hepatocytes. The decrease of hepatic glutathione levels was also observed in vivo in rats 
(Beitia et al. 2000) and in mice that were administered with MDMA (Carvalho et al. 2002a; 
Johnson et al. 2002). Since the intracellular GSH is a crucial defence for the inactivation of 
toxic electrophiles, including ROS and RNS (Wu et al. 2004), low hepatic levels of GSH may 
be an initial step in the hepatotoxic action of MDMA. Cerretani et al. (2011) also observed 
MDMA-induced loss of GSH homeostasis, decreases antioxidant enzyme (GR and 
glutathione peroxidase or GPx) activities, and lipidperoxidation in rat liver. Others have 
corroborated these results (Ninkovic et al. 2004). 
Our research also revealed a concentration-dependent disturbance in the pro-
oxidant/antioxidant cellular status, in favour of the former, when HepG2 cells were exposed 
individually to the tested drugs and to their mixture (Experimental section, Chapter 2). 
Despite the general agreement on the involvement of oxidative stress in 
amphetamines-elicited toxicity, the source of ROS and RNS is still a matter of debate. 
Generally, it has been postulated that the generation of oxidative/nitrosative stress can arise as 
a result of (i) the activity of the mitochondrial respiratory chain, (ii) depletion of antioxidants, 
(iii) redox cycles formed between o-quinones and their semiquinones derived from the 
metabolism of the catecholamines and of the amphetamines, (iv) the combination of produced 
metabolites and GSH, and (v) hyperthermia (Carvalho et al. 2012; Pontes 2009). The 
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produced reactive species interact with and oxidize vital cellular macromolecules such as 
DNA, proteins, and lipids (Pacher et al. 2007). The modification of these macromolecules has 
deleterious effects on their physiological functions. 
Our results agree well with reports that show that the amphetamines, directly or 
through the production of reactive metabolites, are able to increase the generation of ROS and 
RNS, in several systems (Kaushal et al. 2012; Quinton and Yamamoto 2006; Shenouda et al. 
2009). Similarly to the o-quinones resulting from the oxidation of endogenous 
catecholamines, also oxidation of catechol metabolites of MDMA (N-methyl-α-
methyldopamine and α-methyldopamine) results in the formation of aminochromes adducts 
with glutathione and cysteine (Figure 1) (Carvalho et al. 2012; Pontes 2009). The reactivity of 
the formed compounds, the involvement in redox cycles accompanied by the formation of 
ROS and RNS and the ability to induce oxidative stress when intracellular antioxidant 
defences are depleted, are putative mechanisms for the occurrence of cellular damage 
(Carvalho et al. 2012; Pontes 2009). Carvalho et al (2004b) have demonstrated that 
cytotoxicity of the metabolite N-methyl-α-methyldopamine in isolated rat hepatocytes was 
higher than that of MDMA under the same experimental conditions, and that oxidative stress 
played a role on the achieved effects. In another study by the same authors, it was also 
demonstrated the occurrence of decreased levels of intracellular GSH and ATP, inhibition of 
antioxidant enzymes (such as GPx, glutathione reductase or GR, glutathione S-transferase or 
GST) and cell death by exposing isolated rat hepatocytes to α-methyldopamine (Carvalho et 
al. 2004a). Additionally, these reports evidenced the production of adducts of α-
methyldopamine with glutathione (Carvalho et al. 2004a). Taken together, results from these 
studies showed that one of the consequences of MDMA initial metabolism in the expression 
of hepatic cytotoxicity appears to be the disruption of antioxidant homeostasis, which can 
result in loss of important intracellular functions and trigger the cascade of events that leads to 
irreversible cell damage (Carvalho et al. 2012; Carvalho et al. 2004a; Carvalho et al. 2004b; 
Pontes 2009). 
Also, the heat-stimulation per se has been implicated in the increased flux of free 
radicals in the cells, such as superoxide and H2O2 (Flanagan et al. 1998). The mechanism is 
not yet understood, but it appears to involve the mitochondrial chain of electron transport. In 
fact, mitochondria is considered the main source of ROS, but other enzymes, such those 
belonging to CYP P450 system, are also known to produce ROS/RNS following MDMA 
exposure (Darvesh et al. 2005; Gow et al. 2004; Moon et al. 2008; Zheng and Laverty 1998). 
Certainly, the decline of total glutathione content instigated by amphetamines may leave 
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hepatocytes more susceptible to damage, as changes in the intracellular thiol-disulfide 
(GSH/GSSG) homeostasis are considered key determinants in the cellular redox balance. It 
has been vastly reported that glutathione has not only the ability to directly scavenge reactive 
species of both oxygen and nitrogen (acting as an oxidant neutralizing), but it also plays a 
crucial protective role against cellular injury favouring the regeneration of lipid peroxidase 
and tocopheryl-radical activities (Di Mascio et al. 1991). 
The GSH depletion reported in our studies (Experimental section, Chapter 2) has 
already been demonstrated in primary hepatocyte systems (Beitia et al. 1999; Carvalho et al. 
2001; Pontes et al. 2008b) and might be explained by: (i) the increased oxidation of GSH to 
GSSG by ROS and RNS whose formation is also increased, (ii) by the formation of adducts 
with reactive catechol metabolites, or (iii) by the decreased synthesis of GSH as a result of the 
inhibition of the activity of the enzymes of synthesis. This disruption of thiol homeostasis 
may result in a boost of free reactive species that are efficient in promoting loss of protein 
function and initiating a cascade of events leading to mitochondrial electron transport 
impairment, with subsequent exhaustion of ATP supplied and cell death. In accordance, the 
dramatic depletion of intracellular stores of ATP was particularly notorious under 
hyperthermia (Experimental section, Chapter 2). 
Mitochondrial dysfunction was also confirmed by the loss in ∆ψm, at 40.5 oC. These 
results are in agreement with reports showing that amphetamines induce oxidative stress in 
mitochondria (Alves et al. 2007; Brown et al. 2005; Burrows et al. 2000). Custódio et al. 
(2010) compared the direct influence of MDMA and 4-MTA on rat liver mitochondrial 
function (MPT), mitochondrial oxidative stress, and mitochondrial bioenergetics, and showed 
that 4-MTA was more potent than MDMA in decreasing the sensitivity of liver mitochondria 
to MPT, and that higher concentrations of 4-MTA were highly toxic to mitochondria. 4-MTA 
simultaneously increased H2O2 production and uncoupled and inhibited mitochondrial 
respiration. Increased production of ROS and RNS usually results in production of more 
potent ONOO·-, which interacts with cellular macromolecules such as DNA, proteins, and 
lipids to oxidize these components (Pacher et al. 2007). The modification of these 
macromolecules has deleterious effects on their physiological functions. Evidence 
demonstrated that the activities of mitochondrial aldehyde dehydrogenase (ALDH), 3-
ketoacyl-CoA thiolases, and ATP synthase were significantly inhibited following MDMA 
exposure, by oxidative inactivation, which most likely contributes to mitochondrial 
dysfunction and subsequent liver damage in MDMA-exposed rats (Moon et al. 2008). This 
oxidative injury may affect mitochondrial energy processes (Krebs cycle/oxidative 
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phosphorylation and electron transport chain) causing damage to the membranes and/or 
mitochondrial proteins (e.g. NADH dehydrogenase, cyt c reductase, and cyt c oxidase) (Seitz 
and Stickel 2006). Also, oxidative damage to the mitochondria due to excess of reactive 
species can trigger intracellular signaling that ends up in hepatotoxicity. In particular, our 
studies provide evidence supporting that these drugs and their combination induce increases 
in proapoptotic proteins, Bax, cleaved Bid, Puma, Bak and Bim, and decreases in 
antiapoptotic gene expressions of BCL-2 and BCL-XL, which result in the activation of the 
downstream apoptotic cascade, characterized, among others, by activation of caspases-3/-7, 
and the breakdown of several structural cellular proteins, such as PARP. 
Nonetheless, it is still unknown whether the generation of ROS in hepatocytes 
incubated with MDMA depends on either disturbance of the mitochondrial respiratory chain 
or on the redox cycles formed between ortho-quinones and their semiquinones derived from 
MDMA metabolism (Carvalho et al. 2004b; Hiramatsu et al. 1990). In fact, it is not clear 
whether MDMA directly uncouples mitochondrial respiration. In spite of the fact that it has 
been established that MDMA-mediated hyperthermia occurs by UCP3-mediated action, 
recent studies demonstrated that the effects of MDMA on respiratory uncoupling in liver 
mitochondria are modest (Rusyniak et al. 2004). Moreover, uncoupling proteins, particularly 
UCP3, although widely present in other tissues, are not highly expressed in hepatocytes and 
this may be the reasoning for the absence of effects in the liver (Carvalho et al. 2012; Larrouy 
et al. 1997). 
The mitochondrial impairment that we observed has already been noted in several 
investigations. Song et al. (2010) reported MDMA-induced oxidation of several 
mitochondrial proteins involved in protein folding (chaperone proteins), oxidative 
phosphorylation, energy production, anti-oxidant defense, fat metabolism, electron transport, 
etc. In addition, Moon and coworkers (2008) demonstrated that the activities of certain 
enzymes such as NADH-ubiquinone oxidoreductase (complex I), ATP synthase (complex V), 
ALDH2, and 3-ketoacyl-CoA thiolase (involved in ATP production via the fat degradation 
pathway) were significantly inhibited in MDMA-exposed liver, suggesting that hepatocytes 
may not properly convey many cellular functions and eventually undergo cell death 
processes. Inactivation of these key mitochondrial enzymes correlated with increased H2O2, 
decreased ATP level, accumulation of lipid peroxides such as malondialdehyde, and 
triglyceride fat accumulation, which most likely leads to mitochondrial dysfunction and 
subsequent liver damage (Carvalho et al. 2012; Moon et al. 2008). Nakagawa and co-workers 
(2009) showed that the exposure of isolated hepatic mitochondria to MDMA causes 
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mitochondrial impairment and induction of the MPT accompanied by mitochondrial 
depolarization and depletion of ATP through uncoupling of oxidative phosphorylation 
(Nakagawa et al. 2009). Beitia and co-workers (1999) showed that MDMA induced a 
concentration- and time dependent ATP depletion. Carvalho et al (2004b) observed a severe 
ATP depletion subsequent to massive GSH depletion after hepatocytes incubation with 
MDMA metabolite N-Me-α-MeDA, suggesting that altered thiol homeostasis may also 
contribute to mitochondrial dysfunction (Carvalho et al. 2004b). GSH, in conjunction with 
GPx/GR is responsible for the elimination of cellular H2O2 and organic peroxides. Thus, 
depletion of GSH and/or decreased activity of these enzymes may compromise this pathway 
and thereby allow H2O2 to accumulate at toxic levels. It must be stressed that hepatic 
mitochondria are especially vulnerable to this effect since they lack the H2O2 metabolizing 
enzyme, catalase (Carvalho et al. 2012; DeLeve and Kaplowitz 1991; Pontes 2009). 
Despite some reports of lipid peroxidative damage induced by MDMA as a 
consequence of oxidative stress (Skibba et al. 1990), we failed to find significant alterations in 
the lipoperoxidation profile under our experimental settings. Still others have reported 
hyperthermia-related lipid peroxidation in perfused rat liver (Skibba et al. 1991) and in freshly 
isolated rat hepatocytes (Carvalho et al. 1997; Carvalho et al. 2001). 
An overall analysis of our mechanistic data on oxidative stress, energetic status, and 
mitochondrial dysfunction indicated that hepatocytes exposure to the drugs, either 
individually or in mixture, at equieffective concentrations, showed no significant differences 
in the elicited responses. This further suggests that there was, in fact, a similarity in the way 
these agents performed in each assay and supports the validity of the CA premise. 
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PART V – FINAL CONCLUSIONS  
 
Experimental testing of mixture toxicity is hampered by the overwhelming number of 
possible mixtures that an individual, or a population, might be exposed to. Therefore, 
predictive approaches capable of estimating the effect of mixtures on the basis of the known 
toxicities of their individual components are an imperative. The two prevailing theoretical 
concepts of CA and IA, largely used to appraise mixture effects on a variety of fields, such as 
aquatic toxicology and cancer chemotherapy, were never applied to evaluate the combination 
effects of drugs of abuse. We were the first to apply these principles to evaluate joint effects 
between MDMA and three other amphetamines that are known to be concomitantly ingested 
with the drug, in the polydrug abuse settings. Ultimately, the work conducted under the scope 
of the present dissertation allowed us to conclude that: 
 
1. CA is a suitable model to accurately estimate the joint cytotoxic effects of four 
amphetamines – MDMA, METH, 4-MTA and d-AMP – on HepG2 liver cells, using 
information on the individual drug components. This was true for a few different 
mixture designs, including mixtures with individual constituents combined at: (i) 
equipotent concentrations (to avoid different individual contributions to the mixture 
outcomes), (ii) concentrations simulating ‘realistic’ intoxication scenarios (with MDMA 
as the main constituent and the other amphetamines as contaminants), and, (iii) very low 
concentration of all the mixture components, which individually yield no significant 
toxic effects. 
 
2. With basis on the current approach, the joint toxicological effect of all four 
amphetamines could be classified as additive. 
 
3. According to the theoretical approach, our findings strongly suggest that remarkable 
mixture effects occur, even when each single component is present in the mixture at 
concentrations that individually elicit irrelevant cytotoxic effects. These observations 
emphasize the risk that the consumers of ‘rave pills’ are exposed to when ingesting an 
illicit ecstasy pill (often contaminated with other amphetaminic products obtained from 
uncontrolled synthetic processes). 
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4. The predictions according to IA proved to be inadequate for the evaluation of the joint 
effects of the tested amphetamines in our in vitro system. Taken together, these 
observations lead to the conclusion that these drugs of abuse work in a similar way to 
generate the overall mixture effects. 
 
5. All former conclusions hold true also at conditions that more closely represent the in 
vivo situation. Notable additive effects that conformed well with CA where observed, 
even at very low and individually ineffective concentrations, when similar experiments 
were conducted under hyperthermia (40.5 oC), and also with primary rat hepatocytes, 
which are regarded as metabolically more competent. 
 
6. Additionally, MDMA and its main human metabolites MDA, α-MeDA and N-Me-α-
MeDA, interacted additively to produce substantial effects at both physiological and 
hyperthermic temperature settings, suggesting that the metabolism of MDMA has 
dangerous repercussions to liver cells, even when the metabolites are present at 
seemingly negligible concentrations. 
 
7. In some of the tested mixture designs, a small deviation from additivity was observed at 
high effect levels. A possible metabolic interaction might be at play at these higher 
mixture concentrations, contributing to these small divergences from additivity. 
Nonetheless, these concentrations are not representative of those attained in vivo and 
therefore, unlikely to be relevant, when considering real intoxication scenarios. 
 
8. Mechanistic evaluation on the pathways underlying cell death provoked by individual 
and combined amphetamines revealed that the switch of the cell death mode from 
apoptosis to necrosis depends on both temperature and duration of exposure. Under less 
hostile incubation settings, apoptosis was favoured and involved the synchronized 
inactivation of the protective function of anti-apoptopic and the activation of pro-
apoptotic BCL-2 family members. To the best of our knowledge, this is the first time 
that Puma, Bim and Bak have been linked with the toxicity induced by amphetamines. 
Additionally, time-dependent caspase-3/-7 activation, PARP proteolysis, but not ∆ψm 
disruption across mitochondrial membrane, mediated amphetamine-related apoptosis, 
under our experimental conditions. At an increased incubation temperature, similar to 
that elicited in vivo by amphetamines (40.5 oC), necrosis rather than apoptosis was 
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observed, accompanied by a marked impairment of the cellular energetic status and 
lysosomal membrane injury. 
 
9. At hyperthermia (40.5 ºC), very small increases in the concentrations of each 
drug/mixture prompted cytotoxic effects that quickly shifted from roughly undetectable 
to maximal mortality. The decline of antioxidant defences, the dramatic depletion of 
ATP intracellular stores, and the ∆ψm disruption were particularly exacerbated under 
these hyperthermic settings, suggesting a strong correlation with the observed toxicity. 
 
10. Primary hepatocytes revealed greater susceptibility to individual and combined 
amphetamine toxic action when compared to HepG2 cells, especially under 
hyperthermia. Admitting that primary cells are metabolically more competent than the 
HepG2 cell line, this might render the cells more vulnerable when they are exposed to 
substances that are metabolised into harmful metabolites, particularly when subject to 
heat stress, a condition that has already been shown to improve metabolic efficiency.  
 
The research presented herein clearly demonstrates that additive interactions among 
amphetaminic drugs greatly contribute to their in vitro toxicity in liver cells. An overview of 
the mechanisms most likely to be involved in these effects is depicted in Figure 6. 
Significantly, our work highlights the limitations of the traditional emphasis on the effects of 
single agents and stresses the importance of studying amphetamines in combination, when 
evaluating their impact on human health. Validation of the presented data in more complex 
models deserves further experimental investigation, but overall, it can be concluded from our 
studies that risk assessments that overlook the joint action of amphetamine-like drugs will 
almost certainly lead to significant underestimations of risk. 
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